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Abstract 
Tackling antimicrobial resistance (AMR) is a national and global priority. Despite 
this, much of our understanding of the epidemiology and transmission of AMR 
outside the hospital, and thus, how we might control it, remains limited. Long 
term care facilities (LTCFs) play an important role in the care of older people. 
However, there have been few studies of the epidemiology and transmission of 
AMR in this setting. LTCF residents present with frequent co-morbidities which 
increase their risk of hospitalisation and of AMR infection. LTCFs also offer 
opportunities for transmission of AMR strains due to the long lengths of stay of 
residents and the lack of strictly applied infection control measures. This thesis 
focuses on urinary tract infections (UTIs), one of the most common bacterial 
infections in LTCFs, hospitals and the community. I first present a systematic 
review of mathematical models of infectious disease transmission set in LTCFs 
and a critical review of mathematical models evaluating interventions against 
AMR bacteria in LTCFs. A checklist for good quality models in this area is 
proposed. Next, using data from routinely collected microbiology samples, the 
frequency of AMR in urinary tract E. coli and Klebsiella was compared in LTCF 
residents with that in older people living in their own homes. Residents of 
LTCFs had more than four times the rate of E. coli and Klebsiella UTI caused by 
antibiotic-resistant bacteria compared with those living in the community. The 
seasonality of UTI consultations was also assessed. A September to November 
peak in UTI consultation incidence was observed for ages 14-69. This 
seasonality progressively faded in older age groups and no seasonality was 
found in individuals aged 85 and over. Finally, a stochastic compartmental 
mathematical model was developed to explore the transmission of trimethoprim-
resistant E. coli in LTCFs. Different treatment, importation and transmission 
scenarios were addressed.  
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Impact statement 
First, this work contributes towards improving our understanding of the 
dynamics of UTI (Chapter 6). Due to increases in temperature during the 
summer, which can make individuals prone to dehydration, UTIs could be 
expected to peak during this time. These changes could be particularly 
pronounced in the elderly population, as aging is a risk factor for water 
homeostasis impairments and inadequate water intake. However, GP 
consultations for UTI in older people in the UK were not found to be seasonal. 
This contrasts with the autumnal peak observed for individuals aged 14 to 69. 
As UTIs in older people are common year round, UTI prevention in this 
population should warrant attention throughout the year. The autumnal peak in 
UTI consultation incidence observed in younger age groups could also be 
helpful in interpreting the results of interventions and surveillance reports. This 
work was published in the journal Epidemiology and Infection. 1 
Second, UTIs caused by AMR E. coli and Klebsiella were shown to be more 
common in LTCFs in the West Midlands than in older people residing in their 
own homes, even after adjusting for confounders. This highlights that LTCFs 
should be a focus of antibiotic stewardship and infection prevention and control 
interventions aiming to prevent the spread of AMR bacteria, as well as of 
increased surveillance of AMR and antimicrobial prescribing. Findings from this 
thesis also support the recent switch in the national primary care treatment 
guidelines for uncomplicated UTI from recommending trimethoprim to 
nitrofurantoin, as trimethoprim was shown to be ineffective to treat a large 
proportion of the UTIs in LTCF residents due to the high prevalence of 
resistance in this population. This work was published in the Journal of 
Antimicrobial Chemotherapy.2 
Third, antibiotic-resistant Gram-negative bacteria are currently organisms of 
high public health importance and, as shown in the systematic review of the 
literature (Chapter 2), an increasing number of studies modelling the 
transmission of infectious diseases in LTCFs are being published. Therefore, 
the conclusions of mathematical models that simulate the transmission of 
Gram-negative bacteria in LTCFs could be important for policy making. A 
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checklist was developed to guide policy makers in assessing the quality of such 
models. This work was published in Infection Control and Hospital 
Epidemiology.3 
Finally, the output from the mathematical model developed to simulate the 
transmission of E. coli resistant to trimethoprim in the LTCF (in Chapter 7) 
suggested that LTCFs with a high prevalence of resistance could contribute 
towards the prevalence of resistance in hospitals, highlighting the importance of 
reducing avoidable hospital admissions by enhancing support for LTCF 
residents and the potential of screening strategies. In addition, the transmission 
of E. coli resistant to trimethoprim was found to have a greater impact on the 
prevalence of E. coli resistant to trimethoprim in the LTCF than trimethoprim 
treatment, at least in LTCFs with a high incidence of trimethoprim-resistant 
urinary E. coli submitted for laboratory testing. These findings suggest that 
reducing transmission may be key to diminishing the prevalence of carriage of 
trimethoprim-resistant E. coli in LTCFs.  
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Chapter 1 Introduction 
This thesis focuses on the problem of antimicrobial resistance (AMR) in long-
term care facilities (LTCF) for older people, with a particular focus on the 
antibiotic resistance of bacteria that cause urinary tract infections. Previous 
research on antibiotic resistance has mostly focused either on primary care or 
secondary care, and relatively little research has been carried out within LTCFs. 
LTCFs are a critical part of the healthcare system, housing residents whose 
needs do not warrant acute care in hospitals, but cannot be met in their own 
homes. Demographic shifts mean that an increasing proportion of our 
population are elderly.4 In addition, increases in life expectancy have outpaced 
improvements in disability-free life expectancy, meaning that a greater 
proportion of the population lives with disability later in life.5 The combination of 
these factors is driving an increasing demand for LTCF residence in older 
people, which is struggling to be met due to reductions in local authority 
budgets.5,6 Residents of LTCFs have high levels of co-morbidity, predisposing 
them to a wide range of infections, which are an important cause of hospital 
admissions.7–10 High levels of antibiotic exposure are, therefore, likely, and 
infections, including those caused by resistant bacteria, will likely spread readily 
in these congregate settings. It is, therefore, likely that AMR is a significant 
problem in the LTCF setting and that this setting makes an important 
contribution to the overall problem of antimicrobial resistance. This thesis uses 
statistical and mathematical modelling tools to shed light on the epidemiology of 
AMR in LTCFs using routinely available data.  
The problem of antibiotic resistance 
Bacteria can easily spread between humans, animals and the environment. We 
carry approximately 38 trillion of these organisms in our bodies, mostly in our 
gut and on our skin.11 Although most bacteria are not harmful, and in fact play 
an important role in our good health, they also cause infection.12 Bacteria that 
are commonly carried asymptomatically (without any symptoms) are 
problematic to survey, as their spread goes mostly undetected.13 
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Antimicrobials are therapeutic agents used to kill or slow the growth of 
organisms that cause infection such as bacteria, fungi, viruses or parasites. The 
first antimicrobial was discovered by Paul Ehrlich in 1909.14,15 This was a 
synthetic arsenic-based compound that was highly effective at treating syphilis. 
Nineteen years later, in 1928, Alexander Fleming discovered penicillin, the first 
antimicrobial of clinical relevance derived from microorganisms, which was 
introduced as a therapeutic in 1941.16–18 Sulfonamides were discovered soon 
after penicillin, in 1932.18 The discovery of these agents triggered the 
subsequent discovery of most of the antimicrobials used to date, in what is 
known as the “golden age” of antimicrobial discovery (1940s-1960s).16,18 
Antimicrobials have been instrumental in healthcare, enabling the treatment and 
prevention of infections. Surgical procedures and treatments that suppress 
immunity, such as chemotherapy, have become much safer in the knowledge 
that infections may be prevented or treated by antimicrobials.19 Antimicrobials 
are also widely used in veterinary medicine and in agriculture for the treatment 
and prevention of infections in animals and plants.19 However, tied hand in hand 
with antimicrobial use, is the development of AMR. 
AMR arises when organisms develop mechanisms to counteract the effect of 
antimicrobials, enabling them to survive and grow despite the presence of the 
antimicrobial.16 Antibiotics are a type of antimicrobials that target bacteria. 
Bacteria are able to develop and spread antibiotic resistant traits at a high rate 
due to their elevated growth rate and their ability to transfer genes between 
individuals, strains and even families.16 In many cases, genes encoding 
antibiotic resistant traits precede the use of antibiotics in human beings. They 
have been found in bacteria isolated in extreme environments that are unlikely 
to have been contaminated with antibiotics manufactured by humans.16,20 
However, resistant traits are favoured by antibiotic use. Antibiotic treatment 
confers an evolutionary selective advantage for the acquisition of antibiotic 
resistant traits, allowing bacteria with these traits to resist antibiotic treatment, 
survive and proliferate.16 A famous evolutionary hypothesis is the Red Queen 
effect, which proposes that organisms constantly evolve and adapt in response 
to their ever-changing environment.21 This metaphor of an evolutionary arms 
race was coined by Leigh Van Valen in 197321 and was derived from a passage 
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of Through the Looking-Glass by Lewis Carroll (1871): “Now, here, you see, it 
takes all the running you can do, to keep in the same place”. This plight for 
adaption and survival is not unlike that of bacteria in the presence of antibiotic 
drug development.22 
Although the lack of access to antibiotics is still a problem in many countries, 
particularly in the developing world23, antibiotic use has been increasing, thus 
providing a selection pressure for resistant strains of bacteria to prevail.16 
Antibiotics are frequently misused in the treatment and prevention of infection in 
humans.23 The four conditions which contributed most to inappropriate 
prescribing in primary care were sore throat (23.0% of identified inappropriate 
prescriptions), cough (22.2%), sinusitis (7.6%) and acute otitis media (5.7%).24 
Antibiotics are also prescribed in even larger quantities in animal husbandry. 
Although important, this was beyond the scope of this thesis.25,26  
Due to the paucity of new antibiotics being developed, a rise in antibiotic 
resistance limits treatment options and increases the risk of treatment failure, 
leading to increases in morbidity and mortality.19,27 The spread of antibiotic 
resistance is a major healthcare concern nationally and worldwide.19,28,29 In 
particular, antibiotic-resistant Gram-negative bacteria have been highlighted as 
organisms of concern.30–32 Gram-negative bacteria are a group of bacteria that 
contain small levels of peptidoglycan in their cell wall and possess an outer 
membrane, which confers them protection against several antibiotics. Two 
Gram-negative bacteria, Escherichia coli and Klebsiella have recently been 
highlighted as critical priority pathogens for research and development of new 
antibiotics by the World Health Organization.30 E. coli and Klebsiella have also 
been highlighted as bacteria to monitor for resistance in the five year AMR 
strategy for the UK (2013-2018).31  
Urinary tract infections- why do they matter? 
Gram-negative bacteria such as E. coli are part of the natural microflora of the 
gut; however, they are also the primary cause of urinary tract infections (UTIs).  
28 
 
UTIs comprise both infections of the upper and lower urinary tract. Common 
symptoms of UTI include dysuria (painful or difficult urination), a high frequency 
of urination, suprapubic tenderness, urgency in urination, polyuria (abnormally 
large passage of urine), new incontinence, fever and haematuria (blood in the 
urine).  
UTIs impact quality of life and are the most common cause of acute emergency 
admissions to hospitals amongst conditions that could be effectively treated and 
managed in the community10,33. Age and sex adjusted admissions for UTI per 
100,000 population increased from 102 in 2001/2002 to 229 in 2012/201334. In 
2015, UTIs were the second most common cause for antibiotic prescribing in 
primary care and prescribing for UTI has been increasing from 2010 to 201535. 
As such, antibiotic treatment for UTI is an important driver of antibiotic 
resistance. 
UTI sequelae include recurrences, pyelonephritis, complications associated with 
antibiotic use, such as antibiotic resistance and Clostridium difficile colitis, and 
bloodstream infection (BSI).36 BSIs are severe infections associated with high 
mortality, in particular if they are caused by antibiotic resistant bacteria.37 
Studies performed in English hospitals during the winter of 2012/2013, between 
April 2012 and March 2014 and between July 2011 and June 2012 found that 
51.2%, 41.1% and 52.4% of BSIs caused by E. coli, respectively, had a 
urogenital tract focus of infection.37–39 One of these studies showed that 98.4% 
of BSIs that had their origin in the urogenital tract were UTIs.39 In England, the 
Department of Health and NHS England demands the mandatory surveillance 
of the incidence of E. coli BSI by NHS Acute Trusts. From 2012 to 2016, the 
cases reported increased by 24.3%, with 40,272 cases reported in 2016.40 A 
steady increase was also observed from 2002 to 2008 in the BSIs reported to 
EARS-Net from laboratories across Europe.41 The rate of laboratory reports of 
Klebsiella BSI have increased steadily since 2013.42 The incidence of MRSA 
BSI, in contrast, has been decreasing since 2007.43 Given this increase in E. 
coli BSI, the Secretary of State for Health has set an ambition of reducing 
healthcare-associated Gram-negative BSIs by 50% by 2020.32 NHS England 
has developed the Quality Premium Scheme to reward clinical commissioning 
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groups for quality improvements in the aim of meeting this goal. The 
inappropriate prescribing of antibiotics for UTI may result in recurrences or 
treatment failure which may lead to BSI. Therefore, one of the targets in 
reducing BSIs is the reduction of inappropriate antibiotic prescribing for UTIs in 
primary care.44  
Urine has long been thought to be sterile; however, recent evidence suggests 
that bacteria are present in small concentrations in the healthy human bladder, 
and certain bacteria may in fact have a protective effect for UTI. 45 Particularly in 
the elderly, where catheterisation and asymptomatic bacteriuria (the presence 
of bacteria in the urine in the absence of clinical UTI symptoms) are common46–
48, the presence of Gram-negative bacteria in the urine, even in high 
concentrations, does not necessarily equate to a UTI. It is, therefore, important 
that symptoms are accounted for in UTI diagnoses. Accordingly, English 
national guidelines do not recommend sending urines from elderly people with a 
suspected lower UTI for laboratory culture unless two or more signs of infection 
are present or in case of treatment failure, and this is not recommended if 
patients are catheterised. Dipsticks with nitrite are recommended only in women 
under 65 years of age with cloudy urine and either mild symptoms, or two or 
fewer symptoms of UTI.49 The guidelines also recommend that suspected lower 
UTIs in elderly people should be treated empirically only when fever and one 
other symptom is present. 49,50 Due to the high frequency of co-morbidities such 
as dementia, which may hinder the ability to verbalise symptoms, and other 
comorbidities such as incontinence, diagnosis is complex. The distinction 
between colonisation and infection is, therefore, problematic when interpreting 
electronic health records capturing consultation for UTIs or surveillance 
databases capturing antibiotic susceptibility results and attempting to derive 
from this the rate or incidence of infection. Empiric treatment for UTI is frequent 
and may also complicate the interpretation of susceptibility data, as cultures 
may only be taken after treatment failure. 
UTIs are most frequent in the elderly. As mentioned above, the clinical 
management of UTI in this population is complex due to the high frequency of 
co-morbidities. Residence in a LTCF is a known risk factor for UTI.47 
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Long-term care facilities 
LTCFs are defined in different ways in the literature, comprising, for example, 
acute-care hospitals with long lengths of stay, residential facilities, and facilities 
that provide care to people of all ages including those with learning disabilities. 
However, for the purpose of this thesis, LTCFs are defined as facilities that 
provide accommodation for elderly people and support them in their daily 
activities such as washing, dressing and eating.51 They are otherwise known as 
care homes. Some LTCFs additionally provide nursing services. In 2011, 
291,000 people in England over 65 years of age (3.2% of the total population 
aged 65 and over) were recorded in the census as living in LTCFs52. This is 
predicted to increase in the coming years as the population in Europe ages and 
healthcare systems strive for cost optimisation, which frequently results in 
shorter hospital stays.53  
LTCF residents are at an increased their risk of being hospitalised compared to 
elderly individuals residing in their own homes.9 It has been shown that the ratio 
of emergency admissions and A&E attendances to elective attendances is 40-
50% higher in residents of a postcode containing a LTCF than in individuals 
aged >75 that did not live in a postcode containing a LTCF.9 The five year 
forward view suggested that many of these admissions to hospital could be 
avoidable54, which has resulted in the “enhanced health in care home” 
vanguards pioneered by NHS England.55 
Immunosenescence, the progressive decline in immune function that occurs 
during aging, increases the risk of infection in older people.7,56–58 Frailty, which 
is common in the old, increases individuals’ vulnerability to stresses such as 
infection and worsens their prognosis.59 LTCF residents additionally present 
with functional impairment, such as faecal and urinary incontinence; 
malnutrition; frequent co-morbidities, which often require the use of invasive 
devices such as catheters; and are potentially dehydrated.7,8,60  
Infection control can be challenging in LTCFs due to frequent opportunities for 
transmission through group activities; sharing of living space, objects and 
bathroom facilities; poor coordination of medical care; as well as a lack of staff 
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adequately trained in infection control.61,62 Infection control is also challenged by 
the fact that LTCFs are residents’ homes, and, as such, it is neither possible nor 
desirable to implement infection control measures similar to those in hospitals.  
In a point-prevalence survey carried out in LTCFs across Europe, UTIs were 
found to be the joint most common healthcare-associated infection together with 
respiratory tract infections (31%).63 In England, UTIs in LTCFs were the second 
most common healthcare-associated infection after respiratory tract infections 
(35.7%).63  
AMR in Gram-negative bacteria in LTCFs 
Point prevalence studies have also shown that a high proportion of residents 
were prescribed an antibiotic at any one time in LTCFs in Europe and 
Canada.63–66 In 2011, a literature review found that, any one time in Europe, 
between 4.8% and 15.2% of LTCF residents are being treated with antibiotics, 
and between 47% and 79% of LTCF residents in Canada, USA, and Italy 
receive at least one course of antibiotics per year.66 A point-prevalence survey 
co-ordinated by the European Centre for Disease Prevention and Control 
conducted between April and May 2013 in LTCFs across Europe found that 
4.4% of residents were being treated with at least one antibiotic on the day of 
the survey (N=3,367/77,264). Amongst the 16 English LTCFs included in this 
study, the prevalence of antibiotic treatment was higher, at 9% (N=37/409). In 
this subset of facilities, 86.8% of prescriptions made were aimed at treating 
infections (13.2% were prophylaxis prescriptions), and 45.5% of these were 
prescribed for UTIs. 63 However, antibiotic prescription is likely to vary 
significantly between LTCFs. 67 
Antibiotic treatment in LTCF residents and in elderly individuals living in their 
own homes was compared in the literature. A study of the national prescribing 
records in Sweden in 2008 found a higher usage of antibiotics for UTI in LTCF 
residents compared to elderly individuals living in their own homes.68 In 
England, a study of the electronic health records routinely collected by GPs in 
Hampshire showed that care home residents aged 75 or older had an 
unadjusted odd’s ratio of 2.66 (95% CI 2.51-2.82) of being prescribed a UTI 
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antibiotic when compared to individuals aged 75 or older residing in their own 
homes, and 2.12 (95% CI 1.99-2.26) after adjusting for gender, age, co-
morbidities and presence of a urinary catheter.69 With this exception, antibiotic 
usage in England has not yet been linked to LTCF data and is not routinely 
surveyed.  
The prevalence of colonisation with AMR Gram-negative bacteria has been 
shown to be high in several studies of individual LTCFs.70–72 Larger carriage 
surveys of AMR in Gram-negative bacteria have also been carried out in 
LTCFs. For example, a point-prevalence set in 107 LTCFs in the Netherlands 
between October 2012 and July 2014 found that 25% (95% CI 23-27%) of E. 
coli isolated from urine screening samples were resistant to trimethoprim, 1% 
(95% CI 0.6-1.6%) to nitrofurantoin, and 20% (95% CI 18-23%) to 
ciprofloxacin.73 Another study surveyed 20 LTCFs in Belfast (Northern Ireland) 
between July 2005 and May 2006 and found a large variability between LTCFs 
in the prevalence of colonisation by Extended spectrum beta-lactamase-
producing E. coli, ranging from 0% to 75%.74  
Several small studies have aimed to compare the prevalence of resistance in 
urinary isolates from LTCFs and from elderly individuals living in their own 
homes using GP data in Dublin (Ireland)75 and in Vestfold County (Norway)76; 
and using hospital data in Melbourne (Australia)77 and Dundee (Scotland)78. In 
Dublin, Dundee and Australia there was a higher prevalence of resistant Gram-
negative bacteria in the LTCF population compared to elderly individuals living 
in their own homes. The Norwegian study found no significant differences 
between the two groups. 
Only one study analysed the prevalence of carriage of antibiotic resistant Gram-
negative bacteria in English LTCFs. This study was set in Cambridgeshire in a 
LTCF of 105 beds during 2014. Stool and urine specimens were collected 
weekly from 45 participants, and 17 patients (38%) were found to be carriers of 
ESBL-producing E. coli at some point during the six months of the study.79 This 
study additionally showed that the strains isolated from several residents in the 
LTCF were highly related, suggesting that either transmission or acquisition 
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from a common source was occurring. In addition, the lineages of these isolated 
strains were highly related to that of strains associated with BSI in a local 
hospital. Another study found LTCFs to be a driver of hospital outbreaks of 
carbapenem-resistant Klebsiella pneumoniae.80 A prospective study set in three 
LTCFs in Philadelphia (USA) also found a high acquisition rate for 
fluoroquinolone-resistant E. coli, as detected through serial faecal sampling, 
with 47.5% of 120 residents newly acquiring this colonisation during a year of 
follow up.81 
In summary, although the combined evidence from the literature suggests that 
antibiotic usage and antibiotic resistance in Gram-negative bacteria are high in 
the LTCF setting; antibiotic prescribing and susceptibility data is not routinely 
collected and surveyed in LTCFs. Very few studies have investigated this 
problem in England. 
How can mathematical modelling can help? 
By definition, infectious diseases are different from non-communicable diseases 
in that they can be transmitted from one organism to another. Therefore, 
transmission often needs to be considered to fully understand the natural 
history of an infectious disease, or the impact of any intervention to control it.82 
Dynamic mathematical models incorporate transmission, and as a result, have 
become important tools in epidemiology and public health. They are used to 
understand the epidemiology of infectious diseases, to target interventions 
appropriately and to evaluate their health and economic impact.82–85  
Infectious disease transmission has been simulated extensively in the hospital 
setting using dynamic mathematical models.86 These are useful tools to 
simulate different “what if” scenarios under different sets of assumptions. They 
have been used to predict the impact of infection control interventions such as 
hand hygiene, antibiotic stewardship, isolation, healthcare worker cohorting, 
screening, decolonisation, patient cohorting, barrier precautions, environmental 
cleaning, vaccination and prophylaxis in hospitals.86–93 In addition, dynamic 
models have been used to analyse the impact of changes in antibiotic exposure 
and screening upon hospital admission on the prevalence of vancomycin-
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resistant enterococci (VRE).94 Mathematical models have also been used to 
propose novel strategies to reduce antibiotic resistance in hospitals such as 
informed switching between antibiotics.95 Furthermore, findings from 
mathematical models have been used to make policy decisions for hospitals. 
For example, a model used to analyse the cost-effectiveness of screening of all 
patients admitted to hospitals in England for MRSA has helped to shape the 
current national MRSA screening policy.87 Because of their mechanistic nature, 
mathematical models can also help us understand how a particular infection 
control strategy in a hospital can affect the epidemiology of an infection. For 
example, modelling the long-term impact of different mupirocin usage strategies 
for MRSA decolonisation in hospitals has helped identify the fitness cost of 
mupirocin resistance in MRSA.88  
Likewise, mathematical modelling has the potential to provide insight into the 
transmission of infections in LTCFs. Like in hospitals, LTCF residents live in 
close proximity to one another, and are more likely than the general population 
to be older and frailer individuals with chronic conditions which may warrant 
invasive devices such as catheters, or surgical operations, which increase their 
risk of contracting infections.7,9,96 However, LTCFs offer greater opportunities for 
infectious disease transmission than hospitals through many more shared 
objects and spaces, higher contact between residents, and longer lengths of 
stay, which favour prolonged exposure to the organisms residents may be 
carrying.97–99 Hence, existing insights from mathematical models of infectious 
disease transmission in the hospital may not apply in LTCFs.  
In addition, dynamic transmission models can incorporate patient movement 
dynamics between different institutions, which may be important for the spread 
of infectious diseases. Elderly residents in LTCFs are frequently admitted 
directly from their LTCF into a hospital and then discharged from the hospital 
back to the LTCF9. This process may occur repeatedly and is known as the 
“revolving door syndrome”. 96 Patients might acquire infections or become 
carriers of infectious diseases present in hospitals or in LTCFs, and may then 
transmit them to hospitalised patients during their visit or to other residents 
upon their return to the LTCF. In this scenario, infection control measures in 
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LTCFs alone may fail to decrease the prevalence of infection due to the 
constant re-admission of infected or carrier residents to hospital, coupled with 
high rates of transmission within LTCFs. Infection control measures in hospitals 
could also be hampered by this amplification of transmission through LTCFs.  
Thesis objectives 
The objectives of this thesis were four-fold: 
 First, to review the literature of dynamic transmission modelling of 
infectious diseases in LTCFs; to critically compare the mathematical 
models evaluating interventions against AMR bacteria in the LTCF; and 
to establish a checklist for policy makers to review the quality of 
mathematical models of interventions against AMR bacteria in LTCFs. 
 Second, to link antibiotic susceptibility data to the LTCF registry in 
England in order to determine if patients from which the samples were 
taken were LTCF residents, and use this dataset to compare the 
prevalence of AMR in LTCF samples and in older people living in their 
own homes. 
 Third, to determine the seasonality of UTIs in the UK, in order to 
understand whether this needed to be accounted for in transmission 
models. 
 Fourth, to develop a mathematical model to simulate the transmission of 
E. coli resistant to trimethoprim in the LTCF. 
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Chapter 2 Systematic review of published peer-
reviewed dynamic mathematical models of infectious 
disease transmission set in long-term care facilities 
Published in Infection Control and Hospital Epidemiology.3 
 
Aim 
To review the published peer reviewed literature that described any dynamic 
mathematical models relating to infectious disease transmission in LTCFs, and 
summarise their methods and research themes.  
Introduction 
Chapter 1 introduced the use of mathematical models in explaining infectious 
disease dynamics. One of their main features is that they can explicitly simulate 
the transmission infectious diseases between individuals. Infectious disease 
population dynamic models generally represent changes in infection states (e.g. 
being susceptible to infection, being infected or being infectious).82 Changes 
between these states depend on parameters that can vary according to the 
proportion of the population in each infection state and, therefore, can vary over 
time.  
Table 2-1 defines the main terminology relating to mathematical models. 
Broadly, mathematical models used in infectious disease epidemiology can be 
divided into deterministic and stochastic models. In a deterministic model, the 
output of the model is simply determined by its parameters and, as such, the 
model output remains the same every time the model is run. Stochastic models, 
however, take into account randomness or variations which may occur by 
chance, producing different model outputs every time they are run.82,84  
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Table 2-1. Modelling terms definitions. 
Static model Model in which transmission does not change with the number of 
infected or colonised individuals in the population. Therefore, the 
infectious process does not vary over time. This type of model has 
been applied, for example, to the progression of varicella to herpes 
zoster.
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Dynamic model Model representing a process (infection) that changes over time in 
such a way that the transmission to susceptible individuals is 
dependent on the number of infected or colonised individuals in the 
population. This type of model has been used to study most 
infectious diseases, for example measles.
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Deterministic model  Model in which the output of the model is simply determined by its 
parameters and, as such, the model output remains the same every 
time the model is run. Deterministic models have been used to 
describe infections in large populations, for example pertussis 
resurgence in England and Wales.
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Stochastic model Model that takes into account randomness or variations which occur 
by chance, producing different model outputs every time they are 
run. Stochastic models are more appropriate to simulate diseases 
transmitted within small confined environments, for example, in 
hospital wards
103
, where the effect of randomness becomes more 
important.   
Compartmental 
model 
Model that groups individuals into categories (e.g. infectious 
individuals). All individuals in one category are assigned the same 
set of parameter values. Individuals then transition through infectious 
states as groups. Compartmental models have been used, for 
example, to simulate the transmission dynamics of Ebola.
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Individual-based 
model (IBM) 
Model that follows individuals as separate entities and infection 
states are recorded for each individual.
82,83
 Amongst others, IBMs 
have been used to understand sexually transmitted infections such 
as HPV.
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Model fitting The inference of unknown model parameters.
86
 In frequentist theory, 
this is achieved by obtaining the set of parameters that are most 
likely given the data observed. 
Model validation Comparing the model predictions to a second dataset that has not 
been used for model fitting. 
86
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Dynamic transmission models can also be divided into those that are individual-
based and those that are compartmental. Compartmental models group 
individuals into categories (e.g. infectious individuals). All individuals in one 
category are assigned the same set of parameter values. Individuals then 
transition through infectious states as groups. Individual-based models (IBMs), 
however, model individuals as separate entities and infection states are 
recorded for each individual.82,83  
The choice of mathematical model type should be based on the question the 
researcher is aiming to answer.82 Stochasticity is important when modelling 
processes in small populations in which chance events might interrupt 
transmission but are less important in larger populations. Stochasticity also 
becomes important when attempting to understand the persistence of infection. 
IBMs are more complex and computationally intensive than compartmental 
models. They are appropriate when individual patient characteristics such as 
demographics, medical history, or contact patterns are relevant to the question 
addressed, and where the corresponding data is available to inform them. 
A variety of techniques are available to improve the quality of a mathematical 
model. Ideally, models should be fit against empirical data to make them more 
realistic. This empirical data can include, for example, data concerning the 
incidence or the duration of infection. Model fitting can be achieved through the 
statistical calibration of model parameters.86 In frequentist theory, this is 
achieved by obtaining the set of parameters that are most likely given the data 
observed106. Sensitivity analyses explore the impact of varying parameter 
values on model outputs. This could also encompass the sensitivity of the 
model outputs to assumptions surrounding the biology of the infection and 
transmission, which may impact the model structure. Sensitivity analyses are 
important in order to check for errors in models, to test their robustness, to 
increase our understanding of the underlying dynamics and to determine 
uncertainty in model parameters, structure and, therefore, in the outputs.86 
Validation involves comparing the model output to a second dataset.86  
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Chapter 1 highlighted the potential of mathematical models in studying 
infectious disease dynamics in the LTCF setting. To our knowledge, no 
systematic review of mathematical models of infectious disease transmission in 
LTCFs has been conducted. This chapter describes the peer reviewed dynamic 
mathematical models relating to infectious disease transmission in LTCFs and 
summarises their methods and research themes. This was carried out in order 
to identify research gaps, which in turn helped guide the direction of this thesis, 
and was published in Infection Control and Hospital Epidemiology.3 This search 
was then updated for the thesis submission. 
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Methods 
Database search and abstract screening 
The CINAHL, EMBASE, Global Health, MEDLINE and Scopus databases were 
systematically searched on the 27/12/13 for abstracts and titles that included 
terms relating to  “model” AND “long-term care facility” AND “mathematical” 
(see Appendix Chapter 2). An outline of the review process can be found in 
Figure 2-1. The Scopus search alone bore 5,971 results and, therefore, had to 
be limited thematically to immunology and microbiology, computer science and 
mathematics, which yielded 450 results. Under these criteria, the search 
generated 1,562 results (164 CINAHL, 523 EMBASE, 1 Global Health, 424 
MEDLINE, 450 Scopus). Upon de-duplication, these were reduced to 1,067 
records (88 CINAHL, 481 EMBASE, 1 Global Health, 76 MEDLINE, 421 
Scopus). The abstracts of these 1,067 papers were read. All peer reviewed 
dynamic mathematical models describing infectious disease transmission in 
LTCFs written in English were included. Those describing animal work, 
statistical models and within-host models were discarded. This left 21 papers for 
full text assessment.  
This search was performed again on the 19/02/16. Using the same search 
strategy, the EMBASE search yielded 729 new results, MEDLINE 630, Scopus 
133, CINAHL 13 and Global Health zero. Of these, two further studies were 
included for full text assessment. 
Full-text assessment  
Twenty three papers were read in full text. Studies that did not report 
mathematical models of infectious disease transmission in LTCFs were 
excluded. Studies were only considered to be set in LTCFs if they provided 
accommodation and support for elderly people in their daily activities such as 
washing, dressing and eating. LTCFs included facilities with and without nursing 
care. Rehabilitation centres, long-term acute care facilities and facilities for 
younger users did not meet the eligibility criteria for this study.  
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Only one paper was excluded due to access restrictions107. Two papers were 
excluded because they didn’t include mathematical models108,109, two because 
they were congress abstracts and there was no full text available110,111 and two 
because they didn’t include dynamic transmission models but statistical models 
analysing cost-effectiveness112,113. This left 16 papers114–129. From the 
references of the selected 16 papers, two additional papers were identified that 
fulfilled our criteria130,131 giving a total of 18 papers to review. These were 
categorised according to organism, date, setting, theme and methodology. 
Update of review for thesis submission 
The EMBASE and MEDLINE searches were kept active since the completion of 
this review until thesis submission (October 2017). Nine new papers describing 
infectious disease transmission in LTCFs through mathematical modelling were 
published. 132–140 These are also included in the description below. 
 
Figure 2-1. Flow chart of the review process. One thousand five hundred and sixty two 
records were identified through the CINAHL, EMBASE, Global Health, MEDLINE and Scopus 
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databases. After all duplicates were removed, 1,046 records were excluded through abstract 
screening, seven full-text articles were excluded through full-text assessment, two additional 
papers were identified through reference searching and two more through in an updated search 
on the 19/02/16. Nine papers were identified after the review for thesis submission. Twenty-
seven papers were selected for review.   
44 
 
Results 
Twenty-seven papers describing 22 different models were selected for 
review.114–127,130–140 In the original review carried out in February 2016, 1067 
abstracts were identified for screening and 18 papers that examined 15 different 
dynamic models of infectious disease transmission in LTCFs were selected for 
review. In October 2017, nine further papers had been published on this 
subject. In total, therefore, 27 papers were reviewed. 
Organism 
The most commonly studied micro-organisms were influenza viruses (nine 
papers: five seasonal120,123,125,128,131, three pandemic118,124,130 and one both121) 
and methicillin-resistant Staphylococcus aureus (MRSA) (seven papers114–
117,127,138,139). One of the latter studied both MRSA and methicillin-sensitive 
Staphylococcus aureus (MSSA).139 Of the remaining studies, three focused on 
the transmission of Gram-negative bacteria (two of carbapenem-resistant 
Enterobacteriaceae 132,133 and one of E. coli ST131134), three on 
norovirus126,129,137, two on Clostridium difficile.135,136, and in three cases the 
authors did not specify a bacterial species (two generic non-species-specific 
AMR bacteria119,140 and one generic non-species-specific bacteria in 
healthcare122) (see Figure 2-2). 
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Figure 2-2. Infectious disease modelling in LTCFs: publications per year. CRE, 
carbapenem-resistant Enterobacteriaceae; Bacteria in HC, Bacteria in healthcare; AMR 
bacteria, antimicrobial-resistant bacteria; MRSA, methicillin-resistant Staphylococcus aureus.  
Chronology 
The first models studying infectious disease transmission in LTCFs were 
published in 1993125,131. These were two papers describing the same model. 
For the ten subsequent years there were no publications in this field. Since 
2003 there has been a resurgence of publication in this area. From 2003 until 
2016, the number of papers published remained small, averaging at 1.5 
publications per year. In 2016, eight papers were published on this subject. 
Setting 
Eight papers modelled transmission within LTCFs114,118,120,125,126,137,138,141, nine 
in both LTCFs and hospitals115–117,122,127,129,132,139,140, one in the community, 
hospital and LTCFs (stratified into 5 demographic groups)135, one in the 
community, ICU and LTCFs136, one in the community, LTCFs, long-term acute 
care hospitals and acute care hospitals133, one in a small population (a small 
urban US community)124, one in a medium size population of 800,000 with 
0
1
2
3
4
5
6
7
8
9
1993 1995 1997 1999 2001 2003 2005 2007 2009 2011 2013 2015 2017
N
u
m
b
e
r 
o
f 
p
ap
e
rs
 p
u
b
lis
h
e
d
 
Year of publication 
ID modelling in LTCFs: publications per year 
C. difficile
E. coli
CRE
Norovirus
Bacteria in HC
AMR bacteria
MRSA
Influenza
46 
 
3,000 individuals in hospital and 7,000 in LTCFs134, two in larger populations (a 
country-size population and a USA state-sized population)123,128 and three did 
not define their population size119,130,131. Most papers were either explicitly or 
implicitly (though their choice of parameters) set in the USA (N=11 
115,116,119,124,127,128,132,133,135,138,139) or did not indicate a national setting (N=5 
114,118,122,125,131). Three other studies were set in the Netherlands120,121,140, two in 
France130,137, two in England129,136, one in Belgium126, one in Spain134, and one 
in an unspecified developed country123. One was an international study that 
utilised data from both Canada and the USA117.  
Theme 
Twenty-two papers assessed one or several interventions114,116–118,120–124,126–
128,130,132–140. The most common intervention (evaluated in nine 
papers114,118,122,124,126,130,132,133,135) was the isolation of residents. Other 
commonly studied interventions included decolonisation114,122,127,139, 
screening114,118,127, different types of surveillance systems132,133,135,139, contact 
precautions116,122,132,139, hand hygiene measures137, and prophylactic 
treatment120,123,128,130. Two papers researched the impact of altering patterns 
and rates of patient transfer and lengths of stay114,117 and three others 
investigated vaccination121,128,130. Altering staff to patient ratios and increasing 
staff shifts were each researched in one paper114,118. One study assessed the 
impact of reducing community and LTCF transmission, although the precise 
methods of how this would be achieved were not discussed.135 Other themes 
researched included the role of LTCFs in infectious disease prevalence and 
transmission (in seven papers114–116,119,127,132,133), the impact of patient transfers 
among institutions (in three papers117,127,139), the spread of AMR overall (in two 
papers119,140), theoretical concepts about a particular model (in two 
papers125,131) and modelling methodology for small outbreaks129.  
Methodology 
The majority of these papers (N=19115–118,120–122,124,125,128–133,135–137,139,140) 
described stochastic models whilst four papers described deterministic 
models119,123,126,127, one described a deterministic model with a stochastic 
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component for transmission128 and three described both types114,134,138. Thirteen 
papers described compartmental models114,118,119,122,123,126–129,134,135,137,138 and 
thirteen IBMs115–117,120,121,124,125,130–133,136,139. The three models that were 
repeated in two different papers each were stochastic IBMs. One was a network 
model140. 
Various model structures were described in the papers. One was a modification 
of a susceptible-infectious-recovered (SIR) model127; ten were based on a 
susceptible-infectious-susceptible (SIS) model114–117,119,132,133,138–140; one on a 
susceptible-exposed-infectious (SEI) model124; ten on variants of a susceptible-
exposed-infectious-recovered (SEIR) model118,120,121,123,125,126,128–131, one on a 
SEIS variant134, one on a variation of a PSCIC structure (protected, susceptible, 
colonised, infected, colonised) which included colonised individuals that were 
immune and not immune, one on two different structures: susceptible-colonised 
(SC) and susceptible-colonised-infected-isolated (SCII)122, and one on a UCIRc 
structure (uncolonised, asymptomatically colonised, infected and colonised 
subject to recurrence) that was then modified to include treatment.  
Five models were fit to data using formal statistical inference or emulation 
methods.128,129,134,135,137 One used a chi-squared goodness-of-fit test128, two 
using the least-square criterion 134,137, one used Markov Chain Monte Carlo135, 
and one used a gradient-based optimisation code to find the maximum-
likelihood estimate129. Only four studies validated their findings128,129,134,136. Two 
papers described simple fitting processes for some parameters used in the 
models117,126 and 17 of the 27 papers did carry out sensitivity analyses of the 
parameter sets114,116,120,121,123–125,128–131,133,134,136–139. Of these, five were carried 
out through Latin hypercube sampling120,121,125,136,137. 
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Discussion 
From 2003 until 2015, the number of papers publishing dynamic models of 
infectious disease transmission in LTCFs remained small, averaging at 1.5 
publications per year. However, in 2016, eight papers were published on this 
subject, which could indicate a potential increase in interest in studying 
infectious diseases in this setting. 
Up until February 2016, the scope of the organisms studied in the literature was 
limited to three organisms (norovirus, MRSA and the influenza virus) in addition 
to two more generic organism categories which were not sub-specified further 
(bacteria in healthcare and AMR bacteria). Norovirus, MRSA and the influenza 
virus are organisms that frequently cause infections in LTCFs; however, the 
transmission of other organisms such as Gram-negative bacteria, which also 
very commonly cause infection in this setting, were not studied. UTIs (together 
with respiratory tract infections) are in fact the most common infections in 
LTCFs and they are in their majority caused by Gram-negative bacteria. As 
discussed in Chapter 1, infections caused by Gram-negative bacteria are 
increasingly becoming problematic in hospitals as they are now the most 
frequent cause of bloodstream infections (BSIs), and have been highlighted as 
critical priority pathogens for research and development of new antibiotics by 
the World Health Organization.30 Interventions to prevent their spread are being 
trialled28,142–145. For these reasons policy makers are likely to be interested in 
models of Gram-negative bacteria transmission in LTCFs. The transmission of 
other infections such as Clostridum difficile infection and scabies, common in 
older people, had also not been modelled. From February 2016 to October 
2017, nine new papers describing infectious disease transmission in LTCFs 
through mathematical modelling had been published. 132–140 Three papers 
described the transmission of Gram-negative bacteria (two of carbapenem-
resistant Enterobacteriaceae 132,133 and one of E. coli ST131134) and two of 
Clostridium difficile.135,136 These studies begin to address the abovementioned 
gap in the type of organisms modelled in this setting; however, they focus on 
infections caused by particularly pathogenic Gram-negative bacteria, which may 
not be representative of most infections caused by Gram-negative bacteria 
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observed in LTCFs. The dynamics of Klebsiella colonisation and infection have 
also not been studied to date.  
The means of transmission, the time between infection and infectiousness and 
the duration of infectiousness vary greatly between organisms. As such, the 
infection processes of different organisms may warrant different types of 
mathematical models. The conclusions obtained from modelling the spread of 
one specific organism in the LTCF cannot be meaningfully extrapolated beyond 
this to other organisms without the necessary model adaptations, which could 
range from adjusting the model parameters to a completely new model structure 
and model type. 
Either explicitly or through their choice of parameter set, most studies were set 
in the USA and none were set in developing countries. This distribution may be 
reflective both of the mathematical modelling groups worldwide and of the 
countries in which LTCFs are most common. Eight studies modelled the 
transmission of infectious disease in LTCFs without taking into account other 
facilities such as hospitals or the community. Due to their frailty, LTCF residents 
are known to frequently visit hospitals9 and hospitals may act as an amplifier for 
some infections, particularly for healthcare-associated infections. Therefore, 
including patient hospitalisation may be important to accurately reflect the 
dynamics of transmission of infectious diseases in LTCFs.  
Several interventions were rarely addressed or not studied at all in the studies 
reviewed. Vaccination against influenza was explored; however, vaccination 
against bacterial infections was only explored in one study published in 2016136, 
which sought to quantify the impact of vaccination against C. difficile. This was 
perhaps due to the lack of licenced vaccines to this effect. However, as 
vaccines for infections which are common in LTCFs become closer to being 
licenced and are undergoing phase III clinical trials146–148, and in the face of 
growing antibiotic resistance, it becomes important to analyse the effect of 
vaccines on transmission dynamics in this setting.  
Other important interventions to model in LTCFs relate to antibiotic treatment 
and include antibiotic switching and antibiotic stewardship. The effect of these 
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interventions would have on transmission in the LTCF setting is still not well 
understood. Four studies published in 2016/2017 have aimed to address some 
of these questions. One study assessed the impact of switching between 
antimicrobial drug classes on C. difficile infection135. The authors additionally 
assessed the impact of improving hospital hygiene which had also not been 
previously assessed. 135 Another study investigated the effect of reducing the 
exposure to fluoroquinolones and cephalosporins in the population colonised by 
E. coli ST131 from 5% to 0%134. However, this was considered implausible. A 
further study assessed the impact of antibiotic use in the previous 3 months on 
the epidemic potential of MRSA USA-300 and MRSA non-USA-300. The 
authors did not model the reduction of antibiotic use as an intervention but 
rather compared the epidemic potential with and without previous antibiotic 
use.138  
The majority of these papers (N=19115–118,120–122,124,125,128–133,135–137,139,140) 
described stochastic models. The choice of model type, as mentioned in the 
introduction, should be dependent on the question posed. In the LTCF setting, 
stochasticity is important as these are generally small enclosed environments 
where chance events may become critical. Deterministic models would 
therefore not simulate the infection process accurately. Formal fitting techniques 
improve the reliability of model parameters and therefore, of the conclusions 
drawn from the model. However, only seven of the studies reviewed fit their 
models to data in some form117,126,128,129,134,135,137. In absence of formal model 
fitting, the full uncertainty surrounding the parameters should be presented. 
Sensitivity analyses of the parameter sets were carried out in 17 of the 27 
papers 114,116,120,121,123–125,128–131,133,134,136–139. If possible, models should be 
validated through the use of other available data to allow the generalisability of 
their findings to be ascertained. Only four studies validated their 
findings128,129,134,136. 
The range of organisms studied (and therefore, the range of interventions and 
models developed) complicated an in-depth comparison of the methods. 
Chapter 3 aims to address this by focusing on the models of interventions 
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against AMR bacteria identified in the original review of the literature carried out 
in February 2016.  
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Conclusions 
Few (27) mathematical models have characterised the spread of infectious 
diseases in LTCFs, nine of which were published during the last year. Eight of 
the studies reviewed did not account for the movement of individuals between 
LTCFs and hospitals, which are frequent and may act as an amplifier for some 
infections. The scope of the microorganisms studied is also limited. The 
transmission of Gram-negative bacteria is particularly understudied given the 
commonality of the infections they cause and their increasing public health 
importance.30,31 Future models require more robust methodology. Authors 
should carry out extensive sensitivity analyses and, when possible, employ 
formal fitting techniques to ensure the model accurately represents the data and 
is sufficiently robust to produce sound conclusions. In addition, the effect of 
interventions relating to antibiotic treatment such as antibiotic stewardship on 
the transmission of infections caused by antibiotic-resistant bacteria in the LTCF 
has not been investigated rigorously to date and could provide a valuable 
solution for reducing antibiotic resistance in this setting.  
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Chapter 3  Critical review of mathematical models 
of interventions against antimicrobial resistant bacteria 
in LTCFs and checklist of good quality models for 
policy making. 
Published in Infection Control and Hospital Epidemiology.3 
 
Aims 
1. To critically evaluate models of interventions against antimicrobial 
resistant bacteria in LTCFs. 
2. To develop a checklist for epidemiologists and policy makers to 
distinguish good quality models of AMR in LTCFs. 
Introduction 
As described in Chapter 2, dynamic mathematical models have been useful to 
evaluate the impact of a variety of infection control interventions in hospitals.86 
In particular, many of these models have been used to evaluate interventions 
against AMR bacteria. Dynamic mathematical models allow better interpretation 
of the long-term impact of any intervention that aims to prevent infection by 
resistant bacteria than static models, as transmission and patient movement 
dynamics are complex and their impact on control measures are not intuitive.  
Although mathematical models can be useful in evaluating the impact of 
interventions, conclusions from these models will only be as good as the quality 
of the model from which they are drawn. For example, a mathematical model 
that underestimates the importation of AMR bacteria to the LTCF will likely 
conclude that screening upon admission to the LTCF is an ineffective strategy. 
Similarly, a model parameterised with outdated estimates could lead to 
conclusions that are not relevant to current LTCFs. Therefore, it is important to 
assess the quality of mathematical models published prior to their use in policy-
making. 
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When using mathematical models to inform policy at a local or national level 
there is a growing consensus as to what is desirable in model design, 
parameterisation and reporting.82,149–151 Despite this, there is no practical guide 
summarising best practice for mathematical modelling of interventions against 
AMR bacteria in LTCFs. Infection control specialists and policy makers making 
decisions about infection prevention and control in LTCFs may wish to interpret 
the validity of findings from mathematical models in this setting to guide their 
decision-making. For example, they may wish to implement interventions that 
have been shown to be effective in mathematical modelling studies. In order for 
this type of decisions to be successful, they should be based on high quality 
mathematical models that accurately represent the infection dynamics.  
This chapter will evaluate the quality of the existing models that quantify the 
impact of interventions against AMR in LTCFs and create a practical checklist to 
assess the quality of these models. It is important to develop a particular 
checklist for the LTCF setting. Firstly, LTCFs vary greatly in characteristics such 
as their size, the services they provide, and their case mix.152 Therefore, it 
becomes important to define precisely the type of facility being modelled and 
ensure that all the parameters in the model align with the type of facility being 
studied. In addition, LTCFs have strong links with other institutions such as 
hospitals, such that epidemics in one institution may drive epidemics in another 
or one institution may act as a reservoir for another; hence, it is important to 
model the flow of patients between them. LTCFs are also generally small 
institutions where chance events become important and stochasticity should 
also be included.  
This best practice checklist would also be useful in this thesis to aid the 
development of a mathematical model of transmission of E. coli resistant to 
trimethoprim (presented in Chapter 7). 
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Methods 
In order to facilitate the critical evaluation of models of interventions against 
infectious diseases in LTCFs, this analysis focused on models that assessed 
interventions against similar organisms, in this case AMR bacterial infections as 
these were closer to the subject of this thesis. In Chapter 2, 22 papers were 
identified that assessed one or several interventions against infectious diseases 
in the LTCF setting.114,116–118,120–124,126–128,130 Four of these evaluated 
interventions targeted at resistant bacterial infections.114,116,117,127 One of these 
studies was excluded as it evaluated altering transfer rates between hospital 
and LTCFs. This study was not included in the critical review because altering 
transfer rates between hospital and LTCFs was not considered an intervention 
that could realistically be introduced as hospital transfers from LTCFs may not 
be able to be safely reduced. All three remaining studies assessed interventions 
against MRSA.114,116,127 
These studies were critically evaluated. As criteria to evaluate these types of 
model have not yet been developed, these had to be determined in light of 
growing consensus in the literature to what is desirable in model design, 
parameterisation and reporting82,149–151, as well as expert opinion from AMR 
modellers. The following criteria were applied: Firstly, the reporting itself was 
considered important to enable replicability and the understanding of the study. 
The design should be justified, the aims clearly stated, the importance of the 
question studied made clear, the methodology appropriately described, and the 
assumptions made explicit. Secondly, the research question should determine 
the model structure and model type. This is so that the model is able to answer 
the question posed. Thirdly, the outcome measures used to answer the study 
question should be relevant and measured and valued appropriately to facilitate 
the decisions made by policy makers. Ideally, these should permit the 
comparison between studies; therefore, numerical reporting was considered 
preferable. Finally, the model parameterisation is key. Parameters should be 
taken from current sources and be relevant to the setting so that the model 
yields pertinent results to the setting evaluated, and sensitivity analyses should 
be carried out to determine uncertainty and, therefore, the robustness of the 
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model outputs to the parameter values. Preferably, data should be used for 
formal model fitting or validation. 
Using the criteria obtained from this critical evaluation; a checklist was 
developed that will enable clinicians and other decision-makers to appraise 
mathematical models of AMR in LTCFs. 
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Comparison of model results  
Together, the three studies selected for critical review114,116,127 found four 
interventions to be effective in reducing MRSA prevalence in the LTCF setting: 
screening and decolonisation, hand hygiene, contact precautions and 
increasing the staff to patient ratio. Figure 3-1 describes the interventions 
assessed, how their action was simulated in the model and the results 
observed. A detailed description of each model is provided in Appendix Chapter 
3. Barnes et al.127, aimed to evaluate the impact of screening and 
decolonisation on the equilibrium prevalence of MRSA in the LTCF. Chamchod 
and Ruan114, assessed the conditions under which screening and 
decolonisation, hand hygiene, and increasing the staff to patient ratio eliminated 
the probability of invasion of MRSA. Lee et al.116, sought to assess the impact of 
contact precautions for different sub-groups of LTCF residents on the number of 
acquisitions adverted within six months. 
 
  
5
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Figure 3-1. Assessing the effects of interventions against MRSA in LTCFs through modelling. Three papers have published models of interventions 
against methicillin-resistant Staphyloccocus aureus (MRSA) in long-term care facilities (LTCFs). The models have assessed five types of interventions in this 
setting. Two reduced the probability of transmission, one reduced the prevalence of colonisation and one reduced the contact rate. The results from the 
interventions modelled are shown on the right.  
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The likely outcome of an intervention is determined by the model pathways that 
are targeted by an intervention, the parameters associated with it and the 
assumptions behind it. Screening and decolonisation reduces the prevalence of 
colonisation by moving patients from a colonised state (for Barnes et al.127, both 
persistently colonised and transiently colonised) to a susceptible state 
(uncolonised). The opportunities for transmission are also reduced as the pool 
of infectious individuals is decreased. The other three interventions only prevent 
or decrease the rate of colonisation. In this case, interventions will take longer 
to reduce the prevalence of colonisation if there are frequently patients admitted 
to the LTCF who are colonised on admission. The impact of MRSA 
interventions on a generic susceptible-infected-susceptible (SIS) model 
structure is depicted in Figure 3-2. 
  
 60 
 
 
Figure 3-2. Impact of MRSA interventions on a generic susceptible (S) –colonised (C)-
susceptible (S) model structure in the long-term care facility (LTCF). Whilst hand hygiene, 
increase of staff to patient ratio and contact precaution decrease the rate of colonisation, 
screening and decolonisation interventions reduce the prevalence of colonisation, therefore 
increasing the rate of decolonisation.  
Were the model structures and parameters used realistic? 
Chronology 
The main characteristics of the papers reviewed are summarised in Table 3-1. 
The three models114,116,127 were recently published (2011-2013), however, some 
parameters used by Barnes et al.127 and Chamchod and Ruan114 were based 
on older estimates that may be out-dated. Barnes et al.127 (published in 2011) 
based their parameter estimates on literature from 2004 to 2010 and Chamchod 
and Ruan114 (published in 2012) from 1999 to 2010. Lee et al.116 (published in 
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2013) based their estimates on current sources, using data published from 
2010-2011, with the exception of length of stay, which was the only parameter 
they based on data published before 2010 (2007).  
Table 3-1. Characterisation of the papers that modelled MRSA transmission in LTCFs and 
assessed the impact of one or more interventions. 
IBM: individual-based model 
Model structure and model type 
Chamchod and Ruan’s114 model only involved one LTCF and didn’t take into 
account the “revolving door syndrome” of patient transfer between hospital and 
LTCFs which might be important in driving transmission. Lee et al.’s IBM 
model116 was the most complex, incorporating LTCF, hospital and community 
settings and accounting for stochasticity. Barnes et al.’s model127 was the 
simplest, a deterministic compartmental model. 
The patient flow and transmission structures for the models are represented in 
Figure 3-3 and Figure 3-4, respectively. Patients were assumed to mix 
homogeneously within LTCFs across all models. A particular strength of the 
model developed by Lee et al., was that it used data to parameterise patient 
flow between healthcare facilities, where the other models did not. Barnes et al. 
 Barnes et al. Chamchod and Ruan Lee et al. 
Year 2011 2012 2013 
Deterministic/ 
Stochastic 
Deterministic Both Stochastic  
Compartmental/IBM Compartmental Compartmental IBM 
Formally fit to data? No No No  
Sensitivity analysis? No Yes  Yes, but only 
adherence to 
intervention 
Type  Univariate Univariate 
Formally validated? No No No 
Population setting LTCFs and 
hospitals 
LTCF LTCFs, hospital 
and community 
Country setting USA Not stated Orange County, 
CA, USA 
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differentiated between persistently and transiently colonised individuals. 
Evidence for these different types of colonisation by S. aureus is mixed153. 
Chamchod and Ruan114 and Lee et al.116 distinguished between healthcare 
workers and residents and between residents taking contact precautions and 
residents that did not, respectively, adapting the disease states in their model to 
fit the questions addressed. 
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Figure 3-3. Structures of patient flow. 3a: Patient flow between hospitals (H) and example 
long-term care facilities 1 and 2 (LTCF1 and LTCF2) in the compartmental model of Barnes et 
al.
127
. 3b: Patient flow between example hospital 1 (H1), example hospital 2 (H2), example LTCF 
1 (LTCF1), example LTCF 2 (LTCF2) and the community (sub-classified into those that remain 
for more and less than 365 days) in a representation of Lee et al.’s individual-based model. 
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Figure 3-4. Model transmission structures. 4a: Transitions between uncolonised (U), 
persistently colonised (P) and transiently colonised (T) disease states in Barnes et al.’s 
compartmental model
127
. 4b: Transitions between the uncolonised (U) and colonised (C) 
disease states (for residents) and between the uncontaminated (H) and contaminated (Hc) 
disease states (for healthcare workers) in Chamchod and Ruan’s compartmental model
114
. 4c: 
Representation of transitions between the susceptible with precautions (Sp), susceptible without 
precautions (Sφ), infectious with precautions (Ip) and the infectious without precautions (Iφ) 
disease states in Lee et al.’s individual-based model. 
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Parameter validity, estimation and uncertainty 
Table 3-2 summarises the key parameters used by Barnes et al.127, Chamchod 
and Ruan114 and Lee et al.116. The parameters used by the models, including 
the LTCF size, the transmission rates, the prevalence of colonisation and the 
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duration of colonisation, were very different in different models and often 
involved different units of measurement that did not allow for comparison across 
models (for example, the transmission rates). In addition, many parameter 
estimates were based on expert opinion instead of data. None of the models 
were formally fit to data. Chamchod and Ruan114 carried out univariate 
sensitivity analyses, which added credibility to their findings, whilst Barnes et al. 
did not.127 Lee et al.116 only carried out a sensitivity analysis on the adherence 
to the intervention.  
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Table 3-2. Comparison of key parameters used by Barnes et al. (2011)
154
, Chamchod and 
Ruan (2012)
114
 and Lee et al. (2013)
116
. 
 Barnes et al. (2011) Chamchod and 
Ruan.(2012) 
Lee et al. (2013) 
Size of 
institution 
(number of 
beds) 
300 for hospitals, 100 for 
LTCFs and 20 for hospital 
units 
2000 (LTCF) mean for hospital 
228.6 (SD=120.2) 
and mean for LTCF 
108.6 (SD=58) 
Rate(s) of 
transmission of 
MRSA (per day)  
 
0.15 (low), 0.25 (medium), 
0.35 (high) for hospitals 
and hospital units. 0.05 
(low), 0.075 (medium) and 
0.1 (high) for LTCFs.  
0.015 (resident to 
resident), 0.12 
(healthcare worker to 
resident) and 0.12 
(resident to healthcare 
worker) 
mean for hospital 
0.0099
a
 
(SD=0.0402) and 
mean for LTCFs 
0.000082
a
 
(SD=0.000056)  
MRSA 
colonisation 
prevalence on 
admission 
10% for both facilities 10%  mean for hospital 
6.1% (SD=5.4) and 
mean for LTCF 
26.1% (SD=8.6) 
Duration of 
colonisation 
(days) 
5 for transiently colonised 
and 50 for persistently 
colonised across all 
institution types 
60 and 80 (two 
scenarios)  
1/3 of those 
colonised with 
MRSA had 
indefinite carriage. 
The remaining 2/3 
lost their carriage 
linearly with a half-
life of 6 months. 
a
rate of transmission per person per day (vs. effective contact resulting in transmission, rate 
averaged per day) 
The three studies chose different sizes of LTCFs, ranging from 100127 to 2000 
beds114. However, the average number of beds in care homes registered in 
England by the Care Quality commission (the regulator of health and social care 
in England) on the 01/04/2014 was 37 beds152. Only 1.3% (116) of care homes 
were able to cater for over 100 residents and the largest registered LTCF had 
215 residents. In the USA, the average nursing home size was 106 beds 
(ranging from 2 to 1,389) and the average capacity of residential care 
communities was 38 beds (ranging from 4 to 582)155. A LTCF with 2000 
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residents114 is, therefore, highly implausible in the English and American 
settings. A large LTCF size is likely to reduce the effect of stochasticity, diluting 
the importance of a chance event. For example, an additional infected individual 
entering the LTCF won’t be very important in a large population; however, in a 
small population this could greatly increase the infection prevalence in the 
LTCF. Therefore, a large LTCF size will reduce the probability of a “die out” (in 
this case, the AMR bacteria not being dominant in any individual within the 
LTCF) or rapidly increasing due to a chance event.  
Lee et al.116 referenced their transmission parameter for MRSA in LTCFs as 
belonging from a study of MRSA transmission in LTCFs.156 The origin of the 
transmission parameters in the models published by Barnes et al.127 and 
Chamchod and Ruan114 was unclear. Barnes et al.127 modelled three different 
levels of transmission rates for LTCFs (0.05 (low), 0.075 (medium) and 0.1 
(high)) but did not report the source of these estimates. Chamchod and Ruan114 
reported different transmission rates for resident to resident, healthcare worker 
to resident, and resident to healthcare worker. These were derived from their 
respective probabilities of colonisation, which were referenced as originating 
from two studies157,158, multiplied by the average number of contacts between 
residents and between residents and healthcare workers (estimated as 1 and 8, 
respectively). The two studies referenced were a study of MRSA transmission 
carried out in a hospital158 and a modelling study set in a tertiary care 
hospital157. The later, in turn, based their transmission estimates on the 
literature. Chamchod and Ruan114 assumed the probability of colonisation 
between residents, healthcare worker to resident, and resident to healthcare 
worker was the same (0.015). However, as the average number of contacts 
between residents and healthcare workers was eight times higher than between 
residents, the resulting transmission rates were also eight times higher between 
residents and healthcare workers than between residents. It was unclear how 
the average number of contacts between residents and between residents and 
healthcare workers was estimated.  
Lee et al.116 and Barnes et al.127 assumed that transmission rates for hospitals 
were much higher than those for LTCFs, which is not necessarily the case159. 
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As described above, Lee et al.116 parameterised the transmission rate in LTCFs 
using the results of a study of MRSA transmission in LTCFs.156 They then 
parameterised the hospital transmission coefficient using estimates from a 
previous study that calibrated this parameter so as to obtain 1%, 2% and 3% 
incidence of MRSA in general wards, long-term acute care wards and ICUs, 
respectively. 160 Barnes et al.127, in the same way as for LTCFs, modelled three 
different levels of transmission rates for hospitals and did not report the source 
of these estimates. Barnes et al.127 did not provide a justification for the 
transmission rates in hospitals being higher than in LTCFs. 
Other assumptions, such as that the prevalence of MRSA on admission being 
broadly equal to the population prevalence of MRSA in the USA114,127, 10%161, 
may be incorrect as age is a risk factor for MRSA infection162–165. Older studies 
carried out in USA LTCFs (in 2005 and 2003-2004, respectively) have shown 
double this prevalence (59% and 40%, respectively)166,167. It also may not be 
generalisable across settings. Lee et al. estimated MRSA prevalence in LTCFs 
at 26.1%, which is in line with most of the published literature (21% in Leeds 
(England), 23% in Northern Ireland, 17% in Spain and 22% in Hong Kong 168–
170). The population-weighted mean MRSA percentage in the EU/EEA has 
decreased significantly over the recent years.171 Evidence of this decline in the 
USA is conflicting.172 Timely prevalence estimates of MRSA on admission may 
impact the best interventions to implement in the LTCF. For example, 
underestimating prevalence on admission will underestimate the effectiveness 
of interventions relating to screening on admission. 
Antibiotic prescription was not simulated by any of these models; however, it is 
a main driver of resistance. It increases the risk of colonisation and subsequent 
infection by resistant bacteria.28 Antibiotic treatment in the LTCF setting has 
been shown to be high and associated with MRSA carriage. 173–176 Antibiotic 
stewardship is, therefore, a very important strategy to reduce antibiotic 
resistance and should be one of the main interventions modelled.  
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Were the interventions modelled appropriately? 
Barnes et al.127 and Chamchod and Ruan114 did not clearly report their 
intervention outcomes and their relevance for clinical practice was not easy to 
interpret. Barnes et al.127 reported prevalence at equilibrium (a theoretical state 
of model stability) in numerical and graphical form whilst Chamchod and 
Ruan114 reported prevalence at equilibrium only in graphical form. For this 
reason, it was only possible to derive the threshold at which an intervention 
would eliminate MRSA at equilibrium prevalence or eliminate the probability of 
invasion. Lee et al.116 reported the median percentage decrease in MRSA 
prevalence at equilibrium and, in addition, calculated the acquisitions of MRSA 
adverted under certain adherence conditions, which facilitated the interpretation 
of their findings. 
Overall, Barnes et al.127 and Chamchod and Ruan114 described the assumptions 
related to the interventions they modelled in very little detail. Barnes et al.127 
assumed that, on average, two cycles of five-day “decolonisation” treatments 
were necessary for patients to be successfully decolonised (10 days). After 
these 10 days, therefore, the intervention was assumed to be 100% effective. 
Neither the adherence to this protocol, nor the impact of this assumption on the 
results were reported. Chamchod and Ruan114 merely reported the thresholds 
of decolonisation rate, duration of colonisation and resident to staff ratio 
reduction that were necessary to eliminate the equilibrium of prevalence and the 
probability of invasion. They did not report the effectiveness, adherence or time 
necessary for the interventions to be successful in achieving these thresholds; 
therefore, their validity cannot be judged.  
In contrast, Lee et al.116 assessed the effect of contact precautions in LTCFs 
under three different levels of adherence (25%, 50% and 75%). This allowed 
comparison across a spectrum of scenarios that were realistically 
parameterised when compared to the literature177,178. Their findings were also 
comparable to those from hospital models, suggesting that focusing 
interventions on the small minority of clinically apparent MRSA cases will be 
ineffective179. Therefore, the findings from this study are more robust compared 
to the two other papers.  
 69 
 
Summary and critical evaluation 
The results from the critical appraisal are summarised below in Table 3-3. The 
choice of design was justified in all three papers and the importance of the 
question was made clear in the introductions. Barnes et al.127 and Lee et al.116 
set clearly focused questions and aims for their paper. Barnes et al.127 aimed to 
determine the effect of patient movement between hospitals and LTCFs on 
steady-state prevalence. As a secondary question they studied the 
effectiveness of screening and decolonisation. Lee et al.116 aimed to understand 
if contact precautions in LTCFs reduced MRSA prevalence in LTCFs and 
hospitals. In contrast, Chamchod and Ruan114 set broad objectives, to 
understand the persistence and prevalence of MRSA and possible means of 
control in LTCFs. The evaluation of interventions was purely theoretical and 
derived from the model behaviour a-posteriori.  
Chamchod and Ruan114 did not model the transfer of patients between LTCFs 
and hospitals, failing to include the dynamics of the “revolving door syndrome”. 
Barnes et al.127 did not address stochasticity in their model which could be 
important in in LTCFs as these are generally small contained environments, 
heavily influenced by chance events. 
Chamchod and Ruan114 only presented their outcomes in graphical form which 
made comparison with other studies challenging. Model assumptions governing 
structure and transmission were made explicit but the assumptions behind 
interventions were often not explained nor tested. None of the models were 
formally fit to data, and only Chamchod and Ruan and Lee et al. carried out any 
univariate sensitivity analyses114,116. Most of the parameters in these three 
studies were chosen from the literature. Only Lee et al. 116 used data to 
parameterise their model. Parameters chosen from older literature may be out-
dated. Chamchod and Ruan114 chose an unrealistically large LTCF size114 and 
both Barnes et al.127 and Chamchod and Ruan114 based the prevalence of 
MRSA on admission on the population prevalence of MRSA in the USA. This 
did not take into account that the population likely to be admitted to LTCFs is at 
a higher risk of MRSA carriage due to older age and frailty. Antibiotic treatment 
was also not considered in any of the models.  
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In their current state, none of the models reviewed were deemed of sufficient 
quality to inform policy concerning interventions in LTCFs. Although Lee et al.116 
explicitly described the assumptions behind their intervention and considered 
different levels of adherence; used data to parameterise their model and 
adopted a very complete model structure; they did not formally fit their model 
nor, in absence of this, test the robustness of their parameter estimates through 
sensitivity analyses for anything other than the intervention adherence. In 
addition, the authors did not consider antibiotic treatment and how this could 
impact their predictions. 
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Table 3-3. Critical appraisal of Barnes et al. (2011)
127
, Chamchod and Ruan (2012)
114
 and 
Lee et al. (2013)
116
. 
  Barnes et al. (2011) Chamchod and Ruan 
(2012) 
Lee et al. (2013) 
Was the choice 
of design 
justified? 
Authors chose 
deterministic 
compartmental model 
as an “introductory 
model” on the subject 
Authors chose both 
stochastic and 
deterministic models 
model variations due 
to chance 
Authors chose 
individual based model 
to simulate patient 
movement in complex 
Orange County facility 
network 
Were the 
question and 
aims 
appropriately 
focused and 
clearly stated? 
Specific goal: 
Determine the effect of 
patient movement 
between hospitals and 
LTCFs on steady-state 
prevalence Secondary 
question: Study 
screening and 
decolonisation 
effectiveness. 
Broad goals: What is 
the persistence and 
prevalence of MRSA 
and possible means of 
control in LTCFs? 
 
Specific goal: Can 
contact precautions in 
LTCFs reduce MRSA 
prevalence in LTCFs 
and hospitals? 
Was the 
importance of 
the question 
made clear? 
Yes, in introduction of 
paper. 
Yes, in introduction of 
paper. 
Yes, in introduction of 
paper. 
Was the 
methodology 
appropriately 
described? 
Some confusion about 
terms “hybrid” and 
“agency-based model”  
Clearly described Clearly described 
Was the 
structure of the 
model 
appropriate to 
answer the 
research 
question? 
Yes, authors included 
the transfer between 
hospital and LTCFs 
No, authors did not 
include the transfer 
between hospital and 
LTCFs 
Yes, authors included 
the transfer between 
hospital and LTCFs as 
well as the community. 
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Was the choice 
of model type 
appropriate to 
answer the 
research 
question? 
No, stochasticity 
should be included.  
Yes, stochasticity was 
included.  
Yes, stochasticity was 
included and contact 
precautions were 
explicitly modelled as 
disease states to 
address research 
question. 
Were the 
outcome 
measures used 
to answer the 
study question 
relevant and 
measured and 
valued 
appropriately? 
Yes, steady-state 
prevalence reported. 
Resulting graphs 
included numbers 
which helped 
interpretation 
Yes, prevalence and 
equilibrium prevalence 
are commonly used 
measures. Graphical 
outcomes only with no 
numerical reporting. 
Yes, median % 
decrease in MRSA 
prevalence and MRSA 
acquisitions adverted 
(shown in tables) 
reported.  
Graphical example of 
change in prevalence 
over time provided a 
good additional 
explanation. Numerical 
values also reported. 
Were any 
assumptions 
made explicit? 
The adherence to the 
intervention was not 
addressed. Other 
assumptions were 
made explicit. 
The effectiveness of 
the interventions and 
the adherence to these 
were not addressed. 
Other assumptions 
were made explicit. 
Clearly outlined 
Were data used 
for formal model 
fitting and/or 
validation? 
No No Data from a national 
long-term care 
dataset, 2006-2008 
hospital and LTCF 
surveys, 2007 
California mandatory 
hospital dataset and 
patient screenings 
were used to 
parameterise the 
model but the model 
was not formally fit to 
data 
 73 
 
Were the 
parameters 
appropriate?  
Some parameters 
were chosen from the 
literature 2004 to 2010 
and some by the 
authors. Prevalence 
on admission to the 
LTCF was too low. No 
sensitivity analysis. 
Antibiotic prescription 
was not considered 
Parameters were 
chosen from literature 
1999-2010 (some 
could be out-dated). 
LTCF size was 
unrealistic. Prevalence 
on admission to the 
LTCF was too low. 
Univariate sensitivity 
analysis. Antibiotic 
prescription was not 
considered 
Parameters based on 
data published 2007-
2011 (above). 
Univariate sensitivity 
analysis only on 
adherence to 
intervention. Antibiotic 
prescription was not 
considered 
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What makes a good mathematical model for the evaluation of 
interventions? 
A practical guide in the form of checklist that can be used by infection control 
specialists and policy makers for the appraisal of mathematical models of AMR 
in LTCFs is presented in Table 3-4. Many desirable criteria were identified, 
however, not all of them were considered essential to guide policy making. They 
were divided accordingly into low, medium and high criteria. 
In mathematical modelling studies for the evaluation of interventions where a 
high level of certainty is required from clinicians or policy makers, all high 
importance criteria should be met. Defining the LTCF setting clearly was 
considered a high importance criterion due to the extensive diversity between 
LTCFs in case-mix, size and the care provided.152 Findings from one setting 
may, therefore, not be applicable to other types of LTCFs. To avoid this 
confusion, it was considered important to clearly outline the characteristics of 
the LTCF studied. Modelling the flow of patients between hospital and LTCFs 
was also considered to be of high importance. This is because the prevalence 
of colonisation may be different in these two settings. In this scenario, the flow 
of patients between hospitals and LTCFs could highly influence the prevalence 
of colonisation in the LTCF (and in the hospital), and infection control policies 
that target these flows could be very effective in decreasing the prevalence of 
colonisation. Following the same reasoning, it was also considered highly 
important to test whether the prevalence of colonisation in hospitals and the 
community was different, and if so, account for this in different prevalence of 
colonisation on admission to the LTCF from these two settings. The prevalence 
of colonisation on admission to the LTCF from the community also should be 
based on LTCF data or data for older people population. This is to avoid 
underestimating the prevalence of colonisation on admission to the LTCF, 
which could be higher in this population. Another important criterion was the 
transparency in describing the methodology, including the assumptions 
underlying the interventions, and the sources of the model parameters. This 
was considered essential in order to evaluate their quality. Stochasticity was 
also deemed highly important in LTCFs, as these are generally small institutions 
where chance events become important. Finally, sensitivity analyses were 
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considered essential for models of sufficient quality to test policy, as they 
provide an estimate of uncertainty in the model outputs. 
Parameterisation using data and model fitting is preferable; however, data may 
not available for this purpose. In absence of these data, parameters may be 
sufficiently informed using estimates from current high quality studies which are 
relevant to the model setting, provided a full sensitivity analysis is conducted to 
test the robustness of the model to these parameters (a high importance 
criterion). Country specific data for LTCF size, structure and movement would 
best inform differences between LTCFs in different countries. In absence of this 
data, a clear description of these parameters (a high importance criterion) may 
help avoid the extrapolation of findings from LTCFs that are very different to the 
English setting. Antibiotic prescription is also considered desirable, as it is an 
important driver of AMR; however, data available to inform this are scarce. 
Ideally, the outputs of the study should permit the comparison between studies; 
therefore, numerical reporting was considered preferable, albeit not essential.  
The transmission in hospital is likely to impact the prevalence of colonisation on 
admission to the LTCF. Both processes are dynamic, therefore, modelling both 
the transmission in hospital and LTCFs would be best practice. However, 
parameterising both hospital and LTCF transmission would require multiple data 
sources, which are rarely available. In their absence, numerous assumptions 
based on little evidence would have to be made, which would undermine the 
robustness of the conclusions drawn from the model. In absence of this data, 
parameterising the admission to the LTCF from hospital appropriately (a high 
importance criterion) may be sufficient. Validation is also considered best 
practice; however, secondary datasets in this setting are rare. Finally, when 
possible, novel organism-intervention combinations should be studied to 
expand the existing knowledge in this field.   
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Table 3-4. Checklist for the critical appraisal of mathematical models of AMR bacteria in 
LTCFs. Ideally all high importance criteria should be addressed in a high quality model to permit 
the evaluation of interventions, generate and test hypotheses, and explore long term scenarios 
of AMR transmission and control in LTCFs. For the evaluation of interventions where a high 
level of certainty is required from clinicians or policy makers, all high importance criteria should 
be present in models. In both cases, medium and low importance criteria increase the quality of 
the model. 
Themes of appraisal Importance Checklist questions 
Setting and 
methodology 
  
 High Is the LTCF setting clearly defined? 
 High Is the flow of patients between hospitals 
and LTCFs modelled? 
 High Have sensitivity analyses been 
performed? 
 High Is the methodology employed fully 
described in publication including the 
assumptions underlying the 
interventions? 
 High Has stochasticity been addressed in the 
model? 
 Medium Has the model been fit to data? 
 Medium Have formal fitting techniques (e.g. least 
square criterion, maximum likelihood 
estimation, Markov Chain Monte Carlo) 
been used to fit the model to data? 
 Low Is hospital transmission included? 
 Low Have models been validated using an 
auxiliary dataset (if this is available)? 
Parameters   
 High Is the source of the model parameters 
described? 
 High Is the prevalence of colonisation on 
admission to the LTCF from the 
community based on data specific to 
LTCFs or, in its absence, to the elderly 
population? 
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 High If the prevalence of colonisation in 
hospitals is different to that in the 
community, is the prevalence on 
admission to the LTCF from hospitals 
different to that from the community? 
 Medium Are any parameters based on data rather 
than the literature? 
 Medium If any parameters are based on data, are 
the data relevant to the setting? 
 Medium Have transmission parameters 
appropriate to each setting (e. g. 
healthcare facility, bacteria) been 
employed? OR has model fitting been 
used to estimate transmission parameters 
from available data? OR if none are 
available, has a full sensitivity analysis 
been conducted? 
 Medium If any parameters are based on data, are 
these recent data? 
 Medium Is antibiotic prescription included in the 
model? 
 Medium Has country-specific data been used to 
describe institution size, facility structure 
and patient movement? 
Interventions 
 
  
 Medium Have numeric results of the outcome of 
interventions been made available to 
permit comparison across studies? 
 Low Is the model exploring organism-
intervention combinations that are novel 
(i.e. have not previously been evaluated 
in the LTCF context)? 
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Discussion 
Dynamic mathematical models of AMR bacteria have been used extensively to 
evaluate the impact of infection control interventions in the hospital setting and 
have helped shape current infection control policy in hospitals. 86,87 Antibiotic 
resistance is common in LTCFs66 and interventions for the control and 
prevention of AMR infections are being studied.180–184 In addition, LTCFs and 
hospitals are tightly linked due to frail residents of LTCFs being frequently 
admitted to hospital.9 These transfers could play an important role in the 
transmission of AMR bacteria in hospital (and vice-versa). Mathematical 
modelling has the potential to provide insight into the dynamics of AMR 
infections in LTCFs and the interventions that may be useful to control them. 
Robust models that will guide policymaking in this area are needed to this 
purpose. 
It is challenging to parameterise mathematical models of AMR transmission in 
the LTCF setting. Firstly, these facilities vary considerably in their patient 
populations, number of beds, and in the type of care they provide.152 As such, 
data gathered in one LTCF may not be representative of another.  
In addition, there is little data available for fitting and validation purposes. The 
surveillance systems that have been established in hospitals are not in place in 
LTCFs. In England, LTCF residents are seen either by GPs or in hospital. 
Diagnoses and prescriptions made by GPs may be captured by surveillance 
systems such as The Health Improvement Network (THIN) and the Clinical 
Practice Research Datalink (CPRD). Hospitalisation data (treatment, diagnosis) 
are recorded in the Hospital Episode Statistics (HES) database. Susceptibility 
data from laboratories concerning pathogens extracted from samples obtained 
from LTCF residents by GPs or in hospitals are collected centrally by AmSurv. 
LTCF characteristics such as bed numbers and services provided are 
separately gathered by the Care Quality Commission (CQC). Currently, there is 
no unified database where the infection journey of patients residing in LTCFs 
can be analysed. This hinders the calculation of incidence and prevalence of 
colonisation and infection by AMR bacteria, the rate of antibiotic treatment, and 
the duration of treatment in LTCFs. Patient movement between hospital and 
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LTCFs is also difficult to parameterise. Most of the data quantifying these 
parameters are available from small scale studies which may not be 
representative of the national or regional picture.  
Other parameters such as the antibiotic treatment and resistance in the 
community are more readily available as these can be captured by single data 
sources. 
In addition to the problems specific to the LTCF setting, there are general 
problems with parameterising models of AMR bacteria. Firstly, their rapidly 
changing epidemiology results in parameters quickly becoming outdated. 
Secondly, there is a plethora of organism-antibiotic combinations to be studied 
and each of these will require different parameters to be estimated. Thirdly, the 
interactions between these organisms are poorly understood and may be 
relevant to many of the processes surrounding transmission, including the 
duration of colonisation, the progression of colonisation to infection and the rate 
of transmission. Finally, the interactions between antibiotic prescribing and AMR 
are complex and difficult to simplify in a way that still yields valuable insights. 
This often requires making numerous assumptions, the validity of which can be 
disputed. 
The models assessed above are not considered robust enough to test policy; 
therefore, there is room for improvement in the mathematical modelling of 
interventions against MRSA in LTCFs through mathematical modelling. Since 
this review was conducted, several other publications developed models to this 
aim. Lee et al. (2016) expanded the same model explored in this chapter to 
study the impact of ICU screening for MRSA, contact precautions for MRSA 
carriers and decolonisation for all ICU patients, on the transmission of 
Staphylococcus aureus (MRSA and MSSA). 139 The authors stated fitting 
transmission rates in LTCFs to the target prevalence found in the literature; 
however, they did not describe the methods they used to achieve this. The 
effectiveness of contact precautions and decolonisation was varied in a 
univariate sensitivity analysis. No further model fitting nor sensitivity analyses 
were described. Another study assessed the impact of antibiotic use in the 
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previous 3 months on the epidemic potential of MRSA USA-300 and MRSA 
non-USA-300. However, the authors did not model the reduction of antibiotic 
use as an intervention but rather compared the epidemic potential with and 
without previous antibiotic use.138 According to the checklist proposed above, 
these two models would, therefore, also not be considered appropriate for use 
in policy-making. 
The prevalence of MRSA has been decreasing over the recent years in most 
countries of the EU/EEA.171 In contrast, resistant percentages in gram-negative 
bacteria are now high and increasing and gram-negative bacteria are the most 
frequent cause of bloodstream infections (BSIs) in Europe.171 Therefore, it is 
increasingly becoming important to model interventions against AMR gram-
negative bacteria in LTCFs. 
Since this review was conducted, Lee et al. developed a stochastic IBM of 
carbapenem-resistant Enterobacteriaceae transmission132. The authors used 
their existing stochastic IBM model of facilities in Orange County (California, 
USA) including LTCFs and hospitals 116,139. They assessed the impact of active 
surveillance for CRE when patients arrived from another hospital or LTCF and 
contact precautions/isolation in two scenarios: (a) when a facility acted in 
isolation when it had reached a certain threshold number of CRE cases and (b) 
in a scenario of coordinated regional infection and control when CRE cases 
were observed in a certain threshold number of hospitals. The authors tested 
the sensitivity of their results to assumptions made about the intervention. They 
also calibrated their transmission coefficients to reach a target 25% prevalence 
in LTCFs; however, the target itself and the methods used to achieve this were 
not described further. No formal fitting or sensitivity analyses were described. 
Talaminos et al. (2016) coded a model of ESBL and non-ESBL producing E. 
coli ST131 in a population consisting of households, hospitals, nursing homes 
and the general population. 134 They assessed the impact of two theoretical 
interventions, one that would reduce the acquisition rate by 10%, and one that 
would reduce the exposure to fluoroquinolones and cephalosporins from 5% to 
0%. The authors built both stochastic (hospitals and nursing homes) and 
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deterministic (households and general population) processes into their 
compartmental model. They fit the mean probability of colonisation for each 
compartment of the model to clinical data collected using the least squares 
method. They carried out multivariate sensitivity analysis of the dominant 
parameters and univariate sensitivity analysis of the remaining parameters. The 
authors validated their model, although they did not mention what data was 
used for this. 
Toth et al. (2017) developed a stochastic IBM of carbapenem-resistant 
Enterobacteriaceae transmission set in the community, LTCFs, long-term acute 
care hospitals (LTACHs) and acute care hospitals. 133 The authors assessed 
the impact of active surveillance and enhanced isolation in LTACHs. The 
authors fit the transmission rate and the clinical detection rate to data; however, 
their methods were not explained. The sensitivity of model outputs to starting 
interventions at different time points and to different assumptions regarding 
discharge from LTACHs was explored. 
All three of these studies132–134 modelled the flow of patients between hospital 
and LTCFs and performed some form of sensitivity analysis. Talaminos et al. 
(2016) 134 explored the uncertainty in their model in a more consistent way. 
They also fit two of their parameters to data formally and validated their model. 
Therefore, methodologically, this was the best model; however, the 
interventions assessed were theoretical. A 0% exposure to fluoroquinolones 
and cephalosporins is deemed extremely difficult to implement. The 10% 
reduction in acquisition rate could be achieved by result of an intervention. 
Further work would be needed to establish which intervention would produce 
this reduction and whether it would produce it consistently. 
Future studies should aim to model the transmission of gram-negative bacteria 
in LTCFs using robust methodology. The checklist above has been developed 
to facilitate this task; however, further work is needed for its validation. Further 
research is also needed to gather the data necessary to parameterise these 
models. Chapter 4 describes the data obtained from linking AmSurv, an English 
AMR surveillance tool, to the CQC database of registered LTCFs in the West 
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Midlands, in the aim of parameterising a transmission model of E. coli 
resistance to trimethoprim in LTCFs (presented in Chapter 7).   
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Conclusions 
Three dynamic mathematical models assessing interventions against AMR 
bacterial infections in LTCFs were identified through a systematic review of the 
literature and were critically reviewed in this chapter. All three of these models 
simulated the transmission of MRSA. These models were not considered robust 
enough to test policy. The first study, by Barnes et al.127, aimed to evaluate the 
impact of screening and decolonisation on the equilibrium prevalence of MRSA 
in the LTCF. The authors did not address stochasticity, did not formally fit their 
model to data nor, in absence of this, perform a sensitivity analysis. This study 
also based the prevalence of MRSA on admission on the population prevalence 
of MRSA in the USA. By the authors’ own admission, this was an “introductory 
model” on the subject.127 The second study, by Chamchod and Ruan114, 
addressed screening and decolonisation, hand hygiene, and increasing the staff 
to patient ratio. Chamchod and Ruan114 did not model the transfer of patients 
between LTCFs and hospitals and based the prevalence of MRSA on 
admission on the population prevalence of MRSA in the USA. They did not 
formally fit to data, but carried out univariate sensitivity analyses. In addition, the 
authors also chose an unrealistically large LTCF size. The third model, 
developed by Lee et al.116, sought to assess the impact of contact precautions 
for different sub-groups of LTCF residents on the number of acquisitions 
adverted within six months. The authors developed a mathematical model with 
a very complete model structure, explicitly described their assumptions, and 
considered different levels of adherence to their intervention; however, they did 
not formally fit their model nor test the robustness of their parameter estimates 
through sensitivity analyses for anything other than the intervention adherence. 
Antibiotic treatment was also not considered in any of the models.  
A checklist was developed for the evaluation of mathematical models of 
interventions against antimicrobial resistant bacteria in LTCFs by clinicians or 
policy makers. When a high level of certainty is required, for example, for policy-
making, the following minimum criteria should be met: 
1. The LTCF setting should clearly defined. 
2. The flow of patients between hospital and LTCFs should be modelled. 
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3. If the prevalence of colonisation in hospitals and the community is 
different, this should be accounted for in different prevalence of 
colonisation on admission to the LTCF from these two settings.  
4. The prevalence of colonisation on admission to the LTCF from the 
community should be based on LTCF data or data for the elderly 
population. 
5. There should be transparency in describing the methodology, including 
the assumptions underlying the interventions, and the sources of the 
model parameters.  
6. Stochasticity should be considered. 
7. Sensitivity analyses should be carried out to test the robustness of the 
model outputs to the parameters.  
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Chapter 4  AMR in LTCFs: linking the AmSurv 
dataset to the CQC dataset. 
Aims 
1. To introduce the datasets used for the analysis in subsequent chapters. 
2. To describe the cleaning and linkage methods used. 
3. To describe the main characteristics of the clean dataset. 
4. To outline the key strengths and limitations of the dataset. 
Introduction 
This chapter will describe the characteristics of the dataset used to study the 
epidemiology of antibiotic resistance in urinary tract E. coli and Klebsiella from 
residents of LTCFs for older people and adults aged over 70 living in the 
community. Subsequent chapters will describe the results of the analysis of the 
dataset.  
The previous chapter outlined the problems with parameterising mathematical 
models of AMR bacteria in LTCFs. One particular concern was the lack of data 
available for fitting and validation purposes. One important data source required 
is the incidence of infection by AMR bacteria in LTCFs. This chapter described 
how this need was addressed through the linkage of antibiotic susceptibility 
data with LTCF data. 
Chapter 1 introduced the importance of the problem of AMR in Gram-negative 
bacteria, and the reasons why it is of particular concern in LTCFs. Despite the 
many risk factors for AMR infections present in LTCFs, data on AMR is not 
routinely collected from LTCFs. Therefore, the extent of any problem is 
unknown and there is a lack of coordinated action to address the issue. The 
importance of UTIs is also explained in Chapter 1. UTIs are commonly sampled 
in the LTCF population; therefore, routinely collected urine microbiology 
samples provide an available means to study AMR in Gram-negative urinary 
bacteria. E. coli and Klebsiella, which frequently cause UTIs, were selected for 
analysis because they have recently been highlighted as critical priority 
pathogens for research and development of new antibiotics by the World Health 
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Organization and have also been highlighted as bacteria to monitor for 
resistance in the five year AMR strategy for the UK (2013-2018).30,31 In addition, 
the incidence of BSIs caused by both of these organisms has been increasing 
in England. 35,42,43,185 
AmSurv is an AMR surveillance tool established by the Health Protection 
Agency (now Public Health England) in 2009. It collects antibiotic susceptibility 
testing results from routine microbiology samples sent to participating diagnostic 
laboratories in England from both hospitals and GPs.186 Since December 2012, 
all laboratories in the West Midlands report to AmSurv, making data from this 
region the most complete longitudinal source of AMR surveillance information in 
England, with more than 95% of laboratories currently participating. The West 
Midlands Region (England) comprises a population of 700,000 individuals over 
the age of 70.4 Linking the AmSurv West Midlands susceptibility dataset to the 
registry of LTCFs in England enables the study of the epidemiology of antibiotic 
resistance in urinary tract E. coli and Klebsiella from residents of LTCFs. 
Figure 4-1 illustrates the complexity of the AmSurv database. Specimens can 
be collected from any individual in the population independently of whether they 
reside in LTCFs. Specimens can be collected in a GP practice or in a hospital. 
One patient may have one or more specimens taken. The same patient may 
have a specimen taken at their GP practice and another in hospital, which may 
then be sent to different laboratories for antibiotic susceptibility testing. In these 
laboratories, one patient specimen may culture one or several organisms, which 
are then tested for susceptibility against a panel of antibiotics. Antibiotic panels 
for the same organism vary between laboratories. Figure 4-2 defines some 
terms used throughout this chapter. 
 
  
8
7
 
 
Figure 4-1. Flow diagram showing the complexity of the AmSurv dataset. The black characters are those presenting with symptoms that require a 
sample to be taken. LTCF, long-term care facility; S, sample; GP, general practitioner; Ab, antibiotic; S, susceptible; NS, non-susceptible.  
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Figure 4-2. Definition of specimens, specimen sites, samples and tests.  
Specimens: the sample of bodily fluid/material being collected 
(blood/urine/swab, etc.) 
Specimen sites: the body location from which specimens are 
collected (e.g. blood/upper gastrointestinal tract/urine and kidneys) 
Samples: a unique combination of organism, specimen site, patient, 
date, laboratory (i.e. one organism from a particular body site 
collected from one patient on a particular date and tested in one 
laboratory) 
Tests: antibiotic tests carried out on the samples 
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Methods 
Data extraction from AmSurv 
All antibiotic susceptibility results from all specimens collected from individuals 
over 70 years of age reported from the 15 microbiology laboratories in the West 
Midlands to AmSurv from 01/04/2010 to 31/03/2014 were extracted from the 
server. 
Data linkage of the AmSurv and CQC datasets to determine LTCF 
residence 
To determine which antibiotic susceptibility tests in the AmSurv dataset were 
from individuals that resided in LTCFs; the tests were linked with the Care 
Quality Commission registry of LTCFs. The Care Quality Commission, the 
national regulator of health and social care in England, holds a publicly 
available registry of LTCFs in England.152 Only LTCFs in the West Midlands 
region classified as “care homes” for elderly residents and recorded as active in 
the register from 2011/2012 (797 LTCFs) were included. Care homes, as 
defined by the Care Quality Commission, “offer accommodation and personal 
care for people who may not be able to live independently”.187 Care homes with 
24-hour medical care from qualified nursing staff are referred to as nursing 
LTCFs and care homes without this service as residential LTCFs. LTCF status 
(nursing or residential), bed numbers for the entire LTCF, and LTCF postcodes 
were extracted from this registry. 
Individuals’ full postcodes in the AmSurv database, collected on the request 
form for microbiological investigation, were matched against the full postcodes 
of LTCFs in the Care Quality Commission registry as of April 2014. Samples 
from individuals residing in a postcode that contained a LTCF (LTCF-pc) are 
subsequently referred to as LTCF samples and those with a postcode that did 
not (non-LTCF-pc) are referred to as non-LTCF samples.  
Postcodes may cover several buildings; therefore, LTCF postcodes may also 
include some elderly people who are not LTCF residents. Patient postcodes in 
AmSurv were matched to the postcodes in a dataset obtained from open data 
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held by the ONS that described the number of households per postcodes 188. 
Postcodes containing only communal establishments (CE-pc) in the West 
Midlands were identified.  
Cleaning of the overall dataset 
All cleaning was carried out in R 3·1.189 Figure 4-3 depicts the data cleaning 
process of an example bacterium-antibiotic combination (Klebsiella samples 
tested against trimethoprim).  
The first step involved eliminating spaces in the patient ID, NHS number, 
postcodes and AmSurv sender code fields. Tests with patient postcodes in 
incorrect format (172,999 tests), rows with “unknown” patient IDs (12 tests) and 
duplicated tests incorrectly generated in the data linkage from matching to 
LTCFs in the same LTCF postcode but with different names (36,330 tests) were 
eliminated. 
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Figure 4-3. Flow diagram showing the data cleaning process of an example bacterium-
antibiotic combination: Klebsiella samples tested against Trim (trimethoprim). 
Patient IDs were a composite of NHS number and laboratory codes 
automatically created by AmSurv. Blank patient IDs were replaced with NHS 
numbers. Unique combinations of patient ID, laboratory, date, specimen site 
and organism with more than one postcode were eliminated (753 tests). Each 
sample was associated with a unique sample ID. Sample IDs were created with 
unique combinations of patient ID, laboratory, date, body site where the sample 
was taken, bacterium, and patient postcode. The number of samples per 
laboratory year is described in Table 4-1. Tests from laboratory years where 
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laboratories were just beginning to report were also eliminated (184 tests, 15 
samples). The overall dataset comprised 4,862,357 antibiotic tests (96% of the 
full extract). 
Table 4-1. Number of samples per year submitted to AmSurv by laboratories in the West 
Midlands. The numbers in bold depict samples eliminated during the data cleaning process. 
Laboratory 571200 closed during years 3 and 4. Laboratory 610710 received fewer samples as 
it did not receive community samples. Laboratory 591250 did not receive any samples in year 1. 
Laboratory ID 
N samples 
year 1 
N samples 
year 2 
N samples 
year 3 
N samples 
year 4 
Total N 
samples  
(all years) 
571200 963 733 0 0 1696 
573255 3992 4081 4487 4617 17177 
579070 1833 11858 14818 16244 44753 
587635 12026 9341 16613 17321 55301 
591250 0 2030 2741 2887 7658 
597840 1152 6973 6583 6606 21314 
597955 12580 14061 12167 15065 53873 
610660 4586 4252 6391 7194 22423 
610710 71 62 79 69 281 
610735 12080 11904 12128 12630 48742 
610740 7791 7762 8004 8055 31612 
611985 0 15 5968 14008 19991 
612480 4571 5935 5899 7387 23792 
618530 1 3681 3556 6169 13407 
619000 0 1417 6177 6455 14049 
 
Test results were grouped by susceptibility, where resistant tests were those 
where the bacterium was described by the laboratories as intermediately 
resistant or fully resistant to the antibiotic.  
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Microbiology 
All the NHS clinical microbiology laboratories in the West Midland undertake 
UKAS external accreditation to verify competencies and assure conformity to 
standard methods.190 Laboratory information systems are configured to only 
send significant bacteriuria to PHE and PHE, through the national Standard 
Methods for Investigation for urine specimens, which recommends specific cut-
offs for clinical laboratory processing.191  
These laboratories perform antibiotic susceptibility testing using a variety of 
methods: EUCAST (The European Committee on Antimicrobial Susceptibility 
Testing), BSAC (The British Society for Antimicrobial Chemotherapy) and CLSI 
(Clinical Laboratory and Standards Institute); with a mix of automated 
susceptibility testing (e.g. VITEK, Phoenix) and manual laboratory methods 
(e.g. disc and gradient strip MIC testing (E-test)). All laboratories contributing to 
this dataset participate in the UK National External Quality Assurance Scheme 
(NEQAS). Clinical laboratories most commonly use EUCAST breakpoints, and 
until recently BSAC methodology, but where EUCAST breakpoints are 
unavailable for key antibiotics, laboratories use alternative published 
breakpoints such as the National Committee for Clinical Laboratory Standards 
(NCCLS), and are asked to report their methods to NEQAS when reporting 
specific organism antibiotic susceptibility results. Specifically in the West 
Midlands, in 2012, out of 15 laboratories, seven laboratories used BSAC disc 
diffusion, four used Vitek 2, three used breakpoint methods and one used a 
combination of Vitek 2 and BSAC disc diffusion (depending on if tests were 
performed during normal working hours) to test antibiotic susceptibility.192 
Seven of the eight laboratories using the BSAC method reported using the 
latest breakpoints during the study period. The remaining laboratory used an 
earlier version (version 10). Vitek 2 software uses EUCAST v1.1 (2010) 
breakpoints. During the study, two laboratories switched from using the BSAC 
method to a breakpoint technique.  
The CLSI breakpoints for ceftazidime (one of the four 3GC tested) changed in 
2010 and this change was implemented in automated systems between 2012 
and 2013. In 2012, no laboratories in the West Midlands reported using CLSI 
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breakpoints for this antibiotic. The methods used may have changed from 2012 
to 2014, which is a limitation of the percentage of 3GC reported. However, in 
our dataset, ceftazidime resistance constituted a fraction of what is reported as 
third-generation cephalosporin resistance (33% of 3GCs tests for Klebsiella and 
19% for E. coli) and there was no stepwise increase nor decrease in the 
percentage of urinary E. coli and Klebsiella resistant to cefazidime in any of the 
West Midlands laboratories. In addition, across all laboratories providing 
services to non-teaching hospitals in the region, 50% of urine samples come 
from the community with LTCFs sending samples to their closest laboratory 
rather than having a specific managed contract with one laboratory within the 
region. Bacteria that were either fully resistant or intermediately resistant to a 
particular antibiotic were considered resistant. 
Cleaning of the organism-antibiotic combinations 
Of the overall dataset, 249,567 tests were carried out on urine samples (from 
urine or kidney body sites). National guidelines from Public Health England 
state that urine specimens in older people (>65 years) should only be sent for 
culture if two or more signs of infection are present. Therefore, all urine samples 
were assumed to be submitted due to clinical need and, therefore, were 
indicative of a suspected UTI.49,50 The dataset did not contain sufficient clinical 
information to identify urine samples from catheters or distinguish between UTIs 
and asymptomatic bacteriuria, common in the elderly population, and, in 
particular, amongst those residing in LTCFs.193  
The tests carried out on urine samples were further subdivided by bacterium-
antibiotic combinations. Following the Department of Health’s Five Year 
Antimicrobial Resistance Strategy recommendations31 and expert opinion, E. 
coli and Klebsiella that were tested against key antibiotics were selected for 
analysis (see Table 4-2 and Table 4-3). The resistance of Klebsiella and E. coli 
urine samples to key antibiotic treatments in the community (trimethoprim and 
nitrofurantoin) and markers for important resistance profiles (3GCs (ceftazidime, 
cefpodoxime, cefotaxime, or ceftriaxone), ciprofloxacin, and carbapenems 
(imipenem or meropenem)) were included for full analysis. Trimethoprim and 
nitrofurantoin are recommended as first-line treatments for UTI;194 therefore, 
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resistance to these agents can result in treatment failure, hospitalisation, and 
the subsequent use of antibiotics such as ciprofloxacin or 3GCs that should be 
reserved for the treatment of more serious infections. Although they were not 
included in the drug-bug combinations highlighted by the Chief Medical 
Officer31, the reduction of inappropriate antibiotic prescribing for UTIs in primary 
care is in fact one of the targets of the Quality Premium Scheme developed by 
NHS England for reducing gram-negative BSI44. This involves reducing the 
trimethoprim: nitrofurantoin prescribing ratio by 10% and reducing the number 
of trimethoprim prescriptions in patients aged 70 or older by 10% from 
2015/2016 to 2017/2018.44 
Table 4-2. Panel of antibiotic tests selected for E. coli. 1GC refers to first-generation 
cephalosporins, 2GC refers to second-generation cephalosporins, 3GC refers to third-
generation cephalosporins. 
Final antibiotic groups 
Samples tested to any of the 
subcategory antibiotics (N) 
Samples tested to any of the 
subcategory antibiotics (%) 
Trimethoprim 171434 99.98 
Nitrofurantoin 171130 99.80 
3GC 148607 86.66 
Co-amoxiclav 146833 85.63 
1GC 141020 82.24 
Amoxicillin/Ampicillin 138718 80.90 
Ciprofloxacin 129206 75.35 
Gentamicin 114707 66.89 
Imipenem/Meropenem 69980 40.81 
Piperacillin/Tazobactam 50857 29.66 
2GC 57068 33.28 
Temocillin 47023 27.42 
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Table 4-3. Panel of antibiotic tests selected for Klebsiella. 1GC refers to first-generation 
cephalosporins, 2GC refers to second-generation cephalosporins, 3GC refers to third-
generation cephalosporins. 
Final antibiotic groups 
Samples tested to any of the 
subcategory antibiotics (N) 
Samples tested to any of the 
subcategory antibiotics (%) 
Trimethoprim 19267 99.96 
1GC 16151 83.80 
Ciprofloxacin 15950 82.75 
Co-amoxiclav 15895 82.47 
Gentamicin 15292 79.34 
Nitrofurantoin 14052 72.91 
3GC 13739 71.28 
Imipenem/Meropenem 10624 55.12 
Piperacillin/Tazobactam 9401 48.78 
2GC 8488 44.04 
Temocillin 6845 35.51 
 
The percentage of samples that were tested against a particular antibiotic was 
calculated for each year in each laboratory in the West Midlands. Laboratory 
years in which fewer than 80% of samples were tested against a particular 
antibiotic were excluded from the analysis. This was in order to avoid biases 
surrounding rarely tested antibiotics (for example, temocillin). The final number 
of laboratories included for each bacterium-antibiotic combination are described 
below in Table 4-4. 
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Table 4-4. Number of laboratories included after cleaning per bacterium-antibiotic 
combination. 1GC refers to first-generation cephalosporins, 2GC refers to second-generation 
cephalosporins, 3GC refers to third-generation cephalosporins. 
Organism Antibiotic Laboratories included (N) 
Klebsiella Trimethoprim 15 
 
Nitrofurantoin 14 
 
3GC 12 
 
Co-amoxiclav 14 
 
1GC 13 
 
Ciprofloxacin 11 
 
Gentamicin 12 
 
Imipenem/Meropenem 9 
 
Piperacillin/Tazobactam 9 
 
2GC 7 
 
Temocillin 5 
E. coli Trimethoprim 15 
 
Nitrofurantoin 15 
 
3GC 13 
 
Co-amoxiclav 13 
 
1GC 14 
 
Amoxicillin/Ampicillin 13 
 
Ciprofloxacin 9 
 
Gentamicin 11 
 
Imipenem/Meropenem 6 
 
Piperacillin/Tazobactam 5 
 
2GC 9 
 
Temocillin 4 
 
Samples of the same bacterium-antibiotic combination from the same individual 
within a 28 day period were considered to be the same episode of infection. For 
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each bacterium-antibiotic combination, tests were de-duplicated to one per 
patient per infection period (28 day period) and the most resistant test from 
each individual was chosen from each infection period. When there was more 
than one resistant result from tests carried out on different dates, the first test 
date was selected.  
Figure 4-3 shows the cleaning of the example bacterium-antibiotic combination 
Klebsiella-trimethoprim. In this example, more than 80% of samples were tested 
against trimethoprim in all laboratory years; therefore, no tests were eliminated. 
1,450 Klebsiella tested against trimethoprim were considered duplicates and 
were eliminated. 
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Description of the overall dataset 
There were 15 diagnostic laboratories in the West Midlands region testing 
routine microbiological samples, all of which reported to AmSurv during the 
study period (01/04/2010-31/03/2014). The overall dataset comprised 376,089 
samples from 218,251 patients over 70 years of age. There were 8.6% of 
samples were from individuals residing in 750 LTCF-pc. Prior to de-duplication 
per infection period, the three most common tests were for E. coli (41.8%), 
Staphylococcus (28.7%) and Klebsiella (5.7%). Fifty seven percent of all tests 
were carried out on urine specimens. As shown in Figure 4-4, most E. coli and 
Klebsiella samples (91% and 85%, respectively) were urine samples (from urine 
or kidney body sites). 52% of samples were submitted by GPs and 48% by 
hospitals. 
 100 
 
 
Figure 4-4. Distribution of samples per specimen site. Upper GIT refers to upper gastro-
intestinal tract. The “other” specimen site category includes specimen sites labelled as bones 
and joints, brain and cerebral, cardiac, faeces and lower gut, fluids, genital, lower respiratory 
tract, tips and lines, tissue, upper respiratory tract/mouth/ear, unassigned class, and unknown 
class  
Description of the urine dataset 
There were 144,738 individuals over 70 years of age who had at least one 
positive urine specimen reported to the AmSurv database from any of the 15 
diagnostic microbiology laboratories in the West Midlands region. 9.1% of 
samples were from individuals residing in 741 different LTCF-pc. 62% of 
samples were submitted to laboratories by GPs, whilst 38% were submitted by 
hospitals. As shown in Figure 4-5, the most commonly reported bacterium in the 
dataset was E. coli (57.2% samples). Klebsiella spp. accounted for 6.2% of the 
samples (of which 65% were K. pneumoniae, 19% K. oxytoca, and 15% other 
Klebsiella of undefined species). 
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Figure 4-5. Distribution of urine samples by organism.  
Description of urinary tract E. coli and Klebsiella  
There were 171,475 urine E. coli samples and 19,279 urine Klebsiella samples 
(10% and 7%, respectively) from patients residing in LTCF-pc. The number of 
samples received per laboratory over the four years of the study is depicted in 
Figure 4-6 below. 
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Figure 4-6. Total number of samples per laboratory over the four years of the study. 
Laboratory 571200 closed during years 3 and 4. Laboratory 610710 received fewer samples as 
it did not receive community samples. Laboratory 591250 did not receive any samples in year 1. 
The size of the LTCFs that were matched to urine samples reported to AmSurv 
and the size of LTCFs in the Care Quality Commission registry overall (matched 
and unmatched) was similar (see Table 4-5 below).  
Table 4-5. Number of beds in LTCFs in the Care Quality commission dataset compared to 
those that were matched to urine specimens in the AmSurv dataset. 
  
Care Quality 
Commission 
LTCFs 
AmSurv LTCFs 
Mean number of beds in LTCFs 34.47 36.66 
Median number of beds in LTCFs 31 33 
Range beds in LTCFs 1-171 1-214 
% LTCFs under 20 beds 18 (146/797) 16.2 (120/741) 
% LTCFs under 10 beds 4 (31/797) 2.16 (16/741) 
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The number of samples per patient, the age and the percentage of samples 
sent by GPs (vs. hospitals) did not vary greatly across different bacterium-
antibiotic combinations (see Table 4-6 and Table 4-7). The percentage of 
samples from individuals residing in LTCF-pc varied from 5-10%. The number 
of samples per bed is shown in Table 4-8. 
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Table 4-6. Main characteristics of each bacterium-antibiotic combination. 1GC refers to first-generation cephalosporins, 2GC refers to second-generation 
cephalosporins, 3GC refers to third-generation cephalosporins. 
Organism Antibiotic N samples/ 
tests 
N patients  N samples per patient (mean, 
median, min, max) 
Patient age  
(mean, median, min, max) 
N postcodes 
Klebsiella Trimethoprim  
17844 13245 1.35 1 1 16 81.23 81 70 106 10458 
  Nitrofurantoin 
12159 9002 1.35 1 1 16 81.31 81 70 105 7300 
  3GC 
11593 8777 1.32 1 1 13 81.12 81 70 106 7059 
  Co-amoxiclav 
14360 10755 1.34 1 1 16 81.25 81 70 106 8500 
  1GC 
14436 10844 1.33 1 1 16 81.26 81 70 106 8625 
  Ciprofloxacin 
13738 10262 1.34 1 1 16 81.18 81 70 106 8138 
  Gentamicin 
13003 9787 1.33 1 1 16 81.13 81 70 106 7852 
  Imipenem/ 
Meropenem 8397 6368 1.32 1 1 12 81.09 81 70 106 5089 
  Piperacillin/ 
Tazobactam 7542 5795 1.3 1 1 11 81.12 81 70 103 4685 
  2GC 
7384 5657 1.31 1 1 12 81.07 81 70 106 4528 
  Temocillin 
6314 4820 1.31 1 1 12 81 81 70 106 3806 
E. coli Trimethoprim  
158764 96340 1.65 1 1 27 81.15 81 70 113 47742 
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Organism Antibiotic N samples/ 
tests 
N patients  N samples per patient (mean, 
median, min, max) 
Patient age  
(mean, median, min, max) 
N postcodes 
  Nitrofurantoin 
158501 96211 1.65 1 1 27 81.15 81 70 113 47705 
 E. coli 3GC 
134957 82146 1.64 1 1 27 81.2 81 70 113 41967 
  Co-amoxiclav 
128842 79307 1.62 1 1 27 81.14 81 70 113 39472 
  1GC 
126190 78984 1.6 1 1 27 81.15 81 70 113 40200 
  Amoxicillin/ 
Ampicillin 126897 80365 1.58 1 1 27 81.13 81 70 113 40854 
  Ciprofloxacin 
111220 66540 1.67 1 1 27 81.06 81 70 113 32813 
  Gentamicin 
99410 63876 1.56 1 1 27 81.07 81 70 113 33754 
  Imipenem/ 
Meropenem 50718 33240 1.53 1 1 27 80.94 80 70 113 17110 
  Piperacillin/ 
Tazobactam 35648 24912 1.43 1 1 15 80.91 80 70 113 14211 
  2GC 
51386 33637 1.53 1 1 27 81.12 81 70 113 17981 
  Temocillin 
43348 28147 1.54 1 1 26 81 80 70 113 14155 
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Table 4-7. LTCF characteristics of each bacterium-antibiotic combination. 
Organism Antibiotic N LTCFs % samples/tests from 
LTCFs 
% samples sent 
from GPs  (vs. 
hospitals) 
% LTCF samples 
sent from GPs (vs. 
hospitals) 
% non-LTCF 
samples sent from 
GPs (vs. hospitals) 
Klebsiella Trimethoprim  383 7 63.8 77.1 62.8 
  Nitrofurantoin 285 8 64.3 77.7 63.2 
  3GC 257 7 61.6 74.3 60.7 
  Co-amoxiclav 315 7 63.9 76.3 63 
  1GC 335 7 64 76.1 63.1 
  Ciprofloxacin 285 7 62.4 75.2 61.5 
  Gentamicin 269 6 62.5 75.1 61.6 
  Imipenem/ 
Meropenem 
170 6 60.8 70.6 60.2 
  Piperacillin/ 
Tazobactam 
163 6 59.8 69.7 59.2 
  2GC 150 6 61.6 71.8 60.9 
  Temocillin 111 5 62.6 73.7 62 
E. coli Trimethoprim  715 10 67.3 75.2 66.4 
  Nitrofurantoin 715 10 67.3 75.3 66.4 
  3GC 673 10 67.3 74.9 66.4 
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Organism Antibiotic N LTCFs % samples/tests from 
LTCFs 
% samples sent 
from GPs  (vs. 
hospitals) 
% LTCF samples 
sent from GPs (vs. 
hospitals) 
% non-LTCF 
samples sent from 
GPs (vs. hospitals) 
  Co-amoxiclav 626 10 67.2 75.1 66.3 
E. coli 1GC 670 10 67 75.7 66 
  Amoxicillin/ 
Ampicillin 
645 10 68.2 76.1 67.4 
  Ciprofloxacin 464 9 66.3 74.2 65.5 
  Gentamicin 548 9 66.9 72.7 66.3 
  Imipenem/ 
Meropenem 
273 8 66.8 72 66.4 
  Piperacillin/ 
Tazobactam 
237 8 66 70.9 65.6 
  2GC 382 9 66.8 73 66.2 
  Temocillin 185 8 67.9 73.7 67.4 
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Table 4-8. Number of samples per bed in LTCFs 
Organism Antibiotic N LTCFs Number of samples per bed in LTCFs (mean, median, min, max) 
Klebsiella Trimethoprim  383 
0.1 0.06 0.01 2 
  Nitrofurantoin 285 
0.1 0.06 0.01 2 
  3GC 257 
0.09 0.05 0.01 0.88 
  Co-amoxiclav 315 
0.1 0.06 0.01 2 
  1GC 335 
0.09 0.06 0.01 2 
  Ciprofloxacin 285 
0.09 0.06 0.01 0.88 
  Gentamicin 269 
0.09 0.06 0.01 0.88 
  Imipenem/Meropenem 170 
0.09 0.05 0.01 0.88 
  Piperacillin/Tazobactam 163 
0.08 0.05 0.01 0.88 
  2GC 150 
0.09 0.05 0.01 0.88 
  Temocillin 111 
0.09 0.05 0.01 0.88 
E. coli Trimethoprim  715 
0.68 0.48 0.02 7.33 
  Nitrofurantoin 715 
0.68 0.48 0.02 7.33 
  3GC 673 
0.61 0.38 0.01 7.33 
  Co-amoxiclav 626 
0.64 0.43 0.01 7.33 
  1GC 670 
0.59 0.36 0.02 7.33 
  
1
0
9
 
Organism Antibiotic N LTCFs Number of samples per bed in LTCFs (mean, median, min, max) 
  Amoxicillin/Ampicillin 645 
0.6 0.4 0.02 7.33 
 E. coli Ciprofloxacin 464 
0.68 0.5 0.01 6 
  Gentamicin 548 
0.48 0.3 0.01 6 
  Imipenem/Meropenem 273 
0.48 0.25 0.01 6 
  Piperacillin/Tazobactam 237 
0.39 0.25 0.01 6 
  2GC 382 
0.37 0.18 0.01 6 
  Temocillin 185 
0.59 0.35 0.01 6 
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The distribution of Klebsiella species per antibiotic tested is described in Table 
4-9. 
Table 4-9. Distribution of Klebsiella samples tested by species for each antibiotic 
selected. 1GC refers to first-generation cephalosporins, 2GC refers to second-generation 
cephalosporins, 3GC refers to third-generation cephalosporins. 
Organism Antibiotic % K. 
pneumoniae 
% K. 
oxytoca 
% other Klebsiella 
spp. 
Klebsiella Trimethoprim  64.2 18.8 14 
  Nitrofurantoin 58.5 18.6 20 
  3GC 70 19.5 7.1 
  Co-amoxiclav 66.4 18.7 12.4 
  1GC 64.1 18.6 14.8 
  Ciprofloxacin 62.1 17 17.8 
  Gentamicin 64.1 17 15.9 
  Imipenem/Meropenem 76.4 19.5 1.1 
  Piperacillin/Tazobactam 76.3 19.8 1 
  2GC 76.4 19.4 1.1 
  Temocillin 76.8 19.2 1.2 
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Table 4-10 shows the distribution of 1GCs, 2GCs, 3GCs, imipenem/meropenem 
tested against E. coli and Klebsiella and amoxicillin/ampicillin tested against E. 
coli. 
Table 4-10. Distribution of antibiotics tested against E. coli and Klebsiella where the 
precise antibiotic was not specified. 1GC refers to first-generation cephalosporins, 2GC 
refers to second-generation cephalosporins, 3GC refers to third-generation cephalosporins. 
Organism Antibiotic Antibiotics tested 
Klebsiella 1GC Cephalexin (99.9%), Cephalothin (0.08%)  
 3GC Cefpodoxime (35.3%), Ceftazidime (32.8%), 
Cefotaxime (31.8%), Ceftriaxone (0.02%)  
  2GC Cefuroxime (100%) 
  Imipenem/Meropenem Meropenem (98.6%), Imipenem (1.4%) 
E. coli 1GC Cephalexin (99.96%), Cephalothin (0.04%) 
 2GC Cefuroxime (100%) 
  3GC Cefpodoxime (62.8%), Ceftazidime (18.7%), 
Cefotaxime (18.5%), Ceftriaxone (0.007%) 
  Imipenem/Meropenem Meropenem (99.99%), Imipenem (0.006%) 
  Amoxicillin/Ampicillin Amoxicillin (38.4%), Ampicillin (33%), 
Ampicillin/amoxicillin (28.5%)  
 
Table 4-11 describes the characteristics of E. coli and Klebsiella in LTCF 
samples and non-LTCF samples. LTCF samples were more frequently reported 
from very elderly age groups (>85) than non-LTCF samples. Overall, most 
samples were from female residents. This difference in gender was greater for 
LTCF samples than for non-LTCF samples. Slightly more LTCF samples were 
from residential LTCFs than nursing LTCFs. The number of samples increased 
during the study period. LTCF samples (and non-LTCF samples) comprised 
samples both sent by GPs and hospitals (e.g. during a LTCF resident’s hospital 
stay). LTCF samples were more frequently sent by GPs (versus hospitals) than 
non-LTCF samples. 
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Table 4-11. Characteristics of urine E. coli and Klebsiella positive samples.  
  LTCF  
E. coli  
samples 
(N=17,022)  
N(%) 
Non-LTCF  
E. coli 
samples 
(N=154,453) 
N(%) 
LTCF 
Klebsiella 
samples 
(N=1,510)  
N(%) 
Non-LTCF 
Klebsiella 
samples 
(N=21,262)  
N(%) 
Age 
Age 70-74 807  
(4.7%) 
34,984 
(22.7%) 
91  
(6.0%) 
4,621  
(21.7%) 
Age 75-80  2,038  
(12.0%) 
45,300 
(29.3%) 
222  
(14.7%) 
6,445  
(30.3%) 
Age 81-85 3,573  
(21.0%) 
35,178 
(22.8%) 
308  
(20.4%) 
5,034  
(23.7%) 
Age >85 10,604  
(62.3%) 
38,991 
(25.2%) 
889  
(58.9%) 
5,162  
(24.3%) 
Gender 
Female 14,406  
(85.0%) 
124,547 
(80.7%) 
1,080  
(71.8%) 
13,150  
(61.9%) 
Male  2,545  
(15.0%) 
29,753 
(19.3%) 
425  
(28.2%) 
8,094  
(38.1%) 
LTCF 
type 
Residential  10,139  
(59.6%) 
N/A 823  
(54.5%) 
N/A 
Nursing  6,883  
(40.4%) 
N/A 687  
(45.5%) 
N/A 
Year of 
study 
Year 1  2,541  
(14.9%) 
25,220 
(16.3%) 
247  
(16.4%) 
3,615  
(17.0%) 
Year 2  3,958  
(23.3%) 
33,396 
(21.6%) 
337 ( 
22.3%) 
4,926  
(23.2%) 
Year 3  4,911  
(28.8%) 
43,784 
(28.4%) 
414  
(27.4%) 
6,007  
(28.3%) 
Year 4  5,612  
(33.0%) 
52,053 
(33.7%) 
512  
(33.9%) 
6,714  
(31.6%) 
Sender 
GP  12,571  
(74.1%) 
99,727 
(64.9%) 
1,033  
(68.5%) 
11,369  
(53.5%) 
Hospital  4,396  
(25.9%) 
54,011 
(35.1%) 
475  
(31.5%) 
9,872  
(46.5%) 
 
In order to assess the quality of LTCF matching by postcode, the household 
size per postcode using data from the Office for National Statistics (ONS) that 
 113 
 
described the number of households per postcodes was analysed. Of the ONS 
postcodes that matched a LTCF in our dataset, the number of households in the 
postcode ranged from 0 to 91 (mean=19.2, median=16) (see Figure 4-7). Zero 
household postcodes were those classed by the ONS as “communal 
establishment only”. They are used in the subsequent chapter (Chapter 5) as a 
sensitivity analysis for inferring LTCF residence from patient postcodes. 
 
Figure 4-7. Distribution of household size of LTCF postcodes that matched ONS 
postcodes. Zero household postcodes were those that contained only communal 
establishments.  
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Discussion 
AmSurv is a complex surveillance dataset comprising susceptibility tests carried 
out on specimens sent to participating laboratories in England. The subset of 
AmSurv analysed in this thesis includes only specimens taken from individuals 
aged 70 or older residing, and sent to laboratories, in the West Midlands. Most 
E. coli and Klebsiella samples (91% and 85%, respectively) were urine samples 
(from urine or kidney body sites). Conversely, of all urine samples, the most 
commonly reported bacterium was E. coli (57.2% samples, N=171,475), and 
Klebsiella accounted for 6.2% of samples (N=19,279).  
The size of LTCFs for older people in the West Midlands registered in the CQC 
dataset varied greatly, ranging from 1 to 171 beds (mean=34.47 beds). These 
comprised both nursing and residential LTCFs.  
The initial descriptive analysis of the AmSurv dataset revealed differences in 
age, sex, and sender (GP vs. hospital) when comparing LTCF to non-LTCF 
samples. Most samples were taken from females, which is in line with the 
literature which suggests that females are at a higher risk of developing UTIs36.  
In addition, a higher proportion of the female population over 65 years of age 
resides in LTCFs (4.2% in 2011) compared to males (1.9% in 2011).195 This 
also explains that the difference in gender was greater for LTCF samples than 
for non-LTCF samples. LTCF samples were more frequently reported from very 
elderly age groups (>85) than non-LTCF samples. This could be due to a higher 
proportion of the eldest population being female, and a higher proportion of the 
eldest population living in LTCFs.195 
LTCF samples (and non-LTCF samples) comprised samples both sent by GPs 
and hospitals (e.g. during a LTCF resident’s hospital stay). LTCF samples were 
more frequently sent by GPs (versus hospitals) than non-LTCF samples. In 
addition, the number of samples increased during the study period, which was 
only to a small extent reflective of the increase in the 70+ population in the West 
Midlands during that period. Crudely, LTCF E. coli samples increased by 
120.9%, non-LTCF E. coli samples increased by 106.4%, LTCF Klebsiella 
samples increased by 107.3%, and non-LTCF Klebsiella samples increased by 
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85.7% from the first year of the study (2010/2011) to the last year of the study 
(2013/2014). In contrast, the 70+ population in the West Midlands increased by 
8.2% from 2010 to 2014. 
This increase is analysed in more detail in Chapter 6. The differences in age, 
sex, year of study and sender were taken into account when determining 
differences in AMR for samples from LTCF/non-LTCF residents (Chapter 5).  
The major strengths of this dataset are, firstly, that since 2012, all 15 
laboratories in the West Midlands report to AmSurv, making data from this 
region the most complete source of AMR data and providing insight into the 
burden and temporal changes of AMR within a defined population. Secondly, 
matching patient postcodes to LTCF postcodes registered by the national 
regulator of health and social care in England has allowed the development of 
unprecedented knowledge of AMR in this setting over four years. Thirdly, the 
AmSurv surveillance system collects routine diagnostic samples from both 
community and hospital settings, permitting a fuller understanding of AMR in the 
population than other surveillance systems such as the mandatory surveillance 
for BSIs.  
There were, however, a number of limitations associated with using a large 
surveillance dataset. Firstly, the dataset did not contain sufficient clinical 
information to identify urine samples from catheters or distinguish between UTIs 
and asymptomatic bacteriuria, common in the elderly population in particular 
amongst those residing in LTCFs.193 However, clinical guidelines emphasise 
that only urinary samples from patients with a clinically suspected UTI, and 
either a risk factor for resistance or a history of UTIs should be sent for 
laboratory testing, and that catheter samples should not be sent.196,197 This 
dataset only included urine specimens positive for bacterial growth. Separately, 
there is evidence for variation in the rate of submission of community samples 
from GPs to laboratories.198 This is an unquantified potential confounder; 
however, this variation should be less pronounced in older populations, as 
English national guidance advocates sampling all patients over 65 years old 
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with two or more signs of UTI.199 Sampling may be biased towards those failing 
to respond to treatment, which could increase the apparent risk of resistance.  
Another limitation is that the threshold to diagnose UTIs might be lower in 
LTCFs as staff might notice UTI symptoms earlier than would otherwise be 
detected in individuals living in their own homes. Also, cognitive impairment was 
not recorded. Therefore, the analysis could not take into account differences in 
this condition in the two populations, which may lower the diagnosis threshold 
due to the inability of patients to verbalise symptoms. A recent report by the 
Alzheimer’s society showed that the prevalence of dementia was 73% in 
nursing home residents and 57.9% in residential homes.200 In the CQC dataset 
used for matching by postcode to the AmSurv dataset, 64.7% (516/797) LTCFs 
were classified as “Dementia service user band”, indicating they provided care 
to patients suffering with dementia. These difficulties in diagnosing UTIs could 
lead to more samples being sent. 
The study also is limited by the in vitro measurement of resistance, which does 
not always equate to clinical failure. It should also be noted that different 
breakpoints for ceftazidime (one of the four 3GC tested) and co-amoxiclav may 
have been used during the time period. This is described in more detail in the 
subsequent chapter.  
In addition, susceptibility to carbapenems were only tested routinely in very few 
laboratories, giving a less precise estimate of resistance for the bacteria 
causing these infections (nine laboratories were included in the analysis of 
Klebsiella resistance to imipenem/meropenem and six in the analysis of E. coli 
resistance to imipenem/meropenem). A recent study found that 
carbapenemase-producing Enterobacteriaceae increased in the West Midlands 
from 2009 to 2014.201 
A 28 day infection period was used to de-duplicate repeat specimens taken for 
the same infection. This was to prevent repeated samples from the same UTI 
period to be incorrectly interpreted as recurrences, whilst still capturing true UTI 
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recurrences. The 28 day estimate was based on expert opinion and could also 
be subject to error.  
The prevalence of resistance to rarely tested antibiotics is likely to be high and 
not representative of the real prevalence of resistance, as these tests are likely 
to be carried out after treatment failure. In order to avoid this bias, the laboratory 
years in which less than 80% of samples were tested against a particular 
antibiotic were excluded from the analysis. This was also informed by expert 
opinion and subject to error. 
We inferred LTCF residence from patient postcodes. While the methodology 
presented has been employed previously in other studies 9,69 , it does introduce 
a risk of bias. Whilst those living in non-LTCF postcodes are highly unlikely to 
be LTCF residents, a proportion of those living in LTCF postcodes will live in the 
community in neighbouring households. This means that the prevalence of 
resistance for LTCFs is likely to be slightly underestimated. To address this, as 
described in the subsequent chapter, a sensitivity analysis was carried out 
using the more specific postcodes that contained only communal 
establishments (the 64 postcodes that contained zero households in the first bar 
of Figure 4-7).  
The CLSI breakpoints for ceftazidime (one of the four 3GC tested) changed in 
2010 and this change was implemented in automated systems between 2012 
and 2013, which could have influenced the trend in antibiotic resistance for 
3GCs in this study. However, this did not appear to be the case. This is 
discussed in more detail in the methods section. In addition, some laboratories 
used the systemic rather than UTI breakpoint guidelines for co-amoxiclav, which 
resulted in an increase in the percentage of resistant samples between mid-
2011 and early 2012.  
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Conclusions 
This is the first study to link the West Midlands AmSurv dataset to the CQC 
register of LTCFs in England. The subset of AmSurv analysed included all 
antibiotic tests carried out in laboratories in the West Midlands on routinely 
collected microbiological specimens taken from individuals aged 70 or older by 
GPs or in hospitals from April 2010 to March 2014, providing susceptibility data 
from a population of 700,000 individuals over the age of 70. Of all urine 
samples, the most commonly reported bacterium was E. coli (57.2% samples, 
N=171,475), and Klebsiella accounted for 6.2% of samples (N=19,279). LTCF 
samples were more frequently reported from very elderly age groups (>85), 
from females, and were more frequently sent by GPs (versus hospitals) than 
non-LTCF samples. The number of samples reported also increased during the 
study period. There are a number of limitations of this dataset, such as a lack of 
clinical information available from patients from which samples were taken (for 
example, symptoms, catheterisation, and cognitive impairment were not 
recorded). LTCF residence was also inferred from patient postcode, which will 
have over-estimated the number of individuals assumed to reside in LTCFs. In 
addition, sampling may be biased towards those failing to respond to treatment, 
which could increase the apparent risk of resistance. However, this dataset also 
is the first to provide insight into the burden and temporal changes of AMR in 
LTCFs in England within a large population.  
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Chapter 5  Impact of LTCF residence on the 
antibiotic resistance of urinary tract E. coli and 
Klebsiella 
Published in the Journal of Antimicrobial Chemotherapy.2  
Aim 
To compare the frequency of antibiotic resistance in urinary tract bacteria from 
residents of LTCFs for older people and adults aged over 70 or older living in 
the community.  
Introduction 
As explained in Chapter 1, the AMR of urinary tract bacteria is thought to be an 
important problem in the LTCF setting. Due to their frailty and frequent co-
morbidities, LTCF residents are at increased risk of infection and hospitalisation 
compared to elderly individuals living in their own homes.7–10 In addition, LTCFs 
provide opportunities for the transmission of infectious diseases through the 
sharing of objects and spaces. Infection control in these facilities is also 
challenging due to the poor coordination of medical care.62 Due to the frequency 
of infection in LTCF residents, these individuals may be frequently exposed to 
antibiotics, which may select for antibiotic resistant strains. UTIs are common in 
older people, particularly in those residing in LTCFs, where they are the joint 
most common type of infection together with RTI. UTIs are frequently caused by 
Gram-negative bacteria such as E. coli and Klebsiella. AMR E. coli and 
Klebsiella have been identified as organisms of particular public health concern 
by the WHO and the Chief Medical Officer for England.30,31  
In spite of this, AMR infections are not routinely surveyed in LTCFs. Little is 
known about the antibiotic susceptibility of bacterial isolates from LTCF 
residents in England due to the difficulty in identifying these individuals in 
healthcare data in general and in AMR data in particular. This chapter aims to 
compare the frequency of antibiotic resistance in urinary tract bacteria from 
residents of LTCFs for older people and elderly adults living in the community.  
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As highlighted in Chapter 1, only one study analysed the prevalence of carriage 
of antibiotic resistant Gram-negative bacteria in LTCFs in England. This study 
found a high prevalence of carriage of ESBL-producing E. coli in a LTCF of 105 
beds in Cambridgeshire during 2014.67 Other studies set in other countries have 
also found a high prevalence of colonisation with AMR Gram-negative bacteria 
in LTCFs. 70–74  
In addition, several small studies have aimed to compare the prevalence of 
AMR in urinary isolates in individuals residing in LTCFs and in older people 
living in their own homes in Ireland (2132 urine isolates), Norway (3786 urine 
isolates), Australia (4262 urine isolates) and Scotland (45 isolates), using either 
GP or hospital data, but not both.75–78 This comparison has not been made 
using both types of samples, in a large population, nor in England, where 
resistance patterns in LTCFs could be different. 
Chapter 4 outlined the characteristics of the West Midlands AmSurv dataset 
that was linked to the CQC dataset to address this problem. LTCF samples 
were more commonly reported from older age groups and females, and more 
often sent by GPs (vs. hospitals) compared to non-LTCF samples. In addition, 
the number of E. coli and Klebsiella samples sent to AmSurv appeared to 
increase by year of the study. These variables were, therefore, included as co-
variates when comparing AMR in LTCF and non-LTCF samples.  
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Methods 
The dataset used for analysis in this chapter is introduced in Chapter 4. The 
West Midlands AmSurv dataset, which included all antibiotic tests carried out in 
laboratories in the West Midlands on routinely collected microbiological 
specimens taken from individuals aged 70 or older by GPs or in hospitals from 
April 2010 to March 2014, was linked to the CQC register of LTCFs in England 
in order to determine if patients from which the samples were taken were LTCF 
residents. Urine samples positive for E. coli and Klebsiella were selected for 
subsequent analysis in this chapter. 
Crude rate comparisons 
Positive urinary tract bacterial cultures with E. coli and Klebsiella reported to 
AmSurv were used as a surrogate for E. coli and Klebsiella UTI, as urinary tract 
specimens should only be sent to the microbiology laboratory when there is a 
clinical suspicion of a UTI.49,50 E. coli and Klebsiella samples were grouped as 
these were the most common Gram-negative bacteria with similar antibiotic 
treatment. Samples containing Proteus species were not included as these 
bacteria are known to be intrinsically resistant to nitrofurantoin.202 The rates of 
E. coli and Klebsiella UTI in LTCF-pc and in non-LTCF-pc were calculated as 
follows: 
𝐸. 𝑐𝑜𝑙𝑖 and 𝐾𝑙𝑒𝑏𝑠𝑖𝑒𝑙𝑙𝑎 UTI rate in LTCF − pc =
  N 𝐸.𝑐𝑜𝑙𝑖 and 𝐾𝑙𝑒𝑏𝑠𝑖𝑒𝑙𝑙𝑎 UTI in LTCF−pc  per year in those aged 70+in the West Midlands∗
N beds in LTCFs  per year^
  
𝐸. 𝑐𝑜𝑙𝑖 and 𝐾𝑙𝑒𝑏𝑠𝑖𝑒𝑙𝑙𝑎 UTI rate in non − LTCF − pc =
N 𝐸.𝑐𝑜𝑙𝑖 and 𝐾𝑙𝑒𝑏𝑠𝑖𝑒𝑙𝑙𝑎 UTI in non−LTCF−pc  per year in those aged 70+in the West Midlands∗
N population aged  70+ in the West Midlands per year∗∗−N beds in LTCFs  per year^
  
*Calculated for the year 2013/2014, de-duplicated to one sample per person per 28-
day period 
^Obtained from the national regulator of health and social care in England (Care 
Quality Commission) from April 2014 as described above.152 
**Obtained from the population ONS estimate of mid-2014.4 
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The number of beds in each LTCF was used as an indicator of the number of 
person years in each LTCF, assuming full bed occupancy. Similarly, mid-year 
population estimates were used as an estimate of the number of person years 
in the population. 
The denominator for the UTI rate in non-LTCF postcodes was calculated by 
subtracting the number of LTCF residents (using the number of beds in LTCFs 
per year as a proxy of the number of people in LTCFs) from the number of 
residents in the West Midlands that were aged 70+ (as per ONS data). This 
approximately equated to the number of 70+ individuals in the population that 
did not live in a LTCF. 
The rates of UTI caused by resistant E. coli and Klebsiella were calculated 
using the same approach. Confidence intervals were calculated using the 
function epitab in the R package epitools which used normal approximation.203 
Postcodes may cover several buildings; therefore, LTCF postcodes may also 
include some elderly people who are not LTCF residents. In the sensitivity 
analysis, the rates of E. coli and Klebsiella UTI in LTCFs were estimated using 
only data from LTCF postcodes that were classified by the ONS as “communal 
establishment only” postcodes (LTCF CE-pc) (see Chapter 4).  
Comparison of resistance levels in culture confirmed samples 
Logistic regression models coded in the rms package in R were used to 
calculate the odds of resistance for bacteria in LTCF samples compared to non-
LTCF samples.204 Further analyses compared nursing and residential LTCFs. 
Age group (70-74, 75-80, 81-85, and >85), sex, and sender (GP versus 
hospital) were included in the model as categorical covariates because they 
were shown to differ in LTCF samples compared to non-LTCF samples (see 
Chapter 4), and are plausible risk factors of antibiotic resistance in urinary tract 
bacteria. In Chapter 4, it was also noted that the number of samples increased 
each year of study. The year of the study was, therefore, also included as a 
categorical covariate in the model (2010/2011, 2011/2012, 2012/2013, and 
2013/2014). 
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Both univariable and multivariable analyses were undertaken. No interactions 
between the model variables improved model fit, assessed using the Akaike 
information criterion (AIC); therefore, they were not included in the final model 
(see Table 5-1 and Table 5-2). The non-independence of samples in the same 
postcode (and, therefore, in the same LTCF) was accounted for by adjusting the 
standard errors using a clustering term in the robcov function. 205 
The robcov function of the rms package computes the Huber robust covariance 
matrix estimator with an adjustment for clustering: 
𝐻𝑐 = 𝐼
−1(𝑏)[∑{(∑ 𝑈𝑖𝑗)(∑ 𝑈𝑖𝑗)′}]𝐼
−1(𝑏),
𝑛𝑖
𝑗=1
𝑛𝑖
𝑗=1
𝑐
𝑖=1
 
Where c is the number of clusters, 𝑛𝑖 is the number of observations in the 𝑖th 
cluster, 𝑈𝑖𝑗 is the contribution of the 𝑗th observation within the 𝑖th cluster to the 
score vector and 𝐼(𝑏) is the observed information matrix, computed in the same 
way as without the clusters.205 
  
1
2
4
 
Table 5-1. Multivariable model fit with interactions. The largest interaction seen was between age and sender when examining the odds of E. coli 
resistance to ciprofloxacin, which decreased the AIC from 92,338.01 to 92,278.54 (0.064%). In these models LTCF residence was considered as binary 
(LTCF samples vs. non-LTCF samples).  
 
Organism 
Antibiotic Age * 
LTCF 
AIC 
Sex * 
LTCF 
AIC 
Sender * 
LTCF 
AIC 
Year * 
LTCF 
AIC 
Sex * 
Age AIC 
Sex * 
Sender 
AIC 
Sex * 
Year AIC 
Age * 
Sender 
AIC 
Age * 
Year 
AIC 
Sender * 
Year AIC 
E. coli Ciprofloxacin 92358.2 92355.7 92334.5 92366 92372.1 92369.2 92370.2 92308.4 92372.4 92371.2 
Carbapenems
^
 241.1 237.1 237.1 241.1 237.6 237 237.7 232.3 242.2 239.2 
Nitrofurantoin 52229.2 52222.4 52218.8 52234.3 52231 52228.7 52233.3 52224.3 52232.7 52235.9 
3GCs
~
 62596.6 62593.3 62596.3 62601.5 62593.4 62579.6 62596.1 62578.4 62601.9 62598.5 
Trimethoprim 207364 207363.6 207370.4 207356 207347.4 207326.7 207375.2 207354.4 207374 207378.1 
Klebsiella Ciprofloxacin 7512.1 7506.9 7509.6 7511.1 7511.6 7509 7500.8 7507.4 7517.1 7508.6 
Carbapenems
^ 
210.8 206.3 208.5 210.2 207.7 208.2 210.2 211.5 212.4 209.8 
Nitrofurantoin 15492 15484.51 15485.2 15484.6 15490.5 15485.8 15486.5 15491.4 15479 15490.1 
3GCs
~
 5901.3 5896.9 5897.2 5897.8 5898.3 5896.8 5891.1 5899.8 5897 5899.3 
Trimethoprim 20435 20443 20438.1 20446.4 20433 20441.3 20440 20443.5 20452.4 20442.7 
* Interaction between the terms 
^
 Imipenem or Meropenem 
~
 3GCs, third-generation cephalosporins. 3GC resistance was defined as resistance to ceftazidime, cefpodoxime, cefotaxime, or ceftriaxone. 
  
  
1
2
5
 
Table 5-2. Comparing the multivariable model fit with and without interactions. The final column shows the difference between the AIC (Akaike 
information criterion) from the multivariable model without interactions and the model with the lowest AIC for that bacterium-antibiotic combination. In these 
models LTCF residence was considered as binary (LTCF samples vs. non-LTCF samples). 
Organism Antibiotic Normal AIC Min AIC with interactions Normal AIC -Min AIC 
E. coli Ciprofloxacin 92368.2 92308.4 59.8 
Carbapenems
^
 235.1 232.3 2.8 
Nitrofurantoin 52230.6 52218.8 11.8 
3GCs
~
 62597.5 62578.4 19.1 
Trimethoprim 207375.9 207326.7 49.3 
Klebsiella Ciprofloxacin 7507.9 7500.8 7.1 
Carbapenems
^ 
207.3 206.3 1.1 
Nitrofurantoin 15486.2 15479 7.1 
3GCs
~
 5895.9 5891.1 4.8 
Trimethoprim 20441.4 20433 8.4 
* Interaction between the terms 
^
 Imipenem or Meropenem 
~
 3GCs, third-generation cephalosporins. 3GC resistance was defined as resistance to ceftazidime, cefpodoxime, cefotaxime, or ceftriaxone. 
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Rate of E. coli and Klebsiella UTI caused by AMR bacteria in 
LTCF and non-LTCF samples 
The rate of laboratory confirmed E. coli and Klebsiella UTI was 20.6 per 100 
person years in LTCF residents and 7.8 per 100 person years in community 
dwelling older adults; giving a rate ratio (RR) of 2.66 (95% CI=2.58-2.73) (see 
Table 5-3). In the sensitivity analysis, the rate of E. coli and Klebsiella UTI in the 
LTCFs located in CE-pc was similar (21.5 per 100 person years) giving a similar 
RR of 2.77 (95% CI=2.57-2.98) (see Table 5-4). 
Table 5-3. Rate of E. coli and Klebsiella UTI and E. coli and Klebsiella UTI caused by 
antibiotic-resistant bacteria for LTCF and non-LTCF residents per 100 person years. 
 LTCF 
rate 
non-LTCF 
rate 
rate 
ratio 
95% CI 
UTI^ 20.6 7.8 2.7 2.6-2.7 
UTI^ caused by bacteria resistant to 
trimethoprim 
12.7 2.9 4.4 4.3-4.6 
UTI^ caused by bacteria resistant to 
nitrofurantoin 
1.7 0.4 4.4 4.0-4.8 
UTI^ caused by bacteria resistant to 
ciprofloxacin^ 
3.3 0.6 5.2 4.8-5.6 
UTI^ caused by bacteria resistant to 
third-generation cephalosporins~ 
1.8 0.4 4.5 4.1-4.9 
^
 Urinary tract E. coli and Klebsiella reported to AmSurv.  
~
 Third-generation cephalosporins. 3GC resistance was defined as resistance to ceftazidime, 
cefpodoxime, cefotaxime, or ceftriaxone. 
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Table 5-4. Sensitivity analysis for the rate of E. coli and Klebsiella UTI and E. coli and 
Klebsiella UTI caused by antibiotic-resistant bacteria per 100 person years for LTCF and 
non-LTCF residents. The LTCF rate was calculated using only data from LTCF postcodes that 
were classified by the ONS as “communal establishment only” postcodes (LTCF CE-pc). 
 LTCF 
rate 
non-LTCF 
rate 
Rate ratio 95% CI 
UTI^ 21.5 7.8 2.77 2.57-2.98 
UTI^ caused by bacteria resistant to 
trimethoprim 
12.8 2.9 4.44 4.04-4.89 
UTI^ caused by bacteria resistant to 
nitrofurantoin 
1.9 0.4 4.82 3.77-6.16 
UTI^ caused by bacteria resistant to 
ciprofloxacin^ 
5.0 0.6 7.88 6.76-9.19 
UTI^ caused by bacteria resistant to 
3GCs~ 
1.7 0.4 4.09 3.14-5.33 
^
Urinary tract E. coli and Klebsiella reported to AmSurv. 
~
 3GCs, third-generation cephalosporins. 3GC resistance was defined as resistance to 
ceftazidime, cefpodoxime, cefotaxime, or ceftriaxone. 
 
The largest difference in the rate of E. coli and Klebsiella UTI caused by 
resistant bacteria between LTCF and non-LTCF samples was seen for 
ciprofloxacin (RR=5.18, 95% CI=4.82-5.57). Large differences were also seen 
for trimethoprim resistance (RR=4.41, 95% CI=4.25-4.57), nitrofurantoin 
(RR=4.38, 95% CI=3.98-4.83) and third-generation cephalosporins (RR=4.49, 
95% CI=4.08-4.94).  
The sensitivity analysis yielded very similar findings (see Table 5-4). In the 
sensitivity analysis, LTCF residents had a higher rate of E. coli and Klebsiella 
UTI caused by bacteria that were resistant to ciprofloxacin (RR=7.88, 95% 
CI=6.76-9.19). 
  
 128 
 
Prevalence of AMR and odds ratio of AMR 
The prevalence of antibiotic resistance was higher in bacteria from LTCF 
samples than in non-LTCF samples for all bacterium-antibiotic combinations 
(Table 5-5 and Table 5-6). E. coli resistance to trimethoprim was 60% versus 
37% (adjusted odds ratios (aORs)=2.36, 95% CI=2.21-2.53); nitrofurantoin 7% 
versus 4% (aOR=1.74, 95% CI=1.53-1.97); ciprofloxacin 29% versus 14% 
(aOR=2.42, 95% CI=2.17-2.69); and 3GCs 10% versus 6% (aOR=1.89, 95% 
CI=1.64-2.17). The prevalence of Klebsiella resistant to: trimethoprim was 41% 
versus 26% (aOR=1.89, 95% CI=1.6-2.24); nitrofurantoin 41% versus 34% 
(aOR=1.31, 95% CI=1.09-1.59); ciprofloxacin 10% versus 8% (aOR=1.54, 95% 
CI=1.13-2.1); and 3GCs 8% versus 7% (aOR=1.24, 95% CI=0.85-1.83). Further 
results of the univariate and multivariate results are shown in Appendix Chapter 
5. 
 
  
1
2
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Table 5-5 Prevalence of antibiotic resistance in LTCF, non-LTCF, residential LTCF, and nursing LTCF samples. 
Organism Antibiotic % resistance  
overall 
n/N(%) 
% resistance  
LTCF samples 
n/N(%) 
% resistance  
Res LTCF samples 
n/N(%) 
% resistance  
Ns LTCF samples 
n/N(%) 
% resistance  
non-LTCF samples 
n/N(%) 
E. coli Trimethoprim 61879/158764  9513/15914  5491/9438  4022/6476  52366/142850 
 (39.0%) (59.8%) (58.2%) (62.1%) (36.7%) 
Nitrofurantoin 6322/158501  1059/15889  571/9425  488/6464  5263/14261 
 (4.0%) (6.7%) (6.1%) (7.6%) 2 (3.7%) 
Ciprofloxacin 16937/111220  3075/10564  1625/6100  1450/4464  13862/100656  
 (15.2%) (29.1%) (26.6%) (32.5%) (13.8%) 
3GCs
~
 8581/134957  1412/13482  791/8084  621/5398  7169/121475  
  (6.4%) (10.5%) (9.8%) (11.5%) (5.9%) 
Klebsiella 
  
  
  
Trimethoprim 4759/17844  513/1257  282/707  231/550  4246/16587  
 (26.7%) (40.8%) (39.9%) (42.0%) (25.6%) 
Nitrofurantoin 4232/12159  377/916  213/517  164/399  3855/11243  
 (34.8%) (41.2%) (41.2%) (41.1%) (34.3%) 
Ciprofloxacin 1105/13738  95/918  48/510  47/408  1010/12820  
 (8.0%) (10.4%) (9.4%) (11.5%) (7.9%) 
3GCs
~
 846/11593  60/754  29/430  31/324  786/10839  
  (7.3%) (8.0%) (6.7%) (9.6%) (7.3%) 
~
 3GCs, third-generation cephalosporins. 3GC resistance was defined as resistance to ceftazidime, cefpodoxime, cefotaxime, or ceftriaxone. 
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Table 5-6. Unadjusted and adjusted odds ratio of antibiotic resistance in bacteria from 
LTCF samples compared to non-LTCF samples. 
Organism Antibiotic uOR 
LTCF
#
 
Adjusted 
95%CI uOR 
LTCF  
aOR 
LTCF
^
 
Adjusted 95% 
CI aOR LTCF  
E. coli Trimethoprim 2.56 2.4 - 2.7 2.4 2.2 - 2.5 
Nitrofurantoin 1.86 1.6 - 2.1 1.7 1.5 - 2.0 
Ciprofloxacin 2.57 2.3 - 2.9 2.4 2.2 - 2.7 
3GCs
 ~
 1.86 1.6 - 2.1 1.9 1.6 - 2.2 
Klebsiella Trimethoprim 2.01 1.7 - 2.4 1.9 1.6 - 2.2 
Nitrofurantoin 1.34 1.1 - 1.6 1.3 1.1 - 1.6 
Ciprofloxacin 1.36 1.0 - 1.9 1.5 1.1 - 2.1 
3GCs
~
 1.1 0.8 - 1.6 1.2 0.9 - 1.8 
#
uOR LTCF is the unadjusted odds ratio (univariable analysis) of antibiotic resistance in bacteria 
from LTCF samples compared to non-LTCF samples with 95% CIs adjusted for clustering at the 
postcode level 
^
aOR LTCF is the adjusted OR, adjusted for age group, sex, year of study, and sender as 
categorical covariates of antibiotic resistance in bacteria from LTCF samples compared to non-
LTCF samples with 95% CIs adjusted for clustering at the postcode level. Interactions were not 
included in the model as they did not improve model fit (see Table 5-1). 
~
 3GCs, third-generation cephalosporins. 3GC resistance was defined as resistance to 
ceftazidime, cefpodoxime, cefotaxime, or ceftriaxone. 
 
After accounting for LTCF residence, age, sender, and year of study, sex was a 
significant contributor to antibiotic resistance across multiple bacteria-antibiotic 
combinations. E. coli isolated from samples sent from males had significantly 
higher odds of nitrofurantoin, ciprofloxacin, and 3GC resistance than females 
(adjusted odds ratio (aOR) 1.48, 95% CI 1.36-1.61; aOR 1.69, 95% CI 1.58-
1.81; aOR 1.47, 95% CI 1.35-1.6; respectively). Klebsiella from male samples 
had significantly higher odds of ciprofloxacin and 3GC resistance than females 
(aOR 1.34, 95% CI 1.11-1.62; aOR 1.42, 95% CI 1.15-1.75; respectively). 
After accounting for LTCF residence, sex, sender, and year of study, age only 
contributed significantly to antibiotic resistance in a small number of bacterium-
antibiotic groups. The odds of E. coli resistance to trimethoprim, nitrofurantoin, 
and ciprofloxacin were higher in those over 85 years of age than in those aged 
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70-74 (aOR 1.28, 95% CI 1.22-1.34; aOR 1.34, 95% CI 1.19-1.51; aOR 1.35, 
95% 1.24-1.47).  
The odds of antibiotic resistance were higher in bacteria sent from hospitals 
than in samples sent from GPs with the exception of the odds of Klebsiella 
resistance to nitrofurantoin, which was lower in samples sent from hospitals 
than in those sent by GPs (aOR 0.85, 95% CI 0.78-0.93). The odds of E. coli 
resistant to ciprofloxacin and 3GCs were higher in samples sent from hospitals 
than in samples sent by GPs (aOR 1.11, 95% CI 1.06-1.16; aOR 1.36, 95% CI 
1.29-1.45). The odds of Klebsiella resistant to ciprofloxacin and 3GCs were also 
significantly higher in samples from hospital (aOR 1.45, 95% CI 1.25-1.69; aOR 
1.83, 95% CI 1.54-2.17). 
Bacteria isolated from individuals residing in LTCFs with nursing support had 
higher levels of resistance to most antibiotics than those isolated from 
individuals living in residential LTCFs (see Table 5-5 and Table 5-7). Levels of 
antibiotic resistance were also higher in urinary tract bacteria from LTCF 
residents (obtained both from GPs and hospitals) than from hospitals (including 
samples from residents of LTCF-pc and non-LTCF-pc) (Table 5-8). The 
prevalence of E. coli resistant to trimethoprim, nitrofurantoin, ciprofloxacin and 
3GCs was higher in LTCF samples than in samples sent from hospitals (60% 
versus 40%, 7% versus 4%, 29% versus 16%, and 11% versus 8%). The 
prevalence of Klebsiella resistant to trimethoprim and nitrofurantoin was also 
higher in LTCFs (41% versus 27% and 41% versus 32) but ciprofloxacin 
resistance was similar (10% versus 10%) and 3GCs resistance was higher in 
hospitals (8% versus 10%).  
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Table 5-7. Unadjusted and adjusted odds ratio of antibiotic resistance in bacteria from residential LTCF samples compared to non-LTCF samples 
and from nursing LTCF samples compared to non-LTCF samples. 
Organism Antibiotic uOR 
residentia
l LTCF
#
 
Adjusted 
95%CI uOR 
residential 
LTCF  
aOR 
residential 
LTCF
^
 
Adjusted 95% 
CI aOR 
residential 
LTCF  
uOR 
nursing 
LTCF
##
 
Adjusted 
95%CI uOR 
nursing LTCF  
aOR 
nursing 
LTCF
^^
 
Adjusted 95% 
CI aOR 
nursing LTCF  
E. coli Trimethoprim 2.39 2.2 - 2.61 2.2 2.02 - 2.4 2.82 2.55 - 3.13 2.63 2.37 - 2.92 
Nitrofurantoin 1.68 1.43 - 1.99 1.59 1.35 - 1.87 2.12 1.78 - 2.53 1.95 1.64 - 2.33 
Ciprofloxacin 2.28 2 - 2.59 2.17 1.9 - 2.47 3.01 2.58 - 3.51 2.78 2.38 - 3.24 
3GCs
~
 1.73 1.45 - 2.06 1.76 1.47 - 2.1 2.07 1.69 - 2.55 2.09 1.7 - 2.56 
Klebsiella Trimethoprim 1.94 1.52 - 2.46 1.82 1.43 - 2.31 2.11 1.7 - 2.62 1.98 1.59 - 2.46 
Nitrofurantoin 1.35 1.05 - 1.72 1.31 1.02 - 1.68 1.33 1.02 - 1.75 1.31 1 - 1.73 
Ciprofloxacin 1.21 0.79 - 1.87 1.41 0.9 - 2.19 1.56 1.03 - 2.37 1.7 1.13 - 2.56 
3GCs
~
 0.9 0.57 - 1.41 1.06 0.67 - 1.68 1.37 0.75 - 2.49 1.47 0.81 - 2.67 
#
uOR residential LTCF is the unadjusted odds ratio (univariable analysis) of antibiotic resistance in bacteria from residential LTCF samples compared to non-
LTCF samples, with 95% confidence intervals adjusted for clustering at the postcode level 
##
uOR nursing LTCF is the unadjusted odds ratio (univariable analysis) of antibiotic resistance in bacteria from nursing LTCF samples compared to non-LTCF 
samples, with 95% confidence intervals adjusted for clustering at the postcode level 
^
aOR residential LTCF is the adjusted OR, adjusted for age group, sex, year of study, and sender as categorical covariates of antibiotic resistance in bacteria 
from residential LTCF samples compared to non-LTCF samples, with 95% confidence intervals adjusted for clustering at the postcode level. Interactions were 
not included in the model as they did not improve model fit (see Table 5-1). 
^^
aOR nursing LTCF is the adjusted OR, adjusted for age group, sex, year of study, and sender as categorical covariates of antibiotic resistance in bacteria 
from nursing LTCF samples compared to non-LTCF samples, with 95% confidence intervals adjusted for clustering at the postcode level. Interactions were 
not included in the model as they did not improve model fit (see Table 5-1). 
~
 3GCs, third-generation cephalosporins. 3GC resistance was defined as resistance to ceftazidime, cefpodoxime, cefotaxime, or ceftriaxone. 
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Table 5-8. Prevalence of antibiotic resistance in urinary tract bacteria present in LTCF samples, in non-LTCF samples, in samples sent by GPs, and 
in samples sent from hospitals. Samples sent by GPs and from hospitals included both LTCF and non-LTCF samples, and vice-versa. 
Organism Antibiotic % resistance 
samples overall 
n/N(%) 
% resistance 
LTCF sample 
n/N(%) 
% resistance non-
LTCF samples 
n/N(%) 
% resistance GP 
samples n/N(%) 
% resistance 
hospital samples 
n/N(%) 
E. coli 
 
 
 
Trimethoprim 61879/158764 
(38.98%) 
9513/15914 
(59.78%) 
52366/142850 
(36.66%) 
41338/106779 
(38.71%) 
20243/51258 
(39.49%) 
Nitrofurantoin 6322/158501 
(3.99%) 
1059/15889 
(6.66%) 
5263/142612 
(3.69%) 
4184/106645 
(3.92%) 
2111/51130 
(4.13%) 
Ciprofloxacin 16937/111220 
(15.23%) 
3075/10564 
(29.11%) 
13862/100656 
(13.77%) 
10852/73720 
(14.72%) 
6085/37500 
(16.23%) 
Third-generation 
cephalosporins
~
 
8581/134957 
(6.36%) 
1412/13482 
(10.47%) 
7169/121475 
(5.9%) 
5187/90769 
(5.71%) 
3325/43466 
(7.65%) 
Klebsiella 
 
 
 
Trimethoprim 4759/17844 
(26.67%) 
513/1257 
(40.81%) 
4246/16587 
(25.6%) 
3019/11379 
(26.53%) 
1721/6445 (26.7%) 
Nitrofurantoin 4232/12159 
(34.81%) 
377/916 (41.16%) 3855/11243 
(34.29%) 
2821/7822 
(36.06%) 
1402/4317 
(32.48%) 
Ciprofloxacin 1105/13738 
(8.04%) 
95/918 (10.35%) 1010/12820 
(7.88%) 
591/8579 (6.89%) 497/5139 (9.67%) 
Third-generation 
cephalosporins
~
 
846/11593 (7.3%) 60/754 (7.96%) 786/10839 (7.25%) 398/7137 (5.58%) 439/4436  
(9.9%) 
~
 3GC resistance was defined as resistance to ceftazidime, cefpodoxime, cefotaxime, or ceftriaxone. 
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There were differences in resistance to trimethoprim, nitrofurantoin, 
ciprofloxacin, and 3GCs over the study period for bacteria from LTCF samples 
and non-LTCF samples. These patterns are plotted in Figure 5-1. Resistance to 
other antibiotics are plotted in Figure 5-2 and Figure 5-3. 
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Figure 5-1. Percentage of Klebsiella and E. coli samples resistant to trimethoprim, 
nitrofurantoin, third-generation cephalosporins, and ciprofloxacin. The black line 
represents LTCF samples and the grey line represents non-LTCF samples. Yearly point 
estimates are presented with 95% binomial CIs. 3GC resistance was defined as resistance to 
ceftazidime, cefpodoxime, cefotaxime, or ceftriaxone. 
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Figure 5-2 Percentage of Klebsiella and E. coli samples resistant to 
imipenem/meropenem, temocillin, and gentamicin. The black line represents LTCF samples 
and the grey line represents non-LTCF samples. Yearly point estimates are presented with 95% 
binomial confidence intervals. *The carbapenems included in this analysis were imipenem and 
meropenem. 
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Figure 5-3. Percentage of Klebsiella and E. coli samples resistant to 
piperacillin/tazobactam, first-generation cephalosporins (1GC), second-generation 
cephalosporins (2GC), and co-amoxiclav
+
. The black and grey lines represent LTCF samples 
and non-LTCF samples (respectively). Yearly point estimates are presented with 95% binomial 
confidence intervals. 
+
Note that some laboratories used the systemic rather than UTI breakpoint 
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guidelines for co-amoxiclav resulting in an increase in the percentage of resistant samples 
between mid-2011 and early 2012.  
 139 
 
Discussion 
Summary of main findings 
Elderly residents of LTCFs are more than twice as likely as community dwelling 
adults of similar age to have a laboratory confirmed E. coli or Klebsiella UTI. 
UTIs are most commonly caused by E. coli. In LTCF residents, 60% of samples 
that grew E. coli were resistant to trimethoprim, 29% to ciprofloxacin, 10% to 
3GC, and 7% to nitrofurantoin; 41% of samples that grew Klebsiella were 
resistant to trimethoprim, 41% to nitrofurantoin, 10% to ciprofloxacin, and 8% to 
3GCs. LTCF residents were more than four times more likely than community 
dwelling older people to develop a laboratory confirmed E. coli or Klebsiella UTI 
caused by resistant bacteria. The increased risk of antibiotic resistance 
amongst bacteria causing culture confirmed E. coli and Klebsiella UTIs in older 
people residing in LTCFs is seen across different antibiotic classes.  
Strengths 
The linkage of the West Midlands AmSurv dataset, which included samples 
sent by both GPs and hospitals from a large population, with the CQC registry 
of LTCFs in England through patient postcode enabled unprecedented insight 
into the patterns of AMR in Gram-negative bacteria in LTCFs in England. The 
differences in resistance patterns between residential and nursing LTCFs were 
also analysed. 
A multivariable regression model was developed to determine the odds of 
antibiotic resistance in LTCF and non-LTCF settings. This model accounted for 
variation in antibiotic resistance due to key risk factors (for example, samples 
being sent from hospitals versus from GPs), and the odds were adjusted for 
clustering at the postcode level. Interactions between the regression terms were 
also explored, although none were found to improve the model fit.  
In addition, the sensitivity of the model findings to inferring LTCF residence from 
patient postcodes (explained in Chapter 4 in more detail) was explored by 
limiting the analysis to LTCFs in postcodes classed by the ONS as “communal 
establishment only”. The sensitivity analysis yielded very similar findings to the 
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main analysis, indicating the robustness of this methodology in the comparative 
analysis of resistance. 
Limitations 
Bias 
The first limitations that could have biased these results are not knowing 
whether samples were from catheter or mid-stream urines and the fact that 
symptoms are not recorded in AmSurv. English national guidelines state that 
urine samples from catheterised patients should only be sent for susceptibility 
testing in the presence of systemic infection symptoms; and that samples from 
elderly individuals should only be sent in the presence of two or more signs of 
infection.49 Therefore, the underlying presumption is that patients had samples 
sent appropriately. Bacteriuria is very common in older people, particularly in 
patients with indwelling catheters; therefore, if, despite the guidelines, some 
samples from these patients are sent for testing, the burden of UTI is likely to 
have been over-estimated. Asymptomatic bacteriuria is more prevalent amongst 
individuals residing in LTCFs than in those living in their own homes47 (perhaps 
due to increased detection); therefore, the RR of laboratory confirmed E. coli 
and Klebsiella UTI in LTCF residents compared to community dwelling older 
adults could be lower than this analysis suggests. 
Another limitation that could lead to bias is that the threshold to diagnose UTIs 
could be lower for LTCF residents than non-LTCF residents because their 
health is more frequently surveyed by staff and cognitive impairment could be 
more prevalent, which may make patients unable to verbalise symptoms. This 
would result in a greater number of samples overall being submitted for testing 
from LTCF residents compared to their community counterparts; which would 
result in an underestimation of the prevalence of resistance in LTCF residents.  
Sampling may also be biased towards those failing to respond to treatment. 
This would lead to overestimating the prevalence of resistance in both 
populations206; however, it is unclear why this bias would be greater in LTCF 
samples.  
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Inferring LTCF residence from patient postcodes means that a proportion of 
those living in LTCF postcodes will live in the community in neighbouring 
households. This will tend to bias odds ratios toward the null hypothesis, 
potentially leading to underestimates of the impact of LTCF residence on 
antibiotic resistance. However, LTCF UTI rates were similar when using the 
more specific postcodes that contained only communal establishments, 
suggesting that this bias was minimal. In addition, this methodology has 
previously been employed in other studies.9,69  
Laboratory years in which fewer than 80% of samples were tested against a 
particular antibiotic were excluded. This resulted in the exclusion of 1 laboratory 
for Klebsiella tested against nitrofurantoin, 3 for Klebsiella and 2 for E. coli 
tested against 3Gs, and 4 for Klebsiella and 6 for E. coli tested against 
ciprofloxacin from the 15 laboratories in the West Midlands. The analysis of 
antibiotic resistance may not be representative of the catchment areas of the 
laboratories excluded, which could have biased findings if these areas had 
lower or higher rates of antibiotic resistant UTI than those included. 
Confounding 
Antibiotic prescribing and clinical need are likely to be higher in the LTCF 
population and may be drivers of the patterns of resistance observed. However, 
no data was available to inform this. 
The change in breakpoints for ceftazidime (one of the four 3GC tested) is 
deemed unlikely to have confounded the analysis of 3GC resistance. This is 
discussed in more detail in Chapter 4. The observed increase in the prevalence 
of resistance to co-amoxiclav between mid-2011 and early 2012 was an artefact 
caused by some laboratories using the systemic rather than UTI breakpoint 
guidelines for this antibiotic.  
General 
Urinary tract samples reported to AmSurv with confirmed culture results for E. 
coli and Klebsiella accounted for 63% of urinary tract bacteria samples. Caution 
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must also therefore be applied before extrapolating these results to UTIs 
caused by other bacterial species. In addition, resistance was measured in vitro, 
which does not always equate to clinical failure.  
Finally, resistance to pivmecillinam and fosfomycin was not reported in this 
chapter. Pivmecillinam is recommended in the national guidelines if the first-line 
treatment for UTI is deemed unsuitable or if renal function is decreased (GFR is 
lower than 45mls/min). Fosfomycin is recommended in cases where there is a 
high risk of resistance. However, resistance to these antibiotics is not tested 
routinely. The most recent ESPAUR report reported that only 35% and 29% of 
isolates in England were tested against mecillinam and fosfomycin, 
respectively. 40 
Implications for clinical practice and policy 
Our findings suggest that in older people a large proportion of E. coli and 
Klebsiella UTIs will not respond to trimethoprim treatment, and that this problem 
is heightened in LTCFs, where the prevalence of resistance is even higher. 39% 
of UTIs caused by E. coli and 27% of UTIs caused by Klebsiella (60% and 41%, 
respectively, in LTCFs) were resistant to trimethoprim. Resistance to 
trimethoprim is of particular concern because it may result in treatment failure, 
hospitalisation, and the subsequent use of antibiotics such as ciprofloxacin or 
3GCs that should be reserved for the treatment of more serious infections. One 
explanation for these high levels of resistance could be the high consumption of 
trimethoprim in England. In 2014, national primary care prescribing guidelines 
have switched from recommending trimethoprim as first-line treatment for UTI to 
recommending nitrofurantoin (unless there is a low risk for resistance to 
trimethoprim, in which case trimethoprim is also recommended).50 In line with 
these recommendations, trimethoprim prescription has decreased during 2014-
2015; however, trimethoprim treatment and resistance remain high. 
Trimethoprim is still the most commonly prescribed antibiotic in the community 
for UTI. In 2015, 0.17 items were prescribed per 1000 population per day 
compared to 0.11 for nitrofurantoin.35 Resistance to trimethoprim increased 
during the study period (2010/2011-2013/2014), faster for LTCF samples (E. 
coli from 53% to 63% and Klebsiella from 34% to 43%) than for non-LTCF 
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samples (E. coli from 35% to 38% and Klebsiella from 22% to 29%). These 
increases could partly be explained by trimethoprim consumption increasing in 
England by 4.2% between 2010 and 2013.207  
The prevalence of resistance of E. coli and Klebsiella against nitrofurantoin was 
high for Klebsiella (35%) but much lower for E. coli (4%). This suggests 
nitrofurantoin might still remain very effective in treating UTIs caused by E. coli 
in older people, particularly in women, where the aOR of acquiring a UTI 
caused by nitrofurantoin-resistant E. coli are lower. Nitrofurantoin comprised 
3.8% of all antibiotics consumed in England in 2013 in the community and was 
the second most frequently prescribed antibiotic agent of those recommended 
in empiric guidelines for lower UTI (20.8%).207 In the West Midlands, the 
consumption of nitrofurantoin increased by 66% from 2010 to 2014.43 As 
nitrofurantoin consumption continues to increase, resistance to this antibiotic, 
particularly in Klebsiella, may rise. The low resistance in E. coli in spite of the 
selective pressure exerted by the increased consumption of this antibiotic may 
be explained by a high fitness cost of resistance to nitrofurantoin in these 
bacteria.208,209 However, E. coli might develop mechanisms to compensate for 
this, for example through second-site mutations that may increase fitness.210 It 
is therefore, important to continue to monitor nitrofurantoin resistance in both E. 
coli and Klebsiella in the future.  
Ciprofloxacin is a broad-spectrum antibiotic that can be used to treat infections 
caused by both Gram-negative and Gram-positive bacteria. Resistance to 
ciprofloxacin is of particular concern because it is often carried alongside 
resistance to beta-lactams, notably methicillin-resistance in Staphylococci.211–214 
Ciprofloxacin usage, therefore, selects for methicillin-resistance in 
Staphylococcus aureus. Neisseria gonorrhoeae also rapidly acquire resistance 
to ciprofloxacin, which is worrying given that resistance has emerged to all 
antibiotic classes that are used for treatment of gonorrhea.40 In addition, 
fluoroquinolone usage has also been linked to the incidence to C. difficile 
infections.215 In the primary care national guidelines, ciprofloxacin treatment is 
now only recommended for UTIs with acute prostatitis or acute pyelonephritis, 
or as second-line prophylaxis for recurrent UTIs.50 It is also recommended for 
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lower respiratory tract infections under the premise of proven resistance to other 
antibiotics, and for epididymitis. Ciprofloxacin use has been declining in 
England since 2007.40,215 From 2012 to 2016, quinolone usage (81% of which 
are ciprofloxacin prescriptions) declined by 5.8%.40 In this context, the 
prevalence of resistance to ciprofloxacin in E. coli (15%), albeit stable, is 
concerning, in particular in LTCF samples (29%). The levels of resistance to 
ciprofloxacin in Klebsiella were lower (8% in non-LTCF samples and 10% in 
LTCF samples), although they increased from 2010/2011 to 2013/2014, faster 
for LTCF samples (from 6% to 14%) than for non-LTCF samples (7% to 10%). 
The drivers of this increasing prevalence of resistance, given the decrease 
observed in prescribing, warrants further study. The high levels of resistance in 
urinary E. coli isolated from LTCF residents once again highlight the benefit of 
nitrofurantoin treatment for UTI caused by E. coli in this population. 
3GCs are antibiotics that are almost exclusively administered in hospitals for the 
treatment of severe infections. 3GCs are not recommended in the empiric 
treatment of UTIs but are needed to treat more severe infections such as 
bacterial meningitis.194,207 The levels of resistance to 3GC in E. coli and 
Klebsiella were low (6%, and 7%, respectively). Similarly to ciprofloxacin 
resistance, the prevalence of E. coli resistant to 3GCs remained stable during 
the study period, whilst the prevalence of Klebsiella resistant to 3GC increased 
steadily (faster for LTCF samples, 3% to 12%, than for non-LTCF samples, 6% 
to 9%). This increase might be explained by the 21% increase in consumption 
of 3GCs during the study period.43 This emphasises the need to ensure that 
3GCs are prescribed only when it is strictly necessary. 
Importantly, resistance to 3GC and ciprofloxacin do not only result in treatment 
failures but in the prescription of “last resort” antibiotics such as carbapenems 
that should be reserved for the treatment of severe infections in hospitals.28 In 
the present study, the prevalence of resistance in urinary tract bacteria to 
carbapenems in the over 70s was similarly low in both Klebsiella and E. coli 
(0.2% and 0.02%, respectively) to what has been reported in the literature 
between 2010 and 2013 in the overall West Midlands population;192 which 
prevented any formal statistical analysis but is reassuring. 
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Future work 
Our findings highlight the very high levels of AMR bacteria in LTCF residents 
compared to their community counterparts and even to hospital patients; 
showing the importance of improving infection prevention and control; reducing 
antibiotic usage in LTCFs through antibiotic stewardship programmes; and the 
need for LTCF specific surveillance that can guide empiric treatment. There is 
also a need to understand if trimethoprim resistance is reversible through 
antimicrobial stewardship interventions, as evidence from the literature is 
conflicting208,216, and how the mechanisms for the selection of resistances differ 
between species of urinary bacteria. In order to understand the causes of the 
high levels of antibiotic resistance observed in LTCFs, more information about 
antibiotic prescription, recent hospitalisations, and transmission of resistant 
bacteria is required. It is equally important that interventions are developed to 
reduce the risk of transmission of AMR bacteria between LTCF residents. The 
findings from this chapter were published in the Journal of Antimicrobial 
Chemotherapy.2  
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Conclusions 
This was the first study to estimate the burden of antibiotic resistance in urinary 
E. coli and Klebsiella in England in a large number of LTCFs. It is also the first 
study to include both hospital and GP samples when comparing the frequency 
of antibiotic resistance in urinary tract bacteria from residents of LTCFs for older 
people and older people living in the community. Residents of LTCFs for older 
people had more than double the rate of E. coli and Klebsiella UTI and more 
than four times the rate of E. coli and Klebsiella UTI caused by antibiotic-
resistant bacteria compared to those living in the community. The odds of 
resistance of E. coli and Klebsiella to trimethoprim, nitrofurantoin, ciprofloxacin 
and 3GCs were significantly higher in LTCF samples than non-LTCF samples, 
after adjusting for age, sex, sender (GP vs. hospital) and the year of the study. 
The prevalence of E. coli resistant to trimethoprim, nitrofurantoin, ciprofloxacin 
and 3GCs was higher in LTCF samples (obtained both from GPs and hospitals) 
than in samples sent from hospitals (including samples from residents of LTCF-
pc and non-LTCF-pc). The prevalence of Klebsiella resistant to trimethoprim 
and nitrofurantoin was also higher in LTCFs but ciprofloxacin resistance was 
similar and 3GCs resistance was higher in hospitals. Together, these findings 
suggest that LTCFs are important reservoirs of urinary AMR bacteria, and that 
interventions to prevent and control these are warranted in this setting. A large 
proportion of E. coli and Klebsiella UTIs in older people living in LTCFs (60% 
and 41%, respectively) and a high proportion of those living in their own homes 
(37% and 26%, respectively) will not respond to trimethoprim treatment, which 
is the most commonly prescribed antibiotic for lower UTI. However, the 
prevalence of resistance of E. coli and Klebsiella against nitrofurantoin, another 
very commonly prescribed first-line antibiotic treatment for UTI, although high 
for Klebsiella (35%), was much lower for E. coli (4%). This suggests that 
nitrofurantoin might still remain very effective in treating UTIs caused by E. coli 
in older people. The prevalence of resistance of E. coli against ciprofloxacin, a 
second line treatment for UTI was very high in LTCFs (29% versus 14%), which 
is concerning given the high frequency of carriage of this resistance alongside 
resistance to beta-lactams such as methicillin. Resistance to 3GCs and 
carbapenems was low, which is reassuring. However, the prevalence of 
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Klebsiella resistant to 3GC increased steadily (faster for LTCF samples, 3% to 
12%, than for non-LTCF samples, 6% to 9%), which highlights the need for 
antibiotic stewardship interventions targeting the use of this antibiotic. More 
information about antibiotic prescription, recent hospitalisations, and 
transmission of resistant bacteria is required to understand the drivers of the 
high levels of AMR observed in LTCFs.  
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Chapter 6  Seasonality of UTIs in the United 
Kingdom in different age groups: longitudinal analysis 
of THIN data 
Accepted for publication in Epidemiology and Infection.1  
Aim 
To explore the seasonality and trends of UTI in the UK 
Introduction 
As highlighted in Chapter 1, UTIs are a common cause of BSI and the second 
most common cause for antibiotic prescribing in primary care, which is an 
important driver of antibiotic resistance. Chapter 5 found a high prevalence of 
antibiotic resistant E. coli and Klebsiella UTI in LTCF residents, reiterating the 
importance of improving our understanding of the dynamics of these infections. 
In addition, in view of developing a mathematical model of trimethoprim 
resistant E. coli (Chapter 7), it was important to determine whether these 
infections were seasonal. 
Understanding the seasonality dynamics of UTI may provide a valuable insight 
into the determinants of infection, which can help clinicians and infection control 
specialists understand the risk factors for these infections and ultimately 
improve their prevention. Any seasonality should also be accounted for in the 
evaluation of interventions against UTI, as decreases in incidence due to 
seasonality could be misinterpreted as decreases caused by the intervention. 
Seasonality is also important when interpreting surveillance datasets and 
antibiotic prescription datasets, as increases in incidence or prescriptions could 
be misinterpreted as outbreaks or inappropriately high prescribing.  
Whilst some bacterial infections seem to exhibit a winter seasonal pattern in 
temperate climates, such as bacterial meningitis217,218, other infections such as 
Campylobacter and Salmonella infections are more common during the 
warmest months of the year219,220. Dehydration has been suggested to increase 
the risk of UTI, by causing lower rates of urine flow and voiding frequency, 
which may delay bacterial eradication from the urinary tract221.  Due to 
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increases in temperature during summer time, which can make individuals 
prone to dehydration, UTIs could be expected to peak in summer. These 
changes could be particularly marked in the elderly population, who are prone 
to dehydration60. However, drinking more water in summer could also cause 
dehydration to be less common this period. Sexual activity is also a known risk 
factor for UTI and may also influence UTI dynamics36.  
Evidence regarding the seasonality of UTIs from the literature is conflicting 
(Table 6-1). One study showed UTI incidence was higher in the winter222, 1 in 
autumn223, and others in summer224–228. Additional studies suggested 
seasonality varied by causative organism229,230 and by whether patients were 
seen by general practitioners (GPs) or in hospital231. These differences may be 
partly caused by the use of inadequate methodology (for example, comparing 
incidence without any formal statistical analysis222,227,230,232), the assessment of 
seasonality in different geographical areas (for example, in Norway223 vs. in 
Greece225), different species (for example, Escherichia coli and Staphylococcus 
saprophyticus230), and different case-mix (for example, in children222,227,232 vs. in 
all ages223,226,228,230,233, in the community223–225,227,229,230,232 vs. in hospital222,228 
or in females224,229,231,233 vs. both sexes222,223,225–228,230,232).  
Initially, the seasonality of UTI was investigated using the West Midlands 
AmSurv data described in Chapter 4 (see Appendix Chapter 6 PART A). The 
lack of seasonality found in these data drove the assessment of seasonality of 
UTI using other sources. In the first instance, the monthly GP prescriptions 
available per region from the Health & Social Care Information Centre 
website234 were analysed; however, this data is only available for all ages. 
Trimethoprim and nitrofurantoin prescriptions in this dataset were found to be 
seasonal, with a clear autumnal peak (see Appendix Chapter 6 PART A). Many 
confounders such as age and sampling hindered the interpretation of these 
differences. In order to investigate the origin of this discrepancy, the UTI 
consultations and antibiotic prescriptions by GPs in the UK over 2008-2015 for 
different age groups were extracted from a nationally representative database 
of electronic health records from primary care, The Health Improvement 
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Network (THIN). The seasonality of UTI was investigated using this data and is 
presented subsequently in this chapter. 
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Table 6-1. Studies that analysed the seasonality of UTI 
Author Year Country Community/ 
hospital 
Organism Sex Age Seasonality Methods 
Stansfeld
222
 1966 England Hospital All All 0-12 In cases >1 year age, 96 in winter 
and 58 in summer (significant at 
1% level) 
Unknown 
Anderson
224
 1983 Canada Community All Females 15 or 
older 
August peak Edward's test for 
cyclic variation 
Pead et al.
229
 1985 England Community All Females 15-25 S. saprophyticus UTI peak in mid-
September. Coliform (all Gram-
negative bacilli other than Proteus 
spp. and Pseudomonas spp.) UTI 
peak in mid-March 
Chi-squared test 
Vorland et al.
223
 1985 Norway Community E. coli All All Higher incidence from September 
to December (10.2 per 1,000 
inhabitants) than from January to 
April (8.6 per 1000 inhabitants) or 
May to August (6.2 per 1,000 
inhabitants), but non-significant. 
Chi-squared test 
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Author Year Country Community/ 
hospital 
Organism Sex Age Seasonality Methods 
Ferry et al.
230
 1987 Sweden Community All All All No seasonality in E. coli UTI but 
August peak in S. saprophyticus 
UTIs 
Comparing 
incidence 
Stamm et al.
233
 1991 USA Outpatient 
recurrence 
clinic 
All Females All Decrease in incidence November 
to February 
Wilcoxon's 
signed-rank test 
Kwok et al.
232
 2006 Netherlands Community All All 0-18 Decrease in the summer months 
mainly in children 0-12 
Comparing 
incidence rates 
Falagas et al.
225
 2009 Greece Community 
(house call 
visits) 
All All All UTIs correlate with higher 
temperatures and decreased 
relative humidity 
Spearman's 
rank correlation 
Eriksson et 
al.
231
 
2013 Sweden Community and 
hospital 
E. coli, K. 
pneumoniae 
and P. mirabilis 
aggregated and 
S. saprophyticus  
Females 15-29 In GP samples, both peak in 
September, in hospital samples, 
both peak in August. Stronger 
seasonality in S. saprophyticus. 
Chi-squared test 
  
1
5
3
 
Author Year Country Community/ 
hospital 
Organism Sex Age Seasonality Methods 
Rossignol et 
al.
226
 
2013 France, 
Germany, 
USA, China 
Italy, Brazil 
and Australia 
Community 
(online) 
All All All Increases of 8-19% in search 
trends for UTI-related terms in 
summer in France, Germany, USA, 
China and Italy, and peaks in the 
southern hemisphere austral 
summer in Brazil and Australia 
Google trends 
analysis, Mann-
Whitney test 
Yolbas et al.
227
 2013 Turkey Community All All 1 
month- 
15 
years 
More UTIs in summer (53/150) 
than overall in winter (46/150), 
spring (35/150) or autumn (16/150) 
but difference in seasonality by sex 
Comparing 
incidence 
Melamed et 
al.
228
 
2014 USA Hospital All All All Summer peak Lomb-Scargle 
periodograms in 
de-trended data 
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Methods 
THIN is a validated database of primary care consultation data covering over 
3.7 million active patients which are demographically representative of the 
UK.235–237 The dataset contains individual pseudonymised patient ID, 
prescription details, consultation date and time, reason for consultation 
(recorded through diagnostic code), patient registration details and patient 
clinical and demographic information. 
In order to obtain the monthly rate of de-duplicated UTI consultations, 
nitrofurantoin prescriptions and trimethoprim prescriptions by age and sex, for 
2008-2015, diagnostic codes were extracted (listed in Appendix Chapter 6 
PART B), Patient ID, trimethoprim and nitrofurantoin prescriptions (derived from 
the prescribing information in THIN), country, date of UTI 
consultation/prescription, date of registration at GP, date of de-registration at 
GP, patient age, patient sex, and patients registered on the 1st of July (mid-
year) each year for 2008-2015 at each of the GP practices present in THIN 
during the whole duration of the study (for this, practice ID was required). UTI 
consultations and nitrofurantoin and trimethoprim prescriptions from UK 
practices meeting acceptable standard for research (as suggested by the THIN 
Data Guide for Researchers) were de-duplicated to one per patient per 30-day 
period in order to approximate episodes of infection (one nitrofurantoin or 
trimethoprim prescription during the 30-day period) and subsequently 
aggregated by age group, sex and moth of the study. The denominator 
population was the number of patients (of the corresponding age group and 
sex) registered at each of the GP practices on the 1st of July (mid-year) each 
year of the study.  
Reasoning for analysing both GP consultations and antibiotic 
prescriptions 
Consultation codes in THIN are known to be poorly recorded238,239.  However, 
all prescriptions made by GP practices reporting to THIN are automatically 
included in the database and do not suffer from this reporting bias. Hence, the 
analysis of UTI consultations was repeated for trimethoprim and nitrofurantoin 
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prescriptions. Both trimethoprim and nitrofurantoin are almost exclusively 
prescribed for UTIs and account for the majority of antibiotics used for UTIs in 
primary care.  
Only the rate of UTI consultations (and not antibiotic prescriptions) was used to 
assess the trend in UTIs over time, because nitrofurantoin and trimethoprim 
prescriptions for UTI as a proportion of all antibiotic prescriptions increased over 
the study period (Figure 6-1). Although coding for UTI consultations by GPs was 
poor, it remained stable over the study period (the percentage of trimethoprim 
and nitrofurantoin prescriptions that had a UTI consultation coded on the same 
day fluctuated between 35-41% during the study period), enabling the study of 
trend over time (Figure 6-2). 
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Figure 6-1. Percentage of monthly UTI consultation coded with any antibiotic prescription 
on the same day for which that antibiotic was trimethoprim or nitrofurantoin, by age 
group. 
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Figure 6-2. Percentage of monthly trimethoprim and nitrofurantoin prescriptions that had 
a UTI consultation coded on the same day for those aged under 85 and 85 or over. 
Nitrofurantoin and trimethoprim are almost exclusively prescribed for UTI; therefore this can be 
interpreted as a proxy for coding of UTI consultation.  
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Statistical methods 
Separate negative binomial models were fit to the rate of UTI consultations and 
trimethoprim and nitrofurantoin prescriptions in order to assess trend and 
seasonality. Negative binomial models were best suited to model the rates of 
consultations and prescriptions due to the overdispersion in the data. These 
were repeated by age group (14-17, 18-24, 25-45, 46-69, 70-84, 85+) and by 
sex. All models included a trend term modelled as a quadratic function of time. 
This term explained the trend observed better than a linear term, as measured 
by the AIC. A seasonality term was then added. The dispersion parameter was 
fixed at the estimate derived for the seasonal model, which was more complex. 
This enabled the comparison of the fit of the models with and without the 
seasonality term using the AIC and the percentage of deviance explained by the 
model. In addition, a correlogram was plotted to explore the correlations 
between the residuals of the model and the lagged values of the residuals for 
lags 1-12 (over the course of a year).  
The negative binomial model including seasonality can be defined by the 
following equation:  
log(λ𝑡) = a + 𝑡𝑟𝑒𝑛𝑑𝑡 + 𝑠𝑒𝑎𝑠𝑜𝑛𝑎𝑙𝑖𝑡𝑦𝑡 + log (𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛𝑡) 
Where, 𝑡 was the month of the study; λ𝑡 was the number of consultations and 
prescriptions at month 𝑡; a was the intercept; 𝑡𝑟𝑒𝑛𝑑𝑡 was a quadratic term 
defined as 𝑡𝑟𝑒𝑛𝑑𝑡 = a + b𝑡 + c𝑡
2, used to account for the decreasing trend 
observed in the rates; 𝑠𝑒𝑎𝑠𝑜𝑛𝑎𝑙𝑖𝑡𝑦𝑡 was a seasonality term defined as 
𝑠𝑒𝑎𝑠𝑜𝑛𝑎𝑙𝑖𝑡𝑦𝑡 = cos (
2Π𝑡
12
) + sin (
2Π𝑡
12
); and log (𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛𝑡) was an offset used to 
model the rates of consultations and prescriptions instead of the counts. 
Adding an autoregressive term at lag of 1 month in the regression to test for 
local statistical dependence or autocorrelation was also explored, as it is 
common for infection time series data; however, it did not significantly improve 
the fit of the models.  
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All the analysis was carried out in R version 3.3.0240 using the glm.nb function in 
the MASS package241 to obtain the theta (the dispersion parameter) of the full 
model. Subsequently the glm function (stats package) was used to fit the model 
with the fixed theta.  
Sensitivity analysis 
In order to assess coding reliability for UTI consultations in THIN, the 
percentage of monthly trimethoprim and nitrofurantoin prescriptions that had a 
UTI consultation coded on the same day was calculated. These appeared to 
follow a cyclical pattern during the year; therefore, in order to account for any 
seasonality in coding, the monthly UTI consultations were scaled for each age 
group by dividing by a scaling factor. This scaling factor was the percentage of 
UTIs coded in each month (as described above) divided by the maximum 
percentage coded over the study period for that age group. As a sensitivity 
analysis, the seasonality was also assessed in these scaled UTIs. We also 
repeated the analysis for England. 
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Results 
UTI consultations and trimethoprim and nitrofurantoin prescriptions 
Between 1 January 2008 and 31 December 2015, there were 992,803 de-
duplicated UTI consultations and 1719416 de-duplicated trimethoprim and 
nitrofurantoin prescriptions reported to THIN. The mean monthly rate of UTI 
consultations and trimethoprim and nitrofurantoin prescriptions per 100,000 
population for all age groups and by sex is shown in Table 6-2. Both measures 
increased steeply with age, particularly in males. 
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Table 6-2. Descriptive table of the rates of UTI consultations and trimethoprim and nitrofurantoin prescriptions by age group and sex. These were 
de-duplicated to 1 per patient per 30-day period in order to approximate episodes of infection (1 nitrofurantoin or trimethoprim prescription during the 30-day 
period). 
Age 
groups 
Percentage of 
UTI 
consultations 
Mean 
monthly rate 
of UTI 
consultations 
per 100,000 
population 
Mean monthly 
rate of UTI 
consultations 
in females per 
100,000 
population 
Mean monthly 
rate of UTI 
consultations 
in males per 
100,000 
population 
Percentage of 
trimethoprim 
and 
nitrofurantoin 
prescriptions 
Mean monthly 
rate of 
trimethoprim 
and 
nitrofurantoin 
prescriptions 
per 100,000 
population 
Mean monthly 
rate of 
trimethoprim 
and 
nitrofurantoin 
prescriptions in 
females per 
100,000 
population 
Mean monthly 
rate of 
trimethoprim 
and 
nitrofurantoin 
prescriptions in 
males per 
100,000 
population 
0-13 6.3 144.3 232.0 51.5 6.0 238.3 360.3 123.7 
14-17 2.6 195.4 377.4 19.4 2.4 302.1 581.9 55.4 
18-24 10.1 394.0 736.7 25.8 7.9 529.4 1002.0 67.8 
25-45 23.6 257.5 452.6 37.1 20.4 385.5 679.6 83.2 
46-69 28.7 313.1 508.1 93.9 30.5 573.5 941.6 207.2 
70-84 20.0 617.2 830.6 305.1 22.5 1200.2 1663.7 643.5 
85+ 8.7 738.1 845.3 471.2 10.3 1489.5 1793.6 958.3 
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Trend 
Although coding for UTI consultations by GPs was poor, it remained stable over 
the study period (the percentage of trimethoprim and nitrofurantoin prescriptions 
that had a UTI consultation coded on the same day fluctuated between 35-41% 
during the study period), enabling the study of trend over time (Figure 6-3).  
With the exception of males aged 70-84, the rate of UTI consultations for both 
males and females of all age groups decreased during the study period, as 
shown by the greatly improved AIC when adding a linear trend term to the 
model (see Figure 6-3, Table 6-3 and Table 6-4). This decrease was particularly 
pronounced for females aged 85 or older. The trend in the UK was very similar 
to the trend in England (Figure 6-4). 
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Figure 6-3. Monthly UTI consultations coded by GPs per 100,000 person years in the UK 
by age group and sex. The central red lines represent the fitted trend predictions from the 
seasonal regression model. This was a negative binomial polynomial regression model of 
degree two with the number of patients registered at each of the GP practices on the 1
st
 of July 
(mid-year) each year of the study as offset. The UTI consultations were de-duplicated to one 
per 30-day period.  The y axes differ between panels. 
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Table 6-3. Akaike information criteria (AIC) for the models of UTI consultations in the UK 
including a seasonal component with no trend term, a linear trend term and a quadratic 
trend term, by sex and age group. *In order to calculate the AIC, the dispersion parameter 
(theta) was fixed at the estimate derived for the most complex model (the seasonal model with a 
quadratic trend term). The trend term was given by t + t2 and the seasonality term by 
cos (
2Π𝑡
12
) + sin (
2Π𝑡
12
), where t was the month of the study (1 to 96). 
Sex Age group AIC of the 
regression model 
with no trend term* 
AIC of the 
regression 
model with a 
linear trend term 
(𝑡)* 
AIC of the 
regression model 
with a quadratic 
trend term (𝑡 + 𝑡2) 
All UTIs 14-17 1131.302 936.8906 925.5975 
All UTIs 18-24 1375.33 1119.663 1083.569 
All UTIs 25-45 1330.703 1249.725 1234.055 
All UTIs 46-69 1281.198 1244.596 1231.499 
All UTIs 70-84 1193.373 1181.468 1168.383 
All UTIs 85+ 1298.537 1054.343 1036.552 
Female UTIs 14-17 1170.251 930.8574 917.3008 
Female UTIs 18-24 1360.837 1117.974 1078.937 
Female UTIs 25-45 1327.862 1237.177 1221.477 
Female UTIs 46-69 1262.241 1218.761 1205.818 
Female UTIs 70-84 1143.959 1134.796 1123.924 
Female UTIs 85+ 1241.139 1015.206 1001.247 
Male UTIs 14-17 582.4998 568.1808 570.5024 
Male UTIs 18-24 678.9267 624.9811 627.5591 
Male UTIs 25-45 918.8692 802.7613 797.7937 
Male UTIs 46-69 930.2015 922.5998 920.3444 
Male UTIs 70-84 929.6153 931.4508 920.3366 
Male UTIs 85+ 861.6667 830.0555 819.1208 
  
1
6
5
 
Table 6-4. Coefficients and 95% confidence intervals (CI) of the models of UTI consultations in the UK by sex and age group. The trend term was 
given by t + t2 and the seasonality term by cos (
2Π𝑡
12
) + sin (
2Π𝑡
12
), where t was the month of the study (1 to 96). The confidence intervals were calculated using 
the confint function in R. 
Sex ages 𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡  
(95% CI) 
𝑡  
(95% CI) 
𝑡2  
(95% CI) 
cos (
2Π𝑡
12
)  
(95% CI) 
sin (
2Π𝑡
12
)  
(95% CI) 
All UTIs 14-17 -6.08  
(-6.15, -0.00268) 
0.000415  
(-6.15, -0.00268) 
-6.2e-05  
(-6.15, -0.00268) 
0.0994  
(-6.15, -0.00268) 
-0.154  
(-6.15, -0.00268) 
All UTIs 18-24 -5.46  
(-5.49, 0.00013) 
0.00193  
(-5.49, 0.00013) 
-5.85e-05  
(-5.49, 0.00013) 
0.0241  
(-5.49, 0.00013) 
-0.1  
(-5.49, 0.00013) 
All UTIs 25-45 -5.93  
(-5.97, 4.64e-05) 
0.00173  
(-5.97, 4.64e-05) 
-3.83e-05  
(-5.97, 4.64e-05) 
0.0205  
(-5.97, 4.64e-05) 
-0.0818  
(-5.97, 4.64e-05) 
All UTIs 46-69 -5.76  
(-5.79, 0.000349) 
0.00172  
(-5.79, 0.000349) 
-2.9e-05  
(-5.79, 0.000349) 
0.0102  
(-5.79, 0.000349) 
-0.0763  
(-5.79, 0.000349) 
All UTIs 70-84 -5.1  
(-5.13, 0.000806) 
0.00222  
(-5.13, 0.000806) 
-2.98e-05  
(-5.13, 0.000806) 
-0.00302  
(-5.13, 0.000806) 
-0.0524  
(-5.13, 0.000806) 
All UTIs 85+ -5.1  
(-5.13, 0.000806) 
0.00222  
(-5.13, 0.000806) 
-2.98e-05  
(-5.13, 0.000806) 
-0.00302  
(-5.13, 0.000806) 
-0.0524  
(-5.13, 0.000806) 
Female UTIs 14-17 -5.4  
(-5.47, -0.0029) 
0.000229  
(-5.47, -0.0029) 
-6.72e-05  
(-5.47, -0.0029) 
0.101  
(-5.47, -0.0029) 
-0.167  
(-5.47, -0.0029) 
Female UTIs 18-24 -4.84  
(-4.87, 0.000431) 
0.00225  
(-4.87, 0.000431) 
-6.12e-05  
(-4.87, 0.000431) 
0.0236  
(-4.87, 0.000431) 
-0.101  
(-4.87, 0.000431) 
Female UTIs 25-45 -5.36  
(-5.4, -6.22e-05) 
0.00164  
(-5.4, -6.22e-05) 
-3.87e-05  
(-5.4, -6.22e-05) 
0.0201  
(-5.4, -6.22e-05) 
-0.0852  
(-5.4, -6.22e-05) 
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Sex ages 𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡  
(95% CI) 
𝑡  
(95% CI) 
𝑡2  
(95% CI) 
cos (
2Π𝑡
12
)  
(95% CI) 
sin (
2Π𝑡
12
)  
(95% CI) 
Female UTIs 46-69 -5.27  
(-5.3, 0.000253) 
0.00168  
(-5.3, 0.000253) 
-2.98e-05  
(-5.3, 0.000253) 
0.0114  
(-5.3, 0.000253) 
-0.0812  
(-5.3, 0.000253) 
Female UTIs 70-84 -4.81  
(-4.84, 0.000701) 
0.00216  
(-4.84, 0.000701) 
-2.85e-05  
(-4.84, 0.000701) 
-0.00206  
(-4.84, 0.000701) 
-0.0564  
(-4.84, 0.000701) 
Female UTIs 85+ -4.81  
(-4.84, 0.000701) 
0.00216  
(-4.84, 0.000701) 
-2.85e-05  
(-4.84, 0.000701) 
-0.00206  
(-4.84, 0.000701) 
-0.0564  
(-4.84, 0.000701) 
Male UTIs 14-17 -8.43  
(-8.61, -0.00787) 
0.00113  
(-8.61, -0.00787) 
-6.03e-05  
(-8.61, -0.00787) 
0.0924  
(-8.61, -0.00787) 
0.0412  
(-8.61, -0.00787) 
Male UTIs 18-24 -8.08  
(-8.19, -0.00684) 
-0.00185  
(-8.19, -0.00684) 
-3.08e-05  
(-8.19, -0.00684) 
0.0383  
(-8.19, -0.00684) 
-0.0673  
(-8.19, -0.00684) 
Male UTIs 25-45 -7.8  
(-7.85, -0.00216) 
0.000213  
(-7.85, -0.00216) 
-3.67e-05  
(-7.85, -0.00216) 
0.028  
(-7.85, -0.00216) 
-0.0499  
(-7.85, -0.00216) 
Male UTIs 46-69 -6.97  
(-7.01, -0.000274) 
0.0015  
(-7.01, -0.000274) 
-2.24e-05  
(-7.01, -0.000274) 
0.00462  
(-7.01, -0.000274) 
-0.0508  
(-7.01, -0.000274) 
Male UTIs 70-84 -5.84  
(-5.88, 0.00151) 
0.00323 
(-5.88, 0.00151) 
-3.39e-05  
(-5.88, 0.00151) 
-0.0071  
(-5.88, 0.00151) 
-0.036  
(-5.88, 0.00151) 
Male UTIs 85+ -5.84  
(-5.88, 0.00151) 
0.00323 
(-5.88, 0.00151) 
-3.39e-05  
(-5.88, 0.00151) 
-0.0071  
(-5.88, 0.00151) 
-0.036  
(-5.88, 0.00151) 
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Figure 6-4. Monthly UTI consultations coded by GPs per 100,000 person years in England 
and in the UK by age group. The central red lines represent the fitted predictions of the 
negative binomial polynomial regression model of degree two with the number of patients 
registered at each of the GP practices on the 1
st
 of July (mid-year) each year of the study as 
offset. The central blue lines represent the fitted predictions of the same model but with a 
seasonal component included. The shaded areas represent the 95% confidence intervals for 
their respective models. These were calculated using the standard errors from the predict 
function, which calculates the confidence intervals around the mean. The UTI consultations 
were de-duplicated to one per 30-day period. The y axes differ between panels. 
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Seasonality by age 
Adding a seasonal component to the negative binomial regression greatly 
improved the model fit to the data for ages 14-17, 18-24, 25-45 and 46-69, as 
measured by the AIC and the percentage of deviance explained by the model 
(see Table 6-5), showing UTI consultations in these age groups follow a cyclic 
yearly pattern. For ages 70-84, there was also a notable improvement in model 
fit; however, in those aged 85 or older, the improvement was minimal (73.62% 
of the deviance explained by the seasonal model, 72.91% by the non-seasonal 
model). In younger ages there is no overlap between the 95% CIs of the models 
with and without seasonality during the September to November period for most 
years (Figure 6-5), which meant the difference was statistically significant.  
Table 6-5. Akaike information criteria (AIC) and the percentage deviance explained by the 
models of UTI consultations in the UK including a seasonal component and models that 
did not by age group. 
Age group AIC seasonal 
model 
AIC non-
seasonal model* 
% deviance 
explained by the 
seasonal model 
% deviance 
explained by the 
non-seasonal 
model 
14-17 925.60 1063.98 77.46 43.25 
18-24 1083.57 1210.22 80.65 53.94 
25-45 1234.05 1329.14 66.19 30.61 
46-69 1231.50 1353.64 64.17 16.43 
70-84 1168.38 1218.51 46.24 14.95 
85+ 1036.55 1033.14 73.62 72.91 
*In order to calculate the AIC and percentage deviance explained for the non-seasonal model, 
the dispersion parameter (theta) was fixed at the estimate derived for the seasonal model. 
The correlograms in Figure 6-5 show the autocorrelation functions for the 
residuals of the regression models without seasonality at lags of 0-12 months. 
For ages 14-17, 18-24, 25-45 and 46-69, the correlograms show oscillatory 
patterns consistent with seasonality. This pattern is less pronounced in the 70-
84 year olds and disappears in those aged 85+. With 1 exception (January 
2014), the month of the year with the highest number of UTI consultations in 
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those aged under 85 every year from 2008 to 2015 were between September 
and November (Table 6-6).  
 
Figure 6-5. Seasonality in UTI consultations coded in the UK per 100,000 person years by 
age. The left panels show the rate of UTI consultations by age group. The central red lines 
represent the fitted predictions of the negative binomial polynomial regression model of degree 
2 with the number of patients registered at each of the GP practices on the 1
st
 of July (mid-year) 
each year of the study as offset. The central blue lines represent the fitted predictions of the 
same model but with a seasonal component included. The shaded areas represent the 95% 
confidence intervals for their respective models. These were calculated using the standard 
errors from the predict function, which calculates the confidence intervals around the mean. The 
right panels show the correlograms for the residuals of the regression models without 
seasonality at lags of 0-12 months for each age group. The September to November period is 
shaded in grey. The UTI consultations were de-duplicated to 1 per 30-day period. The y axes 
differ between panels. 
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Table 6-6. Month of the year with the highest number of UTI consultations or trimethoprim and nitrofurantoin prescriptions by age group. In 
brackets, the rate of UTI consultations or trimethoprim and nitrofurantoin prescriptions per 100,000 person years for that month. 
Date Trimethoprim and 
nitrofurantoin 
prescriptions in the 
UK <85 
Trimethoprim and 
nitrofurantoin 
prescriptions in the 
UK 85+ 
UTI consultations in 
the UK <85 
UTI consultations in 
the UK 85+ 
UTI consultations in 
England <85 
UTI consultations in 
England 85+ 
2008 Oct (515.08) Jan (1886.24) Sep (352.52) Jan (922.37) Sep (355.56) Jan (826.19) 
2009 Sep (535.13) Oct (1622.4) Sep (350.65) Jan (881.78) Sep (352.6) Jan (817.95) 
2010 Sep (554.32) Mar (1612.09) Sep (344.01) Jul (838.79) Sep (339.61) Jul (764.2) 
2011 Nov (587.15) Mar (1653.98) Sep (342.48) Aug (814) Sep (345.05) Nov (742.15) 
2012 Oct (621.67) Jan (1799.42) Oct (349.52) Jan (817.35) Oct (345.29) Jan (740.61) 
2013 Oct (622.2) Jan (1768.77) Oct (349.18) Jan (809.73) Oct (340.93) Oct (741.06) 
2014 Oct (597.12) Jan (1687.91) Jan (325.01) Jan (756.34) Oct (317.27) Jan (645.86) 
2015 Sep (556.59) Jan (1517.94) Sep (293.28) Jan (692.45) Sep (282.98) Jan (611.35) 
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The same seasonal pattern was observed for the scaled monthly UTI 
consultations (Figure 6-6 and Table 6-7), for trimethoprim and nitrofurantoin 
prescriptions (Figure 6-7), when restricting the analysis to England (Figure 6-8), 
and when analysing the seasonality of urine samples submitted to the AmSurv 
database186 in the West Midlands (Appendix Chapter 6 PART A).  
 
Figure 6-6. Scaled monthly UTI consultations coded per 100,000 person years in the UK 
by age group. The UTI consultations were de-duplicated to one per 30-day period. The red 
lines represent the fitted predictions of the negative binomial polynomial regression model of 
degree two with the number of patients registered at each of the GP practices on the 1
st
 of July 
(mid-year) each year of the study as offset. The blue lines represent the fitted predictions of the 
same model but with a seasonal component included. No confidence intervals are presented as 
these were scaled predictions. The monthly UTI consultations were scaled for each age group 
by dividing by a scaling factor. This scaling factor was the percentage of UTIs coded in each 
month (the percentage of monthly trimethoprim and nitrofurantoin prescriptions that had a UTI 
consultation coded on the same day) divided by the maximum percentage coded over the study 
period for that age group. The right panels show the correlograms for the residuals of the 
regression models without seasonality at lags of 0-12 months for each age group. The y axes 
differ between panels.  
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Table 6-7. Akaike information criteria (AIC) for models of the scaled UTI consultations in 
the UK which included a seasonal component and models that did not by age group. *In 
order to calculate the AIC for the non-seasonal model, the dispersion parameter (theta) was 
fixed at the estimate derived for the seasonal model. 
Age group AIC seasonal 
model 
AIC non-
seasonal model* 
% deviance 
explained by the 
seasonal model 
% deviance 
explained by the 
non-seasonal 
model 
14-17 960.78 1041.58 72.21 46.84 
18-24 1096.01 1196.45 77.92 53.5 
25-45 1242.65 1293.55 54.06 26.85 
46-69 1254.36 1309.21 48.88 16.55 
70-84 1196.56 1217.86 28.74 8.51 
85+ 1108.25 1103.92 44.43 43.47 
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Figure 6-7. Monthly nitrofurantoin and trimethoprim prescriptions administered by GPs 
per 100,000 person years in the UK by age group. The nitrofurantoin and trimethoprim 
prescriptions were de-duplicated to one per 30-day period. The central red lines represent the 
fitted predictions of the negative binomial polynomial regression model of degree two with the 
number of patients registered at each of the GP practices on the 1
st
 of July (mid-year) each year 
of the study as offset. The central blue lines represent the fitted predictions of the same model 
but with a seasonal component included. The shaded areas represent the 95% confidence 
intervals for their respective models. These were calculated using the standard errors from the 
predict function, which calculates the confidence intervals around the mean. The right panels 
show the correlograms for the residuals of the regression models without seasonality at lags of 
0-12 months for each age group. The y axes differ between panels. 
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Figure 6-8. Monthly UTI consultations coded per 100,000 person years in England by age 
group. The UTI consultations were de-duplicated to one per 30-day period. The central red 
lines represent the fitted predictions of the negative binomial polynomial regression model of 
degree two with the number of patients registered at each of the GP practices on the 1
st
 of July 
(mid-year) each year of the study as offset. The central blue lines represent the fitted 
predictions of the same model but with a seasonal component included. The shaded areas 
represent the 95% confidence intervals for their respective models. These were calculated 
using the standard errors from the predict function, which calculates the confidence intervals 
around the mean. The right panels show the correlograms for the residuals of the regression 
models without seasonality at lags of 0-12 months for each age group. The y axes differ 
between panels. 
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Seasonality by sex 
Figure 6-9 shows the seasonality of the rate of UTI consultations by sex and 
large groupings of age for which seasonality varies (<85 and 85+). UTIs in 
males followed a similar pattern to females; however, they were rare, which 
reduced statistical power to detect seasonality. Including a seasonal component 
into the regression model of the younger age group improved the model fit (the 
AIC decreased from 1092.5 to 1066.3 and the percentage deviance explained 
by the model more than doubled from 12.9 to 34.8). There was also an 
oscillatory pattern visible in the correlogram, although few correlations were 
significant. This contrasted with a clear lack of oscillatory shape in the 
correlogram for UTI consultations in males aged 85 and older and a lack of 
improvement in model fit when adding a seasonal term (the AIC increased from 
816.5 to 819.1 and the percentage deviance explained by the model only 
increased very slightly from 32.9 to 35.3). This is similar to what is observed for 
trimethoprim and nitrofurantoin prescriptions (Figure 6-10). 
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Figure 6-9. Seasonality in UTI consultations coded in the UK per 100,000 person years by 
age group and sex. The left panels show the rate of UTI consultations by age group and sex. 
The central red lines represent the fitted predictions of the negative binomial polynomial 
regression model of degree 2 with the number of patients registered at each of the GP practices 
on the 1
st
 of July (mid-year) each year of the study as offset. The central blue lines represent 
the fitted predictions of the same model but with a seasonal component included. The shaded 
areas represent the 95% confidence intervals for their respective models. These were 
calculated using the standard errors from the predict function, which calculates the confidence 
intervals around the mean. The right panels show the correlograms for the residuals of the 
regression models without seasonality at lags of 0-12 months for each age group. The 
September to November period is shaded in grey. The UTI consultations were de-duplicated to 
1 per 30-day period. The y axes differ between panels. 
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Figure 6-10. Monthly nitrofurantoin and trimethoprim prescriptions administered by GPs 
to males per 100,000 person years in the UK by age group. The nitrofurantoin and 
trimethoprim prescriptions were de-duplicated to one per 30-day period. The central red lines 
represent the fitted predictions of the negative binomial polynomial regression model of degree 
two with the number of patients registered at each of the GP practices on the 1
st
 of July (mid-
year) each year of the study as offset. The central blue lines represent the fitted predictions of 
the same model but with a seasonal component included. The shaded areas represent the 95% 
confidence intervals for their respective models. These were calculated using the standard 
errors from the predict function, which calculates the confidence intervals around the mean. The 
right panels show the correlograms for the residuals of the regression models without 
seasonality at lags of 0-12 months for each age group. The AIC of the model in those aged 
under 85 decreases (from 1262.5 to 1237.4) by including seasonality in older people, but 
remains similar in those aged 85+ (928.0 in the model without seasonality and 932.9 in the 
model with seasonality). The y axes differ between panels. 
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Discussion 
Summary 
There was a September to November peak in UTI consultations and in 
trimethoprim and nitrofurantoin prescriptions for UTI in those aged 14-69 in the 
UK; however, this seasonality gradually disappeared with age and was not 
apparent in those aged 85 or older. Similar patterns were observed for males 
and females, although male UTIs were rare, which reduced statistical power.  
Mechanism 
The exact mechanism surrounding the seasonality of UTI consultations 
observed is likely to be complex, involving interactions between real UTI 
incidence, healthcare seeking behaviour, access to care and severity. A full 
analysis of the mechanisms underlying the autumnal seasonality observed in 
younger age groups is beyond the scope of this study and warrants further 
research. However, these could be influenced by sexual behaviour patterns, as 
recent sexual intercourse is an important risk factor for UTI in young women242. 
Given that the seasonal peak was not in high summer, when one might expect 
more dehydration, the influence of dehydration and temperature on UTI 
incidence in younger age groups remains unclear. 
Risk factors for UTI in older people include recurrent UTIs, incontinence, 
catheter use, disruptions to the normal vaginal flora, diabetes mellitus, prostatic 
hypertrophy (in men), and cognitive impairment or other comorbidities that may 
impede adequate self-hygiene47. These risk factors are less likely to be 
influenced by seasonal variation. UTIs in the very old can be considered a 
symptom of general frailty and poor care, such as consistent dehydration 
throughout the year, poor hygiene or inadequate catheter care. Our findings do 
not suggest a different seasonality in men and women; therefore, it is unlikely 
that the lack of seasonality detected in the very old is driven by the increase in 
the proportion of UTIs that are in males in this age group.  
The decrease in GP consultations for UTI contrasts with the steady increase in 
admissions to hospital for UTIs in England (which did not include A&E 
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attendances)10,34. While these are not truly comparable datasets, this difference 
between the GP and hospital data could indicate an increase in severity of UTIs 
or treatment failure due to antibiotic resistance, which means UTIs could more 
frequently warrant hospitalisation. Increases in hospital admissions for UTI 
could also denote shortfalls in the management of UTI in the community, for 
example in social care and community nursing5, as well as correct antibiotic 
treatment in primary care, which are important in preventing admissions to 
hospital. Antibiotic prescriptions were not used to assess the trend in UTIs over 
time, because nitrofurantoin and trimethoprim prescriptions for UTI as a 
proportion of all antibiotic prescriptions increased over the study period. 
Findings in context 
Many studies that addressed seasonality in the literature simply reported 
differences in incidence222,227,230,232. One of the studies set in the UK reported a 
peak in S. saprophyticus UTI in mid-September and a peak in all Gram-negative 
bacilli other than Proteus spp. and Pseudomonas spp. (aggregated) in 
March229. Gram-negative bacteria comprise the majority of the organisms that 
cause UTI; therefore, their findings are not in agreement with ours. That study 
assessed the seasonality of urine specimens from 1978-1983 and the 
epidemiology and sampling of UTIs could have changed greatly since then. The 
other study from the UK found a higher number of UTIs during the winter 
months in children seen in hospital in Durham222. As only adults in this study 
were studied and the authors did not report their methods, a comparison is not 
possible.  
The seasonality of UTIs has been studied in other countries; however, the 
findings from these studies are also conflicting (Table 6-1). Two studies 
reported autumnal peaks in incidence223,231. However, neither employed 
appropriate methods to assess seasonality. Eriksson et al. (2012) only reported 
the monthly total of samples received for 1 year and Vorland et al. (1985) 
studied seasonality in large aggregated time periods, which resulted in loss of 
information.  
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In England, the seasonality of E. coli BSIs varied by region243. As the urinary 
tract has been reported to be a primary source of infection for bloodstream 
infections, the seasonality of UTIs could also vary by region.  
Strengths and limitations 
This study is the first to formally assess the trend and seasonality of UTI 
consultations in the UK. This was a large study carried out in THIN, which is a 
validated database of primary care consultation data covering over 3.7 million 
active patients which are demographically representative of the UK235–237. It was 
carried out over a period of 8 years (January 2008 to December 2015), which 
should help minimize the bias of detecting patterns that only occurred 
sporadically. In addition, the UTI consultations analysis was repeated for 
trimethoprim and nitrofurantoin prescriptions, which confirmed these findings. 
The percentage of trimethoprim or nitrofurantoin prescriptions that had a UTI 
consultation coded on the same day (a proxy for UTI consultation coding) was 
low; however, it remained relatively stable during the study period, at between 
35-41%. As this study focused on patients with UTIs that presented to primary 
care, these conclusions may not extend to complicated UTIs seen in hospital, 
nor to UTIs that resolved with over-the-counter medication such as alkalinising 
agents and didn’t warrant a GP visit. In addition, although the analysis of 
seasonality in trimethoprim and nitrofurantoin prescriptions was used as a 
sensitivity analysis, there are also limitations in using these antibiotics as a 
proxy for UTI consultation as they do not make up the entirety of prescriptions 
for UTIs in secondary care.  
Two alterations could have also been made to the model. Firstly, seasonality 
could have been modelled using alternative shapes. For example, a harmonic 
could have been added; however, although this model may have fit the data 
better, it would not change the findings of the study. Secondly, an alternative to 
separately modelling each age group and sex would be to combine these in a 
model and use interaction terms to estimate age-specific parameters of trend 
and seasonality.  
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Finally, care must be taken when extrapolating these findings beyond the UK 
setting, where the range of temperatures throughout the year is relatively small. 
Clinical implications 
Our findings highlight that UTI prevention in older people should warrant 
attention throughout the year, as UTIs in this population are common year 
round and can be regarded as a symptom of general frailty. We also provide 
helpful information for the interpretation of the results of interventions and 
surveillance reports. For example, a decrease in UTI incidence in spring could 
be due to the effectiveness of a trialled intervention against UTIs, the seasonal 
pattern in UTIs, which yearly decrease during this period, or a combination of 
both, and their effect should be disentangled in order to correctly interpret the 
intervention effectiveness. Oppositely, an increase in incidence or antibiotic 
prescription during the autumn should be interpreted in the context of the yearly 
peak observed during this time.  
Further research  
Further research should focus on the prevention of UTI in older people, as this 
was the population with the highest burden of UTI. This study did not identify an 
impact of season on the incidence of UTI in this population; therefore, further 
research on the impact of patient and clinical factors is needed to identify areas 
that could be targeted for quality improvement. In addition, understanding the 
causes of the peak in UTI incidence during the autumn in those aged 14-69 
could then help select strategies for their avoidance and treatment. It would also 
be interesting to determine the susceptibility of samples taken during GP UTI 
consultations. This would help give more precise estimates of the prevalence of 
resistance, as the proportion of UTIs sampled would be recorded, and identify 
the comorbidity and prescribing practices associated with antibiotic resistance, 
which would help target interventions appropriately. However, there is no 
routinely collected dataset in England that captures both GP consultations and 
susceptibility data. 
The contrast between the decrease in GP consultations for UTI in this analysis 
and the steady increase in admissions to hospital for UTIs in England (which did 
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not include A&E attendances)10,34 also warrants further study. The Clinical 
Practice Research Datalink (CPRD) database, which is a similar dataset to 
THIN, comprising GP consultation data from practices representative of the UK, 
has been linked to the Hospital Episode Statistics (HES) database. This dataset 
may be useful to track the most commonly occurring UTI pathways in older 
people and identify the main adverse outcomes resulting from UTI (e.g. 
recurrent UTI, hospital admission, progression to blood stream infection). The 
association between antibiotic prescribing practice and UTI progression to 
adverse outcomes could also be quantified using these data. This will be 
important in order to improve the community management of UTIs and prevent 
unnecessary admissions to hospital in the future.  
LTCF residence is poorly recorded in GP and hospital records. Identifying LTCF 
residents within the CPRD-HES database would enable the comparison of 
these patient pathways for LTCF residents and older people living in the 
community. In addition, this would provide the first large source of data of 
antibiotic prescribing data for this population in England. 
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Conclusions 
This study is the first to formally assess the trend and seasonality of UTI 
consultations in the UK. This was a large study comprising UTI consultations 
from January 2008 to December 2015. Two distinct age-dependent patterns of 
seasonality were found in the UK. UTI consultations in those aged 14-69 
peaked from September to November. This seasonality gradually disappeared 
with age and was not apparent in those aged 85 or older. Similar patterns were 
observed for males and females, although male UTIs were rare. This analysis 
was repeated for trimethoprim and nitrofurantoin prescriptions, in England, 
confirming these findings. These results suggest that, unlike in those ages 14-
69, UTIs in older people are not associated with seasonal factors, suggesting 
that UTI prevention in this population should warrant attention throughout the 
year. In addition, the autumnal peak observed in those aged 14-69 provides 
helpful information for the interpretation of the results of interventions and 
surveillance reports. Further research should focus on the prevention of UTI in 
older people, and on understanding the causes of the peak in UTI incidence 
during the autumn in those aged 14-69. In addition, GP data provides exciting 
opportunities for linkage with hospital, susceptibility and LTCF data, which could 
yield interesting insights into the pathways of UTI progression in older people. 
Insight from these studies could help identify key factors that could be targeted 
to prevent hospitalisations. 
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Chapter 7  Mathematical modelling of the 
transmission of E. coli resistant trimethoprim in the 
LTCF 
Aims  
1. To develop a mathematical model which describes the movement of 
patients in and out of a LTCF and describes the transmission dynamics 
of trimethoprim resistance 
2. To parameterise this model using the best available data and literature 
sources. 
3. To carry out sensitivity analyses on this parameter set. 
Introduction 
In Chapter 5, it was shown that LTCF residents were more than four times more 
likely than community dwelling older people to develop a laboratory confirmed 
E. coli UTI caused by resistant bacteria; and that 60% of E. coli from urine 
specimens taken from LTCF residents were resistant to trimethoprim. These 
figures highlight the need for understanding the dynamics of trimethoprim 
resistance in this setting. 
Resistance to first-line treatments for UTI such as trimethoprim and 
nitrofurantoin can result in treatment failure, hospitalisation, and the subsequent 
use of antibiotics such as ciprofloxacin or 3GCs that should be reserved for the 
treatment of more serious infections. The reduction of inappropriate antibiotic 
prescribing for UTIs in primary care is precisely one of the targets of the Quality 
Premium Scheme developed by NHS England for reducing gram-negative 
BSIs.244 As explained in Chapter 5, in 2014, national primary care prescribing 
guidelines have switched from recommending trimethoprim as first-line 
treatment for UTI to recommending nitrofurantoin (unless there is a low risk for 
resistance to trimethoprim, in which case trimethoprim is also recommended).50 
Although in line with these recommendations, trimethoprim prescription has 
decreased during 2014-2015; trimethoprim is still the most commonly 
prescribed antibiotic in the community for UTI.35 In addition, 86% of CCGs in 
 185 
 
England found that 25% of their community urine specimens were resistant to 
trimethoprim.  
As described in Chapters 2 and 3, dynamic mathematical models are important 
tools in epidemiology and public health which have been used to understand 
the epidemiology of infectious diseases, including AMR infections, to target 
interventions appropriately and to evaluate their health and economic impact.82–
85 Although infectious disease transmission has been modelled extensively in 
the hospital setting, few mathematical models have characterised the spread of 
infectious diseases in the LTCF setting (27 studies). Only three studies have 
modelled the transmission of AMR Gram-negative bacteria in LTCFs (two of 
carbapenem-resistant Enterobacteriaceae 132,133 and one of E. coli ST131134).  
This is an important gap in the literature for multiple reasons. Firstly, 
understanding the dynamics of AMR Gram-negative bacteria in LTCFs is vital. 
Gram-negative bacteria are now the most common cause of hospital-acquired 
infection in England, Wales, and Northern Ireland, including very severe 
infections such as BSIs28. As shown in Chapter 5, AMR Gram-negative bacteria 
are of particular concern in the LTCF setting, where the prevalence of UTI 
caused by AMR bacteria is higher than in hospitals and the rate of acquiring a 
UTI caused by E. coli and Klebsiella resistant to antibiotics is more than four 
times this rate in the remaining community. Understanding the epidemiology of 
infections caused by AMR E. coli is particularly important, as these bacteria are 
ubiquitous in the human gut.  
Secondly, the dynamics of infections caused by AMR E. coli are poorly 
understood through regression models, as shown in Chapter 6, where a 
negative binomial model including a seasonality component was fit to E. coli 
UTI incidence data and was unable to account for all the residual variance 
observed in the data. A dynamic mathematical model should help elucidate the 
additional variance in the data that has not been accounted for in the negative 
binomial regression. 
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Thirdly, mathematical models can incorporate patient movement dynamics 
between different institutions such as between LTCFs and hospitals, which may 
be important for the spread of AMR. 
The three studies that modelled the transmission of AMR Gram-negative 
bacteria in LTCFs published since the initial review focused on infections 
caused by particularly pathogenic Gram-negative bacteria, such as E. coli 
ST131, or bacteria resistant to third-line antibiotics such as carbapenems. 
These may not be representative of most Gram-negative bacteria transmitted in 
LTCFs. As shown in Chapter 5, in the LTCF setting, the most prevalent 
resistance in UTIs caused by E. coli was the resistance to trimethoprim. 
Antibiotic treatment increases the risk of colonisation and subsequent infection 
by resistant bacteria, and therefore, is an important factor to capture when 
modelling the transmission of AMR bacteria.28 One of these three studies 
explored the effect of antibiotic treatment (fluoroquinolones and cephalosporins) 
on resistance. However, no study to date has explored the dynamics of the 
transmission of trimethoprim resistant E. coli in the LTCF setting.  
The incidence of urinary E. coli resistant to trimethoprim used for model fitting 
was derived from the West Midlands AmSurv dataset (described in Chapters 4 
and 5). Consequently, the model was set in the West Midlands and all other 
parameters were, when possible, adjusted to represent the dynamics of 
transmission of E. coli resistant to trimethoprim in LTCFs within this region.  
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Methods 
Modelling approach 
Modelling the dynamics of trimethoprim resistant E. coli in a LTCF involved a 
number of processes. First, a compartmental stochastic dynamic transmission 
model was developed. This was then parameterised with data from a variety of 
sources. CQC registry data, microbiology samples from hospitals and GPs, and 
electronic health records were used. Where suitable data was not available, 
parameters were informed by the literature. Where possible, data from the West 
Midlands were used. As there were no suitable transmission parameters in the 
literature, the model was fit to incidence data, adjusted for case reporting, using 
maximum likelihood estimation.  
The baseline scenario involved fitting the model to incidence data from a LTCF 
in the highest incidence quartile to determine the values of the transmission 
parameters. All remaining parameters were kept at their most plausible values, 
as estimated from data or the literature. 
Sensitivity analyses were then carried out to test the influence of varying the 
model parameters within plausible ranges to the model outputs. This included 
varying the LTCF selected for model fitting. 
In addition, three scenarios were simulated: one in which the transmission rate 
was varied, one in which the proportion of residents discharged to the LTCF 
from hospital (vs. the community) was varied, and one in which the rate of 
trimethoprim prescription was increased. 
Model structure and description 
A compartmental stochastic dynamic transmission model was developed to 
simulate the transmission of trimethoprim-resistant E. coli in a LTCF in the West 
Midlands and the movement of patients in and out of the LTCF.  
All patients were assumed to be colonised with E. coli. This is because E. coli, 
although also sometimes a pathogen, is a common constituent of the healthy 
gut microbiota.12,245 Therefore, this model assumed no uncolonised individuals 
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were present in the LTCF. Due to the lack of data available to parameterise a 
mathematical model of co-colonisation with sensitive and resistant bacteria, a 
simple model was developed in which individuals could either be dominantly 
colonised with E. coli susceptible to trimethoprim or dominantly colonised with 
E. coli resistant to trimethoprim. In this model structure, those colonised with E. 
coli sensitive to trimethoprim are equivalent to ‘susceptible’ individuals in a 
traditional SIS model. Only the transmission of E. coli resistant to trimethoprim, 
which displaced the ‘normal’ E. coli gut flora (E. coli sensitive to trimethoprim), 
was simulated. It was assumed that residents, if untreated with trimethoprim, 
reverted to being colonised by E. coli sensitive bacteria at rate 𝛾.  
LTCF residents could be either treated with trimethoprim or not. Treatment with 
other antibiotics was not modelled. LTCF residents were divided into four 
compartments according to whether they were colonised with E. coli sensitive to 
trimethoprim or resistant to trimethoprim, and whether they were being treated 
with trimethoprim or not. 
Individuals could leave the LTCF by either dying or being hospitalised, and 
could either enter the LTCF directly from hospital or from the community. 
Transfer between LTCFs and discharges of LTCF residents to the community 
were not accounted for because they were considered to be comparatively rare 
events.  
This model can be subdivided in three distinct types of processes: transmission, 
treatment and movement of patients in and out of the LTCF. A schematic of the 
compartmental model can be found in Figure 7-1. 
In the LTCF, patients were divided into four compartments according to whether 
they were being treated with trimethoprim (𝑇, treated) or not (𝑈, untreated) and 
whether they were colonised with E. coli sensitive to trimethoprim (𝑈𝑠 and 𝑇𝑠) or 
resistant to trimethoprim (𝑈𝑟 and 𝑇𝑟). The size of the LTCF, 𝑁, was the sum of 
the number of individuals in compartments 𝑈𝑠, 𝑈𝑟, 𝑇𝑠 and 𝑇𝑟. This was kept 
constant through the study. 
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Individuals left the LTCF by either dying (D) or by going to hospital (H). 
Individuals were not assumed to re-enter the community. Individuals could 
either enter the LTCF directly from hospital or from the community. 
 
Figure 7-1. Model structure. In purple (C), the community; in blue (Us, Ur, Ts, and Tr), the 
LTCF; in orange (H), the hospital; and in green (D), the dead. 𝑈𝑠 were individuals untreated with 
trimethoprim colonised with E. coli susceptible to trimethoprim, 𝑈𝑟  were individuals untreated 
with trimethoprim colonised with E. coli resistant to trimethoprim, 𝑇𝑠 were individuals treated with 
trimethoprim colonised with E. coli susceptible to trimethoprim, and 𝑇𝑟  were individuals treated 
with trimethoprim colonised with E. coli resistant to trimethoprim. 𝑁 was the total population of 
the LTCF (𝑈𝑠 + 𝑈𝑟 + 𝑇𝑠 + 𝑇𝑟). 𝛽 was the rate of transmission of resistance to untreated 
individuals in the LTCF, 𝛽’ was the rate of transmission of resistance to treated individuals in the 
LTCF, 𝛾 was the rate of recovery from colonisation by E. coli resistant to trimethoprim in the 
LTCF, 𝛼𝑝 was the rate of trimethoprim treatment in the LTCF, 𝛾𝑝 was 1/average duration of 
trimethoprim treatment in the LTCF, 𝑚 was the rate of exit or entrance into the LTCF (the rate of 
deaths from the LTCF + hospitalisations from the LTCF, or  the rate of admissions to the LTCF 
from hospital and the community), ℎ𝑙 was the proportion of admissions to the LTCF from 
hospital (vs. community), and 𝑙ℎ was the proportion of residents who leave the LTCF and go to 
hospital (vs. die). 𝑥1, 𝑥2,  𝑥3, and 𝑥4 were the proportions of 𝑈𝑠, 𝑈𝑟, 𝑇𝑠 and 𝑇𝑟 (respectively) out 
of the total population discharged to the LTCF from hospital (𝑥1 + 𝑥2 + 𝑥3 + 𝑥4 = 1). 𝑦1, 𝑦2,  𝑦3, 
and 𝑦4 were the proportions of 𝑈𝑠, 𝑈𝑟, 𝑇𝑠 and 𝑇𝑟 (respectively) out of the total population 
admitted to the LTCF from the community (𝑦1 + 𝑦2 + 𝑦3 + 𝑦4 = 1). 
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Model equations 
 
In red, the equation terms relating to transmission; in blue, the equation terms 
relating to antibiotic treatment; in green the equation terms relating to 
movement in and out of the LTCF. This model was coded and simulated using 
the pomp package in R.246,247 
Assumptions 
General 
1. All individuals are colonised with E. coli. 
2. There is dominance of a single strain of E. coli in a colonised individual, 
and this strain is either resistant or susceptible to trimethoprim. This 
binary process means that: 
a. Between strain competition is not modelled, and 
b. Colonisation with other bacteria is assumed to not affect the 
colonisation with E. coli. 
3. The time between events is exponential. 
4. The model is run per 0.1 day and the reporting period is weekly. 
5. The proportion of individuals predominantly colonised with E. coli 
resistant to trimethoprim (vs. susceptible) is the same as the proportion 
of individuals presenting with a UTI caused by E. coli resistant to 
trimethoprim (vs. susceptible). 
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6. A separate analysis of the seasonality of uncomplicated UTIs (described 
in Chapter 6) found that UTIs in older people were not seasonal; 
therefore, seasonality was not included in this model. 
Transmission 
7. Only person-to-person transmission is considered. The rate of acquiring 
dominance by an E. coli strain resistant to trimethoprim through 
endogenous factors (for example, spontaneous mutation) is not modelled 
explicitly, as these were considered comparatively rare events and data 
was not available to parameterise this.  
8. Transmission of E. coli resistant to trimethoprim is only modelled 
between LTCF residents (including, implicitly, via healthcare workers). 
The transmission of resistance from the remaining population, including 
from healthcare workers and visitors, was not modelled.  
9. Transmission is frequency dependent (vs. density dependent). This 
means that the contact rate between individuals does not depend on the 
population density. 
10. Patients mix homogenously within the LTCF. This is a simplifying 
assumption but unlikely to be true, as there may be little mixing between 
floors of a LTCF and some highly dependent residents may leave their 
rooms infrequently compared to other more mobile residents. 
11. Control measures in place for colonised individuals are not modelled 
explicitly. 
Treatment 
12. Colonisation with E. coli resistant to trimethoprim cannot be lost during 
trimethoprim treatment. The fitness cost is assumed smaller than the 
selection pressure for the duration of treatment. 
13. Co-selection is assumed not to take place; meaning the effect of other 
antibiotic treatment is minimal in acquiring trimethoprim resistance. 
14. All individuals independently of their carriage status were exposed to 
antibiotic treatment at the same rate. 
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15. Both individuals treated and untreated who are predominantly colonised 
by E. coli resistant to trimethoprim (𝑇𝑟 and 𝑈𝑟, respectively) are able to 
transmit resistant E. coli to individuals treated and untreated who are 
predominantly colonised by E. coli sensitive to trimethoprim (𝑇𝑠 and 𝑈𝑠, 
respectively). 
16. Treated individuals who are predominantly colonised by E. coli resistant 
to trimethoprim (𝑇𝑟) and untreated individuals who are predominantly 
colonised by E. coli resistant to trimethoprim 𝑈𝑟 are able to transmit 
resistance at the same rate.  
17. During the acquisition of resistance by treated individuals predominantly 
colonised by E. coli sensitive to trimethoprim (𝑇𝑠), the transmission rate 
is higher than during the acquisition of resistance by untreated 
individuals predominantly colonised by E. coli sensitive to trimethoprim 
(𝑈𝑠), by a factor of 𝑡𝑟. A successful transmission in the treatment 
scenario is benefited by the removal of other competing bacteria 
susceptible to trimethoprim.  
18. Endogenous acquisition of resistance by treated individuals 
predominantly colonised by E. coli sensitive to trimethoprim (𝑇𝑠) within 
one individual is not explicitly simulated. 
LTCF 
19. In the baseline scenario, the LTCF simulated was selected from the 
LTCFs in the quartile with the highest incidence of urine E. coli samples 
sent to AmSurv, which were resistant to trimethoprim per bed day. This 
was to ensure that sufficient samples were present to enable model 
fitting and to ensure that transmission (if present at all in the LTCF 
setting) was detected. LTCFs from the other three quartiles of incidence 
were simulated in sensitivity analyses. 
20. Full bed occupancy in LTCFs. Therefore, the size of the LTCF was kept 
constant during the study. 
21. Being colonised with E. coli resistant to trimethoprim does not impact the 
length of stay. 
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22. Individuals can be admitted to the LTCF either from hospital or from the 
community, and can be discharged from the LTCF to be hospitalised or 
due to death. Residents cannot transfer between LTCFs. 
23. Transfers from the LTCF to hospital and deaths (respectively) are equally 
probable for residents colonised E. coli sensitive and resistant to 
trimethoprim. 
24. The proportion of individuals admitted to the LTCF treated (vs. untreated) 
and colonised with E. coli resistant (vs. sensitive) to trimethoprim from 
hospital and from the community depend on the proportion of individuals 
within these categories in hospital and the community (respectively). 
Many of these assumptions were simplifications that were driven by a lack of 
data available to inform a more complex model. The validity of these 
assumptions is considered further in the discussion. 
Data 
The model was parameterised using four sources of data: susceptibility data 
from urinary E. coli samples submitted to AmSurv in the West Midlands (linked 
to CQC data, as described in Chapter 4), CQC data on LTCF characteristics, a 
point-prevalence survey of antimicrobial use in acute care hospitals in 
England40, THIN data on trimethoprim prescribing, as well as values from the 
literature.  
The first source of data was the publicly available registry of LTCFs in England 
held by the CQC.152 Only LTCFs in the West Midlands region classified as “care 
homes” for elderly residents and recorded as active in the register from 
2011/2012 (797 LTCFs) were selected for analysis. LTCFs in this registry were 
classified according to the number of beds in each facility and nursing status 
(nursing LTCFs were LTCFs with 24-hour medical care from qualified nursing 
staff and residential LTCFs were those without this service). The length of stay 
in LTCFs (used to parameterise 𝑚), the rate of hospital admission of LTCF 
patients (used to parameterise 𝑙ℎ), and the rate of discharge of hospitalised 
patients to LTCFs (used to parameterise ℎ𝑙) were all derived from studies which 
estimated these parameters by LTCF nursing status. The CQC dataset was 
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used to scale the parameters from the literature to represent the distribution of 
nursing LTCFs registered in the West Midlands.9,248,249 
The second source of data used for parameterisation was the AmSurv dataset, 
which was linked to CQC data and is described in detail in Chapter 4. Briefly, 
AmSurv is an AMR surveillance tool established by the Health Protection 
Agency (now Public Health England) in 2009 which collects antibiotic 
susceptibility testing results from routine microbiology samples sent to 
participating diagnostic laboratories in England from both hospitals and GPs.186 
Since December 2012, all laboratories in the West Midlands report to AmSurv, 
making data from this region the most complete longitudinal source of AMR 
surveillance information in England, with more than 95% of laboratories 
currently participating. Following national guidelines from Public Health 
England, all urine samples were assumed to be submitted due to clinical need 
and, therefore, were indicative of a suspected UTI.196 The AmSurv dataset used 
for parameterisation in this chapter includes the trimethoprim susceptibility 
results from all urine specimens collected from individuals aged 70 or older, 
which were reported from the 15 microbiology laboratories in the West Midlands 
to AmSurv from 01/04/2010 to 31/03/2014. The AmSurv dataset was linked to 
CQC data to determine which antibiotic susceptibility tests in the AmSurv 
dataset were from individuals that resided in LTCFs. This combined dataset 
was used to derive (1) the weekly incidence of UTIs caused by E. coli resistant 
to trimethoprim for each LTCF, which was used to fit the model; (2) the number 
of beds in each LTCF selected for model fitting; (3) the proportion of individuals 
colonised by E. coli resistant to trimethoprim (vs. susceptible to trimethoprim) in 
the community, calculated from samples submitted by GPs from individuals 
residing outside of LTCFs (used to parameterise 𝑝𝑟𝑐); and (4) the proportion of 
individuals colonised by E. coli resistant to trimethoprim (vs. susceptible to 
trimethoprim) in hospitals, calculated from samples submitted by hospitals from 
individuals residing outside of LTCFs (used to parameterise 𝑝𝑟𝑐). 
A point-prevalence survey of antimicrobial use in acute hospitals in England 
performed in 2016 was used to parameterise the proportion of patients treated 
with trimethoprim in hospitals.40 A personalised extract of the West Midlands 
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hospital data was extracted for the purposes of this model. Only three NHS 
Trusts from the West Midlands were included in this dataset. This point-
prevalence survey was carried out in patients of all ages. 
Finally, data from THIN (described in more detail in Chapter 6) was used to 
derive the proportion of registered days in which individuals aged 70 or over in 
the community in the West Midlands were exposed to trimethoprim (𝑝𝑡𝑐). Only 
data from April 2010 to March 2014 was analysed in order to match the AmSurv 
study period. The rate of trimethoprim prescription in the community was also 
calculated from THIN prescription data from this period and scaled using values 
from the literature to derive the rate of trimethoprim treatment in the LTCF (𝛼𝑝). 
Finally, THIN was also used to calculate the duration of trimethoprim treatment 
(used to derive 𝛾𝑝). THIN is a validated database of primary care consultation 
data covering over 3.7 million active patients which are demographically 
representative of the UK235–237.  
Parameter sources and values 
A summary of the parameter sources and values is presented in Table 7-1. 
Parameters relating to the movement in and out of the LTCF were derived from 
the literature and were adjusted using CQC data to match the characteristics of 
the LTCFs in the dataset used for model fitting.152 Parameters relating to 
antibiotic resistance and the incidence data used to fit the model were derived 
from AmSurv data. Parameters relating to treatment were estimated from the 
hospital point-prevalence survey and THIN data (scaled by values from the 
literature when appropriate). Finally, parameters relating to transmission were 
both derived from the literature and were estimated by fitting the model to 
AmSurv data.  
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Table 7-1. Parameters in the model 
Parameter Source type Value 
𝛽 Rate of transmission of 
resistance to untreated 
individuals in the LTCF 
Estimated 0.0062 per person 
per day 
𝛽′ Rate of transmission of 
resistance to treated individuals 
in the LTCF 
Estimated 1.5 per person per 
day 
𝛾 Rate of recovery from 
colonisation by E. coli resistant 
to trimethoprim in the LTCF or 
1/average duration of 
colonisation with E. coli resistant 
to trimethoprim in the LTCF 
Literature
250–254
 
 
0.0035 per person 
per day (sensitivity 
analysis 0.0025-
0.0055)  
αp Rate of trimethoprim treatment in 
the LTCF 
Unpublished data from 
THIN scaled using 
literature. 
69
 
0.001 per person per 
day (varied in 
sensitivity analyses)  
𝛾p 1/average duration of 
trimethoprim treatment in the 
LTCF 
Unpublished data from 
THIN and the national 
guidelines
50
 
0.2 (sensitivity 
analysis 0.16-0.3, 3-
6 days duration) 
𝑚 Entry/exit rate into/out of the 
LTCF or 1/average LOS in LTCF 
Literature
248
 adjusted using 
CQC data. 
0.002 per person per 
day 
𝑙ℎ Proportion of residents who 
leave the LTCF that go to 
hospital (vs. die) 
Literature
9,249
 adjusted 
using CQC data. 
0.8 (sensitivity 
analysis 0.77-0.9) 
ℎ𝑙 Proportion of admissions to the 
LTCF from hospital (vs. 
community) 
Literature
248
 adjusted using 
CQC data. 
0.6057 (sensitivity 
analysis 0.4057) 
𝑝𝑟𝑐 Proportion of residents admitted 
to the LTCF from the community 
colonised with E. coli resistant to 
trimethoprim (𝑈𝑟 + 𝑇𝑟)/𝑁 
Unpublished data from 
AmSurv) 
0.3602 (fitted linear 
regression model in 
sensitivity analysis) 
𝑝𝑡𝑐 Proportion of residents admitted 
to the LTCF from the community 
on trimethoprim treatment (𝑇𝑠 + 
𝑇𝑟)/𝑁 
Unpublished data from 
THIN 
0.0049 (fitted linear 
regression model in 
sensitivity analysis) 
𝑝𝑡ℎ Proportion of treated (𝑇𝑠 + 𝑇𝑟)/𝑁 
discharged to the LTCF from 
hospital 
Data from a point-
prevalence survey in 
hospitals.
40
 
0.0248 (sensitivity 
analysis 0.017-
0.032) 
𝑝𝑟ℎ Proportion of residents 
discharged to the LTCF from 
hospital colonised with E. coli 
resistant to trimethoprim (𝑈𝑟 + 
𝑇𝑟)/𝑁 
Unpublished data from 
AmSurv) 
0.3792 (fitted linear 
regression model in 
sensitivity analysis) 
𝑟ℎ𝑜 Probability of a patient colonised 
with a resistant E. coli 
developing a UTI for which a 
sample is taken and the results 
are reported to AmSurv 
Estimated 
 
0.55 
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Parameters describing the movement in/out of LTCFs 
Parameters in this section relate to the movement of patients in and out of the 
LTCF. 𝑚 describes the rate of entering or exiting the LTCF (which were 
assumed to be the same), 𝑙ℎ and ℎ𝑙 describe the proportion of residents 
admitted to hospital from the LTCF (vs. dying) and discharged to the LTCF from 
hospital (vs. the community), respectively. 𝑝𝑡ℎ, 𝑝𝑡𝑐, 𝑝𝑟ℎ and 𝑝𝑡ℎ describe the 
proportion of individuals treated (vs. untreated) and colonised by E. coli 
resistant to trimethoprim (vs. susceptible) in the community and in hospital. 
Together, these parameters define the flow in and out of the LTCF for each of 
the four types of individuals in this compartmental model (𝑈𝑠, 𝑈𝑟, 𝑇𝑠 and 𝑇𝑟). 
 𝒎: rate of entry or exit into the LTCF- i.e. rate of (deaths from the LTCF + 
hospitalisations from the LTCF) or  rate of (admissions to the LTCF from 
hospital + admissions to the LTCF from the community) 
The length of stay in LTCFs was obtained from the literature, and, in the 
absence of specific data for the West Midlands population, it was scaled to 
represent the LTCFs registered in the West Midlands. Using CQC data 
(described above), values taken from Steventon et al.248 were scaled as follows: 
Steventon et al. estimated the number of days spent in permanent LTCFs 
(544.5 days), and in nursing LTCFs (283 days) using data from three local 
authorities in England (a seaside town, a rural area and a London suburb). In 
the West Midlands CQC dataset, 35.38% of LTCFs were nursing LTCFs and 
64.62% were residential LTCFs. Therefore, the estimated length of stay overall 
was (544.5 * 0.6462) + (283 * 0.3538) = 451.98. 𝑚, and the birth or death rate 
into the LTCF was, therefore, 1/451.98=0.002 per person per day. 
 𝒍𝒉: the proportion of residents who leave the LTCF that go to hospital 
(vs. die) 
The proportion of residents who leave the LTCF and go to hospital (vs. die), 𝑙ℎ, 
was estimated using published values for the rate of hospitalisation of LTCF 
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residents, scaled to represent the LTCFs registered in the West Midlands using 
CQC data (described above), and in combination with parameter 𝑚.   
𝑅𝑎𝑡𝑒 𝑜𝑓 ℎ𝑜𝑠𝑝𝑖𝑡𝑎𝑙𝑖𝑠𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝐿𝑇𝐶𝐹 𝑟𝑒𝑠𝑖𝑑𝑒𝑛𝑡𝑠 = 𝑙ℎ × 𝑚. Therefore,  
𝑙ℎ =
𝑅𝑎𝑡𝑒 𝑜𝑓 ℎ𝑜𝑠𝑝𝑖𝑡𝑎𝑙𝑖𝑠𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝐿𝑇𝐶𝐹 𝑟𝑒𝑠𝑖𝑑𝑒𝑛𝑡𝑠
𝑚
.  
The rate of hospital admission of LTCF residents aged 75 or older estimated by 
Sherlaw-Johnson et al.249 was 0.45 per available bed per year for nursing 
homes and 0.62 per available bed per year for residential homes. In the West 
Midlands CQC dataset, 35.38% of LTCFs were nursing LTCFs and 64.62% 
were residential LTCFs. Therefore, the estimated rate of hospitalisation per day 
was ((0.62 * 0.6462) + (0.45 * 0.3538))/365 = 0.00153. Substituting this value in 
the equation above, 
𝑙ℎ =
0.00153
0.002
= 0.767. 
The Quality Watch study by Smith et al.9 reported 246,031 admission episodes 
to hospital for 374,191 maximum potential service users in a year. Therefore, 
the estimated rate of hospitalisation per day was 246,031/374,191/365=0.0018. 
Substituting this value in the equation above, 
𝑙ℎ =
0.0018
0.002
= 0.9. 
In absence of better estimates that would apply specifically to the LTCFs 
studied in the West Midlands, 𝑙ℎ was set at a value between that of these two 
studies (0.8), and the range of these values (0.77-0.9) was explored in 
sensitivity analyses.  
 𝒉𝒍: the proportion of admissions to the LTCF from hospital (vs. 
community) 
 ℎ𝑙 was derived from published values from the literature, scaled to represent 
the LTCFs registered in the West Midlands using CQC data (described above). 
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Steventon et al. 2012248 reported that 55.9% permanent admissions to 
residential care were preceded by emergency admissions (45.1%) and elective 
admissions (10.8%) to hospital during the 3 months prior to admission, and that 
69.1% admissions to nursing homes were preceded by emergency admissions 
(56.7%) and elective admissions (12.4%) to hospital during the 3 months prior 
to admission. In the West Midlands CQC dataset, 35.38% of LTCFs were 
nursing LTCFs and 64.62% were residential LTCFs. Using these data, the 
values obtained from Steventon et al. 2012248 were scaled to derive the 
estimated proportion of admissions to the LTCF from hospital (vs. community) 
as follows: (55.9* 0.6462) + (69.1 * 0.3538) = 60.57%. This was likely to be an 
overestimate because not all patients that visited hospital within the previous 3 
months will have been directly discharged to the LTCF from hospital. Therefore, 
the value of ℎ𝑙 was decreased by 20% in a sensitivity analysis. 
 𝒑𝒕𝒉: the proportion of treated (𝑇𝑠 + 𝑇𝑟)/𝑁 discharged to the LTCF from 
hospital 
𝑝𝑡ℎ was derived from a point prevalence study of hospitals in England carried 
out in patients of all ages (described above). Two West Midlands NHS trusts 
were included in this survey: the Burton Hospitals NHS foundation trust, in 
which 3.23% patients were being treated with trimethoprim, and The Royal 
Wolverhampton NHS Trust, in which 1.73% of patients were being treated with 
trimethoprim. The mean between these two NHS trusts, (3.23+1.73)/2=2.48% 
was taken as the estimate for 𝑝𝑡ℎ. The range of values between these two 
trusts (1.73-3.23%) was considered in the sensitivity analyses. 
 𝒑𝒓𝒉: the proportion of residents discharged from the hospital to the LTCF 
colonised with E. coli resistant to trimethoprim (vs. susceptible): (𝑈𝑟 + 
𝑇𝑟)/𝑁  
𝑝𝑟ℎ was obtained from West Midlands AmSurv data (described above). Over 
the study period 37.92% of urine E. coli samples sent by hospitals from 
individuals aged 70 or older that did not reside in a LTCF postcode were 
resistant to trimethoprim. This proportion of individuals with a resistant E. coli 
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urine sample submitted to AmSurv (vs. susceptible) was assumed to be the 
same as the proportion of individuals predominantly colonised with E. coli 
resistant to trimethoprim (vs. susceptible).  
Trimethoprim resistance increased during the study period. Therefore, in a 
sensitivity analysis, a linear regression was fit to the weekly AmSurv data and 
𝑝𝑟ℎ was modelled as the function for this linear regression:  
𝑝𝑟ℎ = 0.3424633 +  (0.0003089331 ∗ (week of the study)).  
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Figure 7-2. Percentage of urinary E. coli samples resistant to trimethoprim submitted to 
AmSurv by hospitals in the West Midlands from individuals aged 70 and over.  April 2010 
to March 2014. 
 𝒙𝟏, 𝒙𝟐, 𝒙𝟑, 𝒙𝟒: the proportion of admissions to the LTCF from hospital into 
the 𝑈𝑠, 𝑈𝑟, 𝑇𝑠 and 𝑇𝑟 compartments (respectively) 
𝑥1+ 𝑥2+ 𝑥3+ 𝑥4=1 
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𝑥1: the proportion of 𝑈𝑠/𝑁 discharged to the LTCF from hospital  
= (1 − 𝑝𝑟ℎ) × (1 − 𝑝𝑡ℎ) 
𝑥2: the proportion of 𝑈𝑟/𝑁 discharged to the LTCF from hospital  
= 𝑝𝑟ℎ × (1 − 𝑝𝑡ℎ) 
𝑥3: the proportion of 𝑇𝑠/𝑁 discharged to the LTCF from hospital  
= (1 − 𝑝𝑟ℎ) × 𝑝𝑡ℎ 
𝑥4: the proportion of 𝑇𝑟/𝑁 discharged to the LTCF from hospital  
= 𝑝𝑟ℎ × 𝑝𝑡ℎ 
 𝒑𝒓𝒄: the proportion of residents admitted to the LTCF from the 
community colonised with E. coli resistant to trimethoprim (𝑈𝑟 + 𝑇𝑟)/𝑁 
𝑝𝑟𝑐 was obtained from West Midlands AmSurv data (described above). Over 
the study period 36.66% of urine samples sent by GPs from individuals aged 70 
or older residing in postcodes that did not contain LTCFs were resistant to 
trimethoprim (vs. sensitive). This proportion of individuals with a resistant E. coli 
urine sample submitted to AmSurv (vs. susceptible) was assumed to be the 
same as the proportion of individuals predominantly colonised with E. coli 
resistant to trimethoprim (vs. susceptible). 
Trimethoprim resistance increased during the study period. Therefore, in a 
sensitivity analysis, a linear regression was fit to the weekly data and 𝑝𝑟𝑐 was 
modelled as the function for this linear regression:  
𝑝𝑟𝑐 = 0.3350485 +  (0.0002101702 ∗ (week of the study)).  
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Figure 7-3. Percentage of urinary E. coli samples resistant to trimethoprim submitted to 
AmSurv by GPs in the West Midlands from individuals aged 70 and over.  April 2010 to 
March 2014. 
 𝒑𝒕𝒄 
The proportion of residents admitted to the LTCF from the community on 
trimethoprim treatment (𝑇𝑠 + 𝑇𝑟)/𝑁, 𝑝𝑡𝑐, was derived from West Midlands THIN 
data (described above). The proportion of the registered days in which 
individuals aged 70 or older in the West Midlands were exposed to trimethoprim 
was calculated per month of the study (April 2010 to March 2014). The mean 
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proportion was 0.49% over the study period; however, it increased linearly 
during this time (see Figure 7-4). Therefore, in a sensitivity analysis, a linear 
regression was fit to the THIN data and 𝑝𝑡𝑐 was modelled as the function for 
this linear regression:  
𝑝𝑡𝑐 = 0.004195201 +  (6.732339e − 06 ∗ (week of the study)).  
 
Figure 7-4. Proportion of individuals aged 70 or older in the community in the West 
Midlands treated with trimethoprim.  THIN data, April 2010 to March 2014. 
 𝒚𝟏, 𝒚𝟐, 𝒚𝟑, 𝒚𝟒: the proportion of admissions to the LTCF from the 
community that arrive into the 𝑼𝒔, 𝑼𝒓, 𝑻𝒔 and 𝑻𝒓 compartments 
(respectively) 
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𝑦1+ 𝑦2+ 𝑦3+ 𝑦4=1 
𝑦1: proportion 𝑈𝑠 admitted to the LTCF from the community = (1 − 𝑝𝑟𝑐) ×
(1 − 𝑝𝑡𝑐) 
𝑦2: proportion 𝑈𝑟 admitted to the LTCF from the community = 𝑝𝑟𝑐 × (1 − 𝑝𝑡𝑐) 
𝑦3: proportion 𝑇𝑠 admitted to the LTCF from the community= (1 − 𝑝𝑟𝑐) × 𝑝𝑡𝑐 
𝑦4: proportion 𝑇𝑟 admitted to the LTCF from the community= 𝑝𝑟𝑐 × 𝑝𝑡𝑐 
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Treatment 
Parameters in this section relate to the treatment of patients with trimethoprim. 
αp describes the rate of trimethoprim treatment in the LTCF and 𝛾p describes the 
rate of stopping trimethoprim treatment. 
 𝛂p: rate of trimethoprim treatment in the LTCF 
The rate of trimethoprim treatment in the LTCF, αp, was derived from West 
Midlands THIN data (described above) for individuals aged 70 for the 
community overall (including LTCF and non-LTCF residents). These values 
were then scaled to represent treatment in the LTCF by using estimates from 
the literature69. Sundvall et al. 69 showed that in Hampshire in those aged 75 
and older, without adjustment, antibiotic prescription for UTIs in LTCFs was 
0.69/0.24=2.875 times higher in LTCF residents than in elderly individuals that 
lived in their own homes. The mean monthly rate of trimethoprim prescription in 
the West Midlands from April 2010 to March 2014 per 100,000 population was 
calculated from THIN (=1172.889). Therefore, the rate of trimethoprim 
prescription in the overall community per person per day, αp, was 
1172.889/100,000/30= 0.0003909629. Since 4% of the population >65 lives in 
LTCFs9 (and, therefore, 96% do not), this can be written as two equations: 
0.00039 = (0.96 × x) + (0.04 × y) 
y = 2.875 × x , 
where x  is the rate of trimethoprim prescription in individuals that did not reside 
in LTCFs and y is the rate of trimethoprim prescription in LTCF residents. 
Solving these equations gives y = 0.001.  
As shown in Figure 7-5 the rate of trimethoprim prescription in older people 
West Midlands community overall remained stable during the study period. It 
was therefore modelled as a constant. 
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Figure 7-5. Rate of trimethoprim prescription in the West Midlands in individuals aged 70 
and over.  THIN data, April 2010 to March 2014. 
 𝜸p:1/average duration of trimethoprim treatment in the LTCF 
The trimethoprim prescription guidelines recommend 3 days of treatment for 
women and 7 days for men.50 In THIN, in those aged 70 or over registered in 
practices in the West Midlands from January 2010 to December 2014, the 
median duration of trimethoprim treatment was 5 days. Therefore, 𝛾p, or 1/the 
average duration of trimethoprim treatment in the LTCF, was set at 1/5=0.2 per 
person per day. A sensitivity analysis explored durations of treatment from 3 to 
6 days. (𝛾p =0.16 to 0.3).  
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Transmission 
Parameters in this section relate to transmission of trimethoprim-resistant E. coli 
in the LTCF. 𝛽 and 𝛽’ describe the rate of transmission of resistance in 
untreated and treated individuals (respectively) in the LTCF, and 𝛾 describes 
the rate of recovery from colonisation by E. coli resistant to trimethoprim in the 
LTCF. 
 𝜷 and 𝜷’: the rate of transmission of resistance in untreated and treated 
individuals (respectively) in the LTCF. 
To our knowledge, the transmission rate of trimethoprim resistant E. coli has not 
been reported to date. In the literature, the transmission of E. coli resistant to 
expanded-spectrum cephalosporins in ICUs in various locations across Europe 
was estimated at 0.0078 (95%CIs=0.0029-0.016).255 Haverkate et al. estimated 
the transmission rate of KPC-producing bacteria in LTACHs at 0.014 
(95%CIs=0.0071-0.026).256 Toth et al. assumed the transmission rate of CRE in 
LTCFs to be 0.1 in a low transmission scenario and 0.14 in a high transmission 
scenario.133 Lee et al. modelled the transmission of CRE in LTCFs using a 
transmission parameter of 0.000057895 (range 0-0.00053513). 132 Talaminos et 
al. modelled the transmission of E. coli ST131 in LTCFs using a transmission 
parameter of 0.00008 for colonisation with E. coli ST131 that did not produce 
ESBLs and 0.00003 for colonisation by ESBL-producing E. coli ST131. 
Haverkate et al. (2017) estimated the within-household transmission rate of 
ESBL-producing Enterobacteriaceae (67% E. coli) at 0.0053 per person per 
day.257 Due to the wide range of transmission parameters in the literature and 
the lack of studies that specifically reported the transmission of trimethoprim 
resistant E. coli in LTCFs, 𝛽 and 𝛽’ were estimated (procedure described 
below).  
 𝜸: rate of recovery from colonisation by E. coli resistant to trimethoprim in 
the LTCF, or 1/average duration of colonisation with E. coli resistant to 
trimethoprim in the LTCF 
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The duration of colonisation with E. coli resistant to trimethoprim in LTCF 
residents was not specifically assessed in the literature. Ismail et al. 2016252 
reported a mean duration of carriage of ciprofloxacin-resistant E. coli in nursing 
home residents of 6 months. Birgand et al. 2013250 reported a median duration 
of colonisation after hospital discharge for ESBL-E of 6.6 months. Haverkate et 
al. 2015253 calculated a mean duration of colonisation for E. coli OXA-48 of 225 
days (7.5 months). Titelman et al. 2014251 showed that colonisation with E. coli 
was still apparent 12 months after infection in 64% (n=9), and 40% (n=14) of 
those carrying E. coli ST131 or other STs, respectively (p=0.12). Overdevest et 
al.254 showed that in a Dutch LTCF with high rectal colonisation rate, the half-life 
of ESBL-ST131 E. coli carriage was 13 months. We assumed a duration of 
colonisation of 9.5 months and carried out a sensitivity analysis in which this 
was varied between 6 and 13 months. Therefore, 𝛾, the rate of recovery from 
colonisation by E. coli resistant to trimethoprim in the LTCF, was 
1
365
12
×9.5 days
=
0.0035 per person per day (sensitivity analysis from 
1
((
365
12
)×13)𝑑𝑎𝑦𝑠
= 0.0025 to 
1
((
365
12
)×6)𝑑𝑎𝑦𝑠
= 0.0055). 
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Initial values  
The distribution of individuals in compartments 𝑈𝑠, 𝑈𝑟, 𝑇𝑠, 𝑇𝑟 at time point zero, 
with which the model was initiated, was calculated as follows: 
𝑈𝑠𝑡0 = 𝐿𝑇𝐶𝐹 𝑠𝑖𝑧𝑒 × (1 − 𝑝𝑟𝑙) × (1 − 𝑝𝑡𝑙) 
𝑈𝑟𝑡0 = 𝐿𝑇𝐶𝐹 𝑠𝑖𝑧𝑒 × 𝑝𝑟𝑙 × (1 − 𝑝𝑡𝑙) 
𝑇𝑠𝑡0 = 𝐿𝑇𝐶𝐹 𝑠𝑖𝑧𝑒 × (1 − 𝑝𝑟𝑙) × 𝑝𝑡𝑙 
𝑇𝑠𝑡0 = 𝐿𝑇𝐶𝐹 𝑠𝑖𝑧𝑒 × 𝑝𝑟𝑙 × 𝑝𝑡𝑙 
where 𝑝𝑟𝑙 was the proportion of individuals initially colonised by E. coli resistant 
to trimethoprim in the LTCF, and 𝑝𝑡𝑙 was the proportion of individuals initially 
treated with trimethoprim in the LTCF. These figures were then rounded to give 
whole numbers of individuals. 
𝑝𝑟𝑙 was derived from the proportion of urine E. coli samples sent to AmSurv that 
were resistant to trimethoprim. This proportion increased during the study 
period as can be seen in Figure 7-6 below. 
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Figure 7-6. Percentage of urinary E. coli samples resistant to trimethoprim in the West 
Midlands in individuals aged 70 and over residing in LTCFs.  April 2010 to March 2014. 
The proportion of individuals colonised by E. coli resistant to trimethoprim in the 
LTCF in the first week of the study (51.75%) was calculated by fitting a linear 
regression to the weekly West Midlands AmSurv data (described above):  
𝑝𝑟𝑙 = 0.5168852 +  (0.0006532183 × (week of the study))= 0.5168852 +
 0.0006532183 = 0.5175 
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The proportion of individuals with a resistant E. coli urine sample submitted to 
AmSurv (vs. susceptible) was assumed to be the same as the proportion of 
individuals predominantly colonised with E. coli resistant to trimethoprim (vs. 
susceptible). 
𝑝𝑡𝑙 was informed by data from the HALT-2 study, which found that 2.69% 
(11/409) of English residents in the 16 LTCFs surveyed were being treated with 
trimethoprim/sulphonamides on the survey day63. According to THIN data 
(described above), 97% of trimethoprim/sulphonamides prescriptions to patients 
of all ages in England (2013-2015) were trimethoprim prescriptions.  
LTCF size is described in the incidence section below. 
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Reporting: how does the incidence derived from the model relate to the 
incidence in the data? 
The mathematical model presented describes the transmission of trimethoprim 
resistance amongst individuals colonised with E. coli. The incidence derived 
from the model (𝐼𝑛𝑐) is, therefore, the cumulative number of individuals 
colonised with E. coli resistant to trimethoprim per week. However, the 
susceptibility data available for AmSurv captures UTIs reported to AmSurv. 
Therefore, in order to calculate the observations predicted by the model at each 
time point (𝑜𝑏𝑠), 𝐼𝑛𝑐 was multiplied by 𝑟ℎ𝑜. By multiplying by 𝑟ℎ𝑜, 𝐼𝑛𝑐 is 
adjusted to the level of cases reported. 
𝑜𝑏𝑠 = 𝐼𝑛𝑐 × 𝑟ℎ𝑜 
 𝒓𝒉𝒐: the proportion of colonised patients with a resistant E. coli who 
develop a UTI for which a sample is taken and the results are reported to 
AmSurv. 
Calculating 𝑟ℎ𝑜 would require knowledge of the proportion of individuals 
colonised with E. coli resistant to trimethoprim who go on to develop a UTI and 
the proportion of UTIs in individuals in LTCFs in the West Midlands that are 
then sampled and therefore reported to AmSurv. As these parameters were 
unknown, 𝑟ℎ𝑜 had to be estimated (procedure described below). 
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Incidence data and model fitting procedure: estimating 𝜷, 𝜷′ and 𝒓𝒉𝒐  
Processing of incidence data to allow model fitting 
To estimate the transmission parameters (𝛽, 𝛽′) and 𝑟ℎ𝑜, the incidence of 
colonisation with E. coli resistant to trimethoprim in the model (𝐼𝑛𝑐) was fitted to 
the incidence of urinary E. coli samples resistant to trimethoprim from a LTCF in 
the AmSurv dataset. 
The incidence of colonisation with E. coli resistant to trimethoprim in the model 
(𝐼𝑛𝑐) was the cumulative number of individuals that became dominantly 
colonised by E. coli resistant to trimethoprim (𝑈𝑟 and 𝑇𝑟) in the simulated LTCF 
in each week of the study. This model incidence included both individuals 
entering the LTCF from hospital or from the community already colonised by E. 
coli resistant to trimethoprim, and individuals acquiring this colonisation through 
transmission within the LTCF.  
The incidence of urinary E. coli samples resistant to trimethoprim from a LTCF 
in the AmSurv dataset was the cumulative number of urine samples from 
residents of a LTCF submitted to AmSurv in each week of the study that grew 
E. coli resistant to trimethoprim. The choice of LTCF is described below. 
Assuming that the national guidelines were followed appropriately and urine 
samples were only sent for susceptibility testing for patients with UTIs, the 
incidence of urinary E. coli samples resistant to trimethoprim should capture the 
incidence of UTIs caused by E. coli resistant to trimethoprim. 
The majority of people are colonised with E. coli without developing a UTI. Only 
a proportion of colonised individuals will develop a UTI, and a proportion of 
these will have a urine sample submitted for susceptibility testing. Therefore, 
the model incidence could not directly be fit to the incidence in the data. To 
account for this, the parameter 𝑟ℎ𝑜 was created, which is the ‘case 
development and ascertainment proportion’. We multiplied 𝐼𝑛𝑐 (the incidence in 
the model) by 𝑟ℎ𝑜 in order to adjust 𝐼𝑛𝑐 to the level of cases reported in the 
AmSurv dataset.  
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Processing of incidence data to allow model fitting 
The West Midlands AmSurv dataset (described above) included incidence data 
from 715 different LTCFs. This section describes the process of selecting the 
appropriate LTCF for model fitting. Four LTCFs were selected for model fitting 
(one for the baseline scenario and three for the sensitivity analyses).  
As shown in Chapter 4, the median number of beds in LTCFs submitting at 
least one E. coli urine sample to AmSurv (N=715) was 33 (mean=36.9, range 1-
214). 114 LTCFs were smaller than 20 beds, which were considered difficult to 
fit in isolation. Therefore, LTCFs smaller than 20 beds (N=114/715) were 
excluded. LTCFs submitting less than 10 urine samples per year to AmSurv 
growing E. coli resistant to trimethoprim (557/715) were also excluded as it was 
considered that transmission would be unlikely to occur in these facilities.  
The LTCFs remaining (N=44) were sub-divided by quartiles according to the 
number of urine E. coli samples sent to AmSurv which were resistant to 
trimethoprim per bed per day (see Figure 7-7 below).  
Figure 7-8 shows the number of beds in each of the 44 remaining LTCFs in the 
Amsurv dataset by incidence quartile. LTCFs with higher incidence had a lower 
mean number of beds. The weekly incidence of trimethoprim resistant E. coli 
samples submitted to AmSurv from each LTCF per bed day by incidence 
quartile is plotted in the Appendix Chapter 7.  
One LTCF was selected from each of these quartiles for model fitting. The 
incidence of trimethoprim resistant urine E. coli samples submitted to AmSurv 
for each of the four selected LTCFs is shown in Figure 7-9 below.  
In the baseline scenario, the model was fit to incidence data from a LTCF in the 
highest incidence quartile. This was to ensure that sufficient samples were 
present to enable model fitting and to ensure that transmission (if present at all 
in the LTCF setting) was detected. This was a LTCF of 30 beds. The LTCF size 
in this baseline scenario was therefore set to 30 beds. The prevalence of 
resistance in the LTCF selected for the baseline scenario was 74%, as derived 
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by dividing the urine samples growing E. coli resistant to trimethoprim sent to 
AmSurv by this facility by the total urine samples growing E. coli sent to AmSurv 
by this facility. The other three selected LTCFs were simulated in sensitivity 
analyses (one of 39 beds, one of 57 and another of 83).  
 
Figure 7-7 The number of urine E. coli samples resistant to trimethoprim submitted to 
AmSurv per bed day, by LTCF.  Quartiles are denoted by the horizontal dotted lines. LTCFs 
within each quartile are coloured the same. LTCFs below 20 beds (N=114/715) and LTCFs 
submitting less than 10 urine samples to AmSurv growing E. coli resistant to trimethoprim 
(557/715) were excluded. 
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Figure 7-8. Number of beds per LTCF.  LTCFs are subdivided by colour in quartiles according 
to the number of urine E. coli samples resistant to trimethoprim they sent to AmSurv. In dark 
red, LTCFs in the quartile with the highest incidence; in red, LTCFs in the quartile with the 
second highest incidence; in orange, LTCFs in the quartile with the second lowest incidence; in 
yellow, LTCFs in the quartile with the lowest incidence. The dashed lines represent the mean 
number of beds for the LTCFs in each incidence quartile (from high to low incidence: 27.1, 42.2, 
57.8, 92.8). LTCFs below 20 beds (N=114/715) and LTCFs submitting less than 10 urine 
samples to AmSurv growing E. coli resistant to trimethoprim (557/715) were excluded. 
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Figure 7-9. The weekly incidence of urine E. coli samples resistant to trimethoprim 
submitted to AmSurv for each of the LTCFs that were selected for simulation.  The LTCF 
selected for the baseline simulation scenario (30 beds) is highlighted in grey.  
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Model fitting: estimating 𝛽, 𝛽′ and 𝑟ℎ𝑜  
𝛽, the rate of transmission of E. coli resistant to trimethoprim to untreated 
individuals in the LTCF, 𝛽′, the rate of transmission of E. coli resistant to 
trimethoprim in individuals treated with trimethoprim in the LTCF, and 𝑟ℎ𝑜, the 
proportion of patients colonised with a resistant E. coli who develop a UTI for 
which a sample is taken and the results are reported to AmSurv, were unknown 
and, therefore, had to be estimated through fitting the model to the incidence 
data described in the section above. 𝛽′ was expressed as the product of 𝛽 and 
𝑡𝑟:  
𝛽′ = 𝛽 ∗ 𝑡𝑟  
where 𝑡𝑟 > 1. Therefore, 𝛽′ was assumed to be greater than 𝛽. 
𝛽, 𝑡𝑟 and 𝑟ℎ𝑜 were fit to the incidence of urinary tract E. coli resistant to 
trimethoprim in the LTCF selected for the baseline scenario (described above) 
by maximum likelihood estimation using the function traj.match in the pomp 
package246,247. This function uses the deterministic version of the model for 
model fitting. It calls the optim function in R (using Nelder-Mead optimisation 
method) to maximise the likelihood of the data given the model trajectory, which 
is defined by a function that evaluates the probability density of point 
observations of the model incidence following a Poisson probability distribution 
with mean 𝑟ℎ𝑜 × 𝐼𝑛𝑐, as defined by the following line of C code:  
lik = dpois(obs, rho * Inc, give_log); 
The model fitting was carried out in three stages. 
First, the values of 𝛽 and 𝑟ℎ𝑜 were estimated for different values of 𝑡𝑟 (see 
Table 7-2 below), with all remaining parameters kept as per the baseline 
scenario described above (see values in Table 7-1). The starting value of 𝛽 was 
taken from published literature and set at 0.0053.257 The starting value of 𝑟ℎ𝑜 
was not available in published literature, and so was estimated as 0.7333 
through the following assumption: number of tests per resident, per year. As the 
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length of stay in LTCFs was on average 451.98 days (calculated as described 
above for the 𝑚 parameter), all patients were assumed to remain in the LTCF 
for at least a year. The LTCF simulated in the baseline scenario had 22 urine E. 
coli samples reported to AmSurv in 2013/2014 and 30 beds; therefore, the 
starting value for 𝑟ℎ𝑜 was 𝑟ℎ𝑜 =
22
30
= 0.7333. The cumulative number of cases 
predicted (𝐼𝑛𝑐 × 𝑟ℎ𝑜) over the study period, the prevalence of resistance 
predicted overall (for treated and untreated) and the prevalence of resistance in 
treated individuals compared to untreated individuals were derived from the 
deterministic model at equilibrium.  
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Table 7-2. Estimating 𝜷 and 𝒓𝒉𝒐 for different values of 𝒕𝒓. 
𝑡𝑟 
(fixed) 
Estimated 
𝛽 (per 
person per 
day) 
Estimated 𝑟ℎ𝑜  𝐼𝑛𝑐 × 𝑟ℎ𝑜 
predicted by 
the model (vs. 
65 in data) 
Prevalence 
of resistance 
predicted by 
the model at 
equilibrium 
(
𝑈𝑟+𝑇𝑟
𝑁
) (%) 
Prevalence of 
resistance in 
treated individuals 
compared to 
untreated 
individuals: 
(
𝑇𝑟
𝑇𝑟+𝑇𝑠
)/(
𝑈𝑟
𝑈𝑟+𝑈𝑠
) at 
equilibrium 
1 0.0083 0.53 65.2 51.4 1 
1.5 0.0083 0.53 65.3 51.5 1 
2 0.0082 0.53 64.9 51.1 1 
10 0.0079 0.53 64.7 51 1.2 
50 0.0071 0.54 64.9 50.3 1.5 
70 0.0068 0.54 64.1 49.7 1.5 
100 0.0066 0.55 65.1 49.6 1.6 
140 0.0063 0.56 65.4 48.9 1.7 
180 0.0061 0.56 64.8 48.5 1.8 
200 0.006 0.56 64.5 48.2 1.8 
210 0.006 0.56 64.6 48.3 1.8 
220 0.0059 0.57 65.2 48 1.8 
230 0.0059 0.57 65.3 48 1.8 
250 0.0058 0.57 64.9 47.7 1.9 
300 0.0057 0.57 64.6 47.6 1.9 
350 0.0056 0.58 65.5 47.3 1.9 
400 0.0055 0.58 65.1 47.1 1.9 
500 0.0053 0.59 65.3 46.5 2 
 
As shown in Table 7-2, as the value of 𝑡𝑟 was increased from 1 to 500, 𝛽 
decreased from 0.0083 to 0.0053 and 𝑟ℎ𝑜 increased from 0.53 to 0.59. The 
cumulative number of cases predicted by the model (𝐼𝑛𝑐 ×  𝑟ℎ𝑜) over the study 
period agreed closely with the data (65), implying a reasonable model fit to the 
data. The prevalence of resistance at equilibrium predicted by the model, 
however, was lower for all cases explored (51.5%-46.5%) than that estimated 
from AmSurv data for the LTCF selected (74%).  
As described above, 𝑡𝑟 =
𝛽
𝛽′
. Increasing 𝑡𝑟, therefore, increased the prevalence 
of resistance in treated individuals compared to untreated individuals in the 
model. For values of 𝑡𝑟 between 250 and 400, the prevalence of resistance in 
treated individuals compared to untreated individuals was 1.9. This was similar 
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to the relative risk of resistance in treated individuals compared to untreated 
individuals observed in the literature (1.88).258 Therefore, a value of 𝑡𝑟 between 
250 and 400 was considered reasonable. 𝑟ℎ𝑜 was estimated at between 0.53 
and 0.59. 
Second, 𝑡𝑟 and 𝑟ℎ𝑜 were estimated for different values of 𝛽 in order to explore if 
fixing 𝛽 would condition and change the values of 𝑟ℎ𝑜 and 𝑡𝑟 that best fit the 
model (see Table 7-3). Having found more realistic values for these parameters 
to initiate the model fitting, the starting value for 𝑡𝑟 was increased to 250 and 
the starting value for 𝑟ℎ𝑜 was decreased to 0.6.  
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Table 7-3. Estimating 𝒓𝒉𝒐 and 𝒕𝒓 for different values of 𝜷.  Note that 𝛽 and 𝛽′ are now estimated per person per 1/10 day. 
𝛽 (fixed)  
(per person per 
1/10 day) 
Estimated 𝑟ℎ𝑜  Estimated 𝑡𝑟 𝛽′ = 𝛽 ∗ 𝑡𝑟  
(per person per 
1/10 day) 
𝐼𝑛𝑐 × 𝑟ℎ𝑜 
predicted by the 
model  
(vs. 65 in data) 
Prevalence of 
resistance 
predicted by the 
model at 
equilibrium (%) 
Prevalence of 
resistance in 
treated individuals 
compared to 
untreated 
individuals: 
(
𝑇𝑟
𝑇𝑟+𝑇𝑠
)/(
𝑈𝑟
𝑈𝑟+𝑈𝑠
) at 
equilibrium 
0.0002 0.8 16287940 3257.588    
0.0003 0.72 148806 44.6418    
0.0004 0.64 115238 46.0952    
0.0005 0.59 11049 5.5245 65.3 46.5 2.2 
0.0006 0.56 282.2 0.16932 65.2 48.8 1.8 
0.00065 0.55 134.6 0.08749 65.3 49.8 1.7 
0.0007 0.54 69.7 0.04879 65.3 50.6 1.5 
0.0008 0.52 19.8 0.01584 65.3 52.5 1.3 
0.0009 0.5 0.09 0.000081 64.8 54.1 1 
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𝛽 was increased from 0.0002 per person per 1/10 day (0.002 per day) to 0.0009 
per 1/10 day (0.009 per day). For values of 𝛽 smaller or equal to 0.0004 per 
person per 1/10 day (0.004 per day), the fitting algorithm estimated values of 𝑡𝑟 
that, although produced a similar cumulative number of cases as observed in 
the data; implied that 𝛽′ = 𝛽 × 𝑡𝑟 ≥ 46.1 per person per 1/10 day (4.61 per 
person per day), which was not considered biologically plausible as this would 
imply 𝑅0 = 𝛽 × 𝛾
−1 × 𝑁 = 4.61 × (9.5 ∗
365
12
) × 30 = 39962.94 and there were 
only 30 individuals in the LTCF. Therefore, these values were not presented in 
Table 7-3. As 𝛽 increased, the prevalence of resistance predicted by the model 
also increased, becoming closer to that estimated from AmSurv data (74%). 
However, increasing 𝛽 also resulted in a progressive decrease in 𝑡𝑟, which, in 
turn, decreased the prevalence of resistance in treated individuals compared to 
untreated individuals, lowering it below the estimates reported in the literature 
(1.88).257 When 𝛽 was fixed at 0.0009 per 1/10 day (0.009 per day), the relative 
risk of resistance was equal to 1.  
Third, the value of 𝑡𝑟 and 𝑟ℎ𝑜 and 𝛽 were estimated with starting values of 250, 
0.55 and 0.0008 per person per 1/10 day (0.008 per day), respectively.  𝑡𝑟 was 
set to 250 because it was the lowest value of 𝑡𝑟 at which a relative risk of 
resistance in treated individuals compared to untreated individuals of 1.9 was 
achieved. 𝛽 was set to a value that resulted in the highest prevalence of 
resistance for which the relative risk of resistance in treated individuals 
compared to untreated individuals was greater than 1. 𝑟ℎ𝑜 was set at 0.55 as a 
compromise between 0.52 (estimated for 𝛽=0.0008 per person per 1/10 day 
(0.008 per day)) and 0.58 (estimated for 𝑡𝑟=250). 
The combination of 𝑡𝑟, 𝑟ℎ𝑜 and 𝛽 that best fit the data was 𝑡𝑟=250, 𝑟ℎ𝑜=0.55 
and 𝛽=0.00062 per person per 1/10 day (0.0062 per day), giving 𝛽′=0.155 per 
person per 1/10 day (1.55 per day). These values were subsequently used in 
the baseline scenario.  
In the sensitivity analysis, the model was fit to incidence data from three 
different LTCFs. The LTCF size was modified accordingly. In this secondary 
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model fitting process, 𝑡𝑟 and 𝑟ℎ𝑜 were kept constant and only 𝛽 was estimated. 
The starting values for this estimation were 𝑡𝑟=250, 𝑟ℎ𝑜=0.55 and 𝛽=0.00062, 
the fitted values for the baseline scenario. The maximum likelihood estimation 
optimisation method was changed to “SANN”, as this method was better suited 
to estimating one parameter value than the Nelder-Mead optimisation algorithm. 
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Sensitivity analyses 
Several sensitivity analyses were carried out to test the sensitivity of the model 
output to the choice of parameter set. Firstly, 𝑝𝑡𝑐, 𝑝𝑟𝑐 and 𝑝𝑟ℎ, which are fixed 
at the mean for the study period in the baseline scenario, were increased 
linearly with an intercept and slope defined by the regression models fit to the 
prescription and antibiotic resistance data for this period (described in the 
parameterisation section above). 𝛾, 𝛾𝑝, 𝑙ℎ, and 𝑝𝑡ℎ were varied according to 
plausible ranges (also described in the parameterisation section). The model 
was additionally fit to data from three different LTCFs with lower incidence and 
higher number of beds.  
Scenarios 
Four transmission scenarios were explored: (1) where the transmission rate 
was halved, (𝛽=0.0031 per person per day); (2) where the transmission rate 
was increased by 20% (𝛽=0.0074 per person per day), (3) where the 
transmission rate was doubled (𝛽=0.0124 per person per day); and (4) where 
the rate of transmission of resistance to treated individuals was equal to the rate 
of transmission of resistance to untreated individuals (𝛽= 𝛽′=0.0062 per person 
per day). Two movement scenarios were considered where ℎ𝑙 were increased 
and decreased by 20%. Three treatment scenarios were explored where 𝛼𝑝 
was increased by 20% (to 0.0012), 50% (to 0.0015) and one scenario in which 
𝛼𝑝 was increased by 5.5 fold (to 0.0055). The effect of decreasing the rate of 
trimethoprim treatment was not modelled after a Swedish study demonstrated 
little evidence for reversibility of trimethoprim resistance after a drastic reduction 
in trimethoprim use.208 
Modelling output 
The following output was derived from 1,000 simulations of the stochastic 
model:  
 The number of UTIs caused by E. coli resistant to trimethoprim in the 
LTCF in the last four weeks of the study as predicted by the model 
(median, mean, and 95th percentile for 1,000 simulations)  
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 The number of individuals discharged to hospital from the LTCF 
colonised by E. coli resistant to trimethoprim in the LTCF in the last four 
weeks of the study as predicted by the model (median, mean, and 95th 
percentile for 1,000 simulations)  
 The number of individuals discharged to the LTCF from hospital 
colonised by E. coli resistant to trimethoprim in the LTCF in the last four 
weeks of the study as predicted by the model (median, mean, and 95th 
percentile for 1,000 simulations)  
 The percentage of individuals in the LTCF colonised by E. coli resistant 
to trimethoprim (vs. sensitive to trimethoprim) in the last year of the study 
(median, mean, and 95th percentile for 1,000 simulations) 
 The percentage of individuals in the LTCF treated with trimethoprim (vs. 
untreated) in the last year of the study (median, mean, and 95th 
percentile for 1,000 simulations) 
 The percentage of individuals colonised by E. coli resistant to 
trimethoprim (vs. sensitive to trimethoprim) admitted to hospital from the 
LTCF in the last year of the study (median, mean, and 95th percentile for 
1,000 simulations) 
 The percentage of individuals colonised by E. coli resistant to 
trimethoprim (vs. sensitive to trimethoprim) discharged to the LTCF from 
hospital in the last year of the study (median, mean, and 95th percentile 
for 1,000 simulations) 
 The relative importance of importation from hospital, transmission and 
prescription in increasing the proportion of individuals colonised with E. 
coli resistant to trimethoprim (vs. susceptible to trimethoprim) in the 
LTCF 
 
These same outputs were derived for the baseline scenario, for the 
sensitivity analysis and for the scenarios. 
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Results 
The deterministic model output was consistent with the median stochastic 
model output over 1,000 runs. 
Baseline scenario 
The median LTCF size was kept constant at 30 beds during the study period 
(see Figure 7-10).  
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Figure 7-10. Total LTCF population size by week of the study period.  N was the total 
number of residents in the LTCF. In light and dark pink, the 95
th
 and 50
th
 percentile of 1,000 
stochastic runs (respectively). The solid and dotted dark red lines represent the mean and 
median of the 1,000 stochastic runs (respectively). 
The number of entries and exits to each of the LTCF compartments are shown 
in Appendix Chapter 7. The exit rates from the LTCF were constant over time. 
Therefore, the number of individuals exiting each compartment depended on 
the number of individuals in each compartment at that time. The entry rates 
were also constant over time. 
In the stochastic model, over the last year of the study, the median proportion of 
individuals discharged to the LTCF from hospital colonised by E. coli resistant to 
trimethoprim was 37.5% (95th percentile=13.33%-66.67%, mean=38.39%). The 
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median proportion of individuals admitted to hospital from the LTCF colonised 
by E. coli resistant to trimethoprim over 1,000 runs was 48.28% (95th 
percentile=25%-71.43%, mean=48.15%).  
In the last four weeks of the study, the stochastic model predicted a median of 
one patient colonised by E. coli resistant to trimethoprim being discharged to 
the LTCF from hospital (95th percentile= 0-3, mean=0.91) and a median of one 
patient colonised by E. coli resistant to trimethoprim being admitted to hospital 
from the LTCF (95th percentile= 0-3, mean=1.35). 
Figure 7-11 shows the number of individuals in the LTCF in compartments 𝑈𝑠, 
𝑈𝑟, 𝑇𝑠 and 𝑇𝑟 in the model over the study period (four years) for 1,000 
stochastic model runs, against the deterministic output (black line). The 50th and 
90th percentiles of the stochastic runs and their mean and median are plotted in 
Figure 7-12. There was a similar number of untreated individuals colonised with 
E. coli sensitive to trimethoprim and resistant to trimethoprim. The number of 
treated individuals was much lower. Over the last year of the study, the median 
prevalence of resistant colonisation amongst those untreated for 1,000 
stochastic runs was 47.79% (95th percentiles=31.05%-61.08%, mean=47.30%). 
The median prevalence of resistance in treated residents was 90% (95th 
percentiles=50%-100%, mean=86.2%). Overall, the median prevalence of 
resistance over the last year of the study was 48.02% (95th percentiles=31.24%-
61.24%, mean=47.51%). 
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Figure 7-11. Distribution of individuals between the four compartments of the model 
during the study period.  𝑼𝒔 were individuals untreated with trimethoprim colonised with E. 
coli susceptible to trimethoprim, 𝑼𝒓  were individuals untreated with trimethoprim colonised with 
E. coli resistant to trimethoprim, 𝑻𝒔 were individuals treated with trimethoprim colonised with E. 
coli susceptible to trimethoprim and 𝑻𝒓  were individuals treated with trimethoprim colonised 
with E. coli resistant to trimethoprim. The coloured lines represent the output of 1,000 stochastic 
simulations. The black line represents the output from the deterministic model. 
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Figure 7-12. Distribution of individuals between the four compartments of the model by 
week of the study period. 𝑼𝒔 were individuals untreated with trimethoprim colonised with E. 
coli susceptible to trimethoprim, 𝑼𝒓  were individuals untreated with trimethoprim colonised with 
E. coli resistant to trimethoprim, 𝑻𝒔 were individuals treated with trimethoprim colonised with E. 
coli susceptible to trimethoprim and 𝑻𝒓  were individuals treated with trimethoprim colonised 
with E. coli resistant to trimethoprim. In light and dark pink, the 95
th
 and 50
th
 percentile of 1,000 
stochastic runs (respectively). The solid and dotted dark red lines represent the mean and 
median of the 1,000 stochastic runs (respectively). The median, 95
th
 and 50
th
 percentile of 1,000 
stochastic runs (respectively) for the 𝑻𝒔 compartment are equal to zero. 
Figure 7-13 shows the weekly incidence of UTIs caused by E. coli resistant to 
trimethoprim in the LTCF reported in AmSurv (black points) compared to that 
predicted by the model. The median number of UTIs caused by E. coli resistant 
to trimethoprim in the LTCF for 1,000 runs of the stochastic model over the 
study period was zero (dotted dark red line, 95th percentiles= 0-2).  
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In the last four weeks of the study, the stochastic model predicted a median of 
one UTI caused by E. coli resistant to trimethoprim (95th percentiles= 0-4, 
mean=1.31). Over the study period, there were 65 UTIs caused by E. coli 
resistant to trimethoprim in the LTCF in the data. The stochastic model 
predicted a mean of 63.5 and a median of 63 (95th percentile=38-95) over the 
1,000 simulations. 
 
Figure 7-13. Weekly incidence of UTIs caused by E. coli resistant to trimethoprim in the 
data compared to the model.  The black dots represent the incidence in the AmSurv West 
Midlands dataset for the LTCF selected for model fitting. The solid and dotted dark red lines 
represent the mean and median of the 1,000 stochastic runs (respectively).In light pink, the 95
th
 
percentile of 1,000 stochastic runs (the 50
th
 percentile is not shown as both its limits were equal 
to zero).   
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Sensitivity analysis 
Table 7-4 below shows the number of UTIs caused by E. coli resistant to 
trimethoprim in the LTCF, the number of individuals colonised by E. coli 
resistant to trimethoprim that were admitted to hospital from the LTCF and 
discharged to the LTCF from hospital, the percentage of individuals in the LTCF 
colonised by E. coli resistant to trimethoprim (vs. sensitive to trimethoprim), the 
percentage of individuals in the LTCF treated with trimethoprim (vs. untreated), 
and the percentage of individuals colonised by E. coli resistant to trimethoprim 
(vs. sensitive to trimethoprim) admitted to hospital from the LTCF and 
discharged to the LTCF from hospital in the baseline scenario and in several 
sensitivity analyses. These included increasing 𝑝𝑡𝑐, 𝑝𝑟𝑐 and 𝑝𝑟ℎ linearly with an 
intercept and slope defined by the regression models fit to the prescription and 
antibiotic resistance data for this period, as well as varying 𝛾, 𝛾𝑝, 𝑙ℎ, and 𝑝𝑡ℎ 
according to plausible ranges (described in the parameterisation section).  
The deterministic model output in the baseline scenario compared to when 𝑝𝑟𝑐, 
𝑝𝑡𝑐, and 𝑝𝑟ℎ increase linearly (as derived from the data and explained in the 
parameterisation section above) is shown in Figure 7-14.  
The model was additionally fit to data from three different LTCFs with lower 
incidence and higher number of beds (see Table 7-5). 
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Table 7-4. Sensitivity analysis part 1. 
 Baseline 
scenario 
𝑝𝑟𝑐, 𝑝𝑡𝑐, 
and 𝑝𝑟ℎ 
increase 
linearly 
𝛾=0.0025 𝛾=0.0055 𝛾𝑝=0.
16 
𝛾𝑝=0.3 𝑙ℎ=0.77 𝑙ℎ=0.9 𝑝𝑡ℎ=0.017 𝑝𝑡ℎ=0.032 
N UTIs caused by E. coli resistant 
to trimethoprim in the LTCF in the 
last month of the study* (median, 
mean, and 95
th
 percentile for 1,000 
simulations)  
1, 1.31, 
0-4 
1, 1.18, 
0-4 
1, 1.2, 0-4 1, 1.17, 0-
4 
1, 
1.27, 
0-4 
1, 
1.22, 
0-4 
1, 1.17, 
0-4 
1, 1.16, 
0-4 
1, 1.26, 0-4 1, 1.2, 0-4 
N individuals admitted to hospital 
from the LTCF colonised by E. coli 
resistant to trimethoprim in the last 
month of the study* (median, mean, 
and 95
th
 percentile for 1,000 
simulations) 
1, 1.35, 
0-3 
1, 1.36, 
0-3 
1, 1.36, 0-
4 
1, 1.39, 0-
4 
1, 
1.36, 
0-4 
1, 
1.28, 
0-4 
1, 1.28, 
0-4 
1, 1.53, 
0-4 
1, 1.3, 0-4 1, 1.32, 0-3 
N individuals discharged to the 
LTCF from hospital colonised by E. 
coli resistant to trimethoprim in the 
last month of the study* (median, 
mean, and 95
th
 percentile for 1,000 
simulations) 
1, 0.91, 
0-3 
0, 0.95, 
0-4 
1, 1.03, 0-
4 
1, 1.01, 0-
4 
1, 
1.01, 
0-4 
1, 
0.98, 
0-3 
0, 0.98, 
0-4 
1, 0.99, 
0-3 
1, 0.98, 0-4 1, 0.92, 0-3 
Percentage of individuals in the 
LTCF colonised by E. coli resistant 
to trimethoprim (vs. sensitive to 
trimethoprim) in the last year of the 
study (median, mean, and 95
th
 
percentile for 1,000 simulations) 
48.02, 
47.51, 
31.24-
61.24 
48.51, 
48.01, 
32.54-
62.54 
57.25, 
56.69, 
42.39-
70.13 
34.25, 
33.7, 
18.08-
47.60  
48.22
, 
48.09
, 
32.3-
62.54 
47.94, 
47.17, 
31.84-
60.9 
49.02, 
48.49, 
33.84-
62.17 
47.97, 
47.79, 
32.91-
61.89 
48.24, 
47.77, 
32.68-62.16 
48.21, 
48.13, 
32.47-62.44 
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 Baseline 
scenario 
𝑝𝑟𝑐, 𝑝𝑡𝑐, 
and 𝑝𝑟ℎ 
increase 
linearly 
𝛾=0.0025 𝛾=0.0055 𝛾𝑝=0.
16 
𝛾𝑝=0.3 𝑙ℎ=0.77 𝑙ℎ=0.9 𝑝𝑡ℎ=0.017 𝑝𝑡ℎ=0.032 
Percentage of individuals in the 
LTCF treated with trimethoprim (vs. 
untreated) in the last year of the 
study (median, mean, and 95
th
 
percentile for 1,000 simulations) 
0.49, 
0.52, 
0.12-
0.96 
0.49, 
0.52, 
0.17-
0.94 
0.5, 0.52, 
0.19-0.91 
0.49, 0.51, 
0.14-0.94 
0.6, 
0.63, 
0.21-
1.16 
0.32, 
0.34, 
0.09-
0.65 
0.49, 
0.51, 
0.18-
0.93 
0.49, 
0.52, 
0.17-
0.95 
0.49, 0.52, 
0.17-0.95 
0.48, 0.51, 
0.18-0.94 
Percentage of individuals colonised 
by E. coli resistant to trimethoprim 
(vs. sensitive to trimethoprim) 
admitted to hospital from the LTCF 
in the last year of the study 
(median, mean, and 95
th
 percentile 
for 1,000 simulations) 
48.28, 
48.15, 
25-71.43  
47.62, 
48.22, 
27.27-70 
57.14, 
57.39, 
33.33-80 
33.33, 
33.04, 
11.99-
54.55 
47.62
, 
47.81
, 
26.67
-70 
47.62, 
47.47, 
25-70 
50, 
48.46, 
23.77-
71.43 
48, 
47.98, 
26.67-
70 
50, 48.17, 
25-68.77 
50, 48.06, 
23.51-70.59 
Percentage of individuals colonised 
by E. coli resistant to trimethoprim 
(vs. sensitive to trimethoprim) 
discharged to the LTCF from 
hospital in the last year of the study 
(median, mean, and 95
th
 percentile 
for 1,000 simulations) 
37.5, 
38.39, 
13.33-
66.67 
40, 
40.23, 
16.67-
66.67 
36.84, 
37.23,14.2
4-62.5 
37.5, 
38.07, 
16.67-62.5 
37.5, 
37.59
, 
13.33
-62.5 
36.84, 
37.15,
11.11-
63.67 
37.5, 
37.42, 
12.43-
61.54 
37.5, 
36.95, 
14.29-
62.5 
37.5, 37.63 
13.29-64.29 
36.84, 
37.15, 12.5-
62.5 
* Four weeks, as the data was weekly. The last 4 weeks of the study were selected for analysis as this was representative of the equilibrium state. 
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Figure 7-14. Outputs from the deterministic model in which 𝒑𝒓𝒄, 𝒑𝒕𝒄, and 𝒑𝒓𝒉 were fixed 
at the mean (in red) compared to the scenario in which they were made to increase 
linearly in agreement with the data (in blue). 𝑼𝒔 were individuals untreated with trimethoprim 
colonised with E. coli susceptible to trimethoprim, 𝑼𝒓  were individuals untreated with 
trimethoprim colonised with E. coli resistant to trimethoprim, 𝑻𝒔 were individuals treated with 
trimethoprim colonised with E. coli susceptible to trimethoprim and 𝑻𝒓  were individuals treated 
with trimethoprim colonised with E. coli resistant to trimethoprim.  
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Table 7-5. Sensitivity analysis part 2. 
 Baseline scenario (LTCF 
with 30 beds, incidence of 
trimethoprim resistant 
urinary E. coli=0.0015 per 
bed day, 𝛽=0.0062 per 
person per day 
LTCF with 39 beds, 
incidence of trimethoprim 
resistant urinary E. 
coli=0.00088 per bed day, 
𝛽=0.0024 per person per 
day 
LTCF with 57 beds, 
incidence of trimethoprim 
resistant urinary E. coli= 
0.00075 per bed day, 
𝛽=0.0016 per person per 
day 
LTCF with 83 beds, 
incidence of trimethoprim 
resistant urinary E. coli= 
0.00045 per bed day, 
𝛽=0.000052 per person 
per day 
N UTIs caused by E. coli resistant 
to trimethoprim in the LTCF in the 
last month of the study* (median, 
mean, and 95
th
 percentile for 
1,000 simulations)  
1, 1.31, 0-4 1, 1.01, 0-4 1, 1.08, 0-4 0, 0.92, 0-4 
N individuals admitted to hospital 
from the LTCF colonised by E. coli 
resistant to trimethoprim in the last 
month of the study* (median, 
mean, and 95
th
 percentile for 
1,000 simulations) 
1, 1.35, 0-3 2, 1.78, 0-5 2, 2.49, 0-5 3, 3.63, 1-7 
N individuals discharged to the 
LTCF from hospital colonised by 
E. coli resistant to trimethoprim in 
the last month of the study* 
(median, mean, and 95
th
 
percentile for 1,000 simulations) 
1, 0.91, 0-3 1, 1.38, 0-5 1, 1.86, 0-5 2, 2.67, 0-6 
Percentage of individuals in the 
LTCF colonised by E. coli 
resistant to trimethoprim (vs. 
sensitive to trimethoprim) in the 
last year of the study (median, 
mean, and 95
th
 percentile for 
1,000 simulations) 
48.02, 47.51, 31.24-61.24 27.79, 27.97, 16.17-39.62 23.19, 23.20, 14.18-32.18 13.75, 13.82, 8.79-18.75 
  
2
3
9
 
 Baseline scenario (LTCF 
with 30 beds, incidence of 
trimethoprim resistant 
urinary E. coli=0.0015 per 
bed day, 𝛽=0.0062 per 
person per day 
LTCF with 39 beds, 
incidence of trimethoprim 
resistant urinary E. 
coli=0.00088 per bed day, 
𝛽=0.0024 per person per 
day 
LTCF with 57 beds, 
incidence of trimethoprim 
resistant urinary E. coli= 
0.00075 per bed day, 
𝛽=0.0016 per person per 
day 
LTCF with 83 beds, 
incidence of trimethoprim 
resistant urinary E. coli= 
0.00045 per bed day, 
𝛽=0.000052 per person 
per day 
Percentage of individuals in the 
LTCF treated with trimethoprim 
(vs. untreated) in the last year of 
the study (median, mean, and 95
th
 
percentile for 1,000 simulations) 
0.49, 0.52, 0.12-0.96 0.49, 0.51, 0.23-0.86 0.49, 0.51, 0.26-0.81 0.50, 0.51, 0.3-0.75 
Percentage of individuals 
colonised by E. coli resistant to 
trimethoprim (vs. sensitive to 
trimethoprim) admitted to hospital 
from the LTCF in the last year of 
the study (median, mean, and 95
th
 
percentile for 1,000 simulations) 
48.28, 48.15, 25-71.43  28.57, 28.35, 11.09-45.83 23.08, 23.12, 9.99-36.67 13.6, 13.8, 5.99-22.22 
Percentage of individuals 
colonised by E. coli resistant to 
trimethoprim (vs. sensitive to 
trimethoprim) discharged to the 
LTCF from hospital in the last year 
of the study (median, mean, and 
95
th
 percentile for 1,000 
simulations) 
37.5, 38.39, 13.33-66.67 37.5, 37.95, 18.18-60 38.24, 38.18, 22.22-55.56 37.5, 37.76, 24.13-51.72 
* Four weeks, as the data was weekly. The last 4 weeks of the study were selected for analysis as this was representative of the 
equilibrium  
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Scenario analysis 
Table 7-6 compares the output of 1,000 stochastic runs of the model in the 
baseline scenario; in two scenarios assuming different proportion of patients 
entering the LTCF from hospital (vs. from the community); in three different 
transmission scenarios; and in four scenarios in which the rate of treatment was 
progressively increased.  
The impact of increasing the proportion of admissions from hospital (ℎ𝑙) by 
20%, increasing the rate of treatment (𝛼𝑝) by 20% and increasing the rate of 
transmission (𝛽) by 20% on the percentage of individuals in the LTCF colonised 
by E. coli resistant to trimethoprim (vs. sensitive to trimethoprim) in the last year 
of the study was compared. Note that only increases of 20% in the rates of 
treatment and transmission are strictly comparable, as the admissions from 
hospitals are a proportion. Increasing the transmission rate resulted in a median 
5.42% (mean 5.32%) percentage increase in the number of individuals in the 
LTCF colonised by E. coli resistant to trimethoprim. Increasing ℎ𝑙 and 𝛼𝑝 
resulted in lower increases in resistance (median increases of 0.77% and 
1.54%, respectively, and mean increases of 0.83% and 1.91%, respectively). 
 
  
2
4
1
 
Table 7-6. Movement, transmission and treatment scenarios. 
 Baseline 
scenario 
ℎ𝑙=0.4057 
(20% 
reduction) 
ℎ𝑙=0.8057 
(20% 
increase) 
𝛽=0.0031 
(halved) 
𝛽=0.0074 
(20% 
increase) 
𝛽=0.0124 
(doubled) 
𝛽′= 𝛽=0.0062 
(𝑡𝑟 =1) 
𝛼𝑝=0.0012 
(20% 
increase) 
𝛼𝑝=0.0015 
(50% 
increase) 
𝛼𝑝=0.0055 
(5.5 fold 
increase) 
N UTIs caused by 
E. coli resistant to 
trimethoprim in the 
LTCF in the last 
month of the 
study* (median, 
mean, and 95
th
 
percentile for 
1,000 simulations)  
1, 1.31, 
0-4 
1, 1.19, 0-
4 
1, 1.24, 0-
4 
0, 0.79, 
0-3 
1, 1.37, 
0-4 
1, 1.63, 
0-5 
1, 1.01, 0-4 1, 1.24, 0-4 1, 1.3, 0-4 1, 1.68, 0-5 
N individuals 
admitted to 
hospital from the 
LTCF colonised by 
E. coli resistant to 
trimethoprim in the 
last month of the 
study* (median, 
mean, and 95
th
 
percentile for 
1,000 simulations) 
1, 1.35, 
0-3 
1, 1.36, 0-
3 
1, 1.35, 0-
4 
1, 1.32, 
0-4 
1, 1.33, 
0-4 
1, 1.31, 
0-4 
1, 1.37, 0-4 1, 1.3, 0-3 1, 1.4, 0-4 1, 1.32, 0-3 
N individuals 
discharged to the 
LTCF from hospital 
colonised by E. 
coli resistant to 
trimethoprim in the 
last month of the 
study* (median, 
mean, and 95
th
 
percentile for 
1,000 simulations) 
1, 0.91, 
0-3 
0, 0.65, 0-
3 
1, 1.24, 0-
4 
1, 0.98, 
0-4 
1, 1, 0-4 1, 1, 0-4 1, 0.98, 0-4 1, 0.98, 0-3 1, 1.09, 0-4 1, 0.97, 0-3 
  
2
4
2
 
 Baseline 
scenario 
ℎ𝑙=0.4057 
(20% 
reduction) 
ℎ𝑙=0.8057 
(20% 
increase) 
𝛽=0.0031 
(halved) 
𝛽=0.0074 
(20% 
increase) 
𝛽=0.0124 
(doubled) 
𝛽′= 𝛽=0.0062 
(𝑡𝑟 =1) 
𝛼𝑝=0.0012 
(20% 
increase) 
𝛼𝑝=0.0015 
(50% 
increase) 
𝛼𝑝=0.0055 
(5.5 fold 
increase) 
Percentage of 
individuals in the 
LTCF colonised by 
E. coli resistant to 
trimethoprim (vs. 
sensitive to 
trimethoprim) in 
the last year of the 
study (median, 
mean, and 95
th
 
percentile for 
1,000 simulations) 
48.02, 
47.51, 
31.24-
61.24 
48.29, 
48.17, 
33.25-
62.28 
48.79, 
48.34, 
34.42-
61.92 
31.76, 
31.21, 
15.39-
45.7 
53.44, 
52.83, 
37.82-
66.18 
67.85, 
67.45, 
56.47-
77.62 
39, 38.61, 
21.78-53.93 
49.56, 
49.42, 
34.14-63.35  
51.5, 51.14, 
36.12-64.41 
67.21, 
66.94, 
56.95-
76.09 
Percentage of 
individuals in the 
LTCF treated with 
trimethoprim (vs. 
untreated) in the 
last year of the 
study (median, 
mean, and 95
th
 
percentile for 
1,000 simulations) 
0.49, 
0.52, 
0.12-
0.96 
0.47, 0.51, 
0.18-0.99 
0.49, 0.52, 
0.17-0.96 
0.48, 
0.51, 
0.16-0.95 
0.48, 
0.51, 
0.17-0.96 
0.47, 0.5, 
0.17-0.93 
0.48, 0.5, 
0.16-0.93 
0.58, 0.6, 
0.22-1.07 
0.72, 0.75, 
0.33-1.28 
2.62, 2.66, 
1.84-3.6 
  
2
4
3
 
 Baseline 
scenario 
ℎ𝑙=0.4057 
(20% 
reduction) 
ℎ𝑙=0.8057 
(20% 
increase) 
𝛽=0.0031 
(halved) 
𝛽=0.0074 
(20% 
increase) 
𝛽=0.0124 
(doubled) 
𝛽′= 𝛽=0.0062 
(𝑡𝑟 =1) 
𝛼𝑝=0.0012 
(20% 
increase) 
𝛼𝑝=0.0015 
(50% 
increase) 
𝛼𝑝=0.0055 
(5.5 fold 
increase) 
Percentage of 
individuals 
colonised by E. 
coli resistant to 
trimethoprim (vs. 
sensitive to 
trimethoprim) 
admitted to 
hospital from the 
LTCF in the last 
year of the study 
(median, mean, 
and 95
th
 percentile 
for 1,000 
simulations) 
48.28, 
48.15, 
25-71.43  
48, 48.1, 
25-70.63 
47.37, 
47.84, 25-
70 
31.14, 
31.65, 
9.5-54.55 
53.85, 
53.09, 
28.57-75 
66.67, 
67.2, 
46.67-
87.5 
38.46, 38.7, 
16.67-61.56 
50, 49.1, 
25-71.43 
50, 51.19, 
27.27-73.33 
68, 67.36, 
46.64-87.5 
Percentage of 
individuals 
colonised by E. 
coli resistant to 
trimethoprim (vs. 
sensitive to 
trimethoprim) 
discharged to the 
LTCF from hospital 
in the last year of 
the study (median, 
mean, and 95
th
 
percentile for 
1,000 simulations) 
37.5, 
38.39, 
13.33-
66.67 
37.5, 
37.13, 0-
66.67 
37.5, 
37.97, 
16.67-60 
38.1, 
37.96, 
12.5-62.5 
37.5, 
37.63, 
12.5-
63.64 
37.5, 
37.46, 
14.29-
63.64 
37.5, 37.33, 
13.62-60.9 
38.68, 
38.54, 12.5-
62.5 
36.36, 
36.87, 
13.29-61.54 
36.36, 
36.88, 
12.5-63.64 
* Four weeks, as the data was weekly. The last 4 weeks of the study were selected for analysis as this was representative of the 
equilibrium state 
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Discussion 
Baseline scenario findings: incidence and prevalence of resistance 
In the baseline scenario, a median of one UTI caused by E. coli resistant to 
trimethoprim was predicted to be reported during the last month of the study 
from a 30-bed LTCF over 1,000 stochastic runs (95th percentile range=0-4, 
mean=1.31 for the LTCF, or 0.04 per resident). The model predicted that even 
in scenarios where the prevalence of resistant colonisation neared 70% in the 
LTCF, the number of UTIs caused by E. coli resistant to trimethoprim reported 
would remain at a mean of 1.6-1.7 per month (0.05-0.06 per resident per 
month). This was in agreement with the dataset used for model fitting (range=0-
8, 0.06 per resident per month). The total number of UTIs caused by E. coli 
resistant to trimethoprim in the LTCF over the study period was also similar in 
the data (65) and in the model (mean over 1,000 simulations=63.5, median=63, 
95th percentile=38-95). The LTCF selected for model fitting in the baseline 
scenario had a higher incidence of trimethoprim resistant E. coli urine samples 
submitted to AmSurv than the mean observed for all LTCF residents surveyed 
in the West Midlands AmSurv dataset (from Chapter 5), which was 0.011 per 
resident per month. It should be noted that the incidence predicted by the model 
and the incidence in the West Midlands AmSurv dataset reflected the number of 
sampled and reported urinary E. coli resistant to trimethoprim, and that the 
number of residents developing UTIs caused by E. coli resistant to trimethoprim 
may be higher (as these are not always sampled and reported).  
The median prevalence of colonisation with E. coli resistant to trimethoprim (vs. 
susceptible to trimethoprim) in the baseline scenario was predicted to be 
48.02% (95th percentile range=31.24-61.24). This was lower than the 
prevalence of resistance in urinary E. coli samples reported to AmSurv from 
residents of this same LTCF (77.3%), calculated as the number of E. coli 
urinary samples resistant to trimethoprim divided by the total number of E. coli 
urine samples sent from residents in this facility. However, the prevalence of 
colonisation with E. coli resistant to trimethoprim in this simulated LTCF was still 
higher than that calculated for West Midlands AmSurv samples sent from 
elderly patients in hospitals (mean over 2010-2014=37.92%), which were used 
 245 
 
to parameterise 𝑝𝑟ℎ (the proportion of individuals colonised by E. coli resistant 
to trimethoprim discharged from hospital to the LTCF). Since it was additionally 
assumed that transfers from the LTCF to hospital were equally probable for 
residents colonised by E. coli sensitive and resistant to trimethoprim (both at 
rate 𝑚), and the rate of patient transfer from the LTCF to hospital was higher 
(𝑁 × 𝑚 × 𝑙ℎ = 30 × 0.002 × 0.8) than the rate of patient transfer from the 
hospital to the LTCF (𝑁 × 𝑚 × ℎ𝑙 = 30 × 0.002 × 0.6057), this meant there was 
a net transfer of individuals colonised with E. coli resistant to trimethoprim 
towards the hospital. 
During the process of selecting the LTCF for model fitting, it transpired that 
larger LTCFs had a lower incidence of urinary E. coli resistant to trimethoprim 
per bed day than smaller LTCFs. This requires further study. LTCFs were sub-
divided by quartiles according to the number of urine E. coli samples sent to 
AmSurv which were resistant to trimethoprim per bed per day. One LTCF was 
selected from each of these quartiles. The LTCF selected from the highest 
incidence quartile was used to fit the model in the baseline scenario and the 
remaining three LTCFs from the lower incidence quartiles were used to fit the 
model in sensitivity analyses. The prevalence of resistant colonisation was 
lower in the three LTCFs selected for sensitivity analyses. This was to be 
expected as the incidence of urine E. coli samples in these facilities was lower 
and the transmission parameter was estimated by fitting the model to this 
incidence data (all remaining parameters were kept the same). In all three 
LTCFs in the sensitivity analyses, the prevalence of resistant colonisation was 
lower in the LTCF than in the hospital, therefore, contrasting with the baseline 
scenario, there was a net transfer of individuals colonised with trimethoprim 
resistant E. coli from the hospital to the LTCF. The median prevalence of 
resistance in the LTCF selected amongst those in the lowest incidence quartile 
was 13.75% (8.79%-18.75%). LTCFs submitting fewer than 10 urinary E. coli 
samples resistant to trimethoprim to AmSurv per year were excluded from this 
analysis. Therefore, the prevalence of resistance in some LTCFs may be even 
lower.  
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Movement in and out of the LTCF 
Increasing 𝑝𝑟𝑐 (the proportion of residents admitted to the LTCF from the 
community colonised with E. coli resistant to trimethoprim), 𝑝𝑡𝑐 (the proportion 
of residents admitted to the LTCF from the community on trimethoprim 
treatment) and 𝑝𝑟ℎ (the proportion of residents discharged to the LTCF from 
hospital colonised with E. coli resistant to trimethoprim) resulted in similar model 
outputs than when these proportions were fixed at the mean for the study period 
(as in the baseline scenario).  
The model outputs were also robust to varying 𝑙ℎ, the proportion of residents 
who leave the LTCF that go to hospital (vs. die), between 0.77 and 0.9, to 
reflect different hospital admission rates for LTCF residents reported in the 
literature9,249; and to varying 𝑝𝑡ℎ, the proportion of admissions to the LTCF from 
hospital (vs. community),  between 0.0173 and 0.0323, in line with the range of 
prevalence of trimethoprim treatment found in different hospitals in the West 
Midlands in the point-prevalence survey data.40 Increasing and decreasing 
ℎ𝑙 (the proportion of patients entering the LTCF from hospital (vs. the 
community)) by 20% increased and decreased the mean monthly number of 
individuals colonised by E. coli resistant to trimethoprim discharged to the LTCF 
from hospital from 0.91 to 1.24 and 0.65, respectively. However, this change did 
not alter the prevalence of resistant colonisation in the LTCF. This indicates 
that, in a LTCF similar to that used for model fitting in the baseline scenario, the 
prevalence of resistant colonisation would still be high even when fewer patients 
were admitted to the LTCF from hospital. For example, in a situation where 
hospitals were encouraged to discharge patients to the community with 
supported care in their own homes. The prevalence of trimethoprim resistant 
colonisation was higher in the LTCF than in hospital. This would, however, be 
different for other types of antibiotic resistance which are more prevalent in 
hospital.  
Treatment 
The proportion of LTCF residents treated with trimethoprim at equilibrium was 
lower than that reported in other studies (median=0.49%, mean=0.52%, 95th 
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percentile range=0.12%-0.96%). In HALT-2, 2.69% (11/409) of residents 
surveyed in 16 English LTCFs were being treated with trimethoprim or 
sulphonamides on the day of the study.63 In Ireland, a point-prevalence survey 
carried out in 2011259 showed 1.717% of residents being treated with 
trimethoprim on the survey day. Varying the duration of trimethoprim treatment 
between 3 and 6 days moderately decreased and increased (respectively) the 
proportion of residents treated with trimethoprim (increase of 0.11% and 
decrease of 0.18% in the median); however, this did not affect the prevalence of 
resistance in the LTCF. Only the scenario in which the treatment rate (𝛼𝑝) was 
increased by 5.5 fold (to 0.0055 per person per day) was able to approximate 
(median=2.62%) the proportion of residents treated with trimethoprim found in 
HALT-2.63 This high treatment rate resulted in an increase in the prevalence of 
resistance from a median of 48.02% to a median of 67.21%, which was closer 
to that observed in AmSurv for this LTCF (77.3%). In this scenario, the mean 
monthly number of UTIs reported caused by E. coli resistant to trimethoprim 
predicted by the model also increased, from 1.31 to 1.68. The monthly number 
of UTIs reported caused by E. coli resistant to trimethoprim was not altered by 
smaller increases in 𝛼𝑝. 
Transmission 
Doubling the transmission rate also resulted in a similar increase in the median 
prevalence of resistance in the LTCF (from 48.02% to 67.85%) and a similar 
increase in the mean monthly number of predicted UTIs reported caused by E. 
coli resistant to trimethoprim (from 1.31 to 1.63). Changes in the monthly 
number of UTIs reported caused by E. coli resistant to trimethoprim were not 
evident for smaller increases in transmission (20%). However, a 20% increase 
in the transmission rate still increased the median prevalence of resistance in 
the LTCF from 48.02% to 53.44%. Similarly, varying the duration of colonisation 
between 6 and 13 months altered the prevalence of resistance in the LTCF but 
didn’t result in a significant difference in the number of UTIs reported caused by 
E. coli resistant to trimethoprim predicted by the model. Increasing the duration 
of colonisation to 13 months (instead of 9.5 as per the baseline scenario) 
increased the median prevalence of resistant colonisation in the LTCF by 
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9.23%. Decreasing the duration of colonisation to 6 months caused a 13.77% 
decrease. Setting the transmission rate in treated individuals equal to the 
transmission rate in untreated individuals reduced the median prevalence of 
resistance in the LTCF to 39%. The mean number of predicted UTIs reported 
caused by E. coli resistant to trimethoprim per month dropped slightly from 1.31 
to 1.01.  
What are the main drivers of trimethoprim resistance and what does this 
mean? 
Of the scenarios explored, only doubling the transmission and increasing the 
rate of trimethoprim prescription by 5.5 fold per person per day caused a visible 
increase in the number of monthly UTIs reported caused by E. coli resistant to 
trimethoprim. However, the monthly number of predicted UTIs reported caused 
by E. coli resistant to trimethoprim was low, complicating the comparison of this 
output between different scenarios. The mean number of predicted UTIs 
reported caused by E. coli resistant to trimethoprim over 1,000 simulations had 
to be used for comparison, as the median in every scenario was equal to either 
0 or 1, which was uninformative. Transmission appeared to be the most 
important driver of the prevalence of resistant colonisation in the LTCF. The 
transmission rate was doubled to yield a prevalence of resistance nearing 70%. 
In comparison, the treatment rate had to be increased by 5.5 fold to achieve the 
same prevalence of resistance. In addition, when increasing the transmission 
rate, the treatment rate and the proportion of admissions to the LTCF from 
hospital (vs. from the community) by 20%, the 20% increase in transmission 
resulted in the highest change in the prevalence of resistance within the LTCF. 
These findings were based on the model at equilibrium; therefore, increasing 
the time horizon of the model would have not changed these results. However, 
parameters will change over time; thus, the model outputs are reflective of the 
current model parameterisation and of the structure and assumptions made. 
The high levels of resistance to trimethoprim already present in this population 
mean that the number of transmission events will be higher under the same 
transmission rate than in a scenario where the prevalence of resistance is low 
(as there are more individuals dominantly colonised by E. coli resistant to 
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trimethoprim in the population), provided that there are still sufficient individuals 
dominantly colonised with E. coli susceptible to trimethoprim. It is worth noting, 
therefore, that these conclusions might change in a scenario with low 
prevalence of resistance and the main driver of the prevalence of resistance for 
other organism-antibiotic combinations such as E. coli resistant to nitrofurantoin 
may be different. 
The relative importance of importation from hospital, transmission, and 
prescription in increasing the prevalence of resistant colonisation, coupled with 
the high levels of resistance to trimethoprim in the LTCF compared to hospitals 
and the community in the baseline scenario, suggest that interventions that 
target transmission such as hand washing, contact precautions and isolation 
would be more effective in reducing colonisation by resistant strains in LTCFs 
than interventions that target importations of resistance from hospitals or the 
community (for example, screening on admission to the LTCF). Importations 
from hospital could become more important in LTCFs where the prevalence of 
resistance is low (for example, the LTCFs in the sensitivity analysis). In these 
facilities, the prevalence of resistance was lower than that estimated from 
AmSurv data for hospitals (38%) and the community overall (36%), which 
seems implausible. 
The difference between the prevalence of trimethoprim resistance predicted 
from the model (in the baseline scenario 48.02%) and the prevalence of 
resistance predicted by the AmSurv dataset (for the baseline scenario LTCF 
77.3%) could be explained by a number of alternatives: (1) transmission is 
approximately double than in the baseline scenario, (2) the duration of 
treatment is substantially longer than 6 days, (3) antibiotic prescription is 5.5 
fold higher than in the baseline scenario, (4) the duration of colonisation is much 
longer than 13 months, (5) there is a bias for antibiotic susceptibility testing of 
resistant strains, or (6) a combination of all these factors. 
Strengths 
This was the first study to model the dynamics of trimethoprim resistant Gram-
negative bacteria in LTCFs. The model was informed by data from AmSurv 
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linked to CQC data, THIN data, a point-prevalence survey conducted in 
hospitals, and various studies from the literature. A range of parameter values 
was explored and the model was formally fit to four separate LTCFs with 
different number of beds and prevalence rates. All the high importance criteria 
for good quality mathematical models of AMR bacteria in LTCFs identified in 
Chapter 3 were met.  
In addition, the datasets used to parameterise this model were well matched. 
Although some parameters were obtained from the literature and were not 
specific to the West Midlands, these were adjusted using CQC data to match 
the proportion of nursing LTCFs in the West Midlands. Moreover, the same 
susceptibility data from the West Midlands AmSurv dataset was used for model 
fitting, and informed the proportion of individuals entering the LTCF colonised 
with E. coli resistant to trimethoprim from hospital and from the community, 
which were specifically derived for individuals aged 70 or older. The 
trimethoprim prescription information from THIN was also obtained for the same 
period (April 2010 to March 2014) and for the same population (individuals aged 
70 or older in the West Midlands). The trimethoprim prescription point-
prevalence data from hospitals was also restricted to hospitals in the West 
Midlands.  
Limitations of the assumptions 
The LTCF was assumed to be at full bed occupancy during the duration of the 
study, which simplified the model. This may not have been the case; however, 
no data was available to inform this. In addition, recent reports have highlighted 
the shortage of available beds in care homes in the UK, making this scenario 
not completely implausible.260,261 Residents were also assumed not to transfer 
between LTCFs. Van den Dool et al. (2016)140 similarly did not model transfers 
between LTCFs as these were considered negligible. Residents were also 
assumed not to return to the community.  
Dominance of a single strain in a colonised individual was assumed and 
competition between strains was not modelled as there was not sufficient data 
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available on multi-strain colonisation and infection to parameterise a model 
structure which would allow for co-colonisation. 
In this model the rate of acquiring dominance by an E. coli strain resistant to 
trimethoprim was dependent on the number of individuals colonised with E. coli 
resistant to trimethoprim in the LTCF (and the number of individuals colonised 
with E. coli susceptible to trimethoprim). This model did not explicitly simulate 
neither the acquisition of dominant colonisation by E. coli resistant to 
trimethoprim through endogenous factors such as spontaneous mutation, which 
is assumed to be comparatively rare, nor the transfer of mobile genetic 
elements between bacteria within an individual. Endogenous acquisition of 
resistance was also not explicitly modelled during trimethoprim treatment. 
Therefore, the model did not explicitly account for the possibility that, in an 
individual colonised both by strains of E. coli resistant and susceptible to 
trimethoprim, but in which the susceptible strains dominate; trimethoprim 
treatment might confer a selective advantage for resistant strains, which may 
result in E. coli resistant to trimethoprim dominating within this individual. 
However, the rate of acquisition of resistance endogenously and through 
transmission are grouped into parameter 𝛽 (under no treatment) and 𝛽′ (under 
treatment). 𝛽′ = 𝑡𝑟 × 𝛽; therefore, 𝑡𝑟 is the magnitude by which the rate of 
acquisition of resistance is greater under treatment. 𝑡𝑟 will capture this selection 
of resistance under treatment within an individual as well as the increased 
susceptibility of individuals dominantly colonised by E. coli susceptible to 
trimethoprim to transmission of resistance from other individuals. The limitation 
of this approach is that 𝛽 and 𝛽′ are dependent on the number of people 
colonised with resistant bacteria in the LTCF (and susceptible to acquiring 
dominant resistant colonisation). Whilst this is accurate for the transmission of 
resistance from one individual to another, the endogenous acquisition of 
resistance does not depend on the number of people colonised with resistant 
bacteria in the LTCF. In order to parameterise this endogenous transmission, a 
separate parameter would need to be created; however, data to this effect is 
lacking. The endogenous acquisition of dominant colonisation by E. coli 
resistant to trimethoprim has been shown to be comparatively rare with respect 
to exogenous transmission (dominant colonisation by E. coli resistant to 
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trimethoprim acquired through person-person transmission) for KPC-producing 
bacteria and for E. coli resistant to expanded-spectrum cephalosporins. 
Haverkate et al.256 estimated endogenous acquisition of KPC-producing 
bacteria in LTACH at 0.0026 per person per day (95%CI=0.0015–0.0043), 
compared to exogenous transmission at 0.014 (95%CIs=0.0071-0.026).256 
Gurieva et al. also found a lower endogenous acquisition of E. coli resistant to 
expanded-spectrum cephalosporins (0.0024, 95%CI=0.0013-0.0039 compared 
to 0.0078, 95%CI=0.0029-0.016, respectively).255 These studies estimated 
endogenous acquisition of resistance through an algorithm developed by 
Bootsma et al.262 which requires extensively detailed data on the patient 
trajectory and screening results.  
Transmission of resistance was only modelled between residents and included 
transmission through direct contact or via healthcare workers. The transmission 
of resistance from the remaining population, including from healthcare workers 
and visitors, was not modelled. This was due to the lack of available data to 
parameterise these modes of transmission.  
Only trimethoprim treatment was modelled. However, trimethoprim resistance 
has been correlated with a number of antibiotic resistances, including ampicillin 
and amoxicillin.263,264 Co-selection of trimethoprim resistance by 
ampicillin/amoxicillin treatment has been shown to be an important predictor of 
geographical variation in trimethoprim resistance in urinary samples263 and 
ampicillin and trimethoprim resistance genes are often linked on the same 
mobile genetic elements264–266. Given that amoxicillin and ampicillin are 
commonly prescribed antibiotics in primary care in England267, these antibiotics 
may be an important driver of trimethoprim resistance.  
Limitations of the parameterisation 
The evidence from the literature used to parameterise the rate of exit and entry 
to the LTCF (𝑚) and the proportion of residents leaving the LTCF to be 
hospitalised (vs. dying) (𝑙ℎ) was scaled to represent the distribution of nursing 
LTCFs in the West Midlands using CQC data; however, it was not specific to 
LTCFs in the West Midlands. The proportion of residents entering the LTCF 
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from hospital (vs. from the community) (ℎ𝑙), which was also taken from the 
literature and scaled using CQC data in the same way, was also not specific to 
the West Midlands. In addition, it was likely to be an overestimate because not 
all patients that visited hospital within the previous 3 months would have directly 
been discharged to the LTCF from hospital. Therefore, the prevalence of 
resistance and the proportion of individuals treated in some individuals in this 
population may have been more similar to the community than to hospital. This 
was explored in sensitivity analyses.  
When parameterising 𝑝𝑟𝑐 and 𝑝𝑟ℎ, the proportion of individuals colonised with 
E. coli resistant to trimethoprim was assumed to be the same as the proportion 
of individuals for which a urinary E. coli sample resistant to trimethoprim was 
reported to AmSurv. However, sampling could be biased towards resistance 
due to treatment failure. This would imply that the proportion of individuals 
admitted to the LTCF from the community and from hospital colonised with E. 
coli resistant to trimethoprim could be over-estimated in the model. In addition, 
the assumption that the prevalence of resistance is similar in carriage and 
infection may not be correct. A study characterising the E. coli faecal flora in 
patients with UTI compared to healthy individuals who had never had a UTI 
found that isolates from UTI patients were more frequently associated with 
multidrug resistance compared to healthy individuals.268 However, this was a 
small-scale study (50 patients and 53 controls) set in Denmark in all ages which 
did not specifically study trimethoprim resistance and is subject to many 
possible confounders; therefore, further work is needed to test this assumption. 
The proportion of treated individuals in hospitals, 𝑝𝑡ℎ, was derived from a point-
prevalence survey carried out in hospital in all ages. Only the two NHS trusts 
(five hospitals) in the West Midlands were selected to inform 𝑝𝑡ℎ. There is, 
therefore, a need for point-prevalence surveys that capture antibiotic treatment 
stratified by age for a more representative number of hospitals in the West 
Midlands. In addition, patients were not followed through their hospital journey 
and return to the LTCF, and transmission was not modelled within the hospital 
setting. Due to this lack of history in the model structure, the model was unable 
to fully capture the “revolving door” syndrome. 
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The rate of trimethoprim treatment in the community was derived from THIN 
data for individuals aged 70 and older attending GP practices in the West 
Midlands, adjusted using findings from a study carried out in Hampshire in 
individuals aged 75 and older. In this study antibiotic prescribing for UTIs was 
2.9 times higher in LTCFs than in the community.69 This study was set in 
Hampshire, in which LTCFs could be different to those in the West Midlands. In 
addition, the difference between prescribing in the community and in the LTCF 
could vary by antibiotic used to treat UTI. Another limitation of this 
parameterisation was that it did not address that the rate of antibiotic treatment 
will be different in different LTCFs. The LTCF selected for model fitting in the 
baseline scenario was amongst the LTCFs in the highest quartile of incidence of 
urinary E. coli resistant to trimethoprim; therefore, it stands that this LTCF could 
also have had a higher trimethoprim treatment rate than average. 
Consequently, the treatment rate for the baseline scenario could have been 
underestimated. The lack of linked susceptibility and prescribing data also 
prevented the analysis of the patient journey through treatment and resistance. 
There were no data available in the literature to inform the transmission of 
trimethoprim resistant E. coli in the LTCF, therefore, the transmission 
parameters in this model had to be estimated by fitting the model to incidence 
data. As such, the value of 𝛽 was dependent on the LTCF selected for model 
fitting. This was shown in the sensitivity analyses, in which the estimates for 𝛽 
were smaller than the one derived for the baseline scenario when fitting to the 
LTCFs with lower incidence.  
The baseline scenario transmission parameters were estimated by fitting the 
model to a LTCF with a high incidence of UTIs caused by E. coli resistant to 
trimethoprim per year reported to AmSurv. This was to ensure that sufficient 
samples were present to enable model fitting and to ensure that transmission (if 
present at all in the LTCF setting) was detected. This restricted the 
interpretation of the findings from the baseline scenario to facilities with a high 
incidence. The LTCF selected for model fitting was varied in sensitivity analyses 
to account for this. However, only three LTCFs amongst those with 20 beds or 
more and submitting 10 or more urine samples per year to AmSurv growing E. 
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coli resistant to trimethoprim were selected for model fitting in sensitivity 
analyses; therefore, the full spectrum of incidence in these facilities was not 
explored. It should be noted, therefore, that the conclusions drawn may be 
different for LTCFs smaller than 20 beds or LTCFs submitting fewer than 10 
urine samples per year to AmSurv growing E. coli resistant to trimethoprim. 
It would also be preferable to fit to the incidence of colonisation by E. coli 
resistant to trimethoprim in the LTCF as this is closer to what was estimated in 
the model; however, this data was not available. As a result, the 𝑟ℎ𝑜 parameter 
was created and grouped the proportion of residents colonised with E. coli 
resistant to trimethoprim that would develop a UTI, and the proportion of these 
UTIs that would be reported to AmSurv.  
Maximum likelihood estimation is a formal model fitting procedure that takes a 
frequentist approach, estimating the set of parameters that are most likely given 
the data observed. Several other methods have been developed for model 
fitting in pomp, for example particle Markov-Chain Monte Carlo. This method 
takes a Bayesian approach, taking into account the prior knowledge about the 
distribution of each of the parameters estimated (the priors). One of the 
limitations of using maximum likelihood estimation is that the uncertainty around 
the parameter values estimated cannot be obtained. Maximum likelihood 
estimation also potentially ignores the volume of parameter space where the 
model fits the data well. This is a problem if the likelihood is “flat”, meaning that 
a large number of parameters give estimations consistent with the observed 
data, and less of a problem if the likelihood has a strong “peak”. Hence, 
maximum likelihood estimation can give a false sense of accuracy whilst 
selecting a more or less random value from a vast region of the parameter 
space which is more or less equally consistent with the data. 
The duration of colonisation with E. coli resistant to trimethoprim has not been 
reported in the literature. Therefore, the range of values for this parameter (6-13 
months) was obtained from the literature for E. coli resistant to other antibiotics. 
The duration of colonisation with E. coli resistant to trimethoprim could 
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potentially be longer since this resistance may not have a high fitness cost 
associated with it.208   
Future work 
A simple expansion of this mathematical model would involve parameterising 
the model to reflect the transmission of E. coli resistant to nitrofurantoin. These 
dynamics could then be compared to those of trimethoprim resistance. This 
would be particularly relevant to current English national policy, as the national 
guidelines recently recommended a switch from trimethoprim treatment to 
nitrofurantoin and nitrofurantoin prescriptions in England have been increasing 
accordingly.35 
The model could also be fit to all the data available from all LTCFs or to a 
distribution of the incidence observed in all LTCFs using more complex 
methods such as particle Markov-Chain Monte Carlo, which would strengthen 
the robustness of the estimated parameters for transmission. 
However, in general, the transmission of E. coli resistant to trimethoprim is 
poorly understood. A better understanding and quantification of transmission 
parameters is needed. Endogenous and exogenous acquisition of dominant 
carriage by E. coli resistant to trimethoprim could be derived by using the 
algorithm developed by Bootsma et al. (2007)262 which requires extensively 
detailed data on the day of admission, day of discharge, day at which sample is 
taken, culture results and colonisation at admission, which has not been 
collected in England to date and was not within the remit of this PhD. With this 
information, transmission would ideally be modelled as four parameters: 
endogenous acquisition of resistance under treatment and under no treatment, 
and exogenous acquisition of resistance under treatment and under no 
treatment. Exogenous acquisition of resistance could also be informed by whole 
genome sequencing studies. This would avoid this parameter having to be 
estimated entirely through model fitting. In addition, the relationship between the 
rate of transmission of trimethoprim resistance in treated individuals compared 
to untreated individuals deserves further study. 
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Should incidence data of colonisation by E. coli resistant to trimethoprim in the 
LTCF become available, it would be preferable to fit the model to these data 
instead of to the incidence of urinary E. coli samples resistant to trimethoprim 
reported to AmSurv, as the model reproduces the dynamics of colonisation and 
not of infection. This would then eliminate the need for the 𝑟ℎ𝑜 parameter. 
Alternatively, 𝑟ℎ𝑜 could be better understood through the quantification of the 
relationship between an individual being colonised with E. coli developing a UTI 
and this UTI being reported to AmSurv.  
Another extension of the model could involve simulating the transmission of 
resistance in the hospital. This could help understand how the dynamics of 
transmission of trimethoprim resistance in these two types of institutions are 
linked. Additional data specific to the hospital would be needed to parameterise 
this type of model.  
Other extensions of this model would involve relaxing some of the assumptions 
made. In particular, a co-colonisation model would be interesting albeit currently 
very difficult to parameterise.  
The conflicting evidence on the reversibility of trimethoprim resistance observed 
in the literature208,216 suggests that the impact of antibiotic stewardship would be 
best studied through this type of model that accounts for competition between 
strains and co-selection, as the effect of decreasing the rate of treatment on 
resistance is likely complex and fitness cost and selection dynamics are likely to 
be important.  
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Conclusions 
This was the first study to model the dynamics of trimethoprim resistant Gram-
negative bacteria in LTCFs. A median of one UTI caused by E. coli resistant to 
trimethoprim was predicted to be reported monthly from a 30-bed LTCF (over 
1,000 stochastic runs mean=1.31, 95th percentile range=0-4). The model 
predicted that even in scenarios where the prevalence of resistant colonisation 
neared 70% in the LTCF, the number of UTIs caused by E. coli resistant to 
trimethoprim would remain at 1.6-1.7 per month. The number of residents in 
LTCFs developing UTIs caused by E. coli resistant to trimethoprim is likely to be 
higher, as not all UTIs are sampled. In a LTCF with a high incidence of urinary 
E. coli resistant to trimethoprim reported to AmSurv, transmission appeared to 
be the most important driver of the prevalence of resistant colonisation in the 
LTCF. Therefore, in this type of LTCF where the prevalence of trimethoprim 
resistance is higher than that in hospitals and the community, interventions that 
target transmission such as hand washing, contact precautions and isolation 
would be more effective in reducing colonisation by resistant strains than 
interventions that target importations of resistance from hospitals or the 
community (for example, screening on admission to the LTCF) or antibiotic 
stewardship. These considerations are reflective of the current model 
parameterisation and of the structure and assumptions made. The main driver 
of the prevalence of resistance for other organism-antibiotic combinations such 
as E. coli resistant to nitrofurantoin may be different. A better understanding and 
quantification of the endogenous and exogenous acquisition of resistance; as 
well as antibiotic prescription data specific to the LTCF setting are needed to 
parameterise more informative models of AMR bacteria in the LTCF in the 
future. 
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Chapter 8  Discussion 
Summary of findings 
The objective of this thesis was to improve the current understanding of the 
epidemiology of antibiotic resistant Gram-negative bacteria in LTCFs. The focus 
was particularly set on bacteria causing UTIs. 
Prior to this thesis, the burden of AMR in Gram-negative bacteria in LTCFs in 
England was unknown. This is an important gap in the literature due to the 
public health importance of these organisms.19,28–31 It is also essential 
information to guide interventions aiming to tackle infections caused by AMR 
Gram-negative bacteria in LTCFs, such as antibiotic stewardship, or changes in 
the primary care prescribing guidelines. In addition, by February 2016, no 
mathematical models had simulated the transmission of Gram-negative bacteria 
in LTCFs, and only three had done so by the time of submission of this thesis. 
The latter simulated the transmission of carbapenem-resistant 
Enterobacteriaceae and E. coli ST131. No mathematical models to date have 
studied the transmission of E. coli resistant to more commonly prescribed 
antibiotics, such as trimethoprim. Mathematical models may provide helpful 
insights into the dynamics of colonisation and infection by these bacteria, and 
the effectiveness of potential interventions against them in LTCFs. Another gap 
in the literature was that the seasonality of UTIs in England had not been 
studied rigorously. These infections are a frequent cause of BSIs and antibiotic 
treatment, and an improved understanding of their dynamics may aid their 
prevention.  
The systematic review presented in Chapter 2 highlighted the paucity of 
mathematical models published in the literature simulating the transmission of 
infectious diseases (27 papers). In February 2016, when the original literature 
search was conducted, no studies had modelled the transmission of Gram-
negative bacteria in LTCFs. Since this review, however, three papers have 
described the transmission of Gram-negative bacteria: two of carbapenem-
resistant Enterobacteriaceae132,133 and one of E. coli ST131134. These studies 
begin to address the gap in the type of organisms modelled in this setting; 
 260 
 
however, carbapenem-resistant Enterobacteriaceae are not currently a common 
cause of infections in LTCFs. In Chapter 5, the prevalence of resistance in 
urinary tract bacteria to carbapenems in the over 70s was found to be low in 
both Klebsiella and E. coli (0.2% and 0.02%, respectively). E. coli ST131 are 
highly virulent bacteria that have been associated with resistance to 3GCs, 
fluoroquinolones and aminoglycosides. 269–272 They are a common cause of 
UTIs and BSIs in England. Only two studies modelled the effect of antibiotic 
treatment on resistance in the LTCF. One study investigated the effect of 
reducing the exposure to fluoroquinolones and cephalosporins in the population 
colonised by E. coli ST131 from 5% to 0%134. A further study assessed the 
impact of antibiotic use in the previous 3 months on the epidemic potential of 
MRSA USA-300 and MRSA non-USA-300.138 Antibiotic treatment increases the 
risk of colonisation and subsequent infection by resistant bacteria, and 
therefore, is an important factor to capture when modelling the transmission of 
AMR bacteria.28,273 
In Chapter 3, the models of interventions against AMR bacteria in LTCFs were 
critically evaluated. At the time of review, these were three models of MRSA 
transmission that were not considered robust enough to test policy. A checklist 
was developed for epidemiologists and policy makers to distinguish good quality 
models of AMR in LTCFs as this field begins to expand.  
Chapter 4 described the West Midlands AmSurv dataset, an AMR surveillance 
data comprising the antibiotic susceptibility tests carried out in the West 
Midlands on routinely collected microbiological specimens from individuals aged 
70 or older sent by both GPs and hospitals. This dataset was linked to the CQC 
register of LTCFs in England to determine which samples were taken from 
individuals residing in LTCFs. This linked dataset was used to inform the 
prevalence of resistance in individuals entering the LTCF from hospital and the 
community and estimate the transmission parameters in the mathematical 
model described in Chapter 7. 
Chapter 5 highlighted the burden of AMR in LTCFs, showing that residents of 
LTCFs had more than four times the rate of E. coli and Klebsiella UTI caused by 
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antibiotic-resistant bacteria compared to those living in the community. The 
odds of resistance of E. coli and Klebsiella to trimethoprim, nitrofurantoin, 
ciprofloxacin and 3GCs were significantly higher in LTCF samples than non-
LTCF samples, after adjusting for age, sex, sender (GP vs. hospital) and the 
year of the study. In addition, 39% of UTIs caused by E. coli and 27% of UTIs 
caused by Klebsiella (60% and 41%, respectively, in LTCFs) were found to be 
resistant to trimethoprim, the most prescribed antibiotic for UTI.35 
In Chapter 6, the seasonality of consultations for uncomplicated UTIs was 
explored, as evidence from the literature on this subject was conflicting and had 
not been rigorously assessed in the UK. A September to November peak in UTI 
consultation incidence was observed for ages 14-69. This seasonality 
progressively faded in older age groups and no seasonality was found in 
individuals aged 85 and over, in whom UTIs were most common. 
Finally, in Chapter 7, a stochastic compartmental mathematical model was 
developed to simulate the transmission of trimethoprim resistant E. coli in 
LTCFs. In a LTCF amongst those in the highest quartile of incidence of urinary 
E. coli resistant to trimethoprim reported to AmSurv, there was a net transfer of 
individuals colonised with E. coli resistant to trimethoprim towards the hospital. 
Transmission appeared to be the most important driver of the prevalence of 
resistant colonisation in this LTCF. 
Implications for clinical practice and public health policy 
The implications of this work for clinical practice are the following: 
Firstly, this work contributes towards improving our understanding of the 
dynamics of UTI (Chapter 6). Due to increases in temperature during the 
summer, which can make individuals prone to dehydration, UTIs could be 
expected to peak during this time. These changes could be particularly 
pronounced in the elderly population, as aging is a risk factor for water 
homeostasis impairments.274 Older people are also more prone to dehydration 
due to inadequate water intake caused by impairments in the mechanisms 
controlling thirst, and this risk is potentiated in patients with dementia. 275,276 
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However, GP consultations for UTI in older people in the UK were not found to 
be seasonal. This contrasts with the autumnal peak observed for individuals 
aged 14 to 69. Seasonal differences could be less important in older people due 
to mobility issues, which frequently confine them to indoor environments. Older 
people could then be equally prone to dehydration throughout the year. Other 
risk factors associated with UTI in older people are high postvoid residual urine 
and urinary retention, catheter use, urinary incontinence, as well as co-
morbidities such as stroke and dementia, which may cause symptoms such as 
bladder and bowel incontinence.47 As UTIs in older people are common year 
round, UTI prevention in this population should warrant attention throughout the 
year.  
The autumnal peak in UTI consultation incidence in younger age groups could 
also be helpful in interpreting the results of interventions and surveillance 
reports. For example, if an intervention study were to show a decrease in UTI 
incidence in spring, this could be due to the effectiveness of a trialled 
intervention against UTIs, the seasonal pattern in UTIs, which yearly decrease 
during this period, or a combination of both, and their effect should be 
disentangled in order to correctly interpret the intervention effectiveness. 
Conversely, an increase in the incidence of UTI or antibiotic prescription during 
the autumn should be interpreted in the context of the yearly UTI peak observed 
during this time.  
Secondly, the burden of AMR in urinary tract bacteria in English LTCFs was 
investigated (Chapter 5). UTIs caused by AMR E. coli and Klebsiella were 
shown to be more common in this population than in older people residing in 
their own homes, even after adjusting for confounders. The very high levels of 
AMR bacteria in LTCF residents compared to their community counterparts and 
even to hospital patients highlight that LTCFs should be a focus of antibiotic 
stewardship and infection prevention and control interventions aiming to prevent 
the spread of AMR bacteria. In order to target these interventions appropriately, 
there is a need for a better understanding of the causes of these high levels of 
AMR in LTCFs. Transmission of resistant organisms, antibiotic prescribing and 
high transfer rates between LTCFs and hospitals are key drivers of AMR in 
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LTCFs62; however, their relative importance is unknown for many organism-
antibiotic combinations.  
The high burden of AMR in English LTCFs also suggests that surveillance of 
AMR and antimicrobial prescribing in these facilities is warranted. The routine 
linkage of LTCF and susceptibility data could help LTCF staff become aware of 
the prevalence of AMR in their LTCF. If, additionally, prescribing data could be 
linked to these data, this would give LTCF staff a complete picture of the 
problem of AMR and prescribing in their LTCF, which has been identified as a 
key barrier to successful antimicrobial stewardship interventions in LTCFs.277,278 
Currently, information governance issues make the linkage of susceptibility and 
prescribing data challenging. However, the first pilot study exploring the linkage 
of the NHS Business Services Authority electronic records for antibiotic 
dispensing to Public Health England laboratory surveillance antibiotic 
susceptibility data over three months is currently under way, which suggests 
progress in this area.279 This work should be a priority for AMR research in 
England. In LTCFs this linked data could also help infection prevention and 
control personnel identify the organism-antibiotic combinations of particular 
concern in order to target interventions to their control appropriately. In addition, 
at a CCG, regional, and national level, this information may help increase the 
awareness of the problem of AMR in LTCFs, which may facilitate future funding 
of interventions. It could also inform guidelines on antibiotic prescribing practice 
specifically for this setting. Finally, this information could help hospitals screen 
patients for organism-antibiotic combinations of particular concern in LTCFs 
from which they frequently receive admissions. Patients screening positive 
could be isolated and contact precautions for these individuals could be 
implemented. 
Findings from this thesis also support the recent switch in the national primary 
care treatment guidelines for UTI from recommending trimethoprim to 
nitrofurantoin, as trimethoprim was shown to be ineffective to treat a large 
proportion of the UTIs in LTCF residents due to the high prevalence of 
resistance. Trimethoprim resistance in bacteria causing UTIs can result in 
treatment failure, hospitalisation, and the subsequent use of antibiotics such as 
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ciprofloxacin or 3GCs that should be reserved for the treatment of more serious 
infections. Ciprofloxacin usage, in turn, selects for ciprofloxacin resistance, 
which is often carried alongside resistance to beta-lactams, notably methicillin-
resistance in Staphylococci.211–214 Fluoroquinolone usage (mainly ciprofloxacin 
in England) has also been linked to the incidence to C. difficile infections.215 
Antibiotic-resistant Gram-negative bacteria are currently organisms of high 
public health importance19,28–31 and interventions to prevent their spread are 
being trialled in hospitals.142–145 As highlighted in Chapter 5, LTCFs are also an 
important reservoir of antibiotic-resistant Gram-negative bacteria. In LTCFs, 
most studies have focused on the prevention of infections and on antimicrobial 
stewardship173,280–283. The systematic review of the literature (Chapter 2) 
showed that an increasing number of studies modelling the transmission of 
infectious diseases in LTCFs are being published. Therefore, the conclusions of 
mathematical models that simulate the transmission of Gram-negative bacteria 
in LTCFs could be important for policy making. Modelling the transmission of 
AMR in LTCFs is different to in hospitals, as LTCFs vary greatly in their 
characteristics such as their size, the services they provide to residents (e.g. 
nursing care and dementia care), the staff to patient ratio, and the acuity of 
patients. LTCFs also have strong links with other facilities such as hospitals and 
they are generally small institutions (mean=34.5 beds, median=31 beds, see 
Chapter 4). These models are also difficult to parameterise due to the paucity of 
data available. To this aim, a checklist was developed to guide policy makers in 
assessing the quality of such models.  
The output from the mathematical model developed to simulate the 
transmission of E. coli resistant to trimethoprim in the LTCF (in Chapter 7) 
suggested that in LTCFs with high prevalence, there was a net output of 
individuals colonised with E. coli resistant to trimethoprim from the LTCF to 
hospital. The transfers between LTCFs and hospitals were frequent. These 
findings suggest that LTCFs with a high prevalence of resistant colonisation 
could contribute towards the prevalence of resistance in hospitals. As 
mentioned above, better surveillance in LTCFs could permit hospitals to 
implement screening strategies targeting individuals being transferred from 
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particular LTCFs with high prevalence of resistance. In addition, enhanced 
support for LTCF residents may prevent avoidable hospital admissions. An 
intervention designed by the Health Foundation in partnership with NHS 
England, as part of the NHS Five year forward view New Care Models 
programme in the Principia vanguard site saw a 28% reduction in potentially 
avoidable admissions to hospital.284 This intervention included the alignment of 
LTCFs with general practices and the encouragement of residents to change to 
these general practices through advocacy; rapid review and comprehensive 
geriatric assessments upon residents’ admission to the LTCF; weekly or 
fortnightly visits by named GPs; increased detection of dementia; improvement 
of nursing support through peer-to-peer support, training in infection prevention 
and control, and involvement in GP resident review rounds; as well as a 
programme to engage care home managers. 284 
Finally, using currently available parameter sources, the transmission of E. coli 
resistant to trimethoprim was shown to have a greater impact on the prevalence 
of E. coli resistant to trimethoprim in the LTCF than trimethoprim treatment, at 
least in LTCFs with a high incidence of trimethoprim-resistant urinary E. coli 
submitted to AmSurv. This suggests that reducing transmission may be key to 
diminishing the prevalence of carriage of trimethoprim-resistant E. coli in LTCF. 
In addition, reducing trimethoprim prescription might not greatly reduce the 
prevalence of resistance, although the evidence from the literature on this 
subject is scarce and conflicting.208,216 Transmission events could be reduced 
by limiting the opportunities for transmission. In practice, limiting the 
opportunities for transmission in LTCFs may be challenging, as these are 
residents homes. High standards of environmental cleaning, patient hygiene 
and care, as well as hand hygiene interventions may be viable options. 
However, evidence on their effectiveness from the literature is limited. 
Multimodal interventions and national campaigns have been shown to be able 
to improve hand hygiene in LTCFs effectively.285–289 However, these 
interventions carried out in Norway, USA, and China depend greatly on 
behavioural and cultural elements and may not be effective in LTCFs in 
England. Transmission of E. coli resistant to trimethoprim in the LTCF could 
also be reduced by decreasing the number of individuals colonised with E. coli 
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resistant to trimethoprim already present in the LTCF. This would involve 
measures such as intestinal decolonisation with colistin.290 However, this may 
cause more harm than good as colistin is a “last-resort” antibiotic treatment and 
increasing its use might contribute to the spread and development of colistin 
resistance. Faecal microbiota transplantation that have been effective to treat 
Clostridium difficile infection291,292 are being trialled and could be effective for 
the treatment of persistent colonisation with resistant Gram-negative bacteria.  
However, evidence for this is yet anecdotal.293,294 Finally, the transmission of E. 
coli resistant to trimethoprim in the LTCF could also be decreased by reducing 
the susceptibility of individuals colonised with E. coli susceptible to trimethoprim 
to dominance by a resistant strain. However, no current therapies are available 
that decrease the susceptibility to resistant colonisation. It is worth highlighting 
that another way to counter the prevalence of E. coli resistant to trimethoprim in 
the LTCF is to prevent UTIs in the first place, which is discussed in the future 
work section below. It is also important to note that transmission might not be 
the main driver of the prevalence of resistance for other organism-antibiotic 
combinations such as E. coli resistant to nitrofurantoin.  
Strengths 
The first strength of this thesis was the West Midlands AmSurv dataset for 
those aged 70 or older, which was linked to CQC data. The AmSurv 
surveillance system captures the susceptibility results from all routine 
microbiology samples sent by hospitals and GPs to reporting laboratories for 
testing. The West Midlands was the first region in England to have all 
laboratories reporting to AmSurv. Therefore, this is the most complete source of 
AMR data within a defined population. This data was linked for the first time to 
the CQC registry of LTCFs. This enabled the formal comparison of AMR in 
LTCF residents to that in older people living in the community combining 
hospital and GP surveillance data (Chapter 5). Other studies were too small to 
yield statistically robust conclusions for several resistances, did not include GP 
or hospital samples, or did not carry out a formal statistical comparison. 
75,76,78,295–297 This was also the first large scale study to quantify the burden of 
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AMR in English LTCFs. In England, resistance levels and the LTCFs 
themselves could be different to LTCFs in other countries.  
Another key strength of this work was the eight year UTI consultation, 
trimethoprim prescription and nitrofurantoin prescription data extracted from 
THIN. THIN is a validated database of primary care consultation data covering 
over 3.7 million active patients which are demographically representative of the 
UK235–237. All three sources of data (UTI consultations, trimethoprim 
prescriptions and nitrofurantoin prescriptions) were used to study the trend and 
seasonality of UTI consultation, which had not formally been assessed to date 
in the UK (Chapter 6). The confirmation of our findings through these three 
sources of data strengthened the analysis. This analysis included fitting a 
negative binomial regression model to the data in which seasonality was 
modelled as cos(x)+sin(x) term. The correlations between the residuals of the 
model and the lagged values of the residuals for lags 1 to 12 months were also 
explored. This approach can be used to model the seasonality of UTIs or other 
infections in other countries. 
Finally, this was the first study to model the transmission of trimethoprim 
resistant E. coli in LTCFs (Chapter 7). The model developed included 
trimethoprim treatment and the transfer of residents to and from hospital, as 
well as admissions from the community. Most parameters were informed by 
data from the same population (individuals aged 70 or older in the West 
Midlands) and over the same period (April 2010 to March 2014). When 
estimates were taken from the literature, these were adjusted to reflect the 
distribution of nursing LTCFs in the West Midlands. The transmission 
parameters were estimated through formal model fitting to incidence data from 
AmSurv by maximum likelihood estimation. Sensitivity analyses were carried 
out to determine the robustness of model outputs. This model provides an initial 
framework that may be expanded upon to examine the role of different 
resistances in the LTCF. 
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Limitations 
One limitation of this thesis is the lack of antibiotic prescription data in the LTCF 
setting. Although antibiotic prescription data for the community overall is 
available from databases such as THIN and CPRD, this has not yet been linked 
to CQC LTCF data.  
In order to parameterise the treatment rate in the mathematical model (Chapter 
7), antibiotic prescription data from THIN was adjusted using a study that found 
that antibiotic prescribing for UTIs was 2.9 times higher in LTCFs than in the 
community.69 However, this approach did not address the fact that different 
LTCFs will have different treatment rates. There could be a correlation between 
the incidence of urinary E. coli resistant to trimethoprim reported to AmSurv 
from a LTCF and the rate of trimethoprim prescription in the same facility. 
Antibiotic treatment could also help explain the higher levels of AMR observed 
in LTCFs in the West Midlands AmSurv data, and could have been included as 
an explanatory variable in the logistic regression (Chapter 5). This would have 
enabled the study of the effect of prescription on the risk of resistance. The 
effect of co-selection of resistance from different antibiotics could have also 
been explored. These findings, in turn, would have been beneficial to inform the 
mathematical model (Chapter 7). 
Other important limitations of this work are those related to consultation and 
sampling. Prescription and UTI consultation data captured by THIN are limited 
by biases surrounding the frequency of consultation. The data also only include 
electronic health records from GP practices. Therefore, these data are only 
representative of treatment and consultation for uncomplicated UTIs. 
Consequently, the patterns in seasonality observed for UTI consultations 
(Chapter 6) cannot be extrapolated to all UTIs. AmSurv data includes both GP 
and hospital data but is limited by biases surrounding both consultation and 
sampling. Two conditions are required for a sample to be sent to a laboratory 
for testing, (1) a consultation (2) a urine sample is sent for testing. Sampling 
may be biased towards those failing to respond to treatment, which could 
increase the apparent risk of resistance. This is a limitation that applies both to 
the analysis of the burden of AMR in LTCFs (Chapter 5), and to the modelling 
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study (Chapter 7), in which the prevalence of resistant carriage in hospital and 
in the community were parameterised using these estimates. In addition, due to 
the unavailability of incidence data of colonisation by E. coli resistant to 
trimethoprim in LTCFs, the incidence of colonisation with E. coli resistant to 
trimethoprim in the model was fit to the incidence of urinary E. coli samples 
resistant to trimethoprim from a LTCF in the AmSurv dataset. To this aim, 
parameter 𝑟ℎ𝑜 was created, which was the ‘case development and 
ascertainment proportion’. This parameter aimed to capture both the proportion 
of individuals colonised with E. coli resistant to trimethoprim who develop a UTI 
and the proportion of these who consult a physician and have a urinary sample 
sent for susceptibility testing. This was a crude method that did not capture the 
dynamics of consultation and sampling (as well as UTI development), which are 
likely to be complex and interact with trimethoprim treatment.  
In addition, the difference in acquisition of dominant colonisation by E. coli 
resistant to trimethoprim under trimethoprim treatment and under no treatment 
is poorly understood. In the mathematical model developed (Chapter 7), this is 
assumed to occur through the transmission of trimethoprim resistance from 
individuals colonised with E. coli resistant to trimethoprim in the LTCF. As such, 
it depends on the number of these individuals present in the population and the 
number of individuals colonised with E. coli susceptible to trimethoprim (
𝛽∗𝑈𝑠∗𝑈𝑟
𝑁
). 
Under trimethoprim treatment, it is assumed that (1) the colonisation with E. coli 
resistant to trimethoprim cannot be lost and (2) the rate of transmission 𝛽 is 
greater than in the untreated scenario by a factor of 𝑡𝑟. 𝑡𝑟 was adjusted so that 
the prevalence of resistance in treated individuals was approximately that 
reported in the literature.257 However, data is needed to inform this parameter. 
In addition, part of the increase in transmission captured by 𝑡𝑟 during treatment 
is likely driven by the selection of resistance in an individual. This endogenous 
acquisition of dominant colonisation by E. coli resistant to trimethoprim may not 
be dependent on the number of individuals colonised with E. coli resistant to 
trimethoprim in the LTCF and the number of individuals colonised with E. coli 
susceptible to trimethoprim but may be driven by other factors such as fitness 
cost and selection pressure.  
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Finally, the mathematical model developed simplified many processes, mainly 
due to the lack of available data to inform them. For example, it assumed the 
dominance of a single strain in a colonised individual. However, competition 
between strains is known to be an important element in driving the resistance 
patterns observed in the population.298 The effect of other antibiotic treatment 
such as ampicillin/amoxicillin on trimethoprim resistance was also not included 
in the model, although it has been shown to be an important predictor of 
geographical variation in trimethoprim resistance in urinary samples263 and 
ampicillin and trimethoprim resistance genes are often linked on the same 
mobile genetic elements264–266. The model fitting process by maximum 
likelihood estimation could also be improved, using, for example, the particle 
Markov-Chain Monte Carlo method, which is implemented in pomp and takes a 
Bayesian approach to model fitting. 
Further work 
Further work is required to validate the checklist developed to assess the quality 
of mathematical models simulating transmission in the LTCF setting.  
Prevention of UTIs could help avoid antibiotic treatment in the first place, which 
would help prevent antibiotic resistance. In older people residing in LTCFs, 
where these infections are most common, it is known that catheter use, co-
morbidities such as stroke and dementia associated with bowel and bladder 
incontinence, bladder incontinence and impaired self-care are significant risk 
factors for UTI.47 Effective interventions targeting good quality of care, involving 
appropriate hygiene, fluid intake and catheter care are therefore required and 
important. Various vaccines for UTI are currently being developed that target 
virulence determinants essential for attachment and disease.299 A vaccine 
targeting FimH, which mediates the adherence to the gut epithelium, is currently 
in Phase I clinical trials and has been shown not to alter the gut microbiota.299–
301 Although currently far from licensure, a vaccine could provide an excellent 
option for reducing UTIs without impacting the ecosystem of the gut and, 
therefore, reduce antibiotic prescribing and antibiotic resistance.302 Cranberry 
extracts and probiotics also show potential in the prevention of UTI, although 
they are not yet deemed effective.303–305 In addition, further work is needed to 
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understand the causes of the autumn seasonality of UTI observed for ages 14 
to 69 so as to enable more targeted prevention programmes. 
Several expansions of the mathematical model would enable more robust 
conclusions to be drawn. As mentioned above, antibiotic prescription data 
specific to LTCFs would improve the parameterisation of the treatment rate in 
the model. Co-selection could also be simulated. In addition, LTCFs vary 
substantially in their size and the services they provide. Therefore, antibiotic 
treatment and the flow of patients in and out of the LTCF may also differ 
between facilities, and, therefore, different types of LTCFs may warrant different 
infection control recommendations. Antibiotic treatment data specific to each 
LTCF and detailed information on the flow of patients in and out of the LTCF 
would enable the characterisation of different categories of LTCFs. The 
mathematical model could then be parameterised for these distinct LTCF types. 
Another approach would be to develop an individual-based network model of 
LTCF and hospitals in a local patch area. In addition, whole genome 
sequencing could help quantify the acquisition of dominant resistance by 
endogenous and exogenous mechanisms and, therefore, help parameterise 
transmission in the LTCF setting. The model developed could then be fit to 
colonisation incidence data.  
Another simple expansion of the model would be to parameterise it to reflect the 
transmission of E. coli resistant to nitrofurantoin. Although urinary E. coli 
resistance to nitrofurantoin is still low (7% in LTCFs for 2010-2015, see Chapter 
5), the change in guidelines recommending nitrofurantoin treatment instead of 
trimethoprim for UTI may change this.306 The dynamics of resistance to 
trimethoprim and nitrofurantoin could then be compared and the conditions for a 
high prevalence of E. coli resistant to nitrofurantoin in the LTCF could then be 
predicted. 
Another area requiring further study is the effect of antibiotic stewardship 
interventions on trimethoprim resistance. The reversal of antibiotic resistance is 
not a straightforward process.307,308 The outcome of antibiotic stewardship 
interventions is most frequently antibiotic prescription and the final effect on 
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resistance is not often studied. Further work is needed to understand if 
resistance to trimethoprim can be reversed by antibiotic stewardship, as 
evidence from the literature is conflicting.208,216 The outcome of such studies 
may depend on whether other antibiotics with which trimethoprim has a strong 
co-selection are being prescribed during the intervention309 and may also need 
long time frames to see an effect.  
Finally, more research is needed to understand how E. coli strains resistant and 
sensitive to trimethoprim interact; how dominance of E. coli resistant to 
trimethoprim is achieved and, ultimately, how this is influenced by the 
interaction with different bacterial species. Bacteria do not grow in isolation and, 
therefore, other bacteria surrounding it may play an important role in the 
acquisition or suppression of resistance.   
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Conclusions 
This thesis served to (1) review the literature of dynamic transmission modelling 
of infectious diseases in LTCFs; (2) establish a checklist for policy makers to 
review the quality of mathematical models of interventions against AMR 
bacteria in LTCFs; (3) link antibiotic susceptibility data covering a large 
population to the LTCF registry and highlight the burden of AMR in LTCFs; (4) 
rigorously address the seasonality of consultations for uncomplicated UTIs; and 
(5) develop the first mathematical model to quantify the transmission of E. coli 
resistant to trimethoprim in the LTCF setting. The lack of antibiotic prescription 
data for LTCFs is an important limitation of this work. The availability of this 
data, together with an improved knowledge about the acquisition of dominant 
colonisation by AMR bacteria, could enable a better understanding of the 
drivers of AMR in the LTCF setting.  
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Appendix 
Appendix Chapter 2 
Search terms used in the literature review by database: 
Medline (only) 
model$.ti,ab.  
model?ing.ti,ab.  
framework$.ti,ab.  
 
long-term care.ti,ab. 
long term care.ti,ab. 
residential facilit$.ti,ab 
residential home$.ti,ab. 
residential care.ti,ab. 
nursing home$.ti,ab. 
old age home$.ti,ab. 
old-age home$.ti,ab. 
 
mathematic$.ti,ab. 
compartment$.ti,ab. 
stochastic.ti,ab. 
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deterministic.ti,ab 
transmiss$.ti,ab. 
epidemi$.ti,ab. 
individual-based.ti,ab. 
population-based.ti,ab. 
dynamic.ti,ab. 
comput$.ti,ab. 
reproduction number.ti,ab. 
simulation.ti,ab. 
markov chain$.ti,ab. 
Monte Carlo.ti,ab. 
Bayes.ti,ab. 
patient flow.ti,ab. 
readmission.ti,ab. 
 
EMBASE 
model$.ti,ab. 
model?ing.ti,ab. 
framework$.ti,ab. 
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long-term care.ti,ab. 
long term care.ti,ab. 
residential facilit$.ti,ab 
residential home$.ti,ab. 
residential care.ti,ab. 
nursing home$.ti,ab. 
old age home$.ti,ab. 
old-age home$.ti,ab. 
 
mathematic$.ti,ab. 
compartment$.ti,ab. 
stochastic.ti,ab. 
deterministic.ti,ab 
transmiss$.ti,ab. 
epidemi$.ti,ab. 
individual-based.ti,ab. 
population-based.ti,ab. 
dynamic.ti,ab. 
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comput$.ti,ab. 
reproduction number.ti,ab. 
simulation.ti,ab. 
markov chain$.ti,ab. 
Monte Carlo.ti,ab. 
Bayes.ti,ab. 
patient flow.ti,ab. 
readmission.ti,ab. 
 
SCOPUS 
Restricted by subject to immunology and microbiology, computer science and 
mathematics 
Restricted by type to article or review 
Title, abstract, keywords: 
model (plural did not make a difference) 
modelling (one or two “l” in spelling did not make a difference) 
framework 
 
long-term care 
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long term care 
residential facility 
residential home 
residential care 
nursing home 
old age home 
old age homes 
old-age home 
 
mathematic 
mathematical 
compartment 
stochastic 
deterministic 
transmission 
transmissible 
epidemiology 
epidemiological 
individual-based 
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population-based 
dynamic 
computer 
computing 
computational 
reproduction number 
simulation 
markov chain 
Monte Carlo 
Bayes 
patient flow 
readmission 
readmissions 
 
Global Health 
model$.ti,ab. 
model?ing.ti,ab. 
framework$.ti,ab. 
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long-term care.ti,ab. 
long term care.ti,ab. 
residential facilit$.ti,ab 
residential home$.ti,ab. 
residential care.ti,ab. 
nursing home$.ti,ab. 
old age home$.ti,ab. 
old-age home$.ti,ab. 
 
mathematic$.ti,ab. 
compartment$.ti,ab. 
stochastic.ti,ab. 
deterministic.ti,ab 
transmiss$.ti,ab. 
epidemi$.ti,ab. 
individual-based.ti,ab. 
population-based.ti,ab. 
dynamic.ti,ab. 
comput$.ti,ab. 
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reproduction number.ti,ab. 
simulation.ti,ab. 
markov chain$.ti,ab. 
Monte Carlo.ti,ab. 
Bayes.ti,ab. 
patient flow.ti,ab. 
readmission.ti,ab. 
 
CINHAL 
Searches in abstract: 
Model 
Models 
Modelling 
modeling 
framework 
frameworks 
 
long-term care 
long term care 
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residential facility 
residential facilities 
residential home 
residential homes 
residential care 
nursing home 
nursing homes 
old age home 
old age homes 
old-age home 
old-age homes 
 
mathematic 
mathematical 
compartment 
stochastic 
deterministic 
transmission 
transmissible 
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epidemiology 
epidemiological 
individual-based 
population-based 
dynamic 
computer 
computing 
computational 
reproduction number 
simulation 
markov chain 
Monte Carlo 
Bayes 
patient flow 
readmission 
readmissions 
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Appendix Chapter 3 
Dates, settings and methodologies 
These three models were built within the last five years (2011, 2012 and 2013). 
Lee et al.116 based their estimates on current sources, using data published 
from 2007-2011. Length of stay was the only parameter based on data 
published before 2010. Barnes et al.127, however, based their parameter 
estimates on literature from 2004 to 2010 and Chamchod and Ruan114 from 
1999 to 2010.  
Chamchod and Ruan’s model 114 was set within a LTCF; however, the 
nationality of the setting was not stated. Barnes et al.127 modelled patient 
movement between hospitals and LTCFs in the USA. Lee et al 116 additionally 
included the non-LTFC community into their model. They made a distinction 
between those discharged for a short period of time (less than 30 days) and 
those discharged into the community for longer (patients who were not 
readmitted). Their model represented Orange County, California (USA). 
Barnes et al.127 built a compartmental deterministic model, Lee et al.116 an 
individual-based stochastic model and Camchod and Ruan114 built two 
compartmental models: one stochastic and one deterministic. None of these 
models were formally fit to data or validated. Barnes et al.127 did not carry out a 
sensitivity analysis. Chamchod and Ruan114 and Lee et al.116 carried out 
univariate sensitivity analyses, varying key parameters one at a time and noting 
the effect of these changes on model outcomes. 
Model structure 
a. Patient flow 
The three models varied in the complexity of their institutional structures: 
Chamchod and Ruan114 modelled transmission of MRSA within a LTCF only 
with patients mixing homogenously within it. Barnes et al.127 and Lee et al.116 
modelled patient flow between two types of facility: LTCFs and hospitals (see 
Figure 3).  
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Barnes et al.127 modelled each LFCF and hospital as agents in a network of 
facilities (Figure 3a). Links between each pair of facilities in the network were 
assigned a specific weight, which, together with the facility size, determined the 
probability of transfer between the facilities. Various network configurations with 
different weights associated to the links were compared. In their model, patients 
at each facility type were admitted and discharged at the same rate (μ). Barnes 
et al.127 did not define any finer grain compartments within each LTCF and 
hospital, therefore, patients were assumed to mix homogeneously within 
facilities.  
Lee et al. 116 also included movement between the facilities and the community 
(Figure 3b). The authors modelled bidirectional patient flow between the 100 
inpatient facilities present in Orange County (71 LTCFs and 29 hospitals) as 
well as discharge into the community (permanent or temporary, where patients 
were readmitted within a year of discharge). Their IBM used a 2007 California 
mandatory hospital dataset where patients were tracked between facilities to 
inform hospitalisation and rehospitalisation and data from 2006-2008 surveys to 
inform transfers between hospitals and LTCFs. Patient flow was also 
determined by the number of licensed beds, the average daily census and the 
length of stay in LTCFs obtained from a national long-term care dataset. Length 
of stay distributions for ICU and non-ICU patients in each hospital were used to 
inform transfers from hospitals. MRSA carriers had longer lengths of stay. LTCF 
residents with a length of stay of two or more weeks were assigned a daily 
probability of being transferred to a hospital for a short stay during which their 
LTCF bed was kept free. The authors assumed each hospital comprised 20-bed 
general hospital wards, 12-bed intensive care units and 10-bed long-term acute 
care facilities. Each LTCF contained one ‘ward’ within which patients mixed 
homogenously.  
b. MRSA transmission 
A schematic of the transmission structures of the models can be found in Figure 
4. Each model considered two basic individual states; colonised with MRSA or 
uncolonised with MRSA. Infection was not considered in any model.  
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In Barnes et al.’s model127 (see Figure 4a), individuals could transition between 
three states: U (uncolonised), P (persistently colonised) and T (transiently 
colonised). U individuals could become P or T and vice-versa through 
transmission and recovery, but they could not transition between P and T states 
of colonisation. Transition from P to U was slower than from T to U. The 
proportion of transferred patients in each disease state was established 
according to the proportions of U, P and T in the facility they were transferred 
from.  
Chamchod and Ruan114 modelled MRSA transmission between residents, 
between healthcare workers and between healthcare workers and residents as 
distinct processes (see Figure 4b). The disease states in residents were U 
(uncolonised) and C (colonised). The disease states in healthcare workers were 
H (uncontaminated) and Hc (contaminated). Patients and residents could 
transition between the uncolonised (U) and colonised (C) states through 
transmission and recovery. No distinction was made between the P and T 
colonisation states. Colonised and uncolonised residents had different 
probabilities of admission (λ and 1-λ, respectively) and discharge (γc and γu, 
respectively). Transmission rates were different between residents (βr), from 
healthcare workers to residents (βh) and from residents to healthcare workers 
(αh). Colonisation of an uncolonised resident depended on both βr and βh whilst 
contamination of an uncontaminated healthcare worker depended on αh. 
Decolonisation rates in residents (ω) differed from decontamination rates in 
healthcare workers (μ). 
Lee et al.’s IBM116 distinguished two patient states: S (susceptible) and I 
(infectious) (see Figure 4c) which were analogous to uncolonised and 
colonised. As the authors were analysing the impact of contact precautions on 
transmission, they differentiated between residents in a scenario where contact 
precautions were in use (Sp and Ip) and residents in a scenario where they were 
not (Sφ and Iφ).  The number of new cases of MRSA per unit per day was 
calculated using the equation described below:  
βSφIφ+β(1-θ)SpIφ+β(1-θ)SφIp+β(1-θ)
2SpIp  
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where p= precautions, φ= no precautions, θ=efficacy of contact precautions.  
Parameters used 
The LTCF sizes chosen varied greatly between the three models, ranging from 
100 127 to 2000 beds 114. The research groups also chose different ways of 
quantifying transmission. Barnes et al.127 and Chamchod and Ruan114 reported 
transmission rates as the effective contact (resulting in transmission) rate 
averaged per day whilst Lee et al.116 quantified the rate of transmission per 
person per day, explaining why their figures are not of the same magnitude. In 
addition, Chamchod and Ruan114 broke down their overall transmission rate into 
resident-resident, healthcare worker-resident and resident-healthcare worker 
transmission rates. Resident-resident transmission was assumed to be eight 
times lower than the other transmission types. Their overall transmission rate 
was a combination of these three rates. Barnes et al.127 used three different 
rates that were in a similar range than those provided by Chamchod and 
Ruan114. Barnes et al.127 and Lee et al.116 both used transmission rates for 
hospitals that were much higher than those for LTCFs. Barnes et al.127 and 
Chamchod and Ruan114 assumed the same proportion of patients admitted 
colonised by MRSA (10%).  Lee et al.116, however, reported the prevalence of 
colonisation within the hospitals (6.1%) and LTCFs (26.1%) which was much 
higher than the overall prevalence of all patients that enter the facility from the 
general population. Lee et al.116 did not report their assumed duration of 
colonisation. Camchod and Ruan114 supposed a duration of colonisation similar 
to that of persistently colonised individuals in Barnes et al.’s model127. Barnes et 
al.127 reported recovery rates for persistently and transiently colonised 
individuals of 0.02 and 0.2 respectively that equate to 5 and 50 days of 
colonisation. These estimates were decided by the authors. Chamchod and 
Ruan114 chose a middle estimate from the average decolonisation time range 
published by Kajita et al. (2007)310, which were themselves based on expert 
opinion. Neither of the duration of colonisation estimates were taken from 
literature based on data. 
Interventions 
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Barnes et al. 127 assessed the impact of three screening and decolonisation 
interventions: decolonisation on admission (no screening); screening by 
conventional culture on admission and subsequent decolonisation of positive 
residents and screening by PCR on admission and subsequent decolonisation 
of positive residents. These interventions reduced the prevalence of MRSA by 
moving patients from a colonised state (for Barnes et al.127, both P and T) to a 
susceptible state (uncolonised) where they cannot transmit disease after a 
duration of 10-13 days (depending on the type of screening carried out). Barnes 
et al.127 found that all three interventions yielded the same approximate results 
because facility transfers were frequent, which meant screening at admission 
was also frequent. Decolonisation decreased equilibrium prevalence in LTCFs 
by 0.0287-0.1203 and in hospitals by 0.0029-0.0232 (depending on initial 
institution equilibrium MRSA prevalence). It was assumed that, on average, it 
would take two cycles of five-day treatments for patients to be successfully 
decolonised (10 days). 
Chamchod and Ruan114 considered the theoretical impact of reducing different 
importation and transmission parameters on MRSA prevalence.  Chamchod 
and Ruan114 reported that, increasing the recovery rate by more than 0.05 
resulted in the elimination of MRSA under equilibrium.  
Chamchod and Ruan114 considered the impact of hand hygiene on MRSA 
prevalence. Hand hygiene measures that target residents aim to decrease the 
transmission of MRSA from C to U and H (βr and αh). Implementing improved 
hand hygiene decreases the probability of colonisation per contact of for 
residents (pr) and the probability of contamination per contact for healthcare 
workers (qh). The average number of contacts between residents (a) and the 
average number of required contacts from healthcare workers by residents (b) 
remains the same. Hand hygiene measures that target healthcare workers aim 
to alter the transmission of MRSA from Hc to U (βh) by decreasing the 
probability of colonisation via contacts of healthcare workers (qr) without altering 
the average number of required contacts from healthcare workers by residents 
(b).  The authors found that when the average duration of colonisation was 
reduced below 250 days for residents or below 0.15 hours for healthcare 
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workers, the probability of invasion resulting from the introduction of a 
contaminated healthcare worker/ a contaminated resident was eliminated114. 
Chamchod and Ruan modelled the impact of increasing the staff to patient ratio 
to reduce the contact rate. Assuming that the average number of contacts a 
resident requires by a healthcare worker (b) is a constant and is distributed 
amongst the number of healthcare workers, reducing the resident to staff ratio 
(Nr/Nh) diminishes the frequency at which a particular healthcare worker 
contacts a resident (b/Nh). Lower Nr/Nh reduces the frequency of contacts 
between U and Hc and between C and H. When resident to staff ratio was 
reduced below 6.5, the probability of invasion  resulting from the introduction of 
a contaminated healthcare worker/ a contaminated resident was eliminated114. 
Lee et al.116 compared the effect of contact precautions in LTCFs for residents 
with clinically apparent MRSA infections and for all MRSA carriers. Both 
interventions reduced the probability of transmission. The first intervention 
replaced Iφ individuals in the population with Ip. The second intervention 
replaced individuals in Sφ with Sp in a similar fashion. In their model, contact 
precautions in residents with clinically apparent MRSA did not significantly 
decrease MRSA prevalence and the number of MRSA acquisitions averted in 
Orange County was minimal, even after five years and assuming 75% 
adherence. However, when contact precautions were taken in all MRSA 
carriers, a substantial number of MRSA acquisitions were adverted. Assuming 
50% adherence, 171 acquisitions of MRSA were projected to be adverted within 
six months and 4,876 within five years. Even in situations where adherence was 
lower (25%), 81 acquisitions were to be adverted after six months and 2,442 
after 5 years. With high adherence (75%), 7,291 acquisitions were to be 
adverted after five years116. 
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Appendix Chapter 5 
Table A- 1. Univariable logistic regression results- odds of resistance in bacteria from LTCF samples (vs. non-LTCF samples), residential LTCF 
samples (vs. non-LTCF samples), and nursing LTCFs samples (vs. non-LTCF samples) for all bacterium-antibiotic combinations.  Confidence 
intervals are adjusted for clustering at the postcode level. 
Organism Antibiotic N  N  OR  Adjusted 
95% CI 
LTCF 
OR  Adjusted 
95% CI 
Residential 
LTCF 
OR  Adjusted 
95% CI  
Samples NS Samples LTCF Residenti
al LTCF 
Nursing 
LTCF 
Nursing 
LTCF 
E. coli Amoxicillin/Ampicillin 125958 70128 2.4 2.24 - 2.58 2.21 2.03 - 2.4 2.75 2.43 - 3.11 
Ciprofloxacin 111053 16900 2.57 2.32 - 2.85 2.28 2 - 2.59 3.01 2.58 - 3.51 
Co-amoxiclav
+
 127910 26621 1.74 1.57 - 1.93 1.69 1.48 - 1.93 1.81 1.54 - 2.12 
First-generation 
cephalosporins 
125254 10839 1.74 1.55 - 1.96 1.53 1.32 - 1.78 2.07 1.73 - 2.48 
Gentamicin 98512 6630 1.7 1.48 - 1.94 1.52 1.27 - 1.82 1.96 1.63 - 2.37 
Carbapenems
*
 50641 12 NA NA NA NA NA NA 
Nitrofurantoin 157556 6277 1.86 1.64 - 2.11 1.68 1.43 - 1.99 2.12 1.78 - 2.53 
Piperacillin/ 
Tazobactam 
35600 4756 1.93 1.68 - 2.22 1.79 1.5 - 2.13 2.21 1.77 - 2.77 
Second-generation 
cephalosporins 
51307 9483 1.98 1.68 - 2.33 1.88 1.54 - 2.29 2.13 1.62 - 2.79 
Temocillin 43273 1549 1.31 0.93 - 1.85 1.37 0.9 - 2.1 1.21 0.69 - 2.11 
Third-generation 
cephalosporins
~
 
134105 8507 1.86 1.63 - 2.14 1.73 1.45 - 2.06 2.07 1.69 - 2.55 
Trimethoprim 157818 61469 2.56 2.39 - 2.74 2.39 2.2 - 2.61 2.82 2.55 - 3.13 
Klebsiella Ciprofloxacin 13698 1087 1.36 1 - 1.85 1.21 0.79 - 1.87 1.56 1.03 - 2.37 
Co-amoxiclav
+
 14317 2181 1.53 1.22 - 1.91 1.36 1.01 - 1.82 1.75 1.26 - 2.43 
First-generation 
cephalosporins 
14393 1824 1.33 1.04 - 1.71 1.15 0.82 - 1.62 1.56 1.09 - 2.23 
Gentamicin 12963 655 1.16 0.76 - 1.76 0.79 0.45 - 1.38 1.64 0.92 - 2.92 
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Organism Antibiotic N  N  OR  Adjusted 
95% CI 
LTCF 
OR  Adjusted 
95% CI 
Residential 
LTCF 
OR  Adjusted 
95% CI  
Samples NS Samples LTCF Residenti
al LTCF 
Nursing 
LTCF 
Nursing 
LTCF 
Carbapenems
*
 8364 13 1.33 0.17 - 
10.55 
2.28 0.29 - 17.84 0.01 0 - 0.02 
Nitrofurantoin 12125 4219 1.34 1.11 - 1.61 1.35 1.05 - 1.72 1.33 1.02 - 1.75 
Piperacillin/ 
Tazobactam 
7513 1215 1.55 1.1 - 2.19 1.5 0.93 - 2.41 1.63 1 - 2.65 
Second-generation 
cephalosporins 
7372 1218 1.29 0.91 - 1.83 1.37 0.85 - 2.19 1.19 0.73 - 1.95 
Temocillin 6302 85 0.63 0.15 - 2.62 1.13 0.29 - 4.43 0 0 - 0 
Third-generation 
cephalosporins
~
 
11561 837 1.1 0.75 - 1.62 0.9 0.57 - 1.41 1.37 0.75 - 2.49 
Trimethoprim 17801 4737 2.01 1.7 - 2.38 1.94 1.52 - 2.46 2.11 1.7 - 2.62 
Imipenem or Meropenem. Resistance to carbapenems was very low in both Klebsiella and E. coli which prevented any formal statistical analysis.  
~
 3GC resistance was defined as resistance to ceftazidime, cefpodoxime, cefotaxime, or ceftriaxone. 
+ 
Note that some laboratories used the systemic rather than UTI breakpoint guidelines for co-amoxiclav resulting in an increase in the percentage of resistant 
samples between mid-2011 and early 2012. 
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Table A- 2. Univariable logistic regression results- odds of resistance in bacteria from male samples (vs. females) for all bacterium-antibiotic 
combinations.  Confidence intervals are adjusted for clustering at the postcode level. 
Organism Antibiotic N Samples N NS Samples OR Male Adjusted 95% CI Male 
E. coli Amoxicillin/Ampicillin 125958 70128 1.18 1.14 - 1.23 
Ciprofloxacin 111053 16900 1.62 1.52 - 1.73 
Co-amoxiclav
+
 127910 26621 1.33 1.27 - 1.39 
First-generation cephalosporins 125254 10839 1.47 1.37 - 1.58 
Gentamicin 98512 6630 1.55 1.42 - 1.7 
Carbapenems
*
 50641 12 NA NA 
Nitrofurantoin 157556 6277 1.43 1.31 - 1.56 
Piperacillin/Tazobactam 35600 4756 1.46 1.33 - 1.61 
Second-generation cephalosporins 51307 9483 1.4 1.29 - 1.51 
Temocillin 43273 1549 1.39 1.2 - 1.61 
Third-generation cephalosporins
~
 134105 8507 1.47 1.35 - 1.6 
Trimethoprim 157818 61469 1.03 0.99 - 1.07 
Klebsiella Ciprofloxacin 13698 1087 1.38 1.14 - 1.66 
Co-amoxiclav
+
 14317 2181 1.24 1.1 - 1.41 
First-generation cephalosporins 14393 1824 1.4 1.23 - 1.61 
Gentamicin 12963 655 1.47 1.17 - 1.86 
Carbapenems
*
 8364 13 NA NA 
Nitrofurantoin 12125 4219 0.87 0.79 - 0.96 
Piperacillin/Tazobactam 7513 1215 1.39 1.19 - 1.64 
Second-generation cephalosporins 7372 1218 1.41 1.18 - 1.67 
Temocillin 6302 85 1.72 1.03 - 2.86 
Third-generation cephalosporins
~
 11561 837 1.49 1.2 - 1.84 
Trimethoprim 17801 4737 0.94 0.85 - 1.03 
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*
 Imipenem or Meropenem. Resistance to carbapenems was very low in both Klebsiella and E. coli which prevented any formal statistical analysis. 
~
 3GC resistance was defined as resistance to ceftazidime, cefpodoxime, cefotaxime, or ceftriaxone. 
+
 Note that some laboratories used systemic rather than UTI breakpoint guidelines for co-amoxiclav resulting in an increase in the % resistant samples between mid-2011 and early 2012.  
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Table A- 3. Univariable logistic regression results- odds of resistance in bacteria from samples from those aged 75 to 80 (vs. 70-74), 81-85 (vs. 70-
74), and over 85 (vs.70-74) for all bacterium-antibiotic combinations. Confidence intervals are adjusted for clustering at the postcode level. 
Organism Antibiotic N Samples N NS 
Samples 
OR 75-80 Adjusted 
95% CI 75-
80 
OR 81-85 Adjusted 
95% CI 81-
85 
OR >85 Adjusted 
95% CI >85  
E. coli Amoxicillin/Ampicillin 125958 70128 1 0.96 - 1.04 1.09 1.04 - 1.14 1.35 1.29 - 1.42 
Ciprofloxacin 111053 16900 1.06 0.98 - 1.15 1.2 1.1 - 1.3 1.6 1.47 - 1.74 
Co-amoxiclav
+
 127910 26621 1.02 0.96 - 1.07 1.11 1.05 - 1.18 1.35 1.27 - 1.43 
First-generation 
cephalosporins 
125254 10839 1.02 0.93 - 1.11 1.18 1.08 - 1.29 1.31 1.2 - 1.43 
Gentamicin 98512 6630 1.02 0.91 - 1.13 1.08 0.96 - 1.21 1.27 1.14 - 1.42 
Carbapenems
*
 50641 12 NA NA NA NA NA NA 
Nitrofurantoin 157556 6277 1.07 0.95 - 1.21 1.29 1.14 - 1.45 1.49 1.33 - 1.67 
Piperacillin/Tazobactam 35600 4756 0.96 0.85 - 1.08 1.04 0.92 - 1.17 1.34 1.19 - 1.5 
Second-generation 
cephalosporins 
51307 9483 1.06 0.96 - 1.16 1.29 1.17 - 1.43 1.51 1.36 - 1.67 
Temocillin 43273 1549 1.03 0.85 - 1.25 1.3 1.06 - 1.58 1.13 0.93 - 1.38 
Third-generation 
cephalosporins
~
 
134105 8507 0.98 0.88 - 1.08 1.11 1 - 1.23 1.26 1.13 - 1.4 
Trimethoprim 157818 61469 1.03 0.98 - 1.07 1.17 1.12 - 1.22 1.51 1.45 - 1.58 
Klebsiella Ciprofloxacin 13698 1087 0.78 0.61 - 0.99 0.94 0.72 - 1.22 0.81 0.64 - 1.04 
Co-amoxiclav
+
 14317 2181 0.99 0.83 - 1.17 1.16 0.97 - 1.39 1.19 1 - 1.42 
First-generation 
cephalosporins 
14393 1824 0.94 0.78 - 1.13 1.07 0.88 - 1.3 1.08 0.9 - 1.3 
Gentamicin 12963 655 0.92 0.65 - 1.29 1.31 0.92 - 1.87 1.11 0.8 - 1.55 
Carbapenems
*
 8364 13 NA NA NA NA NA NA 
Nitrofurantoin 12125 4219 1.02 0.9 - 1.16 1.02 0.88 - 1.17 1.03 0.91 - 1.18 
Piperacillin/Tazobactam 7513 1215 0.86 0.68 - 1.09 1.02 0.8 - 1.3 1.06 0.84 - 1.33 
Second-generation 7372 1218 0.94 0.74 - 1.19 1.01 0.79 - 1.3 1.07 0.84 - 1.36 
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Organism Antibiotic N Samples N NS 
Samples 
OR 75-80 Adjusted 
95% CI 75-
80 
OR 81-85 Adjusted 
95% CI 81-
85 
OR >85 Adjusted 
95% CI >85  
cephalosporins 
Temocillin 6302 85 1.08 0.52 - 2.27 0.66 0.3 - 1.45 0.74 0.33 - 1.65 
Third-generation 
cephalosporins
~
 
11561 837 0.91 0.69 - 1.22 1.09 0.8 - 1.5 0.96 0.72 - 1.28 
Trimethoprim 17801 4737 0.93 0.82 - 1.06 1.1 0.96 - 1.26 1.29 1.13 - 1.46 
*
 Imipenem or Meropenem. Resistance to carbapenems was very low in both Klebsiella and E. coli which prevented any formal statistical analysis. 
~
 3GC resistance was defined as resistance to ceftazidime, cefpodoxime, cefotaxime, or ceftriaxone. 
+ 
Note that some laboratories used the systemic rather than UTI breakpoint guidelines for co-amoxiclav resulting in an increase in the percentage of resistant samples between mid-2011 and early 
2012. 
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Table A- 4. Univariable logistic regression results- odds of resistance in bacteria from samples taken in hospital (vs. from GPs) for all bacterium-
antibiotic combinations.  Confidence intervals are adjusted for clustering at the postcode level. 
Organism Antibiotic N Samples N NS Samples OR Hospital Adjusted 95% CI Hospital 
E. coli Amoxicillin/Ampicillin 125958 70128 1.17 1.13 - 1.2 
Ciprofloxacin 111053 16900 1.12 1.07 - 1.18 
Co-amoxiclav
+
 127910 26621 1.36 1.31 - 1.41 
First-generation cephalosporins 125254 10839 1.34 1.27 - 1.41 
Gentamicin 98512 6630 1.43 1.35 - 1.53 
Carbapenems
*
 50641 12 NA NA 
Nitrofurantoin 157556 6277 1.06 0.99 - 1.13 
Piperacillin/Tazobactam 35600 4756 1.32 1.23 - 1.43 
Second-generation cephalosporins 51307 9483 1.45 1.37 - 1.54 
Temocillin 43273 1549 1.41 1.24 - 1.59 
Third-generation cephalosporins
~
 134105 8507 1.37 1.29 - 1.45 
Trimethoprim 157818 61469 1.03 1.01 - 1.06 
Klebsiella Ciprofloxacin 13698 1087 1.45 1.24 - 1.68 
Co-amoxiclav
+
 14317 2181 1.53 1.38 - 1.7 
First-generation cephalosporins 14393 1824 1.55 1.39 - 1.74 
Gentamicin 12963 655 2.08 1.72 - 2.51 
Carbapenems
*
 8364 13 NA NA 
Nitrofurantoin 12125 4219 0.85 0.78 - 0.93 
Piperacillin/Tazobactam 7513 1215 1.58 1.37 - 1.81 
Second-generation cephalosporins 7372 1218 1.54 1.33 - 1.79 
Temocillin 6302 85 1.64 1.02 - 2.65 
Third-generation cephalosporins
~
 11561 837 1.86 1.56 - 2.21 
Trimethoprim 17801 4737 1.01 0.93 - 1.09 
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*
 Imipenem or Meropenem. Resistance to carbapenems was very low in both Klebsiella and E. coli which prevented any formal statistical analysis.
~
 3GC resistance was defined as resistance to 
ceftazidime, cefpodoxime, cefotaxime, or ceftriaxone.
+ 
Note that some laboratories used the systemic rather than UTI breakpoint guidelines for co-amoxiclav resulting in an increase in the 
percentage of resistant samples between mid-2011 and early 2012. 
  
  
3
3
2
 
Table A- 5. Univariable logistic regression results- odds of resistance in bacteria from samples from the second year of the study (vs. the first 
year), the third year of the study (vs. the first year), and the fourth year of the study (vs. the first year) for all bacterium-antibiotic combinations.  
Confidence intervals are adjusted for clustering at the postcode level. 
Organism Antibiotic N 
Samples 
N NS 
Samples 
OR 
Y2 
Adjusted 95% CI 
Y2 
OR 
Y3 
Adjusted 95% CI 
Y3 
OR 
Y4 
Adjusted 95% CI 
Y4 
E. coli Amoxicillin/Ampicillin 125958 70128 1.01 0.97 - 1.06 1.07 1.03 - 1.12 1.09 1.05 - 1.14 
Ciprofloxacin 111053 16900 0.96 0.91 - 1.03 0.93 0.87 - 0.99 0.9 0.85 - 0.97 
Co-amoxiclav
+
 127910 26621 0.9 0.86 - 0.95 0.71 0.67 - 0.74 0.71 0.67 - 0.75 
First-generation 
cephalosporins 
125254 10839 0.89 0.82 - 0.96 0.9 0.83 - 0.97 0.96 0.89 - 1.04 
Gentamicin 98512 6630 0.93 0.84 - 1.02 0.98 0.88 - 1.08 1.02 0.92 - 1.12 
Carbapenems
*
 50641 12 NA NA NA NA NA NA 
Nitrofurantoin 157556 6277 0.84 0.76 - 0.92 0.78 0.71 - 0.86 0.87 0.79 - 0.95 
Piperacillin/Tazobactam 35600 4756 0.66 0.56 - 0.77 0.88 0.8 - 0.97 0.9 0.82 - 1 
Second-generation 
cephalosporins 
51307 9483 1.08 1 - 1.17 1.04 0.96 - 1.13 1.09 1 - 1.18 
Temocillin 43273 1549 2.29 1.79 - 2.92 4.95 3.94 - 6.22 4.15 3.28 - 5.24 
Third-generation 
cephalosporins
~
 
134105 8507 1.01 0.92 - 1.1 1.04 0.95 - 1.14 1.1 1 - 1.2 
Trimethoprim 157818 61469 1.06 1.02 - 1.1 1.15 1.1 - 1.19 1.19 1.14 - 1.24 
Klebsiella Ciprofloxacin 13698 1087 0.95 0.73 - 1.24 1.18 0.91 - 1.54 1.46 1.14 - 1.87 
Co-amoxiclav
+
 14317 2181 1.11 0.94 - 1.33 1.04 0.87 - 1.24 1.31 1.11 - 1.55 
First-generation 
cephalosporins 
14393 1824 1.06 0.87 - 1.3 1.17 0.96 - 1.43 1.25 1.03 - 1.52 
Gentamicin 12963 655 0.76 0.51 - 1.15 1.26 0.86 - 1.84 1.86 1.29 - 2.67 
Carbapenems
*
 8364 13 NA NA NA NA NA NA 
Nitrofurantoin 12125 4219 0.89 0.79 - 1 0.56 0.5 - 0.63 0.61 0.55 - 0.69 
Piperacillin/Tazobactam 7513 1215 0.85 0.66 - 1.09 1.69 1.36 - 2.09 2.1 1.71 - 2.59 
Second-generation 7372 1218 0.95 0.75 - 1.2 1.17 0.93 - 1.46 1.07 0.86 - 1.34 
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Organism Antibiotic N 
Samples 
N NS 
Samples 
OR 
Y2 
Adjusted 95% CI 
Y2 
OR 
Y3 
Adjusted 95% CI 
Y3 
OR 
Y4 
Adjusted 95% CI 
Y4 
cephalosporins 
Temocillin 6302 85 2.28 0.68 - 7.59 2.62 0.81 - 8.5 3.03 0.95 - 9.71 
Third-generation 
cephalosporins
~
 
11561 837 1.16 0.85 - 1.58 1.25 0.93 - 1.69 1.67 1.26 - 2.22 
Trimethoprim 17801 4737 1.22 1.07 - 1.38 1.18 1.04 - 1.34 1.42 1.25 - 1.6 
*
 Imipenem or Meropenem. Resistance to carbapenems was very low in both Klebsiella and E. coli which prevented any formal statistical analysis. 
~
 3GC resistance was defined as resistance to ceftazidime, cefpodoxime, cefotaxime, or ceftriaxone. 
+ 
Note that some laboratories used the systemic rather than UTI breakpoint guidelines for co-amoxiclav resulting in an increase in the percentage of resistant samples between mid-2011 and early 
2012. 
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Table A- 6. Multivariable logistic regression results for all bacterium-antibiotic combinations with LTCF residence included as a binary variable 
(LTCF samples vs. non-LTCF samples) PART A.  95% confidence intervals (aCI) are adjusted for clustering at the postcode level. Interactions were not 
included in the model as they did not improve model fit.* 
Organism Antibiotic OR LTCF 95% aCI LTCF OR Male 95% aCI Male 
E. coli 
 
Amoxicillin/ Ampicillin 2.33 2.16 - 2.5 1.2 1.15 - 1.25 
Ciprofloxacin 2.42 2.17 - 2.69 1.69 1.58 - 1.81 
Co-amoxiclav
+
 1.71 1.55 - 1.9 1.35 1.28 - 1.41 
First-generation cephalosporins 1.75 1.55 - 1.98 1.47 1.37 - 1.59 
Gentamicin 1.69 1.47 - 1.94 1.53 1.4 - 1.68 
Nitrofurantoin 1.74 1.53 - 1.97 1.48 1.36 - 1.61 
Piperacillin/ Tazobactam 1.87 1.62 - 2.17 1.47 1.33 - 1.62 
Second-generation cephalosporins 1.89 1.61 - 2.23 1.38 1.28 - 1.5 
Temocillin 1.39 0.98 - 1.96 1.32 1.14 - 1.53 
Third-generation cephalosporins
~
 1.89 1.64 - 2.17 1.47 1.35 - 1.6 
Trimethoprim 2.36 2.21 - 2.53 1.06 1.02 - 1.11 
Klebsiella 
 
Ciprofloxacin 1.54 1.13 - 2.1 1.34 1.11 - 1.62 
Co-amoxiclav
+
 1.59 1.27 - 1.99 1.23 1.08 - 1.39 
First-generation cephalosporinss 1.42 1.1 - 1.83 1.38 1.2 - 1.58 
Gentamicin 1.29 0.84 - 1.96 1.4 1.1 - 1.77 
Nitrofurantoin 1.31 1.09 - 1.59 0.9 0.81 - 0.99 
Piperacillin/ Tazobactam 1.63 1.14 - 2.32 1.34 1.14 - 1.58 
Second-generation cephalosporinss 1.36 0.95 - 1.94 1.39 1.17 - 1.65 
Temocillin 0.77 0.19 - 3.11 1.58 0.94 - 2.66 
Third-generation cephalosporins
~
 1.24 0.85 - 1.83 1.42 1.15 - 1.75 
Trimethoprim 1.89 1.6 - 2.24 0.97 0.88 - 1.06 
*
Resistance to carbapenems was very low in both Klebsiella and E. coli which prevented any formal statistical analysis. 
~
 3GC resistance was defined as resistance to ceftazidime, cefpodoxime, cefotaxime, or ceftriaxone. 
+ 
Note that some laboratories used the systemic rather than UTI breakpoint guidelines for co-amoxiclav resulting in an increase in the percentage of resistant samples between mid-2011 and early 
2012.   
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Table A- 7. Multivariable logistic regression results for all bacterium-antibiotic combinations with LTCF residence included as a binary variable 
(LTCF samples vs. non-LTCF samples) PART B.  95% confidence intervals (aCI) are adjusted for clustering at the postcode level. Interactions were not 
included in the model as they did not improve model fit.* 
Organism Antibiotic OR 75-80 95% aCI 75-80 OR 81-85 95% aCI 81-85 OR over 85 95% aCI over 85 
E. coli Amoxicillin/ Ampicillin 0.98 0.94 - 1.02 1.02 0.97 - 1.06 1.15 1.1 - 1.21 
 Ciprofloxacin 1.04 0.96 - 1.13 1.11 1.02 - 1.21 1.35 1.24 - 1.47 
 Co-amoxiclav
+
 0.99 0.94 - 1.04 1.04 0.99 - 1.1 1.19 1.12 - 1.26 
 First-generation cephalosporins 0.99 0.91 - 1.08 1.11 1.01 - 1.21 1.15 1.05 - 1.26 
 Gentamicin 0.99 0.89 - 1.11 1.01 0.9 - 1.13 1.13 1.01 - 1.27 
 Nitrofurantoin 1.06 0.94 - 1.19 1.23 1.09 - 1.39 1.34 1.19 - 1.51 
 Piperacillin/ Tazobactam 0.94 0.83 - 1.05 0.97 0.86 - 1.1 1.18 1.05 - 1.33 
 Second-generation cephalosporins 1.04 0.94 - 1.14 1.2 1.09 - 1.33 1.31 1.18 - 1.46 
 Temocillin 1.03 0.85 - 1.25 1.24 1.01 - 1.51 1.07 0.87 - 1.31 
 Third-generation cephalosporins
~
 0.95 0.86 - 1.05 1.02 0.92 - 1.14 1.08 0.97 - 1.21 
 Trimethoprim 1.01 0.96 - 1.05 1.09 1.04 - 1.14 1.28 1.22 - 1.34 
Klebsiella Ciprofloxacin 0.76 0.6 - 0.97 0.9 0.69 - 1.18 0.76 0.59 - 0.97 
 Co-amoxiclav
+
 0.97 0.81 - 1.15 1.12 0.93 - 1.35 1.11 0.93 - 1.32 
 First-generation cephalosporinss 0.92 0.76 - 1.11 1.04 0.86 - 1.27 1.04 0.86 - 1.25 
 Gentamicin 0.89 0.63 - 1.27 1.26 0.89 - 1.8 1.05 0.75 - 1.46 
 Nitrofurantoin 1.01 0.89 - 1.15 1.01 0.88 - 1.16 1 0.87 - 1.14 
 Piperacillin/ Tazobactam 0.84 0.66 - 1.07 0.98 0.77 - 1.26 0.99 0.78 - 1.25 
 Second-generation cephalosporinss 0.93 0.73 - 1.18 0.99 0.77 - 1.28 1.05 0.83 - 1.34 
 Temocillin 1.08 0.51 - 2.27 0.65 0.3 - 1.43 0.78 0.35 - 1.73 
 Third-generation cephalosporins
~
 0.89 0.66 - 1.2 1.06 0.77 - 1.45 0.91 0.68 - 1.22 
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Organism Antibiotic OR 75-80 95% aCI 75-80 OR 81-85 95% aCI 81-85 OR over 85 95% aCI over 85 
 Trimethoprim 0.92 0.81 - 1.05 1.07 0.93 - 1.22 1.16 1.03 - 1.32 
*
Resistance to carbapenems was very low in both Klebsiella and E. coli which prevented any formal statistical analysis. 
~
 3GC resistance was defined as resistance to ceftazidime, cefpodoxime, 
cefotaxime, or ceftriaxone. 
+ 
Note that some laboratories used the systemic rather than UTI breakpoint guidelines for co-amoxiclav resulting in an increase in the percentage of resistant samples 
between mid-2011 and early 2012. 
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 Table A- 8. Multivariable logistic regression results for all bacterium-antibiotic combinations with LTCF residence included as a binary variable 
(LTCF samples vs. non-LTCF samples) PART C.  95% confidence intervals (aCI) are adjusted for clustering at the postcode level. OR H are the odds of 
resistance for bacteria from samples from hospitals compared to that of those from GPs. Interactions were not included in the model as they did not improve 
model fit.* 
Organism Antibiotic OR H 95% aCI H OR Y2 95% aCI Y2 OR Y3 95% aCI Y3 OR Y4 95% aCI Y4 
E. coli 
Amoxicillin/ 
Ampicillin 
1.18 1.14 - 1.21 1 0.96 - 1.05 1.07 1.02 - 1.11 1.09 1.05 - 1.14 
 
Ciprofloxacin 1.11 1.06 - 1.16 0.95 0.9 - 1.01 0.92 0.86 - 0.98 0.9 0.84 - 0.96 
 
Co-amoxiclav
+
 1.34 1.3 - 1.39 0.89 0.85 - 0.94 0.7 0.66 - 0.74 0.71 0.67 - 0.74 
 
First-generation 
cephalosporins 
1.33 1.26 - 1.4 0.88 0.81 - 0.95 0.9 0.83 - 0.97 0.96 0.89 - 1.04 
 
Gentamicin 1.4 1.31 - 1.49 0.92 0.83 - 1.02 0.97 0.88 - 1.07 1.01 0.92 - 1.12 
  Nitrofurantoin 1.03 0.97 - 1.1 0.82 0.75 - 0.9 0.77 0.7 - 0.85 0.86 0.78 - 0.94 
  
Piperacillin/ 
Tazobactam 
1.3 1.21 - 1.41 0.64 0.55 - 0.75 0.88 0.8 - 0.97 0.92 0.83 - 1.02 
  
Second-
generation 
cephalosporins 
1.43 1.35 - 1.51 1.07 0.99 - 1.16 1.03 0.95 - 1.12 1.1 1.01 - 1.19 
  Temocillin 1.41 1.25 - 1.59 2.29 1.79 - 2.93 4.97 3.96 - 6.25 4.21 3.34 - 5.32 
  
Third-generation 
cephalosporins
~
 
1.36 1.28 - 1.44 1 0.91 - 1.09 1.03 0.94 - 1.13 1.09 1 - 1.2 
  Trimethoprim 1.05 1.02 - 1.08 1.05 1.01 - 1.09 1.14 1.09 - 1.18 1.19 1.14 - 1.24 
Klebsiella Ciprofloxacin 1.45 1.25 - 1.69 0.96 0.73 - 1.25 1.19 0.91 - 1.55 1.47 1.15 - 1.89 
  Co-amoxiclav
+
 1.54 1.39 - 1.71 1.13 0.95 - 1.35 1.05 0.88 - 1.25 1.31 1.11 - 1.56 
  
First-generation 
cephalosporins 
1.54 1.37 - 1.73 1.07 0.88 - 1.31 1.18 0.96 - 1.44 1.26 1.03 - 1.53 
  Gentamicin 2.06 1.71 - 2.48 0.77 0.51 - 1.17 1.28 0.87 - 1.87 1.91 1.33 - 2.75 
  Nitrofurantoin 0.85 0.78 - 0.93 0.88 0.78 - 0.99 0.56 0.49 - 0.63 0.61 0.54 - 0.68 
  
Piperacillin/ 
Tazobactam 
1.62 1.41 - 1.86 0.83 0.64 - 1.07 1.69 1.36 - 2.09 2.1 1.7 - 2.6 
  
Second-
generation 
1.51 1.31 - 1.76 0.94 0.74 - 1.19 1.16 0.93 - 1.45 1.07 0.85 - 1.34 
  
3
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Organism Antibiotic OR H 95% aCI H OR Y2 95% aCI Y2 OR Y3 95% aCI Y3 OR Y4 95% aCI Y4 
cephalosporins 
  Temocillin 1.61 1 - 2.6 2.26 0.67 - 7.62 2.62 0.8 - 8.55 3.04 0.95 - 9.76 
  
Third-generation 
cephalosporins
~
 
1.83 1.54 - 2.18 1.15 0.85 - 1.57 1.24 0.92 - 1.68 1.68 1.26 - 2.23 
  Trimethoprim 1.04 0.96 - 1.13 1.22 1.08 - 1.39 1.19 1.04 - 1.35 1.41 1.25 - 1.6 
*
Resistance to carbapenems was very low in both Klebsiella and E. coli which prevented any formal statistical analysis. 
~
 3GC resistance was defined as resistance to ceftazidime, cefpodoxime, cefotaxime, or ceftriaxone. 
+ 
Note that some laboratories used the systemic rather than UTI breakpoint guidelines for co-amoxiclav resulting in an increase in the percentage of resistant samples between mid-2011 and early 
2012. 
  
  
3
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Table A- 9. Multivariable logistic regression results for all bacterium-antibiotic combinations where the odds of resistance of bacteria from 
residential (Res) and nursing (Ns) LTCF samples are each compared to that of non-LTCF samples PART A.  95% confidence intervals (aCI) are 
adjusted for clustering at the postcode level. OR H is the odds of resistance for bacteria from samples from hospitals compared to that of samples from GPs. 
Interactions were not included in the model as they did not improve model fit.
 * 
Organism Antibiotic OR Res LTCF aCI Res LTCF OR Ns LTCF aCI Ns LTCF OR Male aCI Male 
E. coli 
Amoxicillin/ Ampicillin 2.13 1.95 - 2.32 2.67 2.36 - 3.02 1.2 1.15 - 1.25 
Ciprofloxacin 2.17 1.9 - 2.47 2.78 2.38 - 3.24 1.68 1.58 - 1.8 
Co-amoxiclav
+
 1.68 1.47 - 1.91 1.76 1.51 - 2.06 1.34 1.28 - 1.41 
First-generation cephalosporins 1.54 1.33 - 1.8 2.05 1.71 - 2.46 1.47 1.36 - 1.58 
Gentamicin 1.52 1.27 - 1.83 1.93 1.6 - 2.34 1.52 1.39 - 1.67 
Nitrofurantoin 1.59 1.35 - 1.87 1.95 1.64 - 2.33 1.47 1.35 - 1.6 
Piperacillin/ Tazobactam 1.76 1.47 - 2.11 2.09 1.66 - 2.63 1.46 1.33 - 1.62 
Second-generation cephalosporins 1.82 1.48 - 2.22 2.01 1.55 - 2.61 1.38 1.27 - 1.49 
Temocillin 1.43 0.94 - 2.18 1.32 0.76 - 2.28 1.32 1.14 - 1.53 
Third-generation cephalosporins
~
 1.76 1.47 - 2.1 2.09 1.7 - 2.56 1.47 1.35 - 1.6 
Trimethoprim 2.2 2.02 - 2.4 2.63 2.37 - 2.92 1.06 1.02 - 1.1 
Klebsiella 
Ciprofloxacin 1.41 0.9 - 2.19 1.7 1.13 - 2.56 1.34 1.11 - 1.62 
Co-amoxiclav
+
 1.42 1.06 - 1.92 1.81 1.3 - 2.51 1.22 1.08 - 1.39 
First-generation cephalosporins 1.24 0.88 - 1.76 1.64 1.15 - 2.34 1.38 1.2 - 1.58 
Gentamicin 0.91 0.52 - 1.62 1.72 0.97 - 3.05 1.39 1.1 - 1.76 
Nitrofurantoin 1.31 1.02 - 1.68 1.31 1 - 1.73 0.9 0.81 - 0.99 
Piperacillin/ Tazobactam 1.65 1.02 - 2.68 1.6 0.99 - 2.59 1.34 1.14 - 1.58 
Second-generation cephalosporins 1.49 0.92 - 2.4 1.21 0.74 - 1.97 1.39 1.17 - 1.65 
Temocillin 1.5 0.4 - 5.65 0 0 - 0 1.6 0.95 - 2.68 
Third-generation cephalosporins
~
 1.06 0.67 - 1.68 1.47 0.81 - 2.67 1.42 1.15 - 1.75 
Trimethoprim 1.82 1.43 - 2.31 1.98 1.59 - 2.46 0.97 0.88 - 1.06 
 
*
Resistance to carbapenems was very low in both Klebsiella and E. coli which prevented any formal statistical analysis. 
~
 3GC resistance was defined as resistance to ceftazidime, cefpodoxime, cefotaxime, or ceftriaxone. 
+ 
Note that some laboratories used the systemic rather than UTI breakpoint guidelines for co-amoxiclav resulting in an increase in the percentage of resistant samples between mid-2011 and early 
2012. 
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Table A- 10. Multivariable logistic regression results for all bacterium-antibiotic combinations where the odds of resistance of bacteria from 
residential (Res) and nursing (Ns) LTCF samples are each compared to that of non-LTCF samples PART B.  95% confidence intervals (aCI) are 
adjusted for clustering at the postcode level. OR H is the odds of resistance for bacteria from samples from hospitals compared to that of samples from GPs. 
Interactions were not included in the model as they did not improve model fit.
 *
 
Organism Antibiotic OR 75-80 aCI 75-80 OR 81-85 aCI 81-85 OR over 85  aCI over 85 
E. coli Amoxicillin/ Ampicillin 0.98 0.94 - 1.02 1.02 0.97 - 1.06 1.16 1.1 - 1.21 
 Ciprofloxacin 1.04 0.96 - 1.13 1.11 1.02 - 1.21 1.35 1.24 - 1.47 
 Co-amoxiclav
+
 0.99 0.94 - 1.04 1.04 0.99 - 1.1 1.19 1.12 - 1.26 
 First-generation cephalosporins 0.99 0.91 - 1.08 1.11 1.01 - 1.21 1.15 1.05 - 1.26 
 Gentamicin 0.99 0.89 - 1.11 1.01 0.9 - 1.13 1.13 1.01 - 1.27 
 Nitrofurantoin 1.06 0.94 - 1.19 1.23 1.09 - 1.39 1.34 1.2 - 1.51 
 Piperacillin/ Tazobactam 0.94 0.83 - 1.05 0.97 0.86 - 1.1 1.18 1.05 - 1.33 
 Second-generation cephalosporins 1.04 0.94 - 1.14 1.2 1.09 - 1.33 1.31 1.19 - 1.46 
 Temocillin 1.03 0.85 - 1.25 1.24 1.01 - 1.51 1.07 0.87 - 1.3 
 Third-generation cephalosporins
~
 0.95 0.86 - 1.05 1.02 0.92 - 1.14 1.08 0.97 - 1.21 
 Trimethoprim 1.01 0.96 - 1.05 1.09 1.05 - 1.14 1.28 1.22 - 1.34 
Klebsiella Ciprofloxacin 0.76 0.6 - 0.97 0.9 0.69 - 1.17 0.76 0.59 - 0.97 
 Co-amoxiclav
+
 0.97 0.81 - 1.16 1.12 0.93 - 1.34 1.11 0.93 - 1.32 
 First-generation cephalosporins 0.92 0.76 - 1.11 1.04 0.85 - 1.27 1.04 0.86 - 1.26 
 Gentamicin 0.89 0.63 - 1.27 1.26 0.89 - 1.8 1.05 0.75 - 1.46 
 Nitrofurantoin 1.01 0.89 - 1.15 1.01 0.88 - 1.16 1 0.87 - 1.14 
 Piperacillin/ Tazobactam 0.84 0.66 - 1.07 0.98 0.77 - 1.25 0.99 0.78 - 1.25 
 Second-generation cephalosporins 0.93 0.73 - 1.18 0.99 0.77 - 1.28 1.05 0.83 - 1.34 
 Temocillin 1.08 0.51 - 2.29 0.65 0.3 - 1.43 0.77 0.35 - 1.71 
  
3
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Organism Antibiotic OR 75-80 aCI 75-80 OR 81-85 aCI 81-85 OR over 85  aCI over 85 
 Third-generation cephalosporins
~
 0.89 0.66 - 1.19 1.06 0.77 - 1.45 0.92 0.69 - 1.22 
 Trimethoprim 0.92 0.81 - 1.05 1.07 0.93 - 1.22 1.16 1.03 - 1.32 
*
Resistance to carbapenems was very low in both Klebsiella and E. coli which prevented any formal statistical analysis. 
~
 3GC resistance was defined as resistance to ceftazidime, cefpodoxime, cefotaxime, or ceftriaxone. 
+ 
Note that some laboratories used the systemic rather than UTI breakpoint guidelines for co-amoxiclav resulting in an increase in the percentage of resistant samples between mid-2011 and early 
2012. 
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Table A- 11. Multivariable logistic regression results for all bacterium-antibiotic combinations where the odds of resistance of bacteria from 
residential (Res) and nursing (Ns) LTCF samples are each compared to that of non-LTCF samples PART C.  95% confidence intervals (aCI) are 
adjusted for clustering at the postcode level. OR H is the odds of resistance for bacteria from samples from hospitals compared to that of samples from GPs. 
Interactions were not included in the model as they did not improve model fit.
 * 
Organism Antibiotic OR H aCI H OR Y2 aCI Y2 OR Y3 aCI Y3 OR Y4 aCI Y4 
E. coli Amoxicillin/ 
Ampicillin 
1.18 1.15 - 1.21 1 0.96 - 1.05 1.07 1.02 - 1.11 1.09 1.05 - 1.14 
 Ciprofloxacin 1.11 1.06 - 1.16 0.95 0.89 - 1.01 0.92 0.86 - 0.98 0.9 0.84 - 0.96 
 Co-amoxiclav
+
 1.34 1.3 - 1.39 0.89 0.85 - 0.94 0.7 0.66 - 0.74 0.71 0.67 - 0.74 
 
First-generation 
cephalosporins 
1.33 1.26 - 1.4 0.88 0.81 - 0.95 0.9 0.83 - 0.97 0.97 0.9 - 1.04 
 Gentamicin 1.4 1.31 - 1.5 0.92 0.83 - 1.02 0.97 0.88 - 1.07 1.02 0.92 - 1.12 
 Nitrofurantoin 1.04 0.97 - 1.1 0.82 0.75 - 0.9 0.77 0.7 - 0.85 0.86 0.78 - 0.94 
 
Piperacillin/ 
Tazobactam 
1.3 1.21 - 1.41 0.64 0.55 - 0.75 0.88 0.8 - 0.97 0.92 0.83 - 1.02 
 
Second-generation 
cephalosporins 
1.43 1.34 - 1.51 1.07 0.99 - 1.16 1.03 0.95 - 1.12 1.1 1.01 - 1.19 
 Temocillin 1.41 1.25 - 1.59 2.29 1.79 - 2.92 4.97 3.96 - 6.25 4.21 3.33 - 5.32 
 
Third-generation 
cephalosporins
~
 
1.36 1.29 - 1.45 1 0.91 - 1.09 1.03 0.94 - 1.13 1.1 1 - 1.2 
 Trimethoprim 1.05 1.02 - 1.08 1.05 1.01 - 1.09 1.14 1.09 - 1.18 1.19 1.14 - 1.24 
Klebsiella Ciprofloxacin 1.45 1.25 - 1.69 0.96 0.73 - 1.25 1.19 0.91 - 1.55 1.47 1.14 - 1.89 
 Co-amoxiclav
+
 1.54 1.39 - 1.71 1.13 0.95 - 1.35 1.05 0.88 - 1.25 1.31 1.11 - 1.56 
 First-generation 1.54 1.37 - 1.73 1.07 0.88 - 1.31 1.18 0.96 - 1.44 1.26 1.03 - 1.53 
  
3
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Organism Antibiotic OR H aCI H OR Y2 aCI Y2 OR Y3 aCI Y3 OR Y4 aCI Y4 
cephalosporins 
 Gentamicin 2.05 1.7 - 2.48 0.77 0.51 - 1.17 1.28 0.87 - 1.87 1.91 1.33 - 2.74 
 Nitrofurantoin 0.85 0.78 - 0.93 0.88 0.78 - 0.99 0.56 0.49 - 0.63 0.61 0.54 - 0.68 
 
Piperacillin/ 
Tazobactam 
1.62 1.41 - 1.86 0.83 0.64 - 1.07 1.69 1.36 - 2.09 2.11 1.7 - 2.6 
 
Second-generation 
cephalosporins 
1.52 1.31 - 1.76 0.94 0.74 - 1.19 1.16 0.93 - 1.45 1.07 0.85 - 1.34 
 Temocillin 1.63 1.01 - 2.64 2.26 0.67 - 7.63 2.62 0.8 - 8.55 3.05 0.95 - 9.8 
 
Third-generation 
cephalosporins
~
 
1.83 1.54 - 2.17 1.16 0.85 - 1.57 1.24 0.92 - 1.68 1.68 1.26 - 2.23 
 Trimethoprim 1.04 0.96 - 1.13 1.22 1.08 - 1.39 1.19 1.04 - 1.35 1.41 1.25 - 1.6 
*
Resistance to carbapenems was very low in both Klebsiella and E. coli which prevented any formal statistical analysis. 
~
 3GC resistance was defined as resistance to ceftazidime, cefpodoxime, cefotaxime, or ceftriaxone. 
+ 
Note that some laboratories used the systemic rather than UTI breakpoint guidelines for co-amoxiclav resulting in an increase in the percentage of resistant 
samples between mid-2011 and early 2012. 
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Appendix Chapter 6 PART A 
Trends and seasonality of UTIs caused by E. coli and Klebsiella 
in older people and GP trimethoprim and nitrofurantoin 
prescriptions in all ages. 
Methods 
The data sources employed in this analysis were: 
1. The susceptibility tests for E. coli and Klebsiella urinary samples from 
patients aged 70+ sent to AmSurv from April 2010 to March 2014. These 
included samples sent both by GPs and hospitals. 
2. The Office for National Statistics yearly all ages and 70+ population 
estimates for the West Midlands. 4 
3. The monthly GP trimethoprim and nitrofurantoin prescriptions for UTIs in 
all ages in the West Midlands from August 2010 to March 2014 from the 
Health & Social Care Information Centre.234  
Urine/kidney samples that grew E. coli and Klebsiella from older people 
submitted to AmSurv from laboratories in the West Midlands from 2010 to 2014 
(data source 1) were cleaned as described in Chapter 4. They were then 
aggregated by month of the study and are referred to subsequently as the 
monthly E. coli and Klebsiella UTIs.  
The same methodology was employed to describe the trend and (if present) the 
seasonality of E. coli and Klebsiella UTIs and of trimethoprim and nitrofurantoin 
prescriptions. A negative binomial regression model, a type of regression used 
to model over-dispersed count outcome variables, was used, as the data were 
highly over-dispersed.  
As the all ages and 70+ population in the West Midlands increased during the 
study period (see Figure A- 1), an offset was incorporated into the regression. 
This offset accounted for this increase in the population in the regression model. 
The offset was a logged vector that contained the all ages (for the all ages 
prescription dataset) or the 70+ (all other datasets) West Midlands population in 
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each of the months in the UTI dataset. These were obtained from yearly ONS 
estimates of the West Midlands 70+ population which were repeated for the 
months in each year 4.  
 
Figure A- 1. West Midlands yearly 70+ and all ages population. 
The counts were de-trended by fitting a polynomial regression model of degree 
two to the time series: 
𝑓(𝑥) = 𝑎 + 𝑏𝑥 + 𝑐𝑥2 
This allowed a better approximation to the data than achieved through a 
polynomial regression of degree one: 
𝑓(𝑥) = 𝑎 + 𝑏𝑥 
The negative binomial regression was coded in R using the glm.nb function in 
the MASS R package: 
glm.nb(data~ times+I(times^2)+ offset(log(pop))) 
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where “times” was an integer 1:48 (as our data covered 48 months).  
Seasonality was assessed, firstly, graphically by plotting the negative binomial 
model with and without seasonality. The model with seasonality included an 
additional term: 
𝑓(𝑥) = cos (
2𝛱𝑥
12
) + sin (
2𝛱𝑥
12
) 
This regression was also coded in R using the glm.nb function in the MASS 
package: 
c<-cos(2*pi*times/12) 
s<-sin(2*pi*times/12) 
glm.nb(data~ times+I(times^2)+ offset(log(pop.48))+c+s) 
Secondly, a correlogram (or auto-correlation plot) was plotted to explore the 
correlations between the residuals of the model and the lagged values of the 
residuals for lags 1-12 (over the course of a year). The residuals are the 
difference between the estimated model values and the observed data. The 
residual values of the regression that modelled trend were the remaining 
variations in the data after trend was accounted for. The correlogram was used 
to investigate if these residual values were correlated in time. For example, a 
significantly positive correlation at a lag at one month would signify that, after 
accounting for trend, the residual values for one month were significantly 
correlated to the residual values for the next month.  
The autocorrelation function (ACF) confidence intervals were calculated as 
follows: 
±
𝑖
√𝑁
 
where 𝑖 = 𝑞𝑛𝑜𝑟𝑚(
1+𝑐𝑖
2
), and 𝑁 = 48. 
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qnorm is the normal quantile R function, ci is the confidence interval (which was 
set to 0.95), and N is the number of months used to calculate the ACF (48 in 
this case). Therefore:  
±
𝑖
√𝑁
=
1.96
√48
= 0.28 
The trends and seasonality of E. coli and Klebsiella UTIs were assessed for 
LTCF samples and non-LTCF samples, for E. coli and Klebsiella susceptible 
and resistant to trimethoprim as these could potentially be different. The E. coli 
and Klebsiella UTIs that were sent by GPs (vs. hospitals) were also analysed 
separately.  
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Trend in E. coli and Klebsiella UTI (in those aged 70 and over) 
Negative binomial regression models with second degree polynomials were fit 
to the monthly UTIs caused by E. coli and Klebsiella in older people in the West 
Midlands during the study period in LTCFs and outside of LTCFs. The offset for 
these regressions was the elderly West Midlands population.  
As can be seen in Figure A- 2, UTIs caused by E. coli and Klebsiella in older 
people increased in the West Midlands during the study period in LTCFs and 
outside of LTCFs. A similar increase was seen for UTIs caused by E. coli and 
Klebsiella susceptible and resistant to trimethoprim (see Figure A- 3 and Figure 
A- 4). In all cases, UTIs appeared to rapidly increase until early 2013. The rate 
of UTIs caused by E. coli in LTCFs and UTIs caused by Klebsiella outside of 
LTCFs very visibly stabilised from this moment and even dropped slightly in the 
last few months of the study. This tapering off, although present, was less 
apparent for UTIs caused by E. coli outside of LTCFs and UTIs caused by 
Klebsiella in LTCFs. 
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Figure A- 2. Monthly rate of UTIs caused by E. coli and Klebsiella in older people residing 
in and outside of long-term care facilities in the West Midlands from April 2010 to March 
2014.  In red, the fitted predictions of the negative binomial polynomial regression model of 
degree two with offset. 
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Figure A- 3. Monthly rate of UTIs caused by E. coli and Klebsiella that were susceptible to 
trimethoprim in older people residing in and outside of long-term care facilities in the 
West Midlands.  In red, the fitted predictions of the negative binomial polynomial regression 
model of degree two with offset. 
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Figure A- 4. Monthly rate of UTIs caused by E. coli and Klebsiella that were resistant to 
trimethoprim in older people residing in and outside of long-term care facilities in the 
West Midlands.  In red, the fitted predictions of the negative binomial polynomial regression 
model of degree two with offset. 
The rate of UTIs increased by an average of: 
 𝑦 = 0.00021 ∗ 1.056𝑚𝑜𝑛𝑡ℎ ∗ 0.9993𝑚𝑜𝑛𝑡ℎ
2
∗ 100,000 per 100,000 
individuals in the population for E. coli UTIs in LTCFs 
 𝑦 = 0.0023 ∗ 1.034𝑚𝑜𝑛𝑡ℎ ∗ 0.9997𝑚𝑜𝑛𝑡ℎ
2
∗ 100,000 per 100,000 individuals 
in the population for E. coli UTIs not in LTCFs 
 𝑦 = 0.00002 ∗ 1.027𝑚𝑜𝑛𝑡ℎ ∗ 0.9998𝑚𝑜𝑛𝑡ℎ
2
∗ 100,000 per 100,000 
individuals in the population for Klebsiella UTIs in LTCFs 
 𝑦 = 0.00029 ∗ 1.035𝑚𝑜𝑛𝑡ℎ ∗ 0.9996𝑚𝑜𝑛𝑡ℎ
2
∗ 100,000 per 100,000 
individuals in the population for Klebsiella UTIs in LTCFs 
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For example, this meant than in the first month of the study (April 2010), there 
were:  
0.00021 ∗ 1.0561 ∗ 0.99931
2
∗ 100,000 = 22.16 UTIs caused by E. coli in LTCFs 
per 100,000 individuals in the population (~22.29 in Table A- 12, as fewer 
decimals are reported above than are estimated in the model). The numeric 
solutions for eight time points are described in Table A- 12 below. 
  
3
5
3
 
Table A- 12. UTIs caused by E. coli and Klebsiella in LTCF residents and in older people living in their own homes per 100,000 elderly individuals 
living in the West Midlands.  Fitted values from the negative binomial regression model. 
 April  
2010 
September 
2010 
March 
2011 
September 
2011 
March 
2012 
September 
2012 
March 
2013 
September 
2013 
March 
2014 
UTIs caused by E. coli in 
LTCFs per 100,000 pop 22.29 28.52 36.66 44.89 52.33 58.11 61.46 61.9 59.37 
UTIs caused by E. coli outside 
LTCFs per 100,000 pop 241.21 282.06 333.93 387.27 439.94 489.57 533.67 569.86 596.06 
UTIs caused by Klebsiella in 
LTCFs per 100,000 pop 2.32 2.64 3.03 3.44 3.84 4.23 4.59 4.92 5.19 
UTIs caused by Klebsiella 
outside LTCFs per 100,000 
pop 30.51 35.67 41.91 47.85 53.1 57.25 59.99 61.08 60.43 
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Seasonality in E. coli UTI (in those aged 70 and over) 
There was no seasonal pattern observed in UTIs caused by E. coli in older 
people, neither in LTCF residents nor in patients that did not reside in LTCFs 
(see Figure A- 5 and Figure A- 6). Adding a f(x) = cos (
2𝛱𝑥
12
) + sin (
2𝛱𝑥
12
) wave to 
the regression model worsened the model fit for E. coli UTIs (from an AIC of 
495.9 to 499.5 for LTCF residents, and from an AIC of 689.6 to 693.1 for those 
not residing in LTCFs). Graphically, the fit to the rates of E. coli UTI were very 
similar for the two models. The correlograms in Figure A- 6 show the 
autocorrelation functions for the residuals of the regression models without 
seasonality in E. coli UTIs from LTCFs and outside LTCFs (respectively) at lags 
of 0-12 months. Neither had an oscillatory shape consistent with seasonality. 
There was a borderline significant negative correlation at 11 months for UTIs 
caused by E. coli in LTCFs with no plausible biological explanation.  
There was also a lack of clear seasonality in UTIs caused by E. coli susceptible 
and resistant to trimethoprim (Figure A- 7 and Figure A- 8).  
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Figure A- 5. Seasonality in the monthly rate of UTIs caused by E. coli in elderly patients 
residing in and outside of long-term care facilities in the West Midlands from April 2010 
to March 2014.  In red, the fitted predictions of the negative binomial polynomial regression 
model of degree two with offset. In blue, the fitted predictions of the negative binomial 
polynomial regression model of degree two with offset and a seasonality component 
f(x) = cos (
2𝛱𝑥
12
) + sin (
2𝛱𝑥
12
). 
 
 
Figure A- 6. The autocorrelation function (ACF) for lags 0-12 of the residuals of the 
negative binomial regression without seasonality fit to the monthly UTIs caused by E. 
coli in elderly patients residing in LTCFs and outside LTCFs in the West Midlands.  The 
95% confidence intervals are marked with dashed horizontal blue lines.  
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Figure A- 7. Seasonality in the monthly rate of UTIs caused by E. coli susceptible and 
resistant to trimethoprim in elderly patients residing in and outside of long-term care 
facilities in the West Midlands.  In red, the fitted predictions of the negative binomial 
polynomial regression model of degree two with offset. In blue, the fitted predictions of the 
negative binomial polynomial regression model of degree two with offset and a seasonality 
component 𝐟(𝐱) = 𝐜𝐨𝐬 (
𝟐𝜫𝒙
𝟏𝟐
) + 𝐬𝐢𝐧 (
𝟐𝜫𝒙
𝟏𝟐
). 
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Figure A- 8. The autocorrelation function (ACF) for lags 0-12 of the residuals of the 
negative binomial regressions without seasonality fit to the monthly UTIs caused by E. 
coli sensitive (top plots) and sensitive (bottom plots) to trimethoprim in elderly patients 
residing in LTCFs (left plots) and outside of LTCFs (right plots) in the West Midlands.  
The 95% confidence intervals are marked with dashed horizontal blue lines. 
Seasonality in Klebsiella UTI (in those aged 70 and over) 
The number of UTIs caused by Klebsiella was lower than the number of UTIs 
caused by E. coli, and particularly low in the LTCF population, which increased 
stochasticity and hindered the analysis of seasonality. 
There was no clear seasonal pattern observed in UTIs caused by Klebsiella in 
older people; neither in LTCF residents nor in patients that did not reside in 
LTCFs (see Figure A- 9 and Figure A- 10). Adding a f(x) = cos (
2𝛱𝑥
12
) + sin (
2𝛱𝑥
12
) 
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wave to the regression model only improved the model fit very slightly for 
Klebsiella UTIs in LTCF residents (from an AIC of 326.3 to 323.5) and slightly 
worsened the fit for individuals that resided outside of LTCFs (from an AIC of 
516.1 to 517.3). Figure A- 10 shows the correlograms for Klebsiella UTIs at lags 
of 0-12 months. The was a visible oscillation with a significant positive 
correlation at one month, a borderline significant negative correlation at four 
months and a significant negative correlation at five months for UTIs caused by 
Klebsiella outside LTCFs. The correlogram for UTIs caused by Klebsiella in 
LTCFs had a similar shape but none of the lags were significantly correlated. 
This could be due to the number of UTIs caused by Klebsiella in LTCFs being 
much smaller than outside LTCFs, thereby reducing statistical power.  
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Figure A- 9. Seasonality in the monthly rate of UTIs caused by Klebsiella in elderly 
patients residing in and outside of long-term care facilities in the West Midlands from 
April 2010 to March 2014.  In red, the fitted predictions of the negative binomial polynomial 
regression model of degree two with offset. In blue, the fitted predictions of the negative 
binomial polynomial regression model of degree two with offset and a seasonality component 
f(x) = cos (
2𝛱𝑥
12
) + sin (
2𝛱𝑥
12
). 
 
Figure A- 10. The autocorrelation function (ACF) for lags 0-12 of the residuals of the 
negative binomial regression without seasonality fit to the monthly UTIs caused by 
Klebsiella in elderly patients residing in LTCFs and outside LTCFs in the West Midlands.  
The 95% confidence intervals are marked with dashed horizontal blue lines. 
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Similar trends were observed in UTIs caused by Klebsiella that were 
susceptible and resistant to trimethoprim (see Figure A- 11 and Figure A- 12). A 
very similar oscillatory pattern was seen in the correlogram for UTIs caused by 
Klebsiella that were susceptible or resistant to trimethoprim outside LTCF 
residents and, to a lesser extent, in UTIs caused by Klebsiella that were 
susceptible to trimethoprim in LTCFs. There was no clear pattern in the 
correlogram for UTIs caused by Klebsiella that were resistant to trimethoprim in 
LTCFs.  
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Figure A- 11. Seasonality in the monthly rate of UTIs caused by Klebsiella susceptible 
and resistant to trimethoprim in elderly patients residing in and outside of long-term care 
facilities in the West Midlands. 
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Figure A- 12. The autocorrelation function (ACF) for lags 0-12 of the residuals of the 
negative binomial regressions without seasonality fit to the monthly UTIs caused by 
Klebsiella sensitive (top plots) and sensitive (bottom plots) to trimethoprim in elderly 
patients residing in LTCFs (left plots) and outside of LTCFs (right plots) in the West 
Midlands.  The 95% confidence intervals are marked with dashed horizontal blue lines. 
Similar patterns were observed when excluding the samples submitted by 
hospitals and focusing exclusively on the samples submitted by GPs (Figure A- 
13, Figure A- 14 and Figure A- 15).  
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Figure A- 13. Monthly rate of UTIs caused by E. coli and Klebsiella in older people 
residing in and outside of long-term care facilities in the West Midlands reported by GPs.  
In red, the fitted predictions of the negative binomial polynomial regression model of degree two 
with offset. 
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Figure A- 14. Seasonality in the monthly rate of UTIs caused by E. coli and Klebsiella in 
elderly patients residing in and outside of long-term care facilities in the West Midlands 
reported by GPs.  In red, the fitted predictions of the negative binomial polynomial regression 
model of degree two with offset. In blue, the fitted predictions of the negative binomial 
polynomial regression model of degree two with offset and a seasonality component 
f(x) = cos (
2𝛱𝑥
12
) + sin (
2𝛱𝑥
12
). 
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Figure A- 15. The autocorrelation function (ACF) for lags 0-12 of the residuals of the 
negative binomial regressions without seasonality fit to the monthly UTIs caused by E. 
coli (top plots) and Klebsiella (bottom plots) in elderly patients residing in LTCFs (left 
plots) and outside of LTCFs (right plots) in the West Midlands reported by GPs.  The 95% 
confidence intervals are marked with dashed horizontal blue lines. 
The monthly rate of UTIs caused by both E. coli and Klebsiella in older people 
in the West Midlands increased during the study period. There was no evidence 
for seasonality in E. coli UTIs; however, seasonality in UTIs caused by 
Klebsiella cannot be discarded due to the low monthly counts of these infections 
in the study population. 
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However, this could be due to biases in reporting. To this aim, these patterns 
were explored in a different dataset, the monthly trimethoprim and nitrofurantoin 
prescriptions in the West Midlands, which was only available for all ages. 
Trend in trimethoprim and nitrofurantoin prescriptions (all ages) 
A negative binomial model with offset and a second degree polynomial was fit 
to the monthly GP trimethoprim and nitrofurantoin prescriptions for all ages in 
the West Midlands, which were available for 44/48 months of this study. The 
offset in this regression was the all ages West Midlands population. Figure A- 
16 (below) shows that the rate of trimethoprim and nitrofurantoin prescriptions in 
the West Midlands increased by an average of: 
𝑦 = 0.0059 ∗ 1.0084𝑚𝑜𝑛𝑡ℎ ∗ 0.9999𝑚𝑜𝑛𝑡ℎ
2
∗ 100,000 per 100,000 individuals in 
the population.  
This was determined using the equation of the regression model.  
For example, this meant than in the first month of the study where prescription 
data was reported (August 2010), there were:  
𝑦 = 0.0059 ∗ 1.00841 ∗ 0.99991
2
∗ 100,000 = 594.9 trimethoprim and 
nitrofurantoin prescriptions per 100,000 individuals in the population (~598.8, as 
fewer decimals are reported above than are estimated in the model). 
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Figure A- 16. Increasing trend in the monthly rate of GP trimethoprim and nitrofurantoin 
prescriptions for all ages in the West Midlands from August 2010 to March 2014.  In red, 
the fitted predictions of the negative binomial polynomial regression model of degree two with 
offset. 
Seasonality of trimethoprim and nitrofurantoin prescriptions (all ages) 
Adding a f(x) = cos (
2𝛱𝑥
12
) + sin (
2𝛱𝑥
12
) wave to the polynomial improved the fit of 
the regression model to the trimethoprim and nitrofurantoin prescription rates 
from an AIC of 808.8 to 781.1 (see Figure A- 17). The models with and without 
this seasonality term were significantly different as their confidence intervals did 
not overlap. Four waves were apparent with peaks in the autumn. Figure A- 18a 
and Figure A- 18b show the autocorrelation functions for the residuals of the 
regression models without and with seasonality (respectively) at lags of 0-12 
months. The correlogram in Figure A- 18a had an oscillatory shape consistent 
with seasonality. There was a borderline significant positive correlation at a lag 
of two months and a strongly significant positive correlation at a lag of 12 
months. There were also borderline significant negative correlations at four and 
six months and a significant negative correlation at five and seven months. After 
adding the seasonal term to the regression, the correlogram of the residual 
counts lost its oscillatory shape. There was a significant negative correlation at 
a lag of one month indicating large fluctuations and a borderline significant 
positive correlation at 12 months.  
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Figure A- 17. Seasonality in the monthly rate of GP trimethoprim and nitrofurantoin 
prescriptions for all ages in the West Midlands from August 2010 to March 2014. In red, 
the fitted predictions of the negative binomial polynomial regression model of degree 
two with offset.  In blue the fitted predictions of the negative binomial polynomial regression 
model of degree two with offset and a seasonality component f(x) = cos (
2𝛱𝑥
12
) + sin (
2𝛱𝑥
12
) . 
 
 
Figure A- 18. The autocorrelation function (ACF) for lags 0-12 of the residuals of the 
negative binomial regression without (5a) and with (5b) seasonality fit to the monthly GP 
trimethoprim and nitrofurantoin prescriptions for all ages in the West Midlands.  The 95% 
confidence intervals are marked with dashed horizontal blue lines. 
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Discussion 
AmSurv findings 
The analysis of the AmSurv surveillance data showed that the rate of UTIs 
caused by E. coli and Klebsiella in older people living in the West Midlands 
increased dramatically from April 2010 to March 2014. The most rapid increase 
was seen in the rate of UTIs caused by E. coli in LTCFs, which tripled during 
the study period. The slowest increase was seen in the rate of UTIs caused by 
Klebsiella outside LTCFs, which doubled during the study. UTIs caused by E. 
coli and Klebsiella increased sharply from 2010 to 2013; however, in the last 
year of the study, UTIs increased at a much slower rate or even decreased 
slightly. UTIs caused by E. coli in LTCFs per 100,000 elderly in the West 
Midlands decreased from 61.46 in March 2013 to 59.37 in March 2014.  
Whilst there is a clear lack of seasonality in UTIs caused by E. coli in older 
people during the study period, the oscillatory pattern observed for Klebsiella 
UTIs could be consistent with seasonality or with transmission. As, in addition, 
the monthly counts of Klebsiella UTI are low in this population, which decreased 
statistical power; the seasonality of Klebsiella UTIs cannot be discarded. The 
positive correlations at a lag of one month for Klebsiella UTIs in AmSurv are 
consistent with infectious disease transmission 311. These correlations are not 
apparent in the correlograms for E. coli UTI, in agreement with the literature, 
which suggests that E. coli is less readily transmissible than Klebsiella. 255 This 
could be due to E. coli being ubiquitously present in the human gut whilst 
Klebsiella is not as often present. 
The same trend and seasonality pattern was observed for UTIs caused by E. 
coli and Klebsiella that were resistant and susceptible to trimethoprim and for 
those UTIs that were reported only by GPs (vs. hospitals). 
HSCIC findings 
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The Health & Social Care Information Centre all-ages GP trimethoprim and 
nitrofurantoin prescriptions in the West Midlands also increased during the 
study period, albeit at a slower rate.  
These prescriptions were very markedly seasonal with yearly autumn peaks. 
Adding a seasonality component to the model significantly improved the model 
fit and the correlogram of the residuals of the negative binomial model that did 
not include seasonality showed an oscillatory shape consistent with seasonality 
which was not present in the model that included a seasonality component. 
There were no positive correlations at a lag of one month for trimethoprim and 
nitrofurantoin prescriptions. 
Comparison between the two datasets and possible explanations 
The increase in both datasets suggests there is a real increase in the rate of 
UTIs in older people in the West Midlands that was not driven by sampling. The 
clear autumn seasonality observed in the GP trimethoprim and nitrofurantoin 
prescriptions for all ages in the HSCIC dataset contrasts with the lack of clear 
seasonality in the UTIs caused by E. coli and (to a lesser extent) Klebsiella in 
older people in the AmSurv dataset. This suggests that: 
1) UTIs are not seasonal in older people but are seasonal in the overall 
population, or 
2) UTIs in older people are seasonal but the reporting of UTIs in AmSurv is 
not seasonal, or 
3) UTIs caused by E. coli (76% of all urine samples reported in this age 
group) are not seasonal; however, UTIs caused by other bacteria (e.g. 
Proteus) are seasonal, or 
4) Trimethoprim and nitrofurantoin are used to treat other infections which 
peak in the autumn, or 
5) There is a seasonal pattern in the reporting of UTIs to AmSurv with a 
trough in autumn, or 
6) A combination of the above 
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The first hypothesis would indicate that there are different dynamics of infection 
in the elderly population compared to younger age groups. Waning immunity in 
older people could make them more susceptible to these infections throughout 
the year. Older people are also less mobile and may not exhibit major lifestyle 
changes during the summer months. This contrasts with the younger age 
groups, which could exhibit greater behavioural changes according to the 
season (e.g. university and school terms). 
The second hypothesis could be explained by a combination of seasonality in 
the less severe infections (treated by first-line antibiotics such as trimethoprim 
and nitrofurantoin), which are not sampled as frequently and therefore not 
registered in the AmSurv database, and a lack of seasonality in more severe 
infections (treated with more severe antibiotics such as ciprofloxacin or 3GCs), 
which would be reported to AmSurv. 
The third hypothesis implies that UTIs caused by other organisms (e.g. UTIs 
caused by Proteus) are strongly seasonal. This hypothesis is not supported by 
the existing knowledge of UTIs and by the fact that most UTIs treated with 
trimethoprim and nitrofurantoin are caused by E. coli. 
The fourth hypothesis is improbable because, although trimethoprim 
prescription is also indicated for acute and chronic bronchitis and pneumocystis 
pneumonia312, which are known to be seasonal, these are conditions that 
usually peak in the winter months.313 In addition, trimethoprim is primarily 
prescribed for UTI. Nitrofurantoin is not indicated for other infections. 
Finally, the AmSurv dataset included only urines that were reported to 
laboratories for antibiotic susceptibility testing. However, other authors have 
proposed that large differences in reporting during the seasons are unlikely 224.  
The two most plausible explanations are, therefore, the first two hypotheses. 
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Conclusion 
Understanding the differences in seasonality observed requires the analysis of 
primary care electronic health records such as The Health Improvement 
Network (THIN) or the Clinical Practice Research Datalink (CPRD). 
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Appendix Chapter 6 PART B 
Read codes for UTI 
'K190300', 'K190400', '1AG..00', 'K190311', 'K190.11', '14D7.00', 'L166z11', 
'L166800', 'K190.00', 'K190500', 'K190z00', 'K190000', 'K190100', 'K190200', 
'K190600', 'K190X00', 'Q40y100', '1J4..00', '46U3.00', '4617.00', 'K190011', 
'L166600', 
'K15..00', 'K150.00', 'K15z.00', 'K152000', 'K154.00', 'K154000', 'K154300', 
'K154400', 'K154600', 'K154800', 'K154z00', 'K15y.00', 'K15y200', 'K15y300', 
'K15yz00', 'A32y300', 'K153.11', 'K151.00', 'K152y00', 'K152.00', 'K152z00', 
'K155.00', '14D4.00', 
'L166.11', 'L166500', 'K101.00', 'K101000', 'K101100', 'K101200', 'K101300', 
'K101400', 'K101500', 'K101z00', 'K106.00', 'K100.00', 'K100000', 'K100100', 
'K100200', 'K100300', 'K100400', 'K100500', 'K100600', 'K100z00', 'K10y000', 
'A160200', 'K104.00',  
'K10..00', 'K102.00', 'K102000', 'K102100', 'K102200', 'K102z00', 'K103.00', 
'K105.00', 'K10y.00', 'K10y000', 'K10y100', 'K10y200', 'K10y300', 'K10y400', 
'K10yz00','K10z.00', 'K10..11'. 
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Appendix Chapter 7 
The weekly incidence of resistant urine E. coli samples submitted to AmSurv for 
each LTCF by incidence quartile is shown in Figure A- 19, Figure A- 20, Figure 
A- 21 and Figure A- 22. 
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Figure A- 19. The weekly incidence of resistant urine E. coli samples submitted to 
AmSurv for each of the LTCFs in the highest incidence quartile.  The LTCF selected for 
simulation is highlighted in grey. 
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Figure A- 20. The weekly incidence of resistant urine E. coli samples submitted to 
AmSurv for each of the LTCFs in the second highest incidence quartile.  The LTCF 
selected for simulation is highlighted in grey. 
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Figure A- 21. The weekly incidence of resistant urine E. coli samples submitted to 
AmSurv for each of the LTCFs in the second lowest incidence quartile.  The LTCF 
selected for simulation is highlighted in grey. 
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Figure A- 22. The weekly incidence of resistant urine E. coli samples submitted to 
AmSurv for each of the LTCFs in the lowest incidence quartile.  The LTCF selected for 
simulation is highlighted in grey. 
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The number of entries and exits to each of the LTCF compartments are shown 
in Figure A- 23, Figure A- 24, Figure A- 25 and Figure A- 26. The deterministic 
model predicted every week 0.17 individuals were discharged from the 30-bed 
LTCF to hospital colonised by E. coli resistant to trimethoprim. Of all individuals 
discharged from the LTCF to hospital, 49.52% were colonised with resistant 
strains (vs. susceptible strains). Every week, 0.096 individuals were admitted 
into the LTCF from hospital. Of all individuals admitted into the LTCF from 
hospital, 37.92% were colonised with resistant strains (vs. susceptible strains).  
The median number of patients colonised by E. coli resistant to trimethoprim 
admitted to hospital to the LTCF and discharged to the LTCF from hospital 
weekly in the stochastic model were both zero (95th percentiles= 0-2 or 0-1 for 
both, depending on the week of the study). The mean number of admissions 
per week to the LTCF from hospital ranged from 0.19 to 0.31 and the mean 
number of discharges from the LTCF to hospital ranged from 0.29 to 0.39).  
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Figure A- 23. Number of deaths from each of the four compartments of the model by 
week of the study period.   𝑈𝑠 were individuals untreated with trimethoprim colonised with E. 
coli susceptible to trimethoprim, 𝑈𝑟  were individuals untreated with trimethoprim colonised with 
E. coli resistant to trimethoprim, 𝑇𝑠 were individuals treated with trimethoprim colonised with E. 
coli susceptible to trimethoprim and 𝑇𝑟  were individuals treated with trimethoprim colonised with 
E. coli resistant to trimethoprim. The coloured lines represent the output of 1,000 stochastic 
simulations. The black line represents the output from the deterministic model. 
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Figure A- 24. Number of individuals discharged from the LTCF to hospital from each of 
the four compartments in the model by week of the study period.   𝑈𝑠 were individuals 
untreated with trimethoprim colonised with E. coli susceptible to trimethoprim, 𝑈𝑟  were 
individuals untreated with trimethoprim colonised with E. coli resistant to trimethoprim, 𝑇𝑠 were 
individuals treated with trimethoprim colonised with E. coli susceptible to trimethoprim and 𝑇𝑟  
were individuals treated with trimethoprim colonised with E. coli resistant to trimethoprim. The 
coloured lines represent the output of 1,000 stochastic simulations. The black line represents 
the output from the deterministic model. 
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Figure A- 25. Number of individuals admitted to the LTCF from the community into each 
of the four model compartments by week of the study period.   𝑈𝑠 were individuals 
untreated with trimethoprim colonised with E. coli susceptible to trimethoprim, 𝑈𝑟  were 
individuals untreated with trimethoprim colonised with E. coli resistant to trimethoprim, 𝑇𝑠 were 
individuals treated with trimethoprim colonised with E. coli susceptible to trimethoprim and 𝑇𝑟  
were individuals treated with trimethoprim colonised with E. coli resistant to trimethoprim. The 
coloured lines represent the output of 1,000 stochastic simulations. The black line represents 
the output from the deterministic model. 
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Figure A- 26. Number of individuals admitted to the LTCF from hosital into each of the 
four model compartments by week of the study period.   𝑈𝑠 were individuals untreated with 
trimethoprim colonised with E. coli susceptible to trimethoprim, 𝑈𝑟  were individuals untreated 
with trimethoprim colonised with E. coli resistant to trimethoprim, 𝑇𝑠 were individuals treated with 
trimethoprim colonised with E. coli susceptible to trimethoprim and 𝑇𝑟  were individuals treated 
with trimethoprim colonised with E. coli resistant to trimethoprim. The coloured lines represent 
the output of 1,000 stochastic simulations. The black line represents the output from the 
deterministic model. 
 
